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“[This] Executive Guide …  
will serve as a concise  
guide for experts and  
provide fascinating  
insight for all citizens  
of the Brave New World.”
—From the Foreword by Dr. Reddy
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(subject to availability of funding and support)
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Intellectual property can be a powerful tool. When effectively and ethically 
managed, it can accelerate the development of lifesaving, poverty-alleviating 
innovations and provide access to them.
This Executive Guide, companion to the Handbook, discusses and summarizes 
each of the 17 sections of the Handbook and distills best practices related to 
each of the major topics. They are presented in brief, simply worded lists that 
address the concerns of policymakers, heads of universities and R&D centers, 
scientists, and technology transfer officers. 
This book will be invaluable for anyone seeking to use intellectual property 
strategically and put intellectual property to work.
“Pragmatic IP management is building bridges between the world’s islands, be they economic, 
institutional, or geographic. The choice of this metaphor is not accidental. It affirms a key claim 
that reverberates within the pages of this book: the global IP system and innovation management 
are not about changing islands. Rather, it is about building bridges between them.”
—From the Preface by Anatole Krattiger
The companion Handbook, prepared by and for 
policymakers, leaders of public sector research 
establishments, technology transfer professionals, 
licensing executives, and scientists from East, 
West, North, and South, is a resource comprising 
157 chapters and prefatory comments.
“A resource for translating IP rights into realistic deals and practical solutions,  
the Executive Guide demystifies intellectual property, making the subject accessible to all. ”
—From the Foreword by Sam Dryden
ANAtole KrAttIger
with







StANley P. KowAlSKI 
Intellectual Property Management
in Health and Agricultural Innovation
a handbook of best practices
E X E C U T I V E  G U I D E
“I recommend this Guide to anyone interested in the practice of science in the twenty-first century 
or in the promotion of R&D in this new age of globalization of knowledge and trade …”
—From the Foreword by Ismail Serageldin
           Krattiger et al.

Intellectual Property Management
in Health and Agricultural Innovation












stAnley P. KoWAlsKi 
Intellectual Property Management
in Health and Agricultural Innovation
a handbook of best practices
EXECUTIVE GUIDE
© 2007. MIHR, PIPRA, Oswaldo Cruz Foundation, and bioDevelopments-International Institute.
Sharing the Art of IP Management: Photocopying and distribution through the Internet for non-commercial purposes is 
permitted and encouraged providing all such copies include complete citation and copyright notices as given on the first page  
of each chapter. For details, see www.ipHandbook.org. 
Published by
MIHR (Centre for the Management of Intellectual Property in Health Research and Development), Oxford Centre for 
Innovation, Mill Street, Oxford, OX2 0JX, U.K. www.mihr.org, mihr@bioDevelopments.org 
PIPRA (Public Intellectual Property Resource for Agriculture), University of California, Davis, Plant Reproductive Biology 
Bldg., Extension Center Circle, Davis, CA, 95616-8780, U.S.A. www.pipra.org, info@pipra.org
Oswaldo Cruz Foundation (Fiocruz), Av. Brasil 4365, Rio de Janeiro, RJ 21040-900, Brazil. www.fiocruz.br, ccs@fiocruz.br




Paula Douglass (Dryden, New York, U.S.A.) and Faye Farmer (ASU, Tempe, U.S.A.) 
with Jacqueline Stuhmiller (Ithaca, New York, U.S.A.) and Katy Dixon (Champagne, Illinois, U.S.A.)
Layout and Design
Linette Lao (Invisible Engines, Ypsilanti, Michigan, U.S.A.)
Copy Editor
Barry Hall (OmniGlyph, Atlanta, Georgia, U.S.A.) 
Online version
Dynamic Diagram (Providence, Rhode Island, U.S.A.)
Citation
Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 
2007. Executive Guide to Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best 
Practices. MIHR (Oxford, U.K.), PIPRA (Davis, U.S.A.), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil) and 
bioDevelopments-International Institute (Ithaca, U.S.A.). Available online at www.ipHandbook.org.
Translations
Requests for permission to reproduce the book in its entirety or for translations, 
whether for sale or for non-commercial distribution, should be addressed to any of the publishers.
Library of Congress Preassigned Control Number 
2007930234
(ISBN: 978-1-4243-2028-8) 
Distributed free of charge to low- and middle-income countries  







The Biodesign Institute at ASU, bioDevelopments-International Institute, 
and Cornell University, U.S.A. 
With
Richard T. Mahoney 
International Vaccine Institute, Republic of Korea
Lita Nelsen 
Massachusetts Institute of Technology, U.S.A. 
Jennifer A. Thomson 
University of Cape Town, South Africa
Alan B. Bennett 
PIPRA and University of California, Davis, U.S.A.
Kanikaram Satyanarayana 
Indian Council of Medical Research, India
Gregory D. Graff 
PIPRA and Colorado State University, Fort Collins, U.S.A.
Carlos Fernandez 
Foundation for Agriculture Innovation, Chile
Stanley P. Kowalski 
The Franklin Pierce Law Center, U.S.A.
Comprehensive Editorial Consultant
David P. Alvarez 





Over the last decade, the world has been paying increasing attention to the 
agricultural, health, and economic disparities between industrialized and 
developing countries. The Rockefeller Foundation is proud to have helped develop 
and launch some of the numerous initiatives to address these issues—initiatives 
such as the African Agricultural Technology Foundation, the Alliance for a Green 
Revolution in Africa, the International AIDS Vaccine Initiative, the Global Alliance 
for TB Drug Development, and others.
We believe, however, that launching the success of these and other similar 
initiatives requires that we both engage directly with research universities in the 
industrialized world and encourage the growing innovation capacity of developing 
countries. The Public Intellectual Property Resource for Agriculture (PIPRA) and 
the Centre for the Management of Intellectual Property in Health Research and 
Development (MIHR) were created for precisely these reasons. Their mission 
is to enhance the power of publicly funded research institutions to harness new 
technologies and to ensure that the benefits of globalization are shared more 
equitably. This Executive Guide and the companion Handbook and online version 
are a natural outcome of their efforts to contribute new solutions to this two-fold 
challenge. A follow-on interactive electronic version will reach an even wider 
audience and, we hope, provide even greater benefits.
The Rockefeller Foundation is delighted to have supported the creation of this 
unique resource. It holds lessons that are valuable (in many senses of the word) 
for policy makers, leaders of research institutions, researchers, and technology 
managers alike—in both industrialized and developing countries. Indeed, this 
Executive Guide and Handbook, a testament to the committed, excellent work 
of MIHR, PIPRA, and bioDevelopments-International Institute, might be the 
most thorough primer on intellectual property management for the public interest 
ever assembled. As such, it will be an indispensable tool for both planners and 
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The instinctively appealing proposition that knowledge ought to be used for the public 
good—the common cause—is at the core of the debate surrounding the ethics of intel-
lectual property. This notion of the role of knowledge in advancing the public good has 
deep roots in numerous cultures and communities. Rabindranath Tagore, the universally 
celebrated poet and Nobel laureate penned a stirring plea of hope: 
Where knowledge is free 
Where the world is not broken up into fragments by narrow domestic walls 
… Into that heaven of freedom, my Father 
Let my country awake!
 
The debate is particularly intense in relation to health and food, areas in which restrictions 
to access can profoundly affect the human condition. Jonas Salk, the inventor of the first 
polio vaccine, refused to patent it and famously said: “Who owns my polio vaccine? The peo-
ple! Could you patent the sun? ” But the debate over what constitutes patentable subject mat-
ter has actually intensified over the years, as concerns have deepened over access. Nowhere 
is this more pertinent than with antiretrovirals, with the patenting of live organisms, cell 
lines, and plant varieties. 
A persistent disparity in the human condition has accompanied us into the 21st centu-
ry. This disparity is mirrored by differences, within our global community, regarding access 
to knowledge and technology, between the rich and the poor. Despite grave incongruities, 
there is consensus that new knowledge and innovation can contribute significantly to recti-
fying the inequalities. The faster and more efficient the flow of knowledge “through narrow 
domestic walls,” the faster global equity and prosperity will replace global disparity.
The ethical debate over intellectual property rights focuses on the flow of knowledge. 
But there must be innovation initially to trigger the flow. The great centers of education 
and research in the public sector have made enormous contributions to furthering knowl-
edge that have significantly improved the human condition, directly or through inventive 
augmentation by others. Private corporations and individuals have contributed stunning 
advances as well, and have promoted productive and creative uses of knowledge through 
science and technology. The crucial question, therefore, is how to increase investment—in 
Reddy KA. 2007. Foreword. In Executive Guide to Intellectual Property Management in Health and Agricultural 
Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA 
(Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International 
Institute (Ithaca, USA). Available online at www.ipHandbook.org.
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both the public and private sectors—to accelerate innovation and facilitate its flow for the 
greatest possible benefit. 
Though the question may be simple, the answer is not. Yet, clear is the message from the 
writers of the Executive Guide to Intellectual Property Management in Health and Agricultural 
Innovation: A Handbook of Best Practices—that innovation, which can be transformed into 
intellectual property and then owned and sold for profit in order to sustain investment 
for further innovation, can be managed to benefit all people, and particularly those who 
are poor and stand to benefit most from this process. Most experts acknowledge that the 
notion of intellectual property rights is a compromise between the twin imperatives of 
providing a reward system that will spur investment in innovation, on the one hand, and 
use it to effect the greatest public good, on the other. Like all compromises, this one too may 
be imperfect, but it is actionable and practical. 
Winston Churchill foresaw the potential of the knowledge economy and asserted that 
“the empires of the mind are the empires of the future.” The “haves” of the world own the lion’s 
share of global intellectual property and it is no coincidence that they represent the lion’s 
share of global wealth. The challenge for the “have nots” among nations, most of which 
have not had the benefit of experience with a robust intellectual property system, is to 
rapidly develop legislative and policy frameworks to foster a culture of innovation and to 
manage intellectual property for the greatest benefit. This Executive Guide includes many 
thought-provoking ideas that will support such transformations. 
Remarkable in its scope, the Handbook not only provides discussion of broad, general, 
and theoretical issues, it also provides practical ideas that can help institutions and com-
panies strategically manage their intellectual property. The Handbook is an epic compila-
tion of over 2000 pages in two volumes, with contributions from nearly 200 authors. It 
is an invaluable and instructive sourcebook for scholars and students, policymakers and 
practitioners. 
Now, the vast knowledge represented by the Handbook has been distilled in the com-
panion Executive Guide, which summarizes the Handbook’s 17 sections and presents key 
implications and best practices related to each of the major topics. I am delighted to recom-
mend the Executive Guide. It will serve as a concise guide for experts and provide fascinat-
ing insight for all citizens of the Brave New World. 
September 2007
Hyderabad, India
Dr. K. Anji reDDy, Chairman, Dr. Reddy’s Laboratories Ltd., 7-1-27 Ameerpet, Hyderabad 500 016, India. 
drreddy@drreddys.com
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Foreword by Sam Dryden
Intellectual property! The concept seems to some individuals to represent a vague abstraction. 
To others it represents a contradiction. But to many, without doubt, intellectual property is a 
powerful tool. Intellectual property refers to a set of global practices with undeniably real ef-
fects. Indeed, the fundamental cultural, intellectual, and commercial enterprises of any nation 
increasingly intersect with the implementation of intellectual property rights. This is especially 
true with respect to the life sciences, and specifically to health care and agriculture, because the 
way intellectual property is managed dramatically affects the pace of innovation, the dissemina-
tion of knowledge, and the delivery of new technologies.
These reasons alone are enough to warrant the publication of this Executive Guide 
and companion Handbook on intellectual property and innovation. But there are more 
ambitious and more practical reasons as well. These essays (together with the companion 
Handbook) offer a truly global snapshot of the emerging worldwide practice of IP man-
agement. Depending on your point of view (and these essays integrate many points of 
view)—or on how you practice it—IP management either retards or stimulates innova-
tion and access to new technologies. The authors’ views converge, however, on two main 
points: the growing reach of the emerging global IP rights system and the importance of IP 
management practice by the public sector. All agree that both the current IP rights systems 
and IP management practices, in general, are far from perfect. Yet it is evident that solid IP 
management can be a powerful tool for advancing the public interest. To manage intellec-
tual property well, however, requires knowledge—not simply the knowledge necessary to 
navigate these systems, but an understanding of the concepts that govern the systems and 
the values that activate them. With informed use, the public benefits that IP rights regimes 
are capable of providing can be maximized, especially in developing countries. 
Even to function minimally in the modern global economy requires a thorough under-
standing of how IP systems work. Governments that wish to be part of the global economy 
will need to radically adjust their approaches to intellectual property; indeed, both intellec-
tual and real property should be reexamined and redefined in both the public and private 
realms. As new systems evolve, they will need to be understood, established, and enforced 
by countries’ legislative and judicial branches. Innovations will have to be both protected 
and exploited. These demands have broad commercial implications for all parties involved 
Dryden S. 2007. Foreword. In Executive Guide to Intellectual Property Management in Health and Agricultural 
Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA 
(Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International 
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noncommercial purposes is permitted and encouraged.
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in the development and use of intellectual property, including private inventors, academia, 
corporations, and, more recently, farmers.
To many people in the plant sciences, these evolving global systems appear to go against 
the grain of many time-honored precepts, such as breeders’ rights, farmer-saved seed, and 
the free dissemination of germplasm. Many misconceptions exist. Some individuals believe 
IP rights function simply to enable the developed world to take advantage of the develop-
ing world (for example, by depriving farmers of seed that could support their livelihood or 
by depriving nations of the value of their indigenous germplasm). But the exercise of IP 
rights is far more complex than these suspicions represent and the provisions for adapting 
IP rights agreements are much more flexible than is commonly imagined. 
This Executive Guide is important in many ways. It explains what makes IP systems 
work and how the public sector, in particular, can best use the system to achieve its mission 
and objectives. An authoritative undertaking written by world authorities on the subject, 
this Executive Guide is an exceedingly valuable—and timely—contribution to the fields 
of IP management and economic and social development. The Guide is a manual for un-
derstanding, not just the mechanics of IP rights, but also their conceptual foundations. A 
resource for translating IP rights into realistic deals and practical solutions, the Executive 
Guide demystifies intellectual property, making the subject accessible to all. We hope that 
this Guide will level the playing field with respect to developed and developing nations, 
open up new avenues of collaboration between the public and private sectors, and move us 
all in the direction of a healthier and more equitable world.
September 2007
Boulder, Colorado, U.S.A.
SAm DryDen, 1900 9th Street, Boulder, CO 80302, U.S.A. sdryden@wolfensohn.com
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Today, about two-thirds of global research and development (R&D) is being done by the 
private sector. That enormous investment in science, and the technology that ensues from 
it, would not be possible without a system of intellectual property protection that rewards 
innovators and allows the investors to recoup their investments. No one would want to 
jeopardize this enormous investment that advances human welfare so much.
However, it is increasingly apparent that in many quarters, such as in research and 
academia in developing countries, it is difficult to undertake the basic research needed to 
generate new knowledge rather than simply to be users of technology developed elsewhere. 
Obstacles include costs as well as a lack of strategic patented technologies as inputs into the 
research process. True, most of the time a research exemption is included in national law, 
but it is usually accompanied by a “reach back” clause that comes into play if the research 
yields some useful product.
To navigate the shoals of this new legal terrain, many researchers and decisions makers 
need help in setting priorities, developing effective research strategies, and drawing on new 
knowledge and on the experiences of others to make better and more informed decisions. 
It is here that this marvelous book becomes absolutely essential. 
This Executive Guide, a summary of a massive two-volume work, is both readable and 
authoritative. It represents the fruits of enormous effort and much deep thinking by the 
people who are most knowledgeable about these complex subjects. The authors are to be 
congratulated for having put at the fingertips of executives and researchers this most valu-
able guide and to the authoritative resource that they have produced. I recommend this 
Guide to anyone interested in the practice of science in the twenty-first century or in the 
promotion of R&D in this new age of globalization of knowledge and trade, where the 
agenda is increasingly driven by the enormous resources of the private sector.
September 2007
Alexandria, Egypt
iSmAil SerAgelDin, Librarian of Alexandria, Director of the Bibliotheca Alexandrina, P.O. Box 138, Chatby, 
Alexandria 21526, Egypt. secretariat@bibalex.org
Serageldin I. 2007. Foreword. In Executive Guide to Intellectual Property Management in Health and Agricul-
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Preface
“No man is an island, entire of itself,” wrote John Donne. The concept was apropos in the 
17th century and remains so today, perhaps more so. Today, our actions affect everyone, 
our lives knit ever tighter, and the world is now our community. The strength of myriad 
environmental, economic, media, technological, and knowledge connections is propelling 
globalization forward in a complex network of products, people, images, ideals, and aspi-
rations. Intellectual property is perhaps the most scrutinized component of the process of 
globalization, being a process of ever-increasing interconnectedness. Respecting each other’s 
property (intellectual, cultural, or physical), and sharing one’s own properties, is a fundamen-
tal principle of building useful and strong connections between people, institutions, cultures, 
and continents. This is why the Executive Guide is so timely. It lays out the major ideas and 
concerns of the companion Handbook in compact, lucid examinations of the full range of 
intellectual property (IP) issues. It is a virtual map of the basic contours of the IP manage-
ment response to the increasing interconnectedness. This Guide offers readers quick access 
to current information about IP essentials, particularly as they relate to the public sector, to 
developing countries, and to making the world a better place. 
Even a cursory glance at the Guide will reveal the momentous changes that have al-
ready taken place in the field of intellectual property and innovation management and the 
enormous potential that has been generated. The public sector has begun to recognize the 
value of sound IP management. The result: new, creative relationships between the public 
and private sectors that are helping to address the urgent health and agricultural needs of 
people in developing, as well as developed, countries. 
Pragmatic IP management is building bridges between the world’s islands, be they eco-
nomic, institutional, or geographic. The choice of this metaphor is not accidental. It af-
firms a key claim that reverberates within the pages of this book: the global IP system and 
innovation management is not about changing islands. Rather, it is about building bridges 
between them.
The Executive Guide mirrors the principle of building bridges. Approaching topics 
from various expert perspectives, the Guide allows the reader to bridge the conceptual 
structures, case studies, and IP models contained within it to see new connections and craft 
new approaches. 
Krattiger A. 2007. Preface. In Executive Guide to Intellectual Property Management in Health and Agricultural 
Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA 
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Through the Guide and Handbook, we hope to liberate the potential of the global IP system, and 
we believe that such liberation will come through the readers as they react to the chapters, draw their 
own conclusions, imagine their own solutions, and create a positive outcome.
This is clearly not a time for complacent isolation. In fact, it is impossible, as interconnectedness 
continues to increase. The task at hand is to engage in the process of connecting, with awareness and 
intention, to ensure that the needs and wishes of the poor in developing countries are not (once again) 
overlooked or disregarded. It is therefore time to join your voices, your values, your knowledge, and 
your actions to pursue networks of partnerships that will nurture global access to innovation. Solo 
efforts at innovation, as I wrote in the Prelude to the Handbook, will be ineffectual without collabora-
tion; the components of a partnership create a dynamic entity that achieves more than any one party 
could achieve. Imagining and cultivating such partnerships, however, requires an understanding and 
orchestration of numerous components. 
This Executive Guide opens the door to such an understanding and, I hope, will not only empower 
its readers to envision a more equitable world but will also inspire them to realize that vision.
Anatole Krattiger
September 2007
 Fréjus/St. Raphaël, France
AnAtole KrAttiger, Research Professor, the Biodesign Institute at Arizona State University; Chair, bioDevelop-
ments-International Institute; and Adjunct Professor, Cornell University, P.O. Box 26, Interlaken, NY, 14847, U.S.A. 
afk3@cornell.edu
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LThe road from sound principles to best practices must include a broad, clear vision 
of a more equitable world, because when vision is limited, action is circumscribed 
and constrained. One way to achieve this vision is by expanding and accelerating 
access—especially in developing countries—to life-saving and poverty-alleviating in-
novations in health and agriculture. A belief in this path to equity is shared by all of 
the contributors to the Executive Guide and the Handbook. The Message from the 
Editorial Board included in the Handbook elaborates on this path as well as on the 
relationship of intellectual property (IP) to innovation management as this critical 
interface is perceived by the board members. The key points are: 
First, intellectual property is a tool to foster innovation. Intellectual property is 
here—and here to stay—because of its undisputable value as a business asset and an 
instrument to achieve humanitarian objectives. Since inventions can become property 
and can therefore be owned and sold, many individuals have been encouraged to invest 
in innovation, based on the profit potential from resulting technologies. But because 
IP protections by definition—or by design—exclude competitors and encourage higher 
pricing, they limit and, in some cases, can altogether prevent access by some individuals 
and populations. There are many ways, however, for intellectual property to be distrib-
uted and utilized and put to work for the public interest. Hence we agree that intellectual 
property should be neither feared, nor blindly embraced; rather, it should be managed to 
maximize the benefits of innovation for all of society, especially the poor.
Second, IP rights are a compromise and an imperfect solution, representing the 
search for balance between public domain and granting ownership. Historically, we 
have seen that this balance encourages investment—and reinvestment—in innova-
tion, although the innovation too infrequently is directed toward the needs of the 
poor. Fortunately, as numerous case studies have shown, the public sector can craft 
effective solutions that can approach or even achieve a suitable balance. This can be 
accomplished by using the existing IP system, especially as it addresses situations in 
which companies agree to donate or otherwise share their intellectual property.
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Third, genius can flourish anywhere, and the emerging global systems of inno-
vation in health and agriculture open up new prospects for innovation everywhere. 
This notion has profound implications for the management of innovation, tech-
nology transfer, market competition, and economic development in every country. 
Irrespective of whether inventions are home grown or originate abroad, authoritative 
IP management will play a crucial role in enabling and preserving access to the result-
ing technologies.
Fourth, policies to promote the creation and management of intellectual prop-
erty by public sector institutions should give first priority to advancing the mission 
of those institutions. Put differently, technology transfer should support the larger 
mission and not merely be seen as potential revenues.
Fifth, intellectual property has historically benefited mostly the affluent. This is 
due, in part, to the fact that insufficient attention has been paid by the public sector 
to managing intellectual property. This lack of focused attention must be corrected. 
Fortunately, there is growing interest, within both the public and private sectors, in 
putting intellectual property to work for public benefit, although concurrently, there 
is a lack of knowledge and capacity to use IP appropriately and responsibly. 
This Executive Guide and companion Handbook are designed to help address these 
complex needs. We hope the pages that follow (particularly the Key Implications and 
Best Practices) will encourage all parties to take greater advantage of the unprec-
edented opportunity to strategically manage intellectual property to especially benefit 
those who have been unable to benefit from technology. Seizing this opportunity will 
lead, in turn, to a healthier and more equitable world. ■
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Throughout this Guide, best practices refers to the strategies and approaches that 
the public sector in particular can employ to achieve its goals within an evolving IP 
framework. These proven ways that arguably represent the best or most innovative 
ideas in IP management can help the public sector better mobilize the resources to 
take products through the process of innovation, and collaborate with the private 
sector throughout that process. Best practices, therefore, include: 
• enactment of comprehensive national laws and policies
• formulation of institutional IP policies and effective IP management 
strategies
• application of creative licensing practices that ensure global access and 
affordability
• building institutional IP management capabilities
• the creation of functioning national IP systems that include efficient patent 
offices and transparent IP court systems 
It is important to note that the Key Implications and Best Practices throughout 
this Guide are intended as starting points to be adapted to specific institutional con-
texts and national circumstances. Some practices are evolving and will depend on 
context; but most are applicable across countries and continents, and within many 
institutional contexts.1
The pages that follow present in a highly condensed manner the Key Implications 
and Best Practices distilled from this Guide. They are presented in four parts and are, 
in language and content, specifically aimed at four different constituencies (who 
need to act in concert to make innovation work). These are: 
• Government Policymakers (see page 7)
• Senior Management (university presidents, R&D managers, etc.) (see page 10)
• Scientists (see page 14)
• Technology Transfer Officers (see page 18)
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We look forward to feedback on all of the best practices given in this Guide,2 and 
we encourage all parties to take greater advantage of the unprecedented opportunity to 
strategically manage intellectual property to benefit especially those who have, so far, been 
left behind. Seizing this opportunity will lead, in turn, to a healthier and more equitable 
world. ■
AnAtole KrAttiger, Research Professor, the Biodesign Institute at Arizona State University; Chair, bioDe-
velopments-International Institute; and Adjunct Professor, Cornell University, P.O. Box 26, Interlaken, 
NY, 14847, U.S.A. afk3@cornell.edu
StAnley P. KowAlSKi, The Franklin Pierce Law Center, 2 White Street, Concord, NH, 03301, U.S.A. 
spk3@cornell.edu and skowalski@piercelaw.edu
1 The publishers, editors, and authors have given their best efforts in preparing this publication, 
and, while we believe the Executive Guide (including the Handbook and the online version) will 
all be useful resources relating to intellectual property and the management thereof, the Execu-
tive Guide and the Handbook are not intended to serve as the sole source of information on the 
topic. Readers are advised to seek independent legal counsel and/or other professional advice for 
all intellectual property and contractual matters with regard to appropriate practices for specific 
situations and countries. No warranties or representations of any kind are made as to the accuracy, 
usefulness, or completeness of any suggestions or information provided in the Executive Guide. 
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tive Guide and Handbook. This comprehensive limitation of liability applies to all damages of any 
kind, including (without limitation) compensatory, direct, or consequential damages; loss of data, 
income, or profit; loss of or damage to property; and claims of third parties. All Web pages have last 
been accessed between 10 and 21 September 2007.
2 The online version (www.ipHandbook.org) contains, for each of the 153 chapters of the Handbook, 
a detailed Editor’s Summary, Implications, and Best Practices. These are more detailed than the 
summaries provided in this Guide. The Web site will also, in future, contain a blog and discussion 

























The Intellectual Property–Innovation Nexus 
4	 Whether viewed as a legal concept, a social construct, a business asset, or an instrument 
to achieve humanitarian objectives, intellectual property is an important driver of 
innovation. (p. 25)
4	 The use of the IP system, via balanced patenting and sound licensing strategies, can 
serve the public interest through private rights. This has profound implications for the 
management of innovation, technology transfer, market competition, and economic 
development in every country. (p. 25)
4	 Innovation is a complex process, stimulated by coordinated and structured policies and 
programs. An IP management system is one of six important factors in determining a country’s, 
or institution’s, ability to innovate. Others are R&D capacity of the public and private sectors; 
safe and effective regulatory systems; the ability to produce new products to high standards of 
quality; a national distribution system in both the public and private sectors; and international 
distribution systems and trade in technologies. (p. 25)
4	 Policies promoting the management of intellectual property by public sector institutions can 
advance the missions of these institutions, fostering creativity and innovation. (p. 25)
Public Sector Institutions and Intellectual Property
4	 When public research institutions own IP rights, they can use licensing to control how 
technology is deployed, meeting both commercial and noncommercial goals. (p. 35)
4	 Best practices in IP management will facilitate global access, provided the entire 
innovation process is considered from the outset. This includes a mission-driven mindset 
to establish optimum goals for the public sector. (p. 35)
4	 An important best practice by the public sector is incorporating humanitarian use 
reservation provisions in commercial licenses whenever possible. (p. 35)
4	 Public sector institutions should have IP policies and institutional capacity for 
implementing best practices in IP management. Licensors are more likely to grant licenses 
to institutions that respect and protect third party IP rights. (p. 35) 
4	 Public sector institutions need strategies that balance the public domain and IP rights. 
Commercial and humanitarian objectives are not in conflict, but rather are complementary, 
indeed mutually reinforcing, aspects of best practices in IP management. (p. 111)
Building IP Management and Technology Transfer Capacities 
4	 Technology transfer converts scientific findings into useful products or services for society. 
In the increasingly global economy, technology transfer collaborations are particularly 
effective when spanning geographic boundaries. (p. 73)
4	 Strategies for establishing and operating a TTO must be grounded in realistic economic 
expectations. Technology transfer will not make an institution rich. It takes time (ten 
years or more) to build an IP portfolio, establish contacts, and develop skills in technology 
transfer. Furthermore, a critical mass of R&D activity is necessary to justify the costs of a 
fully functioning TTO. (p. 73)
4	 Alternative models for an institutional TTO are possible. For example, costs can be shared 
among a consortium of universities or research institutions. Such hub-and-spokes 
configurations allow essential policy decisions and scalable functions to be centralized, 
while keeping essential context-specific functions localized. (p. 73)
4	 Technology transfer is a talent-based business. Building networks is essential for success. 
Governments should encourage the creation and operation of national technology transfer 
associations that concurrently build international linkages. (p. 73)
KEY IMPLICATIONS AND BEST PRACTICES 
FOR GOVERNMENT POLICYMAKERS
The page numbers refer to the page in this Executive Guide where the specific concept is discussed in detail.
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4	 Putting pressure on TTO officers to break even or to generate revenues can constitute a 
perverse incentive, forcing a TTO to go with up-front payments. (p. 101)
Statutory IP Considerations
4	 The statutory tools of IP (patents, copyright, trademarks, trade secrets, plant variety 
protection) are per se neutral; what matters is how these tools are used. (p. 57)
4	 Membership in the Patent Cooperation Treaty (PCT) will provide national institutions 
(public and private) with greater opportunities for international technology transfer, 
licensing, product development and penetration of global markets. Membership in the PCT 
can also provide for cost-effective examination of patent applications. (p. 111)
4	 Providing for legislation, or for amendments to current statutes, that facilitates patent 
filing by foreign entities can be an important component of technology transfer and 
development. (p. 111)
4	 Patent licenses are most valuable when coupled with access to associated know-how. Trade 
secret laws are thus conducive to the transfer of know-how through licensing. Patents and 
trade secrets are thus complementary forms of IP protection. (p. 121) 
4	 Successful licensing of crop varieties (and of accessing improved varieties from other countries) 
increasingly depends on the strength of plant variety protection legislation. Such legislation 
can support the interests of the variety owner and the farmer and also facilitate the transfer of 
technology and provides incentives for further investments. (p. 121) 
4	 Trademarks allow public and private institutions to capture value. To benefit from 
trademark strategies, internationally harmonized legislation is important, as is the 
maintenance of high quality standards and stewardship, since trademarks (and geographical 
indications) serve as indicators of source and quality. (p. 121) 
4	 Although IP rights are governed by national statutory protection, contract law is also 
important, as contracts are the legal mechanisms that structure the orderly exchange of 
intellectual property. (p. 121) 
4	 A functioning court system is essential to encouraging partnerships and to accelerate 
national and foreign investments. Indeed, suppliers of biological materials (and of confidential 
information and intellectual property) will be encouraged to enter into agreements if the 
suppliers are confident that their property rights will be protected and that agreements will 
be enforced. (p. 85)
4	 Pursuant to the TRIPS Agreement and the Doha Declaration provisions on parallel trade, 
countries can implement patent rights exhaustion regimes that either permit or 
restrict parallel importation. Despite the evident benefits of parallel trade, there are also 
disadvantages. (p. 163)
Public and Private Sector Intersections
4	 Product development partnerships (PDPs), essentially alliances between the public and 
private sectors, facilitate and accelerate the flow of public and philanthropic investment 
through the innovation pipeline. The ultimate measure of success should not be maximum 
profit but maximum social benefit. (p. 133)
4	 PDPs enable industry to invest and apply its expertise to address the needs of the poor. In 
many contexts PDPs are now driving the drug-development pipeline in neglected-disease 
R&D. National institutions in developing countries should be encouraged to participate in 
PDPs. (p. 45)
4	 Negotiating agreements between public and private sectors is an opportunity to forge a 
long-lasting and mutually beneficial relationship. But every partnership is different. National 
institutions need much latitude and flexibility to craft appropriate deals. (p. 133)
4	 Negotiation and technology marketing skills are fundamental for successful licensing and 
technology transfer. People working in the public sector generally need better negotiating 
skills, thereby enabling institutions to take advantage of their own R&D efforts and to 
realize broad public sector and commercial goals. (p. 133)
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Commercialization of Public Sector R&D
4	 Rather than venture capital driving the creation of new companies, it is usually the 
creation of new companies that attracts venture capital. (p. 143)
4	 While a government cannot legislate entrepreneurship, it can encourage entrepreneur-
ship by providing a favorable environment for creating and growing new companies. 
(p. 143, 153)
4	 Policies and legislation that benefit biotechnology companies and start-ups can 
accelerate the pace of innovation, particularly when it comes to commercializing public-
sector-generated inventions. (p. 133)
4	 Much of the success of a spinout or start-up will depend on the entrepreneurial spirit 
at the institution. The more entrepreneurial, the more likely it will be that someone wants 
to set up a new company. Spinouts can create jobs, enhance economic development and 
create international opportunities. (p. 143)
4	 Cluster formation fosters the movement of new technologies into existing industry. This 
requires a commitment to science education and research, a strategically situated anchor 
institution with a technology transfer office, and reliance on market forces as the engine 
for technology transfer. (p. 45)
4	 Governments can encourage regional economic development by fostering and financing 
business incubators. (p. 143)
4	 As intellectual property becomes more prevalent in health and agricultural research, public 
sector institutions need to consider the intellectual property of third parties. Knowledge 
of “who owns what” is needed. That is what a freedom to operate (FTO) analysis provides, 
facilitating the handling of products for further development or commercialization, even 
if the goal is to address the needs of the poor. (p. 153)
IP Dispute Resolution
4	 A country’s statutory code, combined with a reliable system of adjudication and 
enforcement, is the basis for enforcing IP rights. (p. 163)
4	 Alternative dispute resolution procedures for settling differences between parties to an 
agreement can be an effective strategy for public sector institutions. These procedures are 
particularly important in international contract dispute resolution. (p. 163)
4	 Governments and public institutions can help make arbitration or mediation procedures 
accessible by identifying and supporting neutral institutions that can provide cost-
efficient, timely dispute-resolution services. The World Intellectual Property Organization 
offers such services through the WIPO Arbitration and Mediation Center. (p. 163)
4	 IP protection mechanisms depend upon effective and equitable enforcement by national 
governments. This requires effective, transparent, and enforceable contract law. (p. 57)
Biodiversity, Traditional Knowledge and Bioprospecting 
4	 Indigenous communities often play a significant role as gatekeepers to a country’s 
biodiversity wealth. They are the regional specialists with respect to the flora and fauna. 
Their knowledge can often exceed that of leading scientists. (p. 173)
4	 Patent laws per se do not “create” biopiracy. Rather, biopiracy is a form of misappropria-
tion, unfair acquisition, and inequitable sharing of benefits with respect to biological re-
sources. (p. 173)
4	 Formulate procedures for equitable access to traditional knowledge held by indigenous 
societies. However, this requires balance: access should be granted only via authorized 
permission, yet the price that is assessed for permission to bioprospect should not 
dissuade potential development. (p. 173)
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KEY IMPLICATIONS AND BEST PRACTICES 
FOR SENIOR MANAGEMENT
(UNIVERSITY PRESIDENT, R&D MANAGER, ETC.)
Intellectual Property in the Innovation Context
4	 Benefits from public sector health and agriculture investments have tremendous global 
potential. Government-sponsored research can thus make a big difference in meeting the 
needs of the poor, nationally, regionally and globally. (p. 25)
4	 Intellectual property, as a tool to foster innovation, is a compromise, balancing the 
public domain with limited grants of ownership. An appropriate balance requires sound IP 
management and capacity to do so in the public sector. (p. 35). 
4	 Balancing public benefit and economic returns can be influenced through government 
policy. (p. 1). But decisions to place inventions in the public domain can only meaningfully 
be determined on a case-by-case basis. (p. 45)
4	 In order to fulfill both commercial and noncommercial goals, public research institutions 
can, through IP management and licensing strategies, control how their patented 
inventions are deployed and developed. (p. 25, p. 45)
4	 By working with their respective governments to implement national policies, public 
sector institutions can help establish a national IP system that fosters best practices in IP 
management in the public sector. (p. 93)
4	 Well-crafted contracts based on best practices can be instrumental in achieving global 
access, provided the entire innovation process is considered from the outset. Such an 
approach requires preparation, detailed knowledge, and a public sector mission-driven 
mindset. (p. 45) 
4	 The use of IP rights is not a panacea for the management of innovation, nor is the public 
domain. Both public and private goods have utility and limitations. The art of innovation 
management is in using both public and private goods and to manage the interface 
between them. (p. 111)
Institutional Mission and Policy
4	 A sound institutional IP policy typically addresses ownership, conflicts of interest and 
commitment, confidential information, broad IP licensing approaches, and IP generated 
revenues. (p. 65) Other important considerations include ethical guidelines for IP 
management (p. 35) and the reservation of humanitarian rights (also called philanthropic-
use provisions) on IP and the retention of research and teaching rights of all inventions 
and technologies. (p. 45, 121)
4	 An effective institutional IP strategy describes long-term goals and the allocation of resources 
necessary for their realization. Public sector institutions have much to gain by articulating how 
their IP management strategies foster global access to innovations. (p. 65)
4	 IP audits can be useful mechanisms that form the basis for an internal review and revision 
of an institution’s IP strategy and IP policy. (p. 65)
4	 Government policies ought to be flexible and enable research institutions to customize 
technology transfer strategies that align with the institutions’ missions. Different 
approaches will serve different types of research and academic organizations working 
within various disciplines and cultures. (p. 101)
IP Management Principles and Technology Transfer
4	 Technology transfer invariably brings conflicts of interest. These should not be viewed as 
negative. They can usually be managed in a transparent and consistent manner. (p. 65)
4	 Technology transfer and licensing are context-specific. (p. 35). Licensors, public or 
private, are more willing to license to institutions that consistently protect third-party 
property. This builds confidence and thereby promotes licensing and technology transfer. 
The page numbers refer to the page in this Executive Guide where the specific concept is discussed in detail.
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(p. 45) A successful approach is to allow maximum flexibility whereby institutions can 
set, or negotiate, the terms that best fit the mission and goals of the institution and the 
purpose of the partnership. (p. 85)
4	 The core element for successful technology transfer is people. The technology transfer 
office (TTO) should be led by an individual who understands the details of running a 
business. (p. 73). 
4	 Successfully establishing and operating a TTO will require visible and sustained 
support, financial and otherwise, from senior administration. Clear mandates will 
help technology transfer professionals choose among competing priorities. (p. 73). This 
includes the implementation of rigorous IP-related policies and procedures. (p. 57) Above 
all, it requires TTO officers’ ability to assume risks knowing that they have backing from 
senior management. (p. 73)
4	 A critical mass of R&D activity is necessary (typically $100-$500 million) to justify the costs of 
a fully functioning TTO. Consortium approaches to technology transfer can ameliorate this 
imposing initial requirement by pooling resources and expertise. (p. 73)
4	 For companies, the ultimate purpose of IP management is to enhance competitiveness 
and reduce risk. For public sector institutions, the purpose of IP management should be to 
serve the greater public interest. These are not mutually exclusive goals, and they can be 
reconciled through sound technology marketing and licensing practices. (p. 133)
4	 Scientists should be encouraged to use public domain technologies as research 
inputs whenever feasible to reduce possible future constraints in the downstream 
commercialization of innovations. In many circumstances, however, relying on patented 
technologies may be the more effective way to go, particularly when the goal is to develop 
products. (p. 111)
4	 Building strong institutional capacity in IP management will enable technology managers 
and scientists alike to understand the complex array of options that should be considered 
before publishing research results or filing patent applications. (p. 111)
4	 An important element during the development of an IP strategy is to document the 
technologies that already exist in the organization, plus those technologies in development. 
This can be achieved through an IP audit, among other approaches. (p. 111)
4	 Management should encourage good laboratory practices and diligent record keeping of 
data to ensure that research can later be used in possible regulatory filings. Doing so could 
lower costs and reduce the time to market. (p. 111)
4	 To benefit from trademark strategies, the maintenance of high quality standards is 
important, since the trademark (brand) indicates the source and quality of the product. 
(p. 121) 
Supporting Entrepreneurship
4	 The creation of business incubators as a tool for stimulating local economic development 
should not be underestimated. Incubated companies have a dramatically higher rate of 
survival than the average spinouts. (p. 143)
4	 A spinout often creates enhanced opportunities for its faculty. If spinouts remain in 
the region, faculty inventors can remain active as consultants. Also, a university’s success 
with spinouts can attract new talent. But much of the success will depend on the 
entrepreneurial spirit at the institution. The more entrepreneurial, the more likely it will 
be that someone wants to set up a new company. (p. 143)
4	 If public sector institutions found ways to reduce the risk of investing in agricultural 
projects, more venture capital would be attracted. (p. 143)
4	 Rather than venture capital driving the creation of new companies, it is usually the 
creation of new companies that attracts venture capital. (p. 143)
4	 Robust innovation clusters require a commitment to science and entrepreneurship, a 
strategically situated anchor institution, and reliance on market forces as the engine for 
technology transfer. Cluster formation will strengthen the ability of local and national 
economies to absorb new technologies into existing industry or entrepreneurial 
sectors. (p. 25) 
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Licensing
4	 Nonexclusive licensing can be a strategy to maximize the utilization of research tools. 
Exclusive licensing, on the other hand, can be quite effective for broad dissemination of 
patented products, particularly when coupled with milestone clauses. Complementary 
strategies are market segmentation, field-of-use licensing, and the negotiation of tiered 
pricing clauses. (p. 45)
4	 The dual goals of economic growth and social/humanitarian benefits through licensing 
are not mutually exclusive. Indeed, they are often complementary. Much will depend on a 
sound institutional licensing strategy and on good relationships with licensees. (p. 121) 
4	 Business decisions, more than legal aspects, should determine licensing terms. Nevertheless, 
lawyers should ensure that the contracts comply with prevailing law. (p. 121) 
4	 Confidentiality agreements rely on a culture of trust, not a culture of secrecy. They protect 
sensitive information transferred between parties, and, when well managed, and are not 
inconsistent with public sector missions or the publication of research results. (p. 85) 
4	 Patent licenses are most valuable when coupled with access to associated know-how, 
which is often shared under confidentiality provisions. Comprehensive staff training in the 
handling of confidential information from third parties is therefore critical. (p. 121) 
4	 Specific best practices in licensing terms that allow public sector entities to meet public 
sector goals (ensuring broad access to innovation) include area of use, territory, price, 
labeling, white-knight conditions, and royalties. (p. 133)
4	 The key to successful negotiation is having a clear understanding of the value each party 
brings to a relationship. Value may be monetary or non-monetary. (p. 133)
4	 Negotiating between public and private sectors ought not be confrontational, but as 
a first step in a long-lasting and mutually beneficial relationship. Negotiating a fair 
licensing agreement should thus not be seen as a process of “bargaining” toward a win-
win outcome. (p. 133)
4	 For the public sector, a well-tested and successful approach to negotiating an agreement 
is to offer initial terms to a company that the public sector organization itself would be 
willing to agree to if it were on the other side of the negotiating table. (p. 133)
4	 Senior management can set a positive tone for negotiation that will ensure that deals made 
with others are a vehicle for building strong relations and trust between parties. (p. 133)
4	 Networking is essential for successful technology marketing. Technology transfer officers 
and scientists particularly should be encouraged and given opportunities to network. (p. 133)
Managing Risk, Maximizing Benefits
4	 As public sector and nonprofit institutions pursue product development, freedom to 
operate (FTO) will become a strategic component in an organization’s risk-management 
strategy. Implementing the strategy requires clear pathways of communication and 
dialogue between science managers, product development, licensing personnel, counsel, 
and senior management. (p. 153)
4	 FTO is an interdisciplinary endeavor and considered within the context of the institution’s 
mission, business development, research and technology transfer, and tolerance for risk. 
(p. 153)
4	 The more downstream a research-based institution operates, the more important FTO 
considerations become. A system should be in place to help decide whether, when, and how a 
public sector institution should conduct or commission a legal FTO opinion. (p. 153)
Maintenance of IP Rights
4	 It is important to have the flexibility to opt for legal action if this seems to be in their best 
interests. But legal action is often complex due to cost, length of procedure, uncertainty as 
to outcome, confidentiality/publicity, the difficulty of seeking action in foreign jurisdictions, 
and the negative impact on existing business relationships. (p. 163)
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4	 Encouraging alternative dispute-resolution procedures can be a viable strategy and, 
indeed, often a preferred one, for settling differences between parties to an agreement. 
These are particularly important in international contract dispute resolution. (p. 163)
Biodiversity, Traditional Knowledge: Access and Equity
4	 There is a strong interaction between bioprospecting activity and national scientific 
capabilities. In countries with strong scientific capability, bioprospecting is robust. 
Moreover, such capacity increases the negotiating strengths and benefit-sharing 
opportunities. (p. 101)
4	 The technology transfer office should work with senior management to establish policies 
and systems for accessing indigenous or traditional knowledge (TK), bioprospecting 
activities, and benefit sharing in an equitable manner. (p. 173)
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Inventions, Inventors and Innovations
4	 Research is one of the very foundations of innovation. Research leads to discovery; 
discovery fosters invention; inventions nourish innovation. Your work is part of a larger 
innovation process that spans R&D across the public and private sectors. (p. 35) As the 
creator of inventions and technologies, your role in technology transfer is critical. (p. 65) 
So please read on! 
4	 As a scientist, you recognize the interconnected web of science, R&D, technological 
advance, and commercial investment. Take the time to share these insights with your 
institution’s technology transfer office (TTO) and its senior managers. (p. 25)
4	 Determining how to translate an invention into an innovation that makes a difference in 
people’s lives (economically or socially) is one of the principal reasons TTOs exist. (p. 101)
4	 The emerging global system of innovation in health and agriculture creates 
opportunities worldwide. This key concept, that public interest can be served through 
private rights, has profound implications for the management of innovation, technology 
transfer, market competition, and economic development in every country, regardless of 
its economic status. (p. 35)
4	 Countries engaged in reforming their R&D and technology transfer efforts often include 
royalty-sharing provisions for scientists in publicly funded research institutions. This 
often requires assignment of ownership rights to the institution and a duty to disclose 
inventions. This should be seen as an incentive to turn inventions into innovations that 
benefit society. (p. 25)
4	 While access to foreign technology is integral to development, it is also important to focus 
on capturing the national innovation potential of any country. Through the activities of 
your research program, you may be positioned to facilitate the development of indigenous 
innovation and traditional knowledge. (p. 25)
4	 Your continued interest in your invention’s development is important. This will help it 
reach the marketplace, and especially benefit those who most need it, yet can least afford 
it. (p. 35) Hence, as the inventor, you can significantly influence how your technology is 
used. For example, you might request that licenses reserve your right to continue research 
using your inventions or reserve rights for humanitarian uses of your technology. (p. 45)
4	 Collaboration with private sector entities can significantly contribute to your institution’s 
broader participation in innovative initiatives, particularly product development. (p. 45) 
Networks
4	 Collaborations create contacts. Contacts build networks. Networks provide opportunities. 
(p. 133)
4	 Collaboration is often based on establishing personal contacts and building strong 
professional networks; these foster the formation of collaborative research projects 
and are fundamental for effective sharing of know-how and show-how. (p. 25, 73) 
Accessing other’s intellectual property can be facilitated through networks of committed 
professionals. (p. 45)
4	 Keep your TTO informed about your networking activities, particularly if there is a possibility of 
shared research endeavors. These collaborative research projects, and your network in general, 
can be starting points for technology transfer and licensing. (p. 73, 173)
IP Management
4	 Your role can best be carried out if you have good relations with your TTO. But fulfilling 
your role also requires an understanding of your institution’s IP policy. The policy will 
likely articulate ownership of intellectual property, conflict of interest, the handling of 
confidential information, and more. (p. 65)
KEY IMPLICATIONS AND BEST PRACTICES 
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4	 The purpose of such a policy, and more importantly of your institution’s IP strategy, is 
not just to protect your inventions, but also to control technologies and IP assets such 
as to determine how these can be managed to spur economic growth and contribute to 
the greater public good. If your institution does not “own” anything, how can it place 
conditions upon its use? (p. 65)
4	 As your institution implements IP policies and patenting strategies, your right to publish 
is not jeopardized. IP protection and licensing are but one form of knowledge transfer 
that, if well undertaken, can very much be in the public interest. (p. 25)
4	 Philanthropic donors increasingly expect to find IP management components in grant 
applications and to understand how intellectual property will be used to achieve global 
access and humanitarian benefits. This is one reason why a close relationship with your 
TTO is important since your colleagues at TTOs may increasingly be required to prepare 
access strategies as part of your grant applications. (p. 65)
4	 When your institution conducts or commissions an IP audit, view this as an opportunity 
to better identify the intellectual property generated in your research program, to improve 
and streamline the management of third-party intellectual property (allowing you to 
concentrate more on research), and to contribute to the formulation and execution of an 
IP strategy that benefits your program and its global impact. (p. 65)
4	 It is your responsibility to disclose any potential conflict of interest. Know your institutional 
conflict of interest policy. Most conflict of interest issues arise when procedures are not 
properly followed. (p. 73) You are not guilty of anything if you have a potential, perceived, 
or even real conflict of interest. It is only a matter of “managing” these conflicts. (p. 65)
4	 Everyone in your group or laboratory should know the obligations entered into through 
any agreement that affects your program. (p. 85)
4	 Increasingly contracts will include milestones. Research schedules and goals may be 
directly linked to specific milestones, and you need to know how such milestones might 
impact your program. (p. 45)
4	 Published information, or research tools provided by a colleague, may be covered by IP 
rights. This should neither deter nor distract you from good science. An awareness of 
basic IP management best practices will help you to understand and identify potential 
IP issues. (p. 111) Encourage your TTO to organize occasional seminars on the basics of 
IP management. This will facilitate communication with your TTO staff and answer your 
questions about IP management. (p. 93)
Laboratory Notebooks and Records
4	 Good data management and accurate record keeping through comprehensive laboratory 
notebooks (p. 163), is the foundation for building a portfolio of IP assets. Essentially, best 
practices in scientific record keeping should be precisely the same as best practices in 
record keeping for purposes of IP management. (p. 57, 93)
4	 The confidentiality of your data may be critical in ensuring global access. Data is a valuable 
form of intellectual property that can be used in licensing negotiations. (p. 57)
4	 Confidentiality agreements are meant to protect sensitive information exchanged 
between parties and are not inconsistent with public sector missions or research 
publication. Confidentiality agreements rely on a culture of trust, not a culture of 
secrecy. (p. 85)
4	 Make an especially strong effort to document the origin of biological and other materials 
you use in your research, and keep a comprehensive record. (p. 121) 
Invention Disclosures and Patenting
4	 Recognize when you actually have an invention (it is generally much, much earlier than 
most scientists think)! Invention disclosures are the first step in protecting intellectual 
property. Disclose early and often. But expect only a small portion of your invention 
disclosures to lead to patent applications. (p. 93)
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4	 By filing an invention disclosure with your TTO, you are initiating a dialogue. Even if the 
TTO does not immediately file a patent based on your first invention disclosure, it is a 
process that has started, and follow-up will be much easier. (p. 93)
4	 Invite your TTO liaison to visit your laboratory occasionally and discuss with you and 
your research team what you have been doing. Discussions with technology transfer 
experts, especially patent attorneys, can help you to identify inventions. (p. 93)
4	 If patenting and public disclosure are your goals, consult with your institution’s 
technology transfer manager prior to disclosure. Your institution should have a mechanism 
to determine whether or not a patent should be filed without significantly delaying 
publication. Just be aware that premature publication can lead to a loss of IP rights. (p. 
111)
4	 Patents often disclose more technical and scientific information than academic 
publications. Read published patent applications or issued patents in your field. You can 
access this information for free on the Internet. (p. 57)
4	 Your institution’s technology transfer managers will need your input in order to make 
strategic decisions about where to pursue foreign patent applications. You likely know 
where different competitors are located and where products arising from your research 
are needed. (p. 111)
4	 When you disclose an invention to your TTO officers, inform them of any ideas you may 
have on the various fields of endeavor in which your invention could find applicability. 
This will help the TTO plan patent applications and later design license agreements under 
different field-of-use licenses. (p. 121) 
Licensing Inventions and Marketing Technologies 
4	 The “unique selling proposition” of your invention or technology (the features, 
advantages, or benefits it offers) may not be the science behind the technology, but your 
invention’s use. (p. 133)
4	 Technology marketing is a process by which owners of a technology create relationships, 
between themselves and potential users, which will drive technology development and 
availability, through commercialization or other methods. (p. 133)
4	 When speaking to potential licensees or investors, it is often best to, in extremely simple 
language, stress the potential applications of your invention rather than the superb 
science. (p. 133)
4	 Your role in field-of-use licensing is essential. You can provide your TTO with valuable 
information on licensable components for different applications and entities. (p. 121) 
4	 In agreement negotiations, your role may be to share relevant information, advice and 
insights. In some cases, especially with collaborative research agreements, you may be an 
integral member of a team that will address issues such as research plans. (p. 85)
4	 Detailed aspects of negotiations, such as collaboration or license agreements, are 
conducted by the relevant offices of your institution. However, do participate in the 
internal discussions prior to licensing negotiations. Your input will be important and 
should be valued. (p. 121) 
4	 Material transfer agreements are tools for gaining greater access to tangible materials 
from a number of sources (scientists from the public and private sectors, both in your 
own country and abroad). (p. 85)
4	 In most institutions, you will not be authorized to sign most agreements without review 
by counsel or by your TTO. Know whether or not you are authorized to sign a given 
agreement. (p. 85)
4	 Understand the obligations that are attached to different funding sources. The impact of 
joint public and private financial support can be complex but will increase, particularly 
as your institution positions itself strongly within an innovation cluster and engages in 
product development. (p. 25)
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4	 Not all university inventors are entrepreneurs interested in being company founders, 
and not all spinout company founders from a university are the technology’s inventors. 
Involvement as a company founder entails a greater degree of risk and commitment to 
move an invention to commercialization. (p. 143)
4	 Much of the success of a spinout or start-up will depend on the entrepreneurial spirit at 
the institution. The more entrepreneurial, the more likely it will be that someone wants to 
set up a new company. (p. 143)
4	 Venture capital investors combine a broad view of the market with solid technical expertise. 
Venture capital investors can be great allies, but will impose, for good reasons, distinct conditions 
on the project. Be open, patient, and willing to work with investors. (p. 143)
Freedom to Operate
4	 Collaboration among scientists and the professionals who conduct freedom to operate (FTO) 
analyses is essential. The scientist can explain the science and technology to help others 
understand the materials and methods. A scientist is the expert in the area of research and can 
provide important leads to other scientific groups and publications. (p. 153)
4	 Teams conducting FTO analyses will also need to understand precisely what the product 
is, how it was developed, what materials were used, and what reports were prepared. The 
purpose is to ascertain that all relevant information has been considered in the FTO analysis. 
(p. 153)
4	 The results of an FTO analysis may allow you to make better use of technologies in the 
public domain and inform your choice of research tools or vector constructs. The analysis 
also may alert you to scientific discoveries and inventions related to your work. (p. 153)
4	 Knowledge of how to access, manipulate, and mine patent and publication search tools 
for valuable information will serve you and your program well. Hence, become versed in 
Internet database search skills, and ask your TTO to organize short patent search workshops. 
(p. 153)
Maintaining IP Rights and Obligations
4	 As a scientist, you should regularly review all of the agreements that relate to your projects. 
This specifically includes ensuring that milestones are met, royalties paid, and that any 
other obligations are taken care of. (p. 163)
4	 Your institution should continuously monitor patent infringements through various 
surveillance protocols. A lack of patent enforcement can lead to a loss of patent rights. Your 
role in this is important, since you are well connected in the area of your research and can 
indicate to the TTO which companies might be practicing your inventions. (p. 163)
4	 If your institution conducts alternative dispute-resolution procedures such as mediation or 
arbitration, you might be called upon to participate, particularly if aspects of your research 
program are involved in the ongoing discussions. (p. 163)
Biodiversity, Bioprospecting, and Traditional Knowledge
4	 When working with colleagues from foreign countries, be aware that those colleagues 
may be authorized to make collections of biological materials only under specified 
circumstances, ensuring fair and equitable terms with prior informed consent (p. 101.) 
Before proceeding with joint activities, check with your institution’s TTO to make sure that 
all the requirements have been met. (p. 173)
4	 Scientists and anyone else accessing biodiversity must ask, and answer, the following 
questions prior to initiating collecting activities: Under which conditions may I enter 
another sovereign state’s territory in my scientific capacity? Under which conditions may I 
collect biological material and related information? Under which conditions may I carry out 
or export biological material and related information from that sovereign state’s territory? 
Under which conditions may I make further use of collected biological material and related 
information? (p. 173)
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KEY IMPLICATIONS AND BEST PRACTICES 
FOR TECHNOLOGY TRANSFER OFFICERS
The Innovation Landscape and Intellectual Property
4	 The emerging global systems of innovation in health and agriculture open up new 
prospects for innovation everywhere. This has profound implications for the management 
of innovation, technology transfer, market competition, and economic development in 
every country. (p. 25)
4	 Innovation is complex and integral to all six components of innovation: IP management, 
R&D in the public and private sectors, safe and effective regulatory systems, the ability to 
produce new products to high standards of quality, a national distribution system in both the 
public and private sectors, and international distribution systems and trade in technologies. 
Consider this entire innovation process when making patenting and licensing decisions. 
(p. 25)
4	 The use of IP rights is not a panacea for the management of innovation, nor is the public 
domain. Both public and private goods have utility and limitations. The art of innovation 
management is in using both public and private goods and to manage the interface 
between them. (p. 111)
The Role of the Technology Transfer Office
4	 The traditional mission of technology transfer offices (to bring university-generated 
intellectual property to benefit the public) is broadening, reaching the global community. 
Technology transfer also enhances the reputation of academic institutions and facilitates 
their missions of education, research, and community outreach, ensuring social impact. (p. 
25, 45)
4	 A TTO is responsible for creating incentives to move discoveries toward product development 
by motivating public sector researchers, not by a promise of revenue streams, but by the 
satisfaction of seeing their work applied to serve the public good. (p. 45)
4	 The primary role of a technology transfer office should not be the generation of financial 
returns; they can take years to come. Be realistic when making forecasts about expected 
income; a positive return can take eight to ten years to achieve. (p. 45)
4	 Your role in communicating the use of IP tools and the benefits of good IP management is 
critical, thereby cultivates an IP management “culture” throughout the organization. Such 
communication should be directed to senior management, your institution’s board, and to 
scientists. (p. 57, 153)
IP Policy and IP Strategy 
4	 An IP policy should address, at a minimum, ownership of intellectual property, conflicts 
of interest and conflicts of commitment, the handling of confidential information, the 
principles of IP licensing approaches, the sharing of income derived from intellectual 
property, and any rights the institution will retain (such as for research and for humanitarian 
uses). (p. 65)
4	 An institutional IP strategy addresses how IP management will be used to achieve global 
access/humanitarian benefits of the inventions and products developed at an institution. 
It should include how the institution deals with incoming third-party intellectual property, 
how it deals with internally generated intellectual property, and how it will out-license its 
intellectual property to third parties. (p. 65)
Agreements and their Uses
4	 A public sector institution can use a variety of agreements to both manage and protect 
intellectual property, regardless of whether that intellectual property is owned by the public 
sector institution or by licensing partners in the private sector. The key issue is to allow for 
The page numbers refer to the page in this Executive Guide where the specific concept is discussed in detail.
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maximum flexibility whereby institutions can set, or negotiate, the terms that best fit the 
mission and goals of the institution and the purpose of the partnership. (p. 85)
4	 A template agreement should be used only as a starting point for discussions. (p. 85)
4	 Contracts should be tailored to fit local customs and business practices. Be sensitive to 
cultural and linguistic differences between parties to a contract. (p. 85)
4	 Your office ought to be the official repository of all agreements dealing with incoming and 
outgoing biological materials. (p. 85)
4	 Legal jargon in agreements should be avoided. Instead, use short, clear sentences that are 
free of vague adjectives and are written in the active voice. (p. 85)
4	 Confidentiality agreements rely on a culture of trust, not a culture of secrecy. Make sure that 
confidentiality agreements contain the necessary exceptions appropriate for the mandate 
of your institution. (p. 85)
4	 When negotiating collaborative research agreements, involve scientists. Their input will be 
critical at various stages of the process. (p. 85) 
Some IP Management Nuts and Bolts 
4	 Conduct occasionally comprehensive IP audits to determine where your IP assets are, when 
IP protection is needed, whether there are potential IP liability issues, whether there are 
licensing needs and/or opportunities, and whether there are inventions to be harvested. 
(p. 157) IP audits can be useful mechanisms that form the basis for an internal review and 
revision of an institution’s IP strategy and IP policy. (p. 65)
4	 Technology transfer invariably brings conflicts of interest. The challenge is to manage them 
in a transparent and consistent manner. Most problems arise when potential conflicts are 
not disclosed. (p. 65)
4	 All employees (and visitors in some cases) should be required to sign an invention assignment 
agreement on their date of arrival. (p. 65)
4	 Any TTO will have a wide range of legal matters to be addressed, and procedures for working 
with external patent and general counsel should be well established. (p. 73)
4	 Many technology valuation approaches exist. None is perfect. Considering that each deal 
is highly context specific, each technology transfer office should be able to select the best 
approach and adapt it to the specific circumstances. (p. 101)
4	 When devising a patenting strategy, you will need to make three decisions: First, should you 
seek patent protection? Second, what is the best patent-marketing approach? Third, what 
license fees and/or royalties ought to be levied? (p. 101)
Modes of IP Protection
4	 Trademarks are a critical, and often overlooked, option for IP protection. They can be used as 
stand-alone IP protection, or they can be integrated into an overall strategy for integrated IP 
protection. (p. 57)
4	 Because public-domain technologies play an important role in publicly funded research, 
defensive publishing can increase accessibility of technologies in the public domain. 
Scientists need your help to ensure that such disclosure truly places the invention into the 
public domain. (p. 111)
4	 There are advantages in filing provisional patent applications (such as controlling costs and 
providing additional time for weighing options as to whether it is worthwhile to pursue a 
full patent application) but beware of the downsides. (p. 111)
4	 For any invention, evaluate whether foreign patent rights are truly required. Keep in mind 
possible applications in developing countries; a patent may be critical to ensure access. This will 
require a combination of business, marketing, and legal analyses. (p. 111)
Licensing Inventions and Technology
4	 Both nonexclusive and exclusive licenses can be applicable to meeting socio-economic 
goals. Within exclusive licensing, there are many options, such as exclusivity limited to a 
certain field of use, or geography, or for limited periods of time. (p. 35)
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4	 Reserving rights for humanitarian use may require additional work and will likely not 
generate licensing revenue; conversely, such provisions, if used in a strategic way, are 
unlikely to lead to loss of revenues. (p. 35)
4	 Though potentially useful, IP managers should be cautious of imitating open licensing 
procedures in the field of biotechnology. It is still unclear to what extent the software 
models of open source can be adapted to other technological fields. (p. 35)
4	 Any organization engaged in high-volume licensing will find it useful to develop its own 
internal template agreements that are then modified and adapted to suit each special 
circumstance. Checklists for different types of recurring licensing negotiations should 
be reviewed prior to and during negotiations. (p. 121) For the licensing of plant varieties, 
certain software may be useful (p. 123)
4	 Field-of-use licensing should be adopted as the preferred method of licensing whenever 
possible. It allows you to gain greater control while maximizing the use and value of your 
licensed technology. (p. 121) 
4	 In a license agreement, the rights (or prohibitions) to sublicense and assign a license 
ought to be explicitly articulated. (p. 121) 
4	 Licensee agreements are contracts. Hence, a practical understanding of contract law 
will be fundamental to negotiating and drafting good license agreements. TTOs can ask 
counsel to ensure that agreements are compliant with national law. (p. 121)
Milestones
4	 Creative licensing strategies will help your institution gain the greatest benefits from the 
research it conducts. Such strategies include, at a minimum, the balancing of exclusive 
and nonexclusive rights, defining field of use, setting appropriate milestones, requiring 
the delivery of products to developing country markets, and exercising control over pricing. 
(p. 25)
4	 The public sector must specify in writing exactly what it wants to accomplish with 
a commercial partner, detailing when and how this will be achieved by articulating 
milestone obligations. (p. 35)
4	 Avoid “best effort” clauses in agreements. Instead, draft comprehensive contracts with 
articulated milestones. This up-front investment will pay off later if a problem arises. (p. 35)
4	 Developing meaningful milestones that provide the appropriate balance of incentives, 
rewards, and penalties requires detailed preparations, a sound understanding of the 
processes related to developing and marketing the product, realistic forecasting of product 
potential, and a mission-driven mindset. (p. 35)
“Moving” Technologies to the Market
4	 One of your responsibilities will be to bring together individuals with different backgrounds 
and experiences before negotiating agreements. Ideally, a team should include business 
strategy, marketing, legal, scientific, regulatory, production, and finance expertise. (p. 
133)
4	 Marketing inventions should not simply be a push of technologies; rather, it should be an 
approach that allows the needs of buyers to pull inventions. (p. 133)
IP Management and Entrepreneurship 
4	 One of the most important factors for a successful TTO is the institution’s entrepreneurial 
culture. This is strongly influenced by the attitude and degree of support from senior 
management. (p. 73)
4	 Spinouts carry a number of risks, but with certain factors in place they can represent the 
best opportunity for developing early-stage technology. (p. 143)
4	 Potential investors in a spinout will ask two major IP questions. Could previously existing 
intellectual property block the technology? Could your intellectual property dominate the 
market and prevent entry by others? (p. 143)
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4	 When licensing to or creating new ventures, several key attributes are essential for 
attracting venture capital investment: a strong management team, a viable technology, 
a strong IP position, a large potential market, and location in an environment favorable for 
entrepreneurship. (p. 143)
4	 New ventures in developing countries have much to gain by attracting and building on 
international investor networks. They have the potential to open new markets and bring 
in new alliances. (p. 143)
4	 It is often appropriate to strike a balance between reliance on licensing-out to existing 
companies and investing time and resources in creating new companies. (p. 143)
Risk Management and Freedom to Operate (FTO)
4	 The role of the technology transfer officer, and that of attorneys who may produce legal 
FTO opinions, is generally to advise senior management on risks. It is a manager’s purview, 
based on your input, to decide how to deal with the risks identified in your FTO analysis. 
(p. 153)
4	 A freedom to operate (FTO) analysis is an interdisciplinary endeavor best executed through 
FTO teams. These teams, made up of legal, business, and scientific professionals, are in 
themselves useful for strengthening intra-institutional dialogue and communications. 
(p. 153)
4	 For an academic or public institution, legal FTO opinions are unlikely to be needed for the 
majority of technology transfer functions. They would be relevant only if the institution is 
engaged in downstream product development and commercialization. (p. 153)
Monitoring and Protecting Intellectual Property 
4	 Potential patent infringements should be monitored continuously through sound 
surveillance protocols, and action taken to remedy infringement is an essential part of IP 
asset management. The lack of patent enforcement can lead to a loss of patent rights. (p. 
163)
4	 Early communication with potential infringers and good license and licensee diligence, 
are the foundations for policing and maintaining intellectual property, irrespective of 
whether the intellectual property is owned by a public or a private entity. (p. 163)
4	 Essential to contract management is a well-organized electronic filing system. A TTO 
should establish such a system as early as possible and before the number of agreements 
and licenses becomes large. An agreement management system (donated by the 
Whitehead Institute for Biomedical Research) is available on the Handbook’s Web site for 
download. (p. 163)
4	 Most IP disputes should not end up in litigation, as there are many options and strategies 
for resolving disputes. Good contracts and good licensing practices anticipate that disputes 
arise with partnerships and licenses. (p. 163)
4	 Mediation and arbitration can be effective dispute-settlement procedures, provided they 
have been agreed upon and established in contract clauses at a time when a license or 
partnership is being negotiated—and before any problems arise. (p. 163)
4	 A technology transfer office must have systematic procedures to administer, monitor, 
and enforce its technology licenses. This includes compliance with royalty payments and 
reporting obligations in a non-confrontational manner. (p. 163)
IP Training and Capacity Building
4	 When scientists learn the basics of IP management, communications with the technology 
transfer office will improve. Public sector institutions should offer training to every scientist, 
student researcher, and technicianwhen they join an institution. (p. 93)
4	 Part of the aim of IP management training is team building that encourages communication 
between your office and the scientists in your institution. It is part of creating a culture of 
IP awareness and particularly useful to encourage invention disclosures. (p. 93)
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4	 It is good practice to include senior management as participants in the training sessions. 
This is especially useful when the training program includes case studies. (p. 93)
Intellectual Property, Bioprospecting, and Traditional Knowledge 
4	 The technology transfer office should work with senior management to establish policies 
and systems for accessing indigenous or traditional knowledge (TK), bioprospecting 
activities, and benefit sharing in an equitable manner. (p. 173)
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public sector entity, whether in a developing or 
developed country, for addressing neglected dis-
eases, for alleviating poverty, for development in 
agriculture, and for eliminating chronic malnutri-
tion. Mahoney and Krattiger discuss how, within 
the rapidly evolving global IP landscape, public 
sector institutions can better mobilize resources 
in order to accelerate products through the inno-
vation pipeline through best practices in IP man-
agement. These best practices include creative 
licensing practices that ensure global access and 
affordability, improved institutional IP manage-
ment capabilities, the formulation of compre-
hensive national IP policies, and the strengthen-
ing of IP court systems and patent offices.
Recent national and international changes in 
IP treaties, legislation, and frameworks are hav-
ing profound effects on innovation systems and 
on how public and private research and develop-
ment institutions implement their missions and 
how health and agricultural innovations reach the 
poor. Seen within this broader context, intellec-
tual property is one of six interrelated compo-
nents of innovation management3 that focuses 
on developing a variety of issues: 
•  R&D capability by the public and private sectors
•  safe and effective regulatory system that covers 
drugs, vaccines, and agricultural products
•  manufacturing capability for health products 
and for the inputs into and outputs of agri-
cultural production
EXECUTIVE GUIDE TO HANDBOOK SECTION 1
(VOLUME 1: PAGES 3-38)
The pressures on innovative organizations and 
countries are many and varied—economic, tech-
nological, organizational, environmental, politi-
cal, and societal. Leaders of public sector institu-
tions and private companies have limited control 
in most of these areas. But a leader of any entity, 
public or private, can exercise a high degree of con-
trol over the entity’s own intellectual property (IP) 
through sound IP management and critical tools to 
accelerate innovation. Section 1 of the Handbook1 
presents an overview of innovation and IP man-
agement, which are the focal points of the entire 
Handbook, and logically, the Executive Guide. 
IP rights are a critical tool for fostering in-
novation. Managed judiciously, they balance pri-
vate rights and public necessity in a manner that, 
overall, encourages innovation. The first chapter 
of the Handbook, by Mahoney and Krattiger,2 
directly addresses the paradox that underlies the 
Handbook: the pursuit of the public interest 
through private rights. Focusing on the life sci-
ences, the chapter asks how IP rights can best be 
managed to promote public welfare. It finds an 
answer, not in the system of IP rights, but in the 
judicious and skillful use of proprietary science. 
In short, the authors argue that creative manage-
ment of IP rights, especially by public sector insti-
tutions, is essential for achieving public benefits.
Understanding how intellectual property 
fits into the much broader context of innovation 
and product development is important for any 
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•  expansion of national health or agricultural 
delivery systems, including an attractive, 
private sector domestic market for health 
or agricultural products and services
•  international trade systems for health prod-
ucts (including global procurement funds) 
and agricultural inputs and outputs; and an 
IP system (legal framework, judiciary to en-
force it)
•  institutional management capabilities
The authors raise important questions and 
make significant proposals, framing IP manage-
ment within a global context. This global ap-
proach is inexorably spreading and expanding at 
an accelerating pace. Because of the increasing 
interaction between developed and developing 
economies and the increased number and com-
plexity of relationships between the public and 
private sectors, understanding the best ways to 
forge and maximize partnerships has a high pri-
ority. Such partnerships will be the engines that 
drive global innovation. 
The chapter further reviews recent dramatic 
developments in the institutional aspects of intel-
lectual property, as well as global policy shifts and 
international case studies. In the field of health, 
changes have been particularly pronounced with 
the founding of a novel form of institution for 
innovation: product-development partnerships 
(PDPs). Mahoney and Krattiger make the case for 
a fundamental shift in the way IP management in 
health and agricultural innovation is viewed and 
conducted: the public sector can employ new 
ways to achieve its goals within the evolving IP 
framework. In response to rapid global evolu-
tion, nongovernmental organizations (NGOs) 
and PDPs will have important roles to play in the 
global IP environment, particularly for develop-
ing countries. 
It is well established that intellectual proper-
ty advances product development because intel-
lectual property provides incentives for R&D, 
commercialization, and product distribution. 
Investors in biotechnological R&D naturally 
want to protect their investments, and must, 
therefore, secure IP rights for their inventions. 
Before the creation of IP rights protection, the 
private sector had little incentive to develop safe 
and efficacious pharmaceuticals. Historically, 
the public sector had neither the funds nor the 
capability to develop products. Yet, the world is 
changing. As the public sector devotes more of its 
efforts to humanitarian missions, and engages in 
more development partnerships (such as PDPs) 
in the fields of health and agriculture, it will also 
have to consider the critical role of intellectual 
property in a broader innovation context. 
The permanence of intellectual property is 
evident. If the public sector does not effectively 
utilize the IP system, it will neither be serving 
its own interests nor the interests of those it has 
promised to serve. Without effective IP manage-
ment skills, the public sector risks squandering 
the rights, powers, and opportunities that the IP 
system provides. Intellectual property is a tool, 
and, like all tools, its impact depends on how 
it is used, who uses it, and for what purpose. IP 
strategies can serve to either restrict or expand 
access to innovations; it’s all a matter of capac-
ity, management, and context. These three aspects 
are addressed in the creation of a best practices 
document.
For IP management to efficiently function 
within a larger framework of innovation, best 
practices need to be documented. That is what 
the Handbook and this Executive Guide seek to 
do: to provide a teaching and capacity building 
resource for IP management, with a focus on 
health and agricultural biotechnologies. When it 
comes to increasing developing countries’ access 
to fundamental innovations in health and agri-
culture, success requires knowledge, capacity and 
active engagement. This is what best practices in 
IP management strive to bring about and what 
the Handbook promotes. 
To illustrate how best practices may be used, 
Mahoney4 reviews the impact of the Agreement 
on Trade-Related Aspects of Intellectual Property 
Rights (TRIPS) on the development of the phar-
maceutical industry in Korea. Korea was able to 
implement a wide range of initiatives—includ-
ing an upgrade of its IP regulatory systems—that 
benefited its pharmaceutical industries. It is likely 
that Korea’s success was largely achieved because 
its IP systems aligned with those of developed 
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countries. The empirical data gleaned from the 
experience of Korea is promising, suggesting that 
TRIPS compliance will improve biotechnological 
capabilities in developing countries.
Building innovation capabilities in develop-
ing countries often relies less on the creation of IP 
systems and more on the creation of markets and 
support for R&D. Broadly speaking, the evolu-
tion of IP rights in developing countries involves 
three basic stages (before reaching stage 4):
• Stage 1: In the early stage of development, 
little intellectual property is generated do-
mestically and few foreign companies are 
interested in introducing their technolo-
gies to these countries due to inadequate IP 
rights protection. 
• Stage 2: At a later stage of development, the 
country’s innovative capabilities improve, 
but due to the same inadequate IP rights 
protection, there is limited foreign invest-
ment in technology.
• Stage 3: Eventually, when domestic com-
panies are able to generate their own 
intellectual property, they demand more- 
effective IP protection. With more-effective 
protection, foreign investment in technol-
ogy increases along with the presence of 
foreign technologies.
Within the pharmaceutical industry (and 
many parallels exist with the agri-biotechnology 
industry), companies in developing countries 
tend to move through four stages described in 
Table 1.  This shows that technological and IP 
capacities tend to develop in tandem. However, 
such a measured-pace “natural coevolution” is no 
longer likely with TRIPS requirements in effect. 
These state that signatory countries’ pharmaceu-
tical industries must rapidly progress from either 
Stage 1 or Stage 2 on to Stage 3. It remains to be 
seen whether this mandatory accelerated devel-
opment will hinder or help developing-country 
pharmaceutical industries in the longer term and 
to what extent TRIPS will facilitate the transfer of 
technology to and within developing countries. 
However, elsewhere, especially in the United 
States, Europe, Japan, and parts of Australasia, 
technology transfer from universities works and 
works well. Examples of this are when we get into 
a car and buckle up, when we sweeten our coffee 
with saccharin, when we search the Internet using 
Google™, or when we take advantage of the innu-
merable medical and agricultural advances of the 
last quarter-century. In essence, we are reaping the 
benefits of technology transfer. Universities do 
not only educate the next generation and create 
new knowledge, but also create knowledge that 
enhances the quality of life, increases economic 
productivity, and even saves lives. 
Fraser6 points out that university–industry 
collaborations and licensing have soared, for ex-
ample, in the United States, ever since the Bayh-
Dole Act of 1980, which forces the moving of 
inventions from laboratories to store shelves more 
quickly. The law allowed U.S. universities and 
public research institutions to patent inventions 
that were based on federally funded research, then 
to license those inventions to the private sector.
Some people continue to question the fair-
ness of the global IP system, but others are using 
new opportunities created by this system to im-
prove lives in the developing world. Technology 
transfer is thus changing rapidly. Traditionally, 
the mission of technology transfer offices has been 
to make university-generated innovation avail-
able to the public as rapidly as possible. However, 
technology transfer offices now have a broader 
purpose: to enhance the reputation of academic 
institutions and to help them to achieve their 
missions of education and outreach by assisting 
in forming relationships with the private sector. 
Technology transfer has the potential to benefit 
the entire world. As technology transfer develops, 
it will undoubtedly evolve again, in response to 
new conditions. 
University technology transfer profession-
als are already becoming increasingly aware of 
their obligation to ensure that the underserved 
communities of the world have access to medi-
cines and agricultural biotechnology that have 
been developed from basic research conducted 
in their universities. But certain conditions need 
to be remediated, for example: many university 
administrators, technology transfer officers, and 
businesspeople are unaware of the need for new 
health technologies in developing countries; few 
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people know how to incorporate patenting and 
licensing practices into global access strategies; 
and best practices for global access strategies have 
not yet been defined.
Nelsen and Krattiger7 describe several possi-
ble strategies for ensuring both that everyone has 
access to technologies and that for-profit com-
panies have incentives to develop those technol-
ogies. The Association of University Technology 
Managers (AUTM) has formed Technology 
Managers for Global Health (TMGH), the 
purpose of which is to draw attention to global 
health issues and compile and promote a col-
lection of best practices, policies, and licensing 
terms. The National Institutes of Health (NIH) 
issued guidelines on the patenting and licensing 
of research tools as a way to increase global access 
to health innovations. And this Executive Guide 
serves similar and perhaps broader purpose.
Careful patent-filing strategies can help 
ensure that developing countries have access to 
the technologies they need. One example of this 
is when using a prohibition of filing strategy, one 
does not file for patent protection in develop-
ing countries if there is a very large market for 
the product in developed countries. In fact, it 
may be a good idea to file a patent in develop-
ing countries if those countries create a substan-
tial demand for the drug or vaccine in question. 
These patents can provide incentives for private 
sector development, and also provide powerful 
tools for the consolidation of resources via aggre-
gation of developing-world markets (in addition 
to enabling or at least strengthening technology 
transfer through the licensing of know-how as-
sociated with patents).
Questions to consider include: whether it is 
better to prohibit or to require filing patents in 
developing countries, whether patents encour-
age private sector investment by aggregating the 
developing world market, what kinds of licenses 
should be granted, and what requirements for de-
velopment milestones, product delivery in devel-
oping countries, pricing, or sublicensing options 
work best for a particular situation.
There are a number of licensing strategies:
•	 Licenses can be exclusive, nonexclusive, or 
a combination thereof.
•	 Licenses can specify milestones, such a re-
quirement that the licensee has to contrib-
ute a minimum toward the development 
of a product earmarked for developing 
countries.
•	 Establish pricing controls in developing 
countries.
•	 Insist upon sublicensing, which ensures 
that the licensee finds partners who can 
move the product to developing countries.
However, as the chapter points out, there 
are no clear answers as to how best to increase 
global access to necessary technologies. Each of 
the above strategies has been tried, but they are all 
relatively new, besides which each situation will 
require a tailored solution. There is no one-size-
fits-all approach nor are there boilerplate strat-
egies that can be applied in a suite of different 
contexts. For this reason, everyone has to build 
upon his or her own experiences and find creative 
solutions. Universities can take the lead. Indeed, 
their public sector missions compel them to do 
so. When universities implement consistent and 
effective licensing strategies, they not only stimu-
late investment in R&D but also ensure that the 
products of that research are affordable and wide-
ly available in developing countries. Where there 
is a will, there is a way. 
Some individuals and organizations have 
denounced, on ethical grounds, any patents for 
biotechnological applications, genes, or living or-
ganisms, especially patents on pharmaceuticals. 
However, there is neither a single articulation of 
such concerns nor is there a branch of any govern-
ment that can address the concerns. For example, 
patent offices are ill-equipped to address ethical 
questions. In addition, any blanket prohibition 
on patenting genes or other biological materials 
would generally be inconsistent with TRIPS, which 
requires countries to allow IP protection for most 
biotechnology products. Still, under TRIPS, there 
are exceptions to this general prohibition. TRIPS 
also contains a provision that certain unethical in-
ventions or innovations may be denied patents; a 
similar provision is found in the European Union’s 
ordre public clause. U.S. patent law, however, does 
not have this kind of morality provision. 
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But are some or all patents for genes and cells 
unethical per se? How should tissue samples be 
collected? And how exactly are patents used to 
restrict access to medical and ag-biotech inven-
tions? These are some of the fundamental ethical 
questions addressed by Marchant.8
With respect to obtaining biological sam-
ples, the ethical norm is that people who donate 
tissue for research purposes relinquish property 
rights to the donated cells, genes, and other bio-
logical material. Problems can arise, however, 
when human, animal, and plant materials and 
specimens are collected in developing countries 
and subsequently used to create biotechnological 
inventions that are patented in developed coun-
tries; some people have questioned the ethics of 
what they call biopiracy. Marchant explains that 
ethically questionable situations can usually be 
avoided if the following principles are followed:
• Prior informed consent should be obtained 
from the relevant entities before taking any 
samples. 
•	 An organization agrees to share with a de-
veloping country any economic benefits 
that result from patented inventions based 
on biological materials collected in that 
country, called benefit sharing.
The above methods help to minimize, but 
do not eliminate, the ethical quandaries related 
to the collection of biological materials. Many 
questions remain: Who is authorized to give pri-
or consent? Should more than one authority give 
consent (for example, both tribal and government 
officials)? How much must be disclosed about the 
proposed research to ensure that the authorities 
are adequately informed? 
Benefit sharing can also be difficult to imple-
ment. First, many scientific researchers do not have 
funding to properly compensate indigenous peoples 
for their assistance. Second, who decides how ben-
efits will be allocated? Third, if benefits are offered 
to people who assist researchers, some individuals 
may “assist” researchers purely for the money they 
will receive, not unlike some blood donors. 
There are few laws that address the ethics 
of patenting. In the absence of any clear con-
sensus, ethical decisions concerning biotech-
nological patents will need to be made on a 
case-by-case basis. The ethics of patenting is an 
evolving field that currently is more gray than 
black-and-white.
This is just one reason why it is hoped that 
this Executive Guide and Handbook will encour-
age all parties to take greater advantage of the un-
precedented opportunity to benefit from the stra-
tegic management of intellectual property aimed 
at promoting the public welfare—especially those 
people who have, until now, been unable to ben-
efit from today’s technology—and that this will 
contribute to building a healthier and more eq-
uitable world.	■
All chapters refer to: Intellectual Property Management in 
Health and Agricultural Innovation: A Handbook of Best 
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thom-
son, AB Bennett, K Satyanarayana, GD Graff, C Fernandez 
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis, 
U.S.A. Available online at www.ipHandbook.org. The online 
version contains for each chapter a detailed Editor’s Sum-
mary, Implications and Best Practices.
1 Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB 
Bennett, K Satyanarayana, GD Graff, C Fernandez, and SP 
Kowalski. (eds.). 2007. Intellectual Property Management 
in Health and Agricultural Innovation: A Handbook of 
Best Practices. MIHR: Oxford, U.K., and PIPRA: Davis, 
U.S.A. Available online at www.ipHandbook.org.
2 Chapter 1.1 by RT Mahoney and A Krattiger titled The 
Role of IP Management in Health and Agricultural 
Innovation, p. 3.
3 Chapter 1.2 by RT Mahoney titled Building Product 
Innovation Capability in Health, p. 13.
4 Ibid.
5 Ibid.
6 Chapter 1.3 by J Fraser titled IP Management and Deal 
Making for Global Health Outcomes: The New “Return 
on Imagination” (ROI), p. 19.
7 Chapter 1.4 by L Nelsen and A Krattiger titled Ensuring 
Developing Country Access to New Inventions: The 
Role of Patents and the Power of Public Sector Research 
Institutions, p. 23.
8 Chapter 1.5 by GE Marchant titled Genomics, Ethics, 
and Intellectual Property, p. 29.
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4 intellectual property (iP) is a tool to foster innovation. Whether viewed as a legal 
concept, a social construct, a business asset, or an instrument to achieve humanitarian 
objectives, the value of intellectual property cannot be disputed. 
4 iP rights are a compromise and an imperfect solution, representing the search for 
balance between making all knowledge available within the public domain and 
granting ownership of valuable discoveries to the inventors. Reaching an appropriate 
balance requires continuous, sound IP management. 
4	 The use of the existing IP system, especially coupled with sound patenting and licensing 
strategies, resolves the apparent paradox: the pursuit of the public interest through 
private rights. 
4	 the emerging global systems of innovation in health and agriculture open up new 
prospects for innovation everywhere. This notion, that the public interest can be served 
through private rights, has profound implications for the management of innovation, 
technology transfer, market competition, and economic development in every country, 
regardless of its economic status. 
4 innovation is a complex process. It is stimulated by coordinated and structured policies 
and programs. The IP management system is an important factor, but it is only one of 
six factors that determine a country’s or institution’s ability to innovate. 
4 intellectual property is integral to all six components of innovation that are, in 
addition to IP management: R&D in the public and private sectors; safe and effective 
regulatory systems; the ability to produce new products to high standards of quality; a 
national distribution system in both the public and private sectors; and international 
distribution systems and trade in technologies.
4	 Policies to promote the creation and management of intellectual property by public 
sector institutions should give first priority to advancing the missions of those 
institutions. 
4	 There are few laws that address the ethics of patenting. In the absence of a clear 
consensus, ethical decisions concerning biotechnology patents will need to be made 
on a case-by-case basis. 
4 Protection and licensing go hand in hand. Public research institutions have much to gain 
if they are permitted to protect their inventions. A system that allows technologies to 
be patented and that encourages institutions to license them will both help countries 
to reach their economic goals and better serve the poor. 
4	 Policymakers should encourage and fund national technology transfer managers’ 
associations to the extent that doing so is feasible. Such associations are working to 
determine best practices in technology transfer and licensing. 
FOR GOVERNMENT POLICYMAKERS
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4 intellectual property is a tool to foster innovation. Whether viewed as a legal concept, a 
social construct, a business asset, or an instrument to achieve humanitarian objectives, 
the value of intellectual property cannot be disputed. 
4 iP rights are a compromise and an imperfect solution, representing the search for 
balance between making all knowledge available within the public domain and 
granting ownership of valuable discoveries to the inventors. Reaching an appropriate 
balance requires continuous, sound IP management. 
4	 The use of the existing IP system, coupled with sound patenting/licensing strategies, 
resolves the apparent paradox: the pursuit of the public interest through private 
rights. 
4 the emerging global systems of innovation in health and agriculture open up new 
prospects for innovation everywhere. This notion, that public interest can be served 
through private rights, has profound implications for the management of innovation, 
technology transfer, market competition, and economic development in every country, 
regardless of its economic status. 
4 innovation is a complex process. It is stimulated by coordinated and structured policies 
and programs. The IP management system is an important factor, but it is only one of 
six factors that determine a country or institution’s ability to innovate. 
4	 Public sector institutions that optimize their iP management capacity and those that 
have capacity in any of the additional areas, such as regulatory systems, will be better 
equipped to actively participate in innovation. 
4	 Often the most innovative organizations are those with the most dynamic networks, 
and those that reach out to other entities and potential partners.
4	 The case studies in the insert of the Executive Guide demonstrate how public sector 
technology transfer can make a difference in the developing world and elsewhere.
4	 Technology transfer officers should have ample opportunities for professional 
development and networking. Technology transfer is a field in which much information 
is shared informally. 
4 technology transfer and licensing are heavily context-specific. A one-size-fits-all 
patenting and licensing policy and strategy is rarely effective for an institution. 
4	 Public sector institutions ought to have ethical guidelines for IP management that are 
consistent with national laws and an institution’s mission. 
FOR SENIOR MANAGEMENT
(UNIVERSITY PRESIDENT, R&D MANAGER, ETC.)
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4 intellectual property is a tool to foster innovation. Whether viewed as a legal concept, a 
social construct, a business asset, or an instrument to achieve humanitarian objectives, 
the value of intellectual property cannot be disputed. 
4 iP rights are a compromise and an imperfect solution, representing the search for 
balance between making all knowledge available within the public domain and 
granting ownership of valuable discoveries to the inventors. Reaching an appropriate 
balance requires continuous, sound IP management. 
4	 The use of the existing IP system, coupled with sound patenting and licensing 
strategies, resolves the apparent paradox: the pursuit of the public interest through 
private rights. 
4 the emerging global systems of innovation in health and agriculture open up new 
prospects for innovation everywhere. This notion, that public interest can be served 
through private rights, has profound implications for the management of innovation, 
technology transfer, market competition, and economic development in every country, 
regardless of its economic status. 
4 innovation is a complex process. It is stimulated by coordinated and structured policies 
and programs. The IP management system is an important factor, but it is only one of 
six factors that determine a country’s or institution’s ability to innovate. 
4	 Your work is part of a larger innovation process that spans R&D across the public and 
private sectors, using regulatory systems, enabling the ability to produce new products 
to high standards of quality, allowing for the national distribution of new products 
through the public and private sectors, accessing foreign technologies, and managing 
intellectual property in a way that fosters partnerships.
4 research is the very foundation of innovation. Research leads to discovery; discovery 
fosters invention; inventions nourish innovation.
4 your sustained interest in your invention is important if it is to reach the marketplace, 
especially if it is to benefit those who most need it.
4	 It will be wise to consider the ethical implications of your research.
4	 You should always obtain prior informed consent when you access other people’s 
materials or samples irrespective where they originate. 
FOR SCIENTISTS
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4 intellectual property is a tool to foster innovation. Whether viewed as a legal concept, a 
social construct, a business asset, or an instrument to achieve humanitarian objectives, 
the value of intellectual property cannot be disputed. 
4 iP rights are a compromise and an imperfect solution, representing the search for 
balance between making all knowledge available within the public domain and 
granting ownership of valuable discoveries to the inventors. Reaching an appropriate 
balance requires continuous, sound IP management. 
4 the emerging global systems of innovation in health and agriculture open up new 
prospects for innovation everywhere. This notion has profound implications for the 
management of innovation, technology transfer, market competition, and economic 
development in every country, regardless of its economic status. 
4 innovation is a complex process and coordinated and structured policies and programs 
stimulate it. The IP management system is an important factor, but it is only one of six 
factors that determine a country’s or institution’s ability to innovate. 
4 intellectual property is integral to all six components of innovation which are, in 
addition to IP management: R&D in the public and private sectors; safe and effective 
regulatory systems; the ability to produce new products to high standards of quality; a 
national distribution system in both the public and private sectors; and international 
distribution systems and trade in technologies.
4	 An IP manager should consider the entire innovation process when making patenting 
and licensing decisions. 
4	 The traditional mission of technology transfer offices (to bring university-generated 
intellectual property to the public as rapidly as possible) is broadening. technology 
transfer enhances the reputation of academic institutions and helps them achieve 
their missions, both at home and abroad. 
4	 IP managers should join professional national and international licensing and 
technology transfer societies whenever possible. 
4 creative licensing strategies will help your institution gain the greatest benefits from 
the research it conducts. Such strategies include, at a minimum, the balancing of 
exclusive and nonexclusive rights, defining field of use, setting appropriate milestones, 
requiring the delivery of products to developing country markets, and exercising control 
over pricing.
4	 In benefit sharing, an organization agrees to share with a developing country any 
economic benefits that result from patented inventions based on biological materials 
collected in that country. Make sure the individuals in your organization who collect 
biological resources are aware of this and obtain prior informed consent.
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they function in partnerships that extend beyond 
their primary missions and include others who 
can turn inventions and knowledge into products 
and services that become economically successful 
or that have major social and humanitarian im-
pacts. This impact can be measured through three 
key conditions that jointly determine whether an 




In addressing the needs of developing coun-
tries, achieving these three conditions concur-
rently can conveniently constitute global access. 
But translating the three into an effective inno-
vation management plan or operational strategy 
is more challenging. To manage these goals, a 
strategy that consists of six thrusts should be 
considered:2
1.  Development of R&D capability by the 
public and private sectors
2.  Development of a safe and effective regula-
tory system that covers drugs, vaccines, and 
agricultural inputs and outputs 
3.  Development of manufacturing capability 
for health products, seed production sys-
tems, and value-added processing
4.  Development of an IP system (legal frame-
work, judiciary to enforce it, and institu-
tional management capabilities) 
EXECUTIVE GUIDE TO HANDBOOK SECTION 2
(VOLUME 1: PAGES 41-144)
Innovation is a wonderful thing. Innovation oc-
curs when any new knowledge is introduced into 
and utilized in an economic and/or social setting. 
People and institutions (agents) orchestrate this 
process. Simple economic theory states that such 
agents act in a rational way, responding to price 
signals as a way of maximizing investments. But 
modern innovation research indicates that this 
is not so, particularly when noncommercial or 
humanitarian goals are being pursued. Agents, 
both public (governments, universities, extension 
services) and private (small, medium, and large 
companies, as well as farmers, individual con-
sumers, and communities) are essentially strate-
gists who respond to other agents’ behaviors. For 
example, a governmental “behavior” in this con-
text would be changing a range of policies, such 
as research, regulatory, trade, and IP (intellectual 
property) policies. Each of these agents directly or 
indirectly engages in the production, processing, 
marketing, or distribution of products and servic-
es. Simultaneously, agents engage in the processes 
of knowledge creation or dissemination and the 
application of knowledge through both market 
and nonmarket relationships.
Using this definition of innovation, public 
research institutions and universities may be in-
vention creators. They are not necessarily innova-
tors per se but are important actors in the innova-
tion process. Their roles are strengthened if they 
are well connected. That is, they are stronger if 
Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007. 
2: Specific Strategies and Mechanisms for Facilitating Access to Innovation. In Executive Guide to Intellectual Property 
Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). 
MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-
International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for 
noncommercial purposes is permitted and encouraged.
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5.  Development and expansion of national 
health or agricultural delivery systems, in-
cluding an attractive, private-sector domes-
tic market for health or agricultural prod-
ucts and services
6.  Development of international trade sys-
tems for health products (including global 
procurement funds) and agricultural inputs 
and outputs
Although IP management is but one of six 
components, it can be viewed as the thread that 
runs through the innovation process or as the glue 
that holds partnerships together. Partnerships are 
based on the mutual interests of two or more par-
ties and agreed upon in contracts. The terms and 
provisions of a contract can be almost limitless 
(provided they are both legal and agreed to by 
the parties) and are discussed elsewhere in great 
detail.3 The present section focuses on the com-
ponents that are most specific to global access. 
And one of the first and foremost sets of licens-
ing terms, at least for universities and other pub-
lic sector research institutions in the licensing of 
invention, is the reservation of certain rights. 
Indeed, Bennett4 urges universities and public 
sector institutions to ensure that they preserve the 
right to use licensed technologies for educational, 
research, and humanitarian goals—including dis-
tribution rights in developing countries.
In essence, the terms of a license can subdi-
vide the rights with respect to a technology. Rights 
can be segmented and apportioned across:
• technological fields, markets, or economic 
contexts in which the technology is used 
(such as farm size, farm income, or income 
derived from a particular crop, in the case 
of agriculture; or certain drugs to combat 
neglected diseases in the case of health)
• income levels (for example, per capita gross 
domestic product)
• geographic regions (by country, or by low-
land or highland agricultural systems) or by 
customer (public procurement or private 
hospitals and pharmacies)5 
This practice can be used by any technol-
ogy owner to maximize the application of its 
inventions. Most importantly, subdividing and 
field-of-use licensing can allow both commercial 
and noncommercial uses of the technology to 
proceed in parallel and, thus, constitutes a central 
element in a global access strategy. Bennett pro-
vides suggestions for creating explicit reservation 
of rights in a commercial technology license. This 
will ensure that institutional objectives to support 
humanitarian applications of technologies that 
have applications to the needs of the poor are not 
inadvertently compromised. 
The global importance of humanitarian li-
censing is also discussed in detail by Brewster, 
Hansen, and Chapman6 with pragmatic answers 
about the why, who, and how of the process. The 
authors encourage IP managers, in both private 
and public sectors, to adopt such strategies, noting 
in particular that they are not incompatible with 
commercially driven businesses. The why for hu-
manitarian-use licensing is obvious, with the vast 
unmet health and agricultural needs of developing 
countries. The who is increasing as more and more 
organizations have been using IP management 
practices to promote the health and food security 
of poor people (and the chapter offers many recent 
examples). The how is discussed through a num-
ber of case studies7 on humanitarian licensing. The 
authors conclude, with others, that much can be 
achieved using best practices, many of which are 
enumerated at the end of the chapter.
Eiss, Hanna, and Mahoney8 look at the same 
topic but on the basis of how various product-
development partnerships (PDPs) seized upon 
public and private sector strengths and how they 
are leveraging existing infrastructure and re-
search in developed and developing countries. 
Although each of the PDPs reviewed are very 
different, they nonetheless share some common 
strategies for maximizing IP management for 
global health. These include:
•	 defining a discrete territorial market
•	 establishing different structural incentives 
in public sector and private sector markets
•	 extending field of use to make the prod-
uct applicable to diseases in developed 
countries
•	 using royalties to benefit the party that 
needs the most incentive
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•	 providing access to the developed technol-
ogy, should the private sector not follow 
through on the project
The authors conclude that whereas these is-
sues can be complex, they should be addressed as 
early as possible in the formation of partnerships. 
But most importantly, the chapter concludes 
with the observation—grounded in much experi-
ence—that an approach that takes into account 
the six components of innovation discussed at the 
beginning of this chapter will have a much better 
chance of success than those efforts that take a 
piecemeal approach to product development and 
distribution. Such a comprehensive effort should 
not be considered daunting, but rather an oppor-
tunity for creativity. 
It is widely acknowledged that IP rights are 
important drivers of innovation, and this applies 
equally to the private sector and the public sec-
tor. This is especially the case for product patents. 
However, for research tools9 in both medical and 
agricultural innovation, Clift10 demonstrates that 
patents related to research tools can have nega-
tive implications and, hence, should be balanced 
carefully with disclosure to place inventions in 
the public domain. Developing countries need to 
think about how to implement patent legislation 
(that is consistent with the Agreement on Trade-
Related Aspects of Intellectual Property Rights, 
best known by its acronym TRIPS) while meet-
ing their own objectives, particularly those relat-
ed to genetic discoveries. For example, legislation 
should be formulated to set forth appropriate re-
search exemptions, and patenting and licensing 
policies should be aimed at maximizing the avail-
ability of innovations in order to aid the develop-
ment of urgently needed products.
For product patents, the decision to pat-
ent or not to patent is much simpler. For many 
products, even those aimed at developing coun-
tries’ needs, patenting provides a mechanism 
to extend licenses, with specific provisions for 
licensees to meet these needs according to well-
understood and well-defined market conditions. 
But this only works if best licensing practices are 
adopted (such as those defined and spelled out 
throughout the Handbook). A compelling reason 
for best practices in IP management is well il-
lustrated by Stevens11 who discusses how student 
activists ensured that Yale University and Bristol-
Meyers Squibb quickly adopted humanitarian 
licensing (also called fair-access licensing).12 The 
objectives for such humanitarian licensing provi-
sions should be to maximize the possibility that 
the patented invention will be produced and to 
structure arrangements for tiered pricing, which 
will allow the poorest countries access to the drug 
at the lowest cost. 
Best practices adopted by PDPs have also had 
the following important effects:
•	 Large companies have been motivated to 
contribute their drug-discovery skills and 
resources because they are assured that oth-
ers are responsible for funding late-stage 
clinical development.
•	 Small companies have secured funding to 
develop technologies with dual-market 
uses, with the PDPs securing license rights 
for developing countries at zero or low roy-
alty rates and the small company retaining 
rights for use in developed countries.
•	 Academic institutions have had a new 
channel to advance their neglected-disease 
discoveries.
•	 Developing country pharmaceutical com-
panies have found their production and 
distribution skills in demand.
For products needed in developing countries, 
it could be argued that the question of patent-
ing should not even arise. Some argue that not 
to patent would be the best strategy. Others be-
lieve that open source licensing may be an effec-
tive option for managing intellectual property. 
Indeed, the chapter by Hope13 discusses the pos-
sibilities of open source licensing. Open source 
does not mean to place something squarely into 
the public domain nor does the decision to pur-
sue open source licensing follow only from altru-
ism: it can be based on commercial self-interest. 
Open source licensing has been most successful 
in the computer software field (Linux being the 
most prominent example), where anyone, any-
where, and for any purpose is essentially allowed 
to copy, modify, and distribute the company’s 
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software (either for free or for a nominal fee) 
and, therefore, anyone is allowed full access to 
the software’s source code. The only condition is 
that everyone has to share its improvements with 
everyone else.
Open source is thus a form of IP licensing, 
and so it differs significantly from placing tech-
nology in the public domain via publication.14 
An open source strategy may indeed be a viable 
approach to encourage the widespread adoption 
and development of an innovation. Some inno-
vations (such as software) are automatically pro-
tected by copyright, so a license clarifies the terms 
of its use. An open source license gives the in-
novator the right to set terms of use and exclude 
users who will not abide by those terms. But most 
of the incentives for open source licensing are in-
direct: cost savings, productivity gains, the capital 
provided by a good reputation, and, most impor-
tantly, an expanded user base, which correspond-
ingly expands complementary goods and services. 
As the market expands, revenues from sales, one-
time licenses, dual licensing, and complementary 
products and services may be enough to offset the 
opportunity cost of open source licensing. IBM 
has successfully used this approach. Importantly, 
open source licensing can place an institution in 
a network of innovation with enormous collab-
orative potential. Finally, open source licensing 
can encourage the development of alternatives to 
proprietary technologies. The greater the number 
of nonproprietary tools in a given tool kit, the 
greater the incentive for everyone in the field to 
invest in developing substitutes for the remaining 
proprietary technologies, since it will allow free-
dom to operate for the whole tool kit.
All of the foregoing relates to software li-
censing. Despite several attempts to adapt open 
source approaches to the biological sciences in 
both health and agriculture, none has been suc-
cessful. Given the possible benefits associated 
with open source licensing, pursuing it further 
is warranted but will require additional work. 
Hope discusses the various unresolved challenges 
in the biotechnological field. She distinguishes 
between “copyleft” and “academic” forms of 
open source licensing. Using a proposed five-step 
decision-making process, Hope shows how open 
source technologies, for example, can be tailored 
to serve small agricultural and pharmaceutical 
markets in developing countries. And given the 
growing reliance on computer technologies in the 
life sciences—bioinformatics software programs, 
for example—the possibilities for open source li-
censing in this field have great potential. 
Returning to the PDPs and their goal of mov-
ing candidate products through various stages up 
to clinical development and eventual distribu-
tion, many PDPs face a series of highly practical 
challenges. The central challenges are ensuring 
high-quality and low-cost production, sustained 
supply, affordable pricing, and effective deliv-
ery of their products. Indeed, the World Health 
Organization’s Commission on Intellectual 
Property and Innovation in Health has found 
that many PDP research-and-development con-
tracts defer issues related to manufacturing and 
distribution.15 As a result, PDPs now increasingly 
face both negotiating and operational challeng-
es regarding manufacturing sites, pricing to the 
public sector, market segmentation, market siz-
ing, ensuring the lowest sustainable cost of pro-
duction while guaranteeing sustainable supplies, 
quality control, and post-launch issues, such as 
pharmacovigilance and product liability.
Elaborating the requirements and approach-
es for global access early on is critical; otherwise, 
plans are developed incrementally or even after 
the product is developed. This leads to delays 
and creates large inefficiencies for the crucial last 
steps of distribution in developing countries. In 
addition, negotiating power may be diminished 
after development. In such cases, product up-
take can be sluggish or stalled due to a variety 
of downstream considerations. A useful way to 
approach these situations is to apply milestones 
in the initial licensing agreements to ensure that 
key goals are met along the product development 
pathway. The kinds of milestones will vary based 
on product profiles and target markets, but in all 
cases, as Oehler16 states, milestones require the 
following:
•	 intensive preparations
•	 detailed knowledge of the processes related 
to developing and marketing the product
•	 realistic forecasting of product potential
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•	 persistence in quantitative forecasting and 
establishing a master plan for the entire 
product rollout
•	 a mission-driven mindset to establish opti-
mum goals for the public sector
When public-private partnerships manage 
intellectual property, they are trying to balance 
the private sector’s commercial interests with the 
public sector’s goal of obtaining access to phar-
maceutical products at the lowest possible cost. 
Although the goals and paradigms of the public 
and private sectors may appear too far apart, this 
chapter provides the tools and materials required 
to build the contractual architecture to span that 
divide. According to Oehler, a large part of the 
problem is simply a failure to communicate be-
tween the public and private sectors. Discussions 
between the public sector and industry are cross-
cultural, no matter how well public sector players 
think they understand industry. In such a cross-
cultural environment, there is nothing more dan-
gerous and conducive to misunderstandings than 
to assume the obvious, since what is obvious for 
one person with a public sector background will 
not necessarily be the same for the other partner. 
Obligations and contractual performance cannot 
be left to vague best efforts and common sense. 
The experiences of the Concept Foundation, 
which are the platform for the chapter by Oehler, 
demonstrate the successful use of milestones as 
a tool. The Foundation’s business model initial-
ly considers downstream issues such as product 
delivery, and it utilises contractual milestones to 
achieve its principal goal of providing developing 
countries access to new medicines.
Milestones and open source are but one way 
for institutions to have easier access to inventions 
from third parties; there are many other mecha-
nisms to assemble intellectual property. Krattiger 
and Kowalski17 provide a brief overview of dif-
ferent IP assembly options (royalty collection 
agencies, information clearinghouses, technology 
clearinghouses, open source innovation clearing-
houses, brokers and other kinds of facilitators, 
IP management services, IP commercialization 
agents, integrated commercial services, compa-
ny-to-company arrangements, and other public 
technology transfer and financing mechanisms). 
The authors focus on the pros and cons of patent 
pools, which are receiving more and more atten-
tion as possible tools for improving technology 
transfer to developing countries. 
There are many forms of patent pools: essen-
tially they all allow for the interchange (cross-li-
censing) of rights to essential patents by a num-
ber of entities. They also include an agreed-upon 
framework for out-licensing the pooled intel-
lectual property to third parties. A patent pool 
offers several benefits, a major one being that it 
cuts through patent thickets. But patent pools are 
also risky: the agreement to share technologies 
may run into problems based on antitrust legisla-
tion. Other considerations vis-à-vis patent pools 
include:
•	 They allow for the transfer of intellectual 
property. Know-how and trade secrets 
may also be required to use the intellectual 
property.
•	 They have generally flourished when all 
companies in a sector are stymied by re-
strictions on access to intellectual property. 
This makes them willing to compromise. 
It is unclear whether or not pharmaceuti-
cal companies feel similar inclinations. In 
agriculture, the interests of companies are 
not aligned to make patent pools feasible at 
the moment but this could be different for 
public sector organizations.
•	 They have been most successful in the elec-
tronics industry, since they facilitate indus-
try-wide standards that create larger mar-
kets. Again, this may not apply to drug or 
agricultural biotechnology companies.
•	 They are typically expensive to create and 
maintain.
Despite these reservations, the benefits of 
patent pools are strong. They create an efficient 
“one-stop shop” for intellectual property, elimi-
nate stacking licenses, avert litigation, decrease 
research and administrative costs, and can greatly 
improve the speed and efficiency of technologi-
cal development. It is worth remembering, how-
ever, that patent pools are not the only ways to 
achieve these benefits. To help policymakers 
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determine the appropriateness of patent pools for 
their unique situations, Krattiger and Kowalski 
provide a ten-step checklist for deciding wheth-
er or not to set up a patent pool and a ten-step 
procedure for setting one up. The authors point 
out legal pitfalls associated with patent pools and 
general suggestions are offered for identifying and 
avoiding them. 
In sum, the reservation of rights, open source 
licensing, milestones, and different forms of IP 
assembly are all part of the toolbox of best prac-
tices that facilitate access to innovation. But to de-
termine which specific rights should be retained, 
which elements should be licensed on an open- 
source basis, which milestones lead to the best re-
sults, and which assembly option works best, will 
always be difficult to determine because the an-
swers depend heavily on the context. The context 
will include the actors involved in the innovative 
process, their relationships, and their connectivity 
within a global innovation network. Irrespective 
of which options are selected for greater global 
access, all strategies will require highly intensive 
preparations, detailed knowledge of processes re-
lated to the development and marketing of the 
product, detailed knowledge of markets, realistic 
anticipation and forecasting of product potential, 
and persistence in quantitative forecasting, as well 
as a master plan for the entire product rollout. 
The tools described in this section can be power-
ful for achieving public sector goals, and they are 
certainly worth the effort. ■
All chapters refer to: Intellectual Property Management in 
Health and Agricultural Innovation: A Handbook of Best 
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thom-
son, AB Bennett, K Satyanarayana, GD Graff, C Fernandez, 
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis, 
U.S.A. Available online at www.ipHandbook.org. The online 
version contains for each chapter a detailed Editor’s Sum-
mary, Implications, and Best Practices.
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biotechnology, acceptability is particularly relevant.
2 The choice of the six strategic components stems from 
work in innovation theory and management and has 
been adapted for health by RT Mahoney (see Chapter 
1.2 titled Building Product Innovation Capability in 
Health, p. 13).
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part 12. 
4 Chapter 2.1 by AB Bennett titled Reservation of Rights 
for Humanitarian Uses, p. 41.
5 See Chapter 11.8 by SL Shotwell titled Field-of-Use 
Licensing, p. 1113.
6 Chapter 2.2 by AL Brewster, SA Hansen and AR 
Chapman titled Facilitating Humanitarian Access to 
Pharmaceutical and Agricultural Innovation, p. 47.
7 The special insert in this Executive Guide offers 24 
successful case studies.
8 Chapter 2.3 by R Eiss, KE Hanna and RT Mahoney 
titled Ensuring Global Access through Effective IP 
Management: Strategies of Product-Development 
Partnerships, p. 63.
9 These encompass a wide range of resources, including 
genes and gene fragments, cell lines, monoclonal 
antibodies, reagents, animal models, growth factors, 
combinatorial chemistry and DNA libraries, clones and 
cloning tools (such as the polymerase chain reaction 
or PCR), methods, laboratory equipment and machines, 
databases, and computer software.
10 Chapter 2.4 by C Clift titled Patenting and Licensing 
Research Tools, p. 79.
11 Chapter 2.5 by AJ Stevens titled Valuation and Licensing 
in Global Health, p. 89.
12 Yale University had granted an exclusive license for an 
anti-HIV compound to Bristol-Meyers Squibb, which 
also gave the company the right to file for patent 
protection in foreign countries. Fatefully, the company 
filed in South Africa, Mexico, and Egypt, among other 
countries. South Africa (and the rest of Africa) needed 
this anti-HIV drug (D4T), but it was far too expensive for 
all but a very few. Pressure was put on Yale University 
to make this drug available generically in South Africa. 
Yale resisted, but student activists brought the issue to 
the attention of the national press, and Bristol-Myers 
Squibb quickly acted to make the drug available at no 
cost to treat AIDS in South Africa. 
13 Chapter 2.6 by J Hope titled Open Source Licensing, p. 107.
14 For a detailed discussion on patenting versus the public 
domain, see chapter 10.1 by S Boettiger and C Chi-Ham 
titled Defensive Publishing and the Public Domain.
15 WHO. 2006. Public Health Innovation and Intellectual 
Property Rights. Report of the Commission on Intellectual 
Property Rights, Innovation and Public Health. WHO: 
Geneva. www.who.int/intellectualproperty/en/.
16 Chapter 2.7 by J Oehler titled Using Milestones in 
Healthcare Product Licensing Deals to Ensure Access 
in Developing Countries, p. 119.
17 Chapter 2.8 by A Krattiger and SP Kowalski titled 
Facilitating Assembly of and Access to Intellectual 
Property: Focus on Patent Pools and a Review of Other 
Mechanisms, p. 131.
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4 One of the benefits of enabling public research institutions to own iP rights is that 
institutions can control how technology is deployed through the terms of licensing 
contracts, thus meeting both commercial and noncommercial goals. 
4 Well-crafted contracts, based on best practices, can be instrumental in achieving 
global access, provided the entire innovation process is given due consideration from 
the outset. This includes consideration of R&D capabilities, regulatory environment, 
manufacturing capabilities, IP management, access to markets, and trade-related 
concerns. Such an approach requires a lot of preparation and detailed knowledge of 
the processes related to developing and marketing the invention; realistic forecasting 
of product potential; persistence in quantitative forecasting and establishing a master 
plan for the entire product rollout; and a mission-driven mindset to establish optimum 
goals for the public sector.
4 One of many components of best practices by the public sector is incorporating 
humanitarian-use reservation provisions in commercial licensing contracts. This is 
becoming increasingly common with certain universities around the world, particularly 
with respect to agricultural inventions. There is conceptually no reason why this should 
not become common practice globally. 
4 Public sector institutions should have explicit IP policies and demonstrated institutional 
capacity to implement best practices in IP management. Any licensor, public or private, 
is more willing to give licenses to institutions that proactively protect third-party-
property, which leads to confidence building and a higher degree of motivation to 
proceed with more licensing and technology transfer arrangements.
4 open source may offer an alternative mechanism for facilitating access to innovations 
in health and agriculture, provided the open-source approaches that are so popular and 
effective in the software area can be successfully adapted to the biological sciences. 
More conceptual research is needed to make open source an effective way to accelerate 
innovation in health and agriculture.
4 Other policies and laws can foster and enable efficient IP assembly (or in-licensing 
by national institutions to obtain freedom to operate and the freedom to license 
bundles of technologies to manufacturers). These may include patent pools and other 
mechanisms.
FOR GOVERNMENT POLICYMAKERS
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
FOR SENIOR MANAGEMENT
(UNIVERSITY PRESIDENT, R&D MANAGER, ETC.)
4 One of the benefits of enabling public research institutions to own iP rights is that 
institutions can control how technology is deployed through the terms of licensing 
contracts, thus meeting both commercial and noncommercial goals. 
4 Well-crafted contracts based on best practices can be instrumental in achieving global 
access, provided the entire innovation process is given due consideration from the outset. 
This includes consideration of R&D capabilities, regulatory environment, manufacturing, 
IP management, access to markets, and trade-related concerns. Such an approach requires 
a lot of preparation and detailed knowledge of the processes related to developing a 
mission-driven mindset to establish optimum goals for the public sector.
4 One of the central elements for public sector institutions is to have explicit IP policies and 
demonstrated institutional capacity to implement best practices in IP management. Any 
licensor, public or private, is more willing to license to institutions that proactively protect 
third-party property, which leads to confidence building and a higher degree of motivation 
to proceed with more licensing and technology transfer arrangements.
4 Humanitarian licensing can benefit both the research and public service missions of a 
university or public sector research institution. Consider creating an institutional policy 
that standardizes the reservation of humanitarian rights on all technologies, including, as 
appropriate, the right to practice the invention for nonprofit goals. Potential licensees are 
less likely to resist if they know that the terms being requested are “standard” and part of 
the deal in doing business with an institution.
4 Implementing the various best practices discussed and presented in this section is complex 
and requires experience. Public sector institutions need to plan and implement focused 
capacity building in iP management. 
4 networks with individuals and organizations, such as foreign universities, corporations, 
product development partnerships (PDPs), and government agencies, should be seen as 
critical elements that enhance the innovative potential of any institution. 
4 Indeed, partnerships are an important way to fill in the capacities that are required to 
make an institution innovative. Few, if any, institutions have the entire range of capacities 
to bring ideas to market.
4 Under many circumstances, patenting may be unnecessary and publication might offer 
the widest dissemination. The decision to place inventions in the public domain should 
be calculated and made on a case-by-case basis. open source licensing might be another 
complementary component of an IP management strategy.
4 Whenever possible, consider nonexclusive licensing as a strategy to maximize the utilization 
of research tools. On product patents, exclusive licensing may, in many circumstances, be more 
effective to reach broad dissemination, particularly if coupled with strong milestone clauses.
4 Complementary strategies are the segmenting or apportioning of markets, whereby 
different licensees obtain exclusivity but only for one portion of the field of use. This 
strategy can also be used to implement tiered pricing. 
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4 As the inventor, in most circumstances, you can significantly influence how your 
technology is used. For example, you can very reasonably request that your technology 
transfer office draft license terms that reserve for you the rights to continue research 
using your inventions or terms that reserve the rights for humanitarian uses of your 
technology. 
4 Notwithstanding the above, you must follow the IP policies of your institution. And there 
is no reason a priori that your interests in licensing practices should not be reflected 
in your institutional IP policies. Changing them, if necessary, requires a dialogue with 
senior management and technology transfer personnel and a good understanding 
of the purpose of intellectual property and how sound IP management can be put to 
work for the benefit of the public sector.
4 Your interest and activities in licensing and partnership building can raise the profile of 
your research program and also of your institution. It may create goodwill, catalyzing 
additional scientific and development interest by partner organizations and individuals. 
And it can lead to earlier and more efficient translation of your research findings into 
useful products or services.
4 In particular, collaboration with private sector entities can be a most valuable 
contribution to your institution’s broader participation in innovative initiatives, 
particularly as it pertains to product development.
4 The R&D work that you carry out in your program can often (perhaps serendipitously) 
lead to the invention of new research tools. But the patenting strategies for research 
tools may need to be different from those related to products if maximum dissemination 
and use are sought. 
4 One such avenue for research tools in particular may be open source licensing. This is 
a complex and evolving area in the biological sciences and requires further refinement 
to be effective and useful.
4 Importantly, open source licensing is not the same as placing an invention into the 
public domain. open source entails contractual obligations. An open source license may 
be extremely complex and may require your institution to agree to certain obligations. 
Several universities are unable to sign such open source licenses because they cannot, 
in good faith, agree to the conditions. Make sure you always consult your technology 
transfer officers before signing any agreement. 
4 Increasingly contracts will include milestones, which may affect your work, although 
quite often not directly. Research schedules and goals may be directly linked to specific 
milestones, and you need to know how such milestones might influence your program.
4 Accessing other people’s intellectual property can be facilitated through networks of 
committed professionals; your contributions in this area can be substantial, and strong 
professional networks will make you a more valued and essential member of the team.
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
FOR TECHNOLOGY TRANSFER OFFICERS
4 licensing and valuation practices between a public sector institution and product-
development partnerships show that one valuation formula is to ask for the licensees in 
developing countries to take over responsibility for future patent costs but to ask for no 
up-front fees, no milestone payments, and no running royalties. Any financial return to the 
university should be derived from opportunities in developed countries. 
4 Both nonexclusive and exclusive licenses can be applicable to meeting socio-economic 
goals. Within exclusive licensing, there are many feasible options, such as exclusivity 
limited to a certain field of use, or geography, or for limited periods of time.
4 Certain equitable access provisions in licenses can be instrumental in enabling competition 
in low- and middle-income countries. 
4 The practice of reserving rights for humanitarian use may require additional work and will 
likely not generate licensing revenue; conversely, such provisions, if used in a strategic way, 
are unlikely to lead to loss of revenues. 
4 Potential licensors of intellectual property connected to critical agricultural and health 
care technologies will be motivated by your institution’s demonstrated iP capacity, and 
will be more likely to enter into more licensing agreements.
4 If you are a licensor, put yourself in the position of the other party. If the roles of licensor/
licensee were reversed, would your position seem unreasonable? Inflexibility may be 
detrimental when the licensee has technologies you may wish to utilize.
4 IP managers should be cautious of simply imitating the open licensing procedures of the 
software industry. Such licenses are not generic enough to cross fields of endeavor, and it 
is still unclear whether and to what extent biotechnology innovations in general will lend 
themselves to open source licensing.
4 The public sector must specify in writing exactly what it wants to accomplish with 
a commercial partner, detailing when and how this will be achieved by specifying 
milestones—and related penalties should these milestones not be fulfilled.
4 Avoid “best effort” clauses in agreements. Instead, make the extra effort to draft 
comprehensive contracts with articulated milestones. This up-front investment in time and 
effort will pay off if a problem arises. During the drafting and negotiation of agreements 
containing milestones, do not hesitate to involve people from other departments 
(including business schools), outside consultants, and experts in the relevant industries 
and markets.
4 Developing meaningful milestones that provide the appropriate balance of incentives, 
rewards, and penalties requires detailed preparations, a sound understanding of the 
processes related to developing and marketing the product, realistic forecasting of product 
potential, persistence in quantitative forecasting and in putting together a master plan for 
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that would hear all patent appeals) as the first 
profound change in over 100 years concerning 
IP-related dispute resolution. A single appellate 
court would better understand and correct policy 
misperceptions, largely created by judicial deci-
sions that had negatively influenced investment 
incentives in relation to patenting. A uniform 
and predictable application of the law across the 
United States and a concomitant end to forum 
shopping would promote innovation. And indeed 
it has. The effects have been dramatic: industrial 
activity, based on strengthened patent incentives, 
has surpassed the most optimistic expectations.
In addition to the establishment of the 
CAFC, two other critical events at the beginning 
of the 1980s catalyzed the growth of the biotech-
nology industry. In 1980, the Supreme Court’s 
landmark decision in Diamond v. Chakrabarty, 
despite dire predictions to the contrary concern-
ing the patenting of life forms, opened the na-
tion’s economy to biotechnology as an industry, 
enabling investment and commercialization in 
this nascent field. Also in 1980, the Bayh-Dole 
Act catalyzed the revitalization of commercial 
products arising from government investments 
in academic research. The combination of the 
CAFC, the Chakrabarty decision, and the Bayh-
Dole Act synergistically drove the biotechnology 
revolution in the United States.
Because of rapid scientific developments, 
new issues of law constantly arise. Advances in 
EXECUTIVE GUIDE TO HANDBOOK SECTION 3
(VOLUME 1: PAGES 147-333)
Changes in both national and international legal 
frameworks have profoundly affected how com-
panies manage their intellectual assets in further-
ance of economic and strategic business objec-
tives and how they pursue their R&D. Moreover, 
the changes have enabled a broader distribution 
of health-related technology to people in devel-
oping countries. Public sector institutions like-
wise have had to adapt to an increasingly global-
ized knowledge-based economy. One adaptation 
is the ever-increasing interaction between devel-
oped countries and developing economies, par-
ticularly more innovative developing countries 
(for example, Brazil, China, India, Korea, South 
Africa). A second adaptation is the increased 
complexity of interactions between public and 
private sector actors. A third involves an evolu-
tion in the judiciary: toward a clearer judicial 
structure with more reliable and predictable 
mechanisms of dispute resolution. Many inno-
vative developing countries are undergoing far-
reaching changes within the judiciary, and expe-
rience from the creation of the Court of Appeals 
for the Federal Circuit (CAFC) in the United 
States offers many useful insights. 
In order to help revitalize flagging technologi-
cal innovation in the faltering economy of the late 
1970s in the United States, a fundamental change 
in the judicial structure took place in 1982. As a 
judge at the CAFC, Newman1 describes the cre-
ation of the CAFC (the national appellate court 
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health and agriculture raise legal questions for 
which there are no direct precedents and about 
which there is no consensus. Therefore, the courts 
take an incremental approach to such questions, 
building on indirect precedents that attempt to 
balance the competing visions of patent theory 
and that respond to the quick pace of scientific 
discovery. In other words, the present builds on 
the past to create a coherent and stable body of 
law. 
When technology and biology are involved, 
the overview of jurisprudence (as well as deci-
sions in individual cases) will affect the nation’s 
economy and the public interest, and, addition-
ally, have an even broader global impact. This 
Handbook arises from the premise that the de-
velopment of the products of science and tech-
nology profoundly benefits the public and that 
both scientific and industrial participation are 
required in order for their benefits to be realized. 
This is a many-faceted concept; yet we exist in a 
time of such pervasive scientific and technologi-
cal advance that the development of these ben-
efits and their movement into commerce among 
nations warrant our most concerted efforts. 
But are public research institutions really 
delivering public goods? This question might 
appear foolish. In the past 50 years, the inten-
sity of research and the pace of discovery in the 
biomedical and health fields have accelerated dra-
matically, not only in the United States, but in 
many parts of the world, particularly in the more 
innovative developing countries. As a result, the 
number of safe and effective drugs, vaccines, and 
medical devices for a broad range of illnesses and 
conditions has skyrocketed, as have sales in de-
veloped countries. But in an increasingly global 
world—in which the risk of disease and the ben-
efits of research can come from any corner—the 
benefits from public sector health investment 
should be global. Keusch and Nugent,2 there-
fore, argue, on the basis of their experiences in 
the United States, that the public-benefit aspect 
of government-sponsored research investments 
should include (the poor) in countries outside 
the United States. 
Because of the “public goods” aspect of 
health, governments should fund health research, 
and indeed they do. For similar reasons, they also 
fund agricultural research and extension services. 
Such publicly supported research fills knowledge 
gaps that private industry ignores, even though 
public sector inventions are usually brought to 
market by private sector product development. 
The choice of whether to develop new ideas into 
products is largely left up to the private sector. 
Thus, technology development from public re-
search proceeds largely according to private sector 
priorities. So what role do public agencies have 
in ensuring that the public benefits from its in-
vestments in health research? The answer is not 
obvious. Under current arrangements, the public 
sector has limited capacity and experience in the 
downstream steps of developing and delivering 
biomedical products to patients. These steps typi-
cally require a significant investment of money. 
They are also not aligned with the public sector’s 
comparative advantages.
The public sector, therefore, needs to be cre-
ative, and Keusch and Nugent outline several 
ways that decision makers can strengthen and 
reorient the public sector’s intellectual property 
(IP) strategies to expand the ability of develop-
ing countries to access the benefits derived from 
public research investments. They discuss several 
strategies that public institutions can adopt to in-
crease the resources and tools devoted to the pub-
lic health needs of the developing world:
•	 At the upstream end, the public sector can 
direct funds toward research on diseases in 
developing countries and can partner with 
private and nonprofit entities wishing to do 
the same. 
•	 At the downstream end, public sector insti-
tutions can directly provide products to us-
ers in poor countries, reduce barriers to the 
transfer of technology that benefit develop-
ing countries, or partner with industry and 
academia to expedite the development of 
products from research. 
As much as the Bayh-Dole Act successfully 
created a large body of intellectual property from 
publicly funded research, it has reduced, in some 
regards, the availability of public goods for health 
and agriculture. Current practice undervalues the 
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public-benefit aspect of the mandate, especially 
for the poor. As developing countries increas-
ingly consider implementing Bayh-Dole-relat-
ed legislation, these countries should carefully 
study the conclusions from this chapter so they 
may improve upon the experiences in the United 
States. It should be pointed out that the intent 
of Bayh-Dole was not to produce supplemental 
revenue streams to universities. Rather, it was to 
encourage private innovation and increase the use 
of technology for economic development. 
Graff 3 surveys the opportunities available 
in 18 developing countries4 for new technolo-
gies to flow to the private sector and the public 
policy issues needing to be addressed to facili-
tate this. Three key aspects of public policy are 
considered:
1. The availability of IP protection 
2. The designation of IP ownership
3. The existence of the infrastructure needed 
to make IP protection and ownership a 
reality
The chapter reveals that strong IP protection 
capabilities are correlated with robust scientific 
research efforts, to the strength of the countries’ 
IP laws through history, and support of, through 
membership in, international trade agreements, 
particularly the Agreement on Trade-Related 
Aspects of Intellectual Property (TRIPS) and 
the International Union for the Protection of 
New Varieties of Plants (UPOV). Regarding IP 
ownership issues, policies in most countries are 
moving toward granting the rights and respon-
sibilities of ownership to research institutions. 
Finally, sophisticated institutional IP manage-
ment is correlated to research capacity and to 
government investment in public sector and 
university research and development. Generally 
speaking, vigorous IP protection policies and the 
capacity to enforce and manage them are mu-
tually strengthening. The biggest factor for this 
strengthening is the amount of research and de-
velopment a country conducts, followed by the 
ability of its economy to absorb new innovations 
into existing or new industries. Those seeking to 
use intellectual property as part of an integrated 
strategy to grow the economy through public 
financing and commercialization of innovation 
will find these trends worth considering.
In the chapter by Finston,5 the discussion 
moves away from broad national policies to spe-
cific technology transfer policies. Finston reveals, 
using many colorful examples, how such policies 
can have a broad-ranging, positive impact for a 
country, raising the standard of living, improv-
ing the economy, and opening many commercial 
opportunities. Primarily addressing government 
policymakers, this chapter defines the policy con-
ditions needed for a robust national technology 
transfer system: 
1. Government support of science education, 
research, and related infrastructure that to-
gether will create an enabling environment 
2. Rule-of-law protections (predictable laws, 
fair enforcement, judicial remedies), includ-
ing those relating to intellectual property 
3. A reliance on market forces, which foster 
informed risk-taking and private sector in-
vestment, to determine which technologies 
and products should be developed 
Finston argues that these three factors are 
mutually interdependent and should all be pres-
ent to create a favorable environment for technol-
ogy transfer. To support her claims, the experi-
ences of five geographically and developmentally 
diverse countries with existing technology transfer 
policies are described: Brazil, Israel, Jordan, India, 
and Ireland. As a result of technology transfer re-
forms, these countries enjoyed growth in R&D, 
technology transfer, and economic activity. If one 
or more of the above three requirements were 
missing, a country would not have advanced as 
far technologically or economically. 
The key lesson offered by her chapter is that 
the strength of government and of the private sec-
tor can be synergistically applied to improve the 
lives of all. Technology transfer works best when 
there is strong, consistent government support of 
basic research, including science education and 
technology-related infrastructure and robust IP 
protection. 
Given the success of technology transfer in 
the United States, many countries’ expectations 
of similar programs in their own countries are 
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grossly overestimated (if not outright misdirect-
ed). Indeed, Heher6 points out that many poli-
cymakers in developing countries proclaim that 
a technology transfer program should become a 
major source of income. Too often, such programs 
begin too optimistically, but within a few years, 
end up disillusioned. 
Unless the central reasons for undertaking 
technology transfer (for long-term social and 
economic benefits) are understood, a boom-and-
bust cycle, replete with unrealistic financial ex-
pectations, is likely to prevail at considerable cost 
to those involved. Indeed, countries have yet to 
develop answers to basic questions. For example, 
what exactly is the nature of success in technol-
ogy transfer? And what precisely are the elements 
that make this success possible? This chapter uses 
international technology transfer benchmark 
data to benchmark and understand the implica-
tions of promoting technology transfer and the 
likely outcomes of a technology transfer initiative 
under realistic conditions.
Heher provides comprehensive data and 
concludes that income generation from technol-
ogy transfer is an inadequate—if not inappropri-
ate—reason for an institution to invest in tech-
nology transfer. Governments should not expect 
revenues from technology transfer to be able to 
fund research institutions. Indeed, the financial 
benefits of technology transfer activities are cap-
tured primarily at the national economic level 
through business creation, with national returns 
arising from indirect economic effects. The ex-
tended time period required for individual insti-
tutions to derive benefits together with the fact 
that the benefits are largely felt by the national 
economy suggest that appropriate national sup-
port measures are needed to encourage technol-
ogy transfer. 
Bringing this realistic approach to the in-
stitutional level is the topic of the chapter by 
Taubman and Ghafele.7 First, the authors strong-
ly endorse the indigenous innovation potential 
of developing countries. Second, they detail the 
inadequacies of a top-down approach to devel-
oping IP management policies and approaches, 
as such an approach would almost invariably ig-
nore the unique strengths of a particular country 
or institution. Rather, to seize on such strengths, 
a thoughtful dialogue between policy-conscious 
practitioners and practically informed policy-
makers is advocated by the authors. This requires 
knowledge one to act flexibly. 
Taubman and Ghafele insist that IP manage-
ment for the public interest should go beyond li-
censing arrangements and consider the full range 
of two continuums: degrees of exclusivity and 
degrees of market engagement. To demonstrate, 
the efforts of Jordan and Indonesia to manage 
intellectual property for the public good are ex-
amined. Both countries have passed IP legislation 
and have developed their IP policies in relation 
to broader public policy goals. The authors con-
clude that success requires flexible use of market 
mechanisms and the strategic deployment of the 
full range of exclusive rights afforded by IP pro-
tection. This can lead to some creative solutions. 
Public sector institutions should learn to use the 
rules at least as well as their private sector coun-
terparts to achieve their public policy aims. This 
has never been more urgent than with the com-
ing into force of the TRIPS Agreement in most 
developing countries.
TRIPS mandates minimum IP protections 
for patented pharmaceutical products.8 Within 
this requirement, countries have considerable 
freedom on many specific aspects of TRIPS, and 
it is wise (if not imperative) for developing coun-
tries to exercise these flexibilities to the maximum 
extent possible. Thus, TRIPS can have profound 
effects on innovation, on the scope and magni-
tude of R&D investments, and on product avail-
ability. Product price in low- and middle-income 
countries is vigorously debated. Predicting and 
measuring the impacts of TRIPS on innovation 
is an unwieldy task because of the numerous vari-
ables in play and also because TRIPS only came 
into force in 2005, in many of the innovative de-
veloping countries. This is a short time to mea-
sure specific impacts; a simple measure like the 
price of a product is but one of the factors that 
determine “access” to patented health and agri-
cultural products. Another factor would be the 
types of drugs or vaccines that are becoming avail-
able. Indeed, based on a conference held in India, 
the conclusion was drawn by Eiss, Mahoney, 
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and Satyanarayana9 that much of the impact of 
TRIPS will depend on how countries and insti-
tutions respond to the new IP regime.
There is every indication that IP management 
skills appear to be one of the crucial elements 
for harnessing the positive potential of TRIPS, 
and mitigating the negative ones, and such skills 
will allow developing countries to gain access to 
emerging tools, technologies, and resources that 
can dramatically improve the health and welfare 
of their citizens. Effective IP management can al-
low public research institutions to use their own 
research products to benefit the poor and to enter 
into public-private partnerships that can direct 
the power of industry to the needs of the poor. 
Without knowledge of sophisticated IP manage-
ment techniques, however, such efforts—and 
their benefits—will be impossible. 
The World Trade Organization (WTO) 
offers many initiatives and instruments that 
seek to enhance IP capacities in the developing 
world. Specific initiatives and instruments are 
also aimed at mitigating the possible negative ef-
fects of TRIPS. These are discussed by Watal and 
Kampf10 and include compulsory licensing, the 
Doha Declaration, elements of the Convention 
on Biological Diversity, traditional knowledge 
projects, technology transfer programs, and IP ca-
pacity building programs. 
Of particular relevance here is the Doha 
Declaration, which sought to address the poten-
tial constriction brought about by TRIPS regard-
ing access to patented medicines in developing 
countries. The Doha Declaration emphasizes that 
the TRIPS Agreement does not and should not 
prevent members from taking measures to protect 
public health, and it reaffirms the right of mem-
bers to use, to the full extent, the provisions of the 
TRIPS Agreement that provide flexibility in terms 
of accessing medicines. The Declaration states 
that each member has the right to determine what 
constitutes a national emergency, or other circum-
stances of extreme urgency, and explains that pub-
lic health crises, including those relating to HIV/
AIDS, tuberculosis, malaria, and other epidemics, 
can represent such circumstances. 
By virtue of WTO member states hav-
ing signed and ratified the agreement, TRIPS 
constitutes international law. It must be trans-
lated or adapted into national law individually by 
each member state. Though not directly related to 
TRIPS, the chapter by Bremer11 provides an over-
view of key legal provisions in the United States 
that have profoundly affected the evolution of IP 
rights and technology transfer. The fundamental 
basis underlying the transfer of technology as in-
tellectual property is embodied in the country’s 
Constitution, which embraces patents, copyrights, 
and trademarks within its scope. The terms and 
provisions governing these forms of intellectual 
property are codified in various statutes, but two 
pieces of legislation are especially important.
The first is the Stevenson-Wydler Act enacted 
to promote the utilization of technology owned 
by the government and generated with its help. 
It aids the transfer of that technology to the pri-
vate sector and government at the state and local 
levels. The second law is the Patent and Trademark 
Amendment Act of 1980—known as the Bayh-
Dole Act. The Bayh-Dole Act established a uni-
form federal patent policy and provided the first 
statutory authority for the U.S. government to 
take title to and hold patents through its agencies. 
The success of this act makes it of special interest 
to countries seeking to establish IP regulatory sys-
tems, and this chapter explains the structure and 
history of Bayh-Dole. 
Bremer also discusses the important interplay 
between patents and antitrust laws, recognized as 
complementary tools that enhance competition. 
The laws are based on the important premise that 
patents per se do not convey market power. Only 
when coupled with other assets, or when acquired 
in order to build a monopolistic behavior, can 
patents create market power. Antitrust scrutiny is 
triggered when patents (and certain other market 
positions) are combined with apparent predatory 
practices that restrain trade and competition. The 
point of this chapter then becomes very clear: a 
country strengthening its patent laws should, 
concurrently, strengthen its antitrust laws as 
well as its capacities to enforce them.
One such enforcement is the capacity of a 
government to bring about a compulsory licens-
ing action. A compulsory license is an authoriza-
tion given by a national authority to a natural or 
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legal person for the exploitation of the subject mat-
ter protected by a patent; the consent of the patent 
holder is not necessary. Compulsory licenses may 
be required to import or produce a given prod-
uct or to use a patented technology for research. 
They are especially important when there are no 
close substitutes for a product or process and a re-
search exception is not available or is too narrow. 
Compulsory licenses are granted in order to attain 
various public policy objectives, such as: to address 
emergencies and public health needs, to counteract 
anticompetitive business practices, or to permit the 
exploitation of patents that are not used. 
Correa12 discusses the usefulness of compul-
sory licensing and provides a step-by-step guide 
to obtaining compulsory licenses to ensure that 
the R&D of drugs needed by people in devel-
oping countries is kept free from unnecessary 
entanglements in the global IP system. His chap-
ter provides many illustrations and a useful dis-
cussion of the patenting and licensing strategies 
of universities and other public sector research 
institutions. These institutions often hold patents 
on research tools, underscoring the importance of 
the public sector retaining research-use and hu-
manitarian-use rights in all licenses.13 While there 
are several ways to circumvent patented upstream 
technologies, and the compulsory license is es-
pecially powerful. But, perhaps due to its power, 
the strategy also has drawbacks. The flexibility of 
compulsory licensing should be considered in the 
context of all of the options available to TRIPS 
member countries. Importantly, applicants need 
to be certain that they have the capacity to ex-
ploit the licenses and the financial ability to re-
munerate the patent holder or holders. Nonprofit 
research institutions may often find this particu-
larly difficult because, even with a compulsory li-
cense, commercial partners need to be willing to 
produce and distribute products developed under 
compulsory licenses. This is one reason for fur-
ther investments in technological and IP capacity 
building and the establishment of strong institu-
tional networks. 
Institutional networks are most power-
ful when formed around geographic clusters. 
Innovation in health and modern agriculture re-
lies on a sophisticated open system of knowledge 
sharing. Recent studies suggest that successful 
innovation indeed requires development of clus-
ters of institutions, businesses, and personnel. 
“Location, location, location,” the battle cry for 
property realtors everywhere, is heard increas-
ingly with respect to innovation dynamics and 
knowledge-based growth. 
A cluster is a group of similar things posi-
tioned or occurring closely together. Although 
companies and various not-for-profit entities in 
the same sector or product market have tradition-
ally located themselves in close geographic prox-
imity (rather than spreading out evenly across the 
geography or economy), the express search for 
ways to encourage clustering has only recently 
begun. One paradigm, as discussed extensively by 
Phillips and Ryan,14 is that local competition is 
the primary engine behind cluster development 
and sustainability. Additionally, innovation now 
involves and generates significant externalities; 
innovators increasingly rely on an array of for-
mal and informal collaborators, and the efficacy 
of those relationships will determine their ability 
to successfully launch an innovation into product 
development. 
Offering an overview of recent research on 
clusters in Canada, this chapter observes that one 
factor encouraging cluster formation is the de-
velopment of a cost-effective, efficient IP man-
agement system. Equally important is the use of 
social capital, which can lead to less formal col-
laborations that can better disseminate and uti-
lize discoveries. While the traditional strategy of 
protecting infant industries in order to develop 
them made some sense in the industrial world, 
its value in a knowledge-based world is unclear. 
Knowledge-based development is inherently dif-
ferent from traditional industrial development. 
Indeed, multiple types of knowledge are involved 
in such a system, and Phillips and Ryan address 
how clusters integrate four distinct types of 
knowledge: “know-why,” “know-what,” “know-
how,” and “know-who.” A cluster’s ability to use 
and share these types of knowledge is largely what 
empowers individual entities within the cluster to 
innovate. Basing their ideas on varied illustrations 
and deep analysis, the authors conclude that gov-
ernments have an important role to play in the 
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process of cluster formation and that ensuring a 
mix of “local buzz” and “global reach” is part of 
the recipe for success. 
A specific experience of cluster develop-
ment and the role of government are presented 
by Viljamaa,15 who discusses the case of Turku, 
Finland. The city is home to a large concentration 
of biotechnology activities. This model can be de-
scribed as a science-led strategy, led from above, 
with a range of important lessons for policymak-
ers and institutional leaders alike. The experienc-
es suggest that sharing facilities with companies 
and combining forces with other universities and 
R&D institutes are vital ways of building clusters 
and momentum in innovation. Active partner-
ships with larger entities are important, as is a 
global network of scientists. Viljamaa offers many 
ideas that are particularly pertinent to developing 
countries that wish to encourage the formation 
of clusters. One is that building clusters from 
scratch is basically impossible; success comes 
from building upon existing strengths. Many 
successful clusters have been based on older but 
related industries. 
Probably the most famous example of a 
cluster that is grounded on entrepreneurship is 
the biotechnology cluster of the greater Boston 
area, which encompasses Massachusetts Institute 
of Technology (M.I.T.), Harvard University, 
Boston University, and others. M.I.T., some ar-
gue, has led the translation of university-gener-
ated research from the laboratory to the private 
sector through the cultivation of an entrepre-
neurial culture. Indeed, the entrepreneurial ac-
tivities of M.I.T. have served as an incubator for 
generation after generation of entrepreneurial 
engineers and scientists who view risk as an op-
portunity. Seeing risk and opportunity as two 
sides of the same coin, students at M.I.T. don’t 
utter, “Why do you want to do that?” but in-
stead proclaim “Hey! Why not?” This positive 
attitude, this sense of self-confidence, typifies 
M.I.T.’s culture, from professors to students to 
its licensing professionals. 
Nelsen16 points out that M.I.T.’s licensing 
office also has served as a focal point for the for-
mation of the greater Boston area’s biotechnol-
ogy cluster. By coordinating the management of 
M.I.T.’s intellectual property, the office contributes 
to the robust development of many companies 
that form the cluster. This promotes further devel-
opment, economic progress, investment in innova-
tion, creation of networks, and ultimately, success. 
Although Boston is quite unlike most develop-
ing-country cities, the fundamental principles that 
drive its economic development are universal.
With respect to working with developing 
countries, M.I.T. recognizes that there are often 
special circumstances requiring creative practices 
(for example, preferential pricing for develop-
ing country public sectors, strategic patent fil-
ing, and differential licensing practices). Hence, 
with M.I.T. licensing, there are no rigid written 
policies guiding how technologies are handled 
(the exception to this is clear and nonnegotiable 
conflict of interest policies and practices); instead, 
the choices are left open in order to creatively craft 
agreements to maximize access. This flexible man-
agement fuels the innovation engine, and this ap-
proach can be adapted by many other regions.
But what are the potentials for individual 
countries to develop thriving cluster complexes 
without misspending scarce funds? What variables 
are essential for cluster development? In another 
chapter, Phillips and Ryan17 identify six factors: 
manufacturing capacity, domestic market, export 
market, R&D, an IP system, and a functioning 
drug regulatory system. The authors explore these 
factors across three development stages to mea-
sure a country’s cluster capacity. The authors go 
further and provide a five-stage process for real-
istic cluster building:
1. Assessing capacities, resources, and 
opportunities
2. Choosing an anchor strategy (different 
cluster approaches will have different sets 
of requirements, leaders, and tactics, and 
different success rates.)
3. Identifying organizational and institutional 
leaders to take the lead in developing the 
cluster.
4. Adopting proactive tactics, spanning nu-
merous areas, including having the neces-
sary legal and social structures, efficient 
mechanisms to protect and adjudicate 
property, the lowest possible barriers for 
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entering or exiting key input and output 
markets, the ability to trade domestically 
and internationally, and effective tax, regu-
latory, and trade rules.
5. Sustaining the lifecycle of the cluster 
(Recognizing that the evolutionary dynam-
ics of markets are unavoidable, clusters 
should re-invent themselves every now and 
then to prevent cluster decay.)
Importantly, clusters thrive when local strengths 
are nurtured rather than when companies are lured 
with subsidies. Building infrastructure does not fill 
the buildings with innovative enterprises, but rath-
er, innovative enterprises make buildings happen. 
Hence different types and sources of capital flow 
are needed at different stages of cluster develop-
ment. Government money sometimes gets in the 
way of private money and vice versa. 
The real and most effective catalysts for 
change are key individuals who serve as ambassa-
dors or entrepreneurs for geographic regions; they 
cross-fertilize public-private partnerships which, 
in turn, alert the public sector to market demands 
and provide companies with access to basic re-
search, infrastructure, and people capacity. This is 
why many institutions look for “people policies” 
to nurture clusters. Indeed, people are at the cen-
ter also of these intellectual assets. Knowledge-
based development is inherently different from 
traditional industrial development. Today’s in-
novation potential requires, above all, global, 
institutional, and personal links and networks. 
They are the necessary fertile ground that en-
ables innovation to flourish. ■
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4 Countries have considerable freedom to control the effects of TRIPS. Indeed, the impact 
of triPS will depend on how countries and institutions respond to the new iP regime. 
At a minimum, countries should take full advantage of the flexibilities offered by TRIPS, 
in line with the Doha Declaration.  For example, a country strengthening its patent 
laws should concurrently strengthen its antitrust laws as well as capacities to enforce 
them.
4	 Technology transfer efforts can be powerful when combined with government’s efforts 
to reorient the public sector’s iP strategies to enable the poor to benefit from public 
investments in innovation. To be effective, this should acknowledge the inadequacies 
of a top-down approach to developing IP management policies and approaches. Each 
institution has its unique strengths. To seize on these strengths, thoughtful dialogue 
between policy-conscious practitioners and practically informed policymakers should 
be encouraged.
4	 Public institutions’ IP policies should address the institution’s obligation, whenever 
possible, to retain humanitarian-use rights to its inventions, and the government’s 
right to a license for technology developed with public funds, in case the public benefit 
is not being served adequately. Under extreme, well-defined circumstances, this may 
include full “march-in rights” . The potential for such government action will encourage 
companies to make products widely available in the market. 
4	 Public-private collaborations within publicly funded r&D programs can be powerful 
arrangements for optimizing public research investment. 
4	 Public-private partnerships aimed at product development are effective arrangements 
through which industry can invest and apply its expertise to address the needs of the 
poor. In many contexts such product-development partnerships (PDPs) are now driving 
the drug-development pipeline in neglected-disease r&D. National institutions in 
developing countries should be encouraged to participate in PDPs.
4	 The ability of the local and national economy to absorb new technologies into existing 
industry or business sector can be strengthened through the encouragement of cluster 
formation.  They require a long-standing and durable commitment to science education, 
research and related infrastructure, a strategically situated anchor institution with a 
proactive technology transfer office, and reliance on market forces as the engine for 
technology transfer.
4	 Overall, public funds should be directed at product development partnerships that 
create collaborations, as opposed to buildings with bricks and mortar. Such strategies 
have proven most effective in strengthening and sustaining clusters.
4	 Governments should support local entrepreneurship with much attention given to 
endogenous development, specifically to local, small- to medium-size enterprises and 
to spinouts. An effective short-term strategy may be to attract foreign companies to 
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
FOR SENIOR MANAGEMENT
(UNIVERSITY PRESIDENT, R&D MANAGER, ETC.)
4	 In an increasingly global world—in which the risk of disease and the effects of agricultural 
disasters span borders and the benefits of research can come from any corner—the 
society that benefits from public sector health investment will be global. The public-
benefit aspect of government-sponsored research investments should include the poor 
in every society, including those of neighboring countries.
4	 There are many strategies available to increase the resources and tools devoted to the 
public good that do not run counter to economic development goals and private sector 
interests. At the upstream end, funds can be directed toward research in developing 
countries, and partnerships with private and nonprofit entities can be effective. At the 
downstream end, funds can directly provide products to users in developing countries, 
reduce barriers to the transfer of technology that benefits these countries, or partner 
with industry and academia to expedite the development of products from research. 
4	 The main issue for universities is to ensure a high level of education, comprehensive 
partnerships with other universities, and collaboration with the private sector. This 
requires clear IP policies, transparent IP management practices, and sound management 
of conflicts of interest. 
4	 Public-Private Partnerships and Product-Development Partnerships (PDPs) are novel, 
tightly focused organizations, dedicated to providing products to benefit the poor in 
developing countries. PDPs require that scientists put a priority on delivering global 
benefits and that universities fully embrace their larger role in society and the global 
community. 
4	 A major policy objective is to find a balance between public benefit and economic returns. 
A university can include a public-benefit clause in its licenses to the private sector, invest 
part of its royalty stream in a foundation, establish an “ethical” investment fund, license 
technologies to nonprofits or others who would develop and manufacture products for 
developing countries, and bundle technologies to encourage development of medicines 
aimed at diseases of the poor. 
4	 The ability of the local and national economy to absorb new technologies into existing 
industry or an entrepreneurial sector can be strengthened through the encouragement 
of cluster formation. But robust innovation clusters are not created from scratch. 
They require a long, durable commitment to science education, research, and related 
infrastructure; a strategically situated anchor institution with a proactive technology 
transfer office; and reliance on market forces as the engine for technology transfer.
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4	 Global changes in IP regimes, especially changes that affect developing countries, 
have been tremendous. Within the evolving IP regime, your country has considerable 
freedom to control the effects of these changes. Indeed, much of the impact of these 
changes will depend on how countries and institutions respond to the new iP regime. 
4	 An important response is the creation of an effective technology transfer program. 
Your role in this process is essential.
4	 As a scientist, you understand the interrelatedness of science, r&D, technological 
advance, and commercial investment. Share these insights with your institution’s 
technology transfer office, as well as with its senior managers. 
4	 Countries engaged in reforming their R&D and technology transfer efforts are today 
often including royalty-sharing provisions for scientists in publicly funded research 
institutions. This approach also comes with obligations to assign ownership rights to 
your institution and a duty to disclose inventions. All of these changes should be seen 
as incentives to turn inventions into innovations that benefit society. 
4	 As your institution implements IP policies and patenting strategies, your right to 
publish is not jeopardized. IP protection and licensing are but one form of knowledge 
transfer that, if well undertaken, can very much be in the public interest.
4	 While access to foreign technology is integral to development, it is increasingly 
important to focus directly on capturing the national (or indigenous) innovation 
potential of developing countries. Through the activities of your research program, 
you may be positioned to facilitate such capture and development of the benefits 
arising from indigenous innovation and traditional knowledge. These efforts should be 
coupled with benefit-sharing provisions.
4	 Understand the obligations that are attached to different funding sources when funds 
are used within the same program. The impact of joint public and private financial 
support can be complex but will increase, particularly as your institution positions 
itself strongly within an innovation cluster and engages in product development.
4	 As a scientist, you play an increasingly important role in knowledge-based innovation 
clusters. Do not shy away from becoming an entrepreneur yourself.
4	 Collaboration is often based on establishing personal contacts, for example, building 
close connections and networks to other scientists and research groups in the same 
field via conferences and reciprocal visiting arrangements; these all foster the formation 
of collaborative research projects and are fundamental for effective sharing of know-
how and show-how.
FOR SCIENTISTS
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.



























4	 Traditionally, the mission of a technology transfer program was to bring university-
generated intellectual property into use as rapidly as possible. But public sector 
technology transfer has evolved to serve broader purposes: to enhance the reputation 
of the institution. Successful technology transfer can help it achieve its missions of 
education, research, and community outreach; to ensure social impact; and to provide 
funds for further research.
4	 The laws relating to new technologies are evolving. Recent court decisions may have 
an impact on business and technological matters relevant to the operations of your 
technology transfer office (TTO). 
4	 A TTO has much responsibility in creating incentives to move discoveries into the 
product development arena, motivating public sector researchers, not by the promise 
of revenue streams (which rarely appear), but by the satisfaction of seeing their work 
developed and applied to serve the public good.
4	 An understanding of not only the law, but also the public policy that underlies it. 
For example, with the Bayh-Dole Act in the United States, the policy rationale is not 
directed toward revenue generation, but rather toward moving publicly funded R&D 
into the marketplace to serve the public good. 
4	 Financial benefits from technology transfer can take many years to realize—if they 
ever do materialize—so it is important to be realistic when making forecasts about 
expected income. International benchmark data indicate that a positive return can 
take eight to ten years to achieve. It is prudent not to justify the cost of technology 
transfer functions on the basis of financial returns.
4	 the difficulties of managing and promoting technology transfer within a smaller 
research institution need to be recognized, and the office should actively seek 
partnerships with other entities, such as local venture capital firms, incubators, and 
business development agencies. Alliances with other institutions, or a central TTO for 
several institutions, may also constitute viable alternative strategies.
4	 In a dynamic innovation cluster, authoritative IP management capacity, technology 
transfer, and licensing are all essential. Flexibility in licensing and partnership 
arrangements, and speedy action and decision making are equally important.
4	 TTOs are often ideally placed to define and nurture an entrepreneurial culture in the 
faculty. There can be large gains from such efforts. 
4	 TTOs can, if appropriately structured, become a source of creative networking and 
collaboration, generating both academic and commercial success. Hence, this role in 
driving the success of clusters will be absolutely essential. 
FOR TECHNOLOGY TRANSFER OFFICERS
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government to an inventor for any invention that 
is a new and useful process, machine, article, man-
ufacture, or composition of matter or any new and 
useful improvement thereof. The invention, that is 
the intellectual property itself, is a product of the 
inventor’s mind. The patent, then, confers certain 
rights to this property; it is the right to exclude 
others from making, using, selling, or importing 
the invention in the country where the patent is 
granted, normally for a period of 20 years from 
the date of the patent application. 
In patents, many aspects of inventions are dis-
closed. Patents should thus not be seen as the ex-
clusive domain of lawyers. Scientists in particular 
are well advised to be up-to-date on patents is-
sued in their field of endeavor, and Nottenburg2 
in Chapter 4.2 provides a comprehensive guide 
to patents, using biotechnology patents as an ex-
ample, that instructs scientists and others how to 
read utility patents. 
Trademarks are a form of IP protection that 
serves to distinguish the products or services of 
one individual, company, or organization from 
the products or services of others. A trademark 
can be a word, phrase, symbol, design, or a com-
bination thereof. Trademarks can even be sounds 
or colors, if they are in some way distinctive, that 
create an immediate association in the mind of 
the consumer between the trademark and the 
good. IP protection for a trademark confers an 
exclusive right to use the mark in commerce.
EXECUTIVE GUIDE TO HANDBOOK SECTION 4
(VOLUME 1: PAGES 335-455)
Best practices in the management of intellectual 
property require a basic understanding of the var-
ious forms of IP protection that are available. The 
forms of IP rights in most countries include pat-
ents, trademarks, geographical indications, copy-
rights, and trade secrets. Special provisions for 
plants are also offered in many countries in the 
form of plant variety protection, or plant breed-
ers’ rights. A further emerging type of protection 
is that related to regulatory data, which can be 
protected from disclosure or acquisition for a 
certain period of time and offer data exclusivity. 
Although each of these statutory mechanisms 
of IP rights protect different forms of intellec-
tual property, thus conferring different IP rights, 
when used alone or in combination, they provide 
a set of options for organizing and then making 
the most out of an organization’s IP assets. 
All of the above are reviewed in detail by 
Dodds and Krattiger1 in Chapter 4.1, which in-
cludes short sections on institutional aspects in-
cluding employee agreements, how to integrate the 
various rights, and how to identify infringement. 
Importantly, the form of protection chosen for a 
given invention should be guided by the mission 
of the institution (whether public or private), the 
purpose of the work it conducts, and the nature of 
the invention, or other intellectual property that 
will be subject to IP rights protections. 
A utility patent is a type of statutory IP pro-
tection covering inventions, that is, a grant by the 
Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 
2007. 4: The IP Toolbox. In Executive Guide to Intellectual Property Management in Health and Agricultural Innovation: A 
Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz 
Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at 
www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for non-
commercial purposes is permitted and encouraged.
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Trademarks are an often overlooked and un-
dervalued form of intellectual property by the 
public sector and this is well argued by Needle3 in 
Chapter 4.3 on the basis of many colorful exam-
ples. Trademarks should be a valuable component 
of any IP management strategy, complementing 
the protection afforded by other forms of statu-
tory IP protection. Trademarks can complement 
other forms of IP protection, and, as in the case 
of many pharmaceuticals, serve to strengthen the 
period of proprietary rights to a product.
Geographical indications are signs used on 
goods that have specific geographic origin and 
possess qualities or a reputation that are derived 
from their place of origin. Geographical indica-
tions are another type of intellectual property, 
similar to trademarks in that they are source indi-
cators. Most commonly, a geographic indication 
consists of the name of the place of origin of the 
particular goods (for example, Roquefort cheese 
or champagne). 
Copyright is a type of statutory IP protec-
tion for the original works of authors, such as the 
chapters in the Handbook. Such works include lit-
erary, musical, dramatic, and architectural works. 
The copyright protects the work immediately af-
ter it is fixed in a tangible medium, for example, 
words on a page (what you are reading at this 
very moment) are copyrighted. The owner of the 
copyright, for example, we, the authors of this 
chapter, have certain rights to the work. Typically, 
these rights include moral rights (that is, having 
our names associated with the work) as well as the 
right to reproduce the work, to prepare adapta-
tions of the work, and to distribute the work to 
the public. However, these rights can be either 
licensed or assigned to others. In the case of this 
chapter, we agreed to make it freely available to all 
through the Internet. 
Trade secrets (in certain circumstances and 
jurisdictions called know-how) are an important 
form of intellectual property. Trade secrets pro-
tect know-how and any confidential information 
so designated. To be protected as a trade secret, 
the inrellectual property must, of course, be kept 
secret, and must also confer some sort of com-
mercial advantage to the holder. Enforcement 
of IP rights for trade secrets is possible when a 
competitor has misappropriated and/or stolen 
the trade secret.
A point often raised is when one should file 
for a patent or maintain the information as a trade 
secret. What is important to note is that patents 
and trade secrets are not in conflict with each oth-
er but are complementary IP assets. Depending 
on the nature of the know-how, or the invention, 
the organization may choose to either file a patent 
or to continue to hold as a trade secret. Dodds 
and Krattiger in Chapter 4.1 discuss trade secrets 
briefly, but they are fully discussed in the context 
of licensing in another section of the Handbook.4
The protection of intellectual property re-
lated to plants, germplasm, and varieties is cov-
ered in several chapters because there are many 
dimensions to the topic. Kesan5 in Chapter 4.4 
describes the various forms of intellectual prop-
erty applicable to plants. These are utility patents 
(available in a few countries only), plant variety 
protection (or plant breeders’ rights), plant pat-
ents, trade secrets, geographic indications, and 
trademarks. The strengths and weaknesses and 
pros and cons of each are discussed. It is worth 
noting that the use of one form of protection is 
not necessarily exclusive, in that a single plant 
may be simultaneously covered by several forms 
of IP protection. 
Plant variety protection (PVP) is the most 
common tool for protecting varieties, and many 
countries have legislated and implemented a 
PVP system. Lesser6 describes the PVP system in 
Chapter 4.5. PVP regimes are implemented in 
order to:
•	 provide breeders (both public and private 
sectors) with an opportunity to receive a 
reasonable return on past investments 
•	 provide an incentive for continued or in-
creased investment in future breeding 
research
•	 recognize the legal right of the innovator to 
be recognized as such
•	 acknowledge the economic right to remu-
neration for his or her efforts
In general, there are two exemptions to the 
protection provided: 1) a research exemption and 
2) a farmer’s exemption (this is not to be confused 
GUIDE TO SECTION 
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with farmers’ rights). A research exemption allows 
for breeders to develop a new variety by using a 
protected variety; a farmer’s exemption allows for 
the saving of seed for the sole use of replanting 
the farmer’s land. 
Given the advantages of a PVP system in at-
tracting private investments and offering farmers 
a broader range of improved varieties, countries 
may gain substantially in internationally harmo-
nizing their PVP regimes, as it lowers costs for 
users, simplifies the introduction of new varieties, 
and thus leads to the availability of more varieties 
and choices for farmers.
Lesser also points out that those countries that 
are members of the Agreement on Trade-Related 
Aspects of Intellectual Property Rights (TRIPS) 
agreed to implement special protection for plants 
(the so called sui generis protection). Many elect 
to follow the principles of the International 
Convention for the Protection of New Varieties 
of Plants (UPOV), an international treaty that 
provides an effective framework for PVP. 
Plants can also be protected through trade 
secrets, trademarks, and geographical indications. 
Geographical indications might be used to com-
municate to consumers the association between a 
plant’s special characteristics and the territory from 
which it originates. Trademarks can have particu-
lar value if the variety has market potential, and 
consumers come to specifically associate the trade-
mark with desirable characteristics and qualities of 
the variety. Such value has important implications 
for developing countries that are exporters of agri-
cultural commodities and products, as it can add 
significant additional value to their exports.
The management of intellectual property re-
lated to crops and germplasm is an essential func-
tion of a technology transfer office (TTO) and 
is the focus of Chapter 4.6 by Dodds and col-
leagues.7 They also discuss specific issues related 
to IP management involving genebanks and prac-
tical aspects on the establishment of a PVP office. 
Blakeney8 in Chapter 4.7 reviews international 
aspects, including the international exchange of 
germplasm. A working knowledge of the relevant 
international treaties related to genetic resourc-
es is important for anyone dealing with genetic 
resources as they increasingly affect the interna-
tional exchange and use of germplasm.
One such treaty is UPOV. Significantly, the 
latest revisions of 1991 expanded the scope of 
protections that could be granted to include essen-
tially derived varieties. This has important impli-
cations for genetically modified organisms. These 
revisions also allow countries to limit  farmers’ 
rights, allowing them only to save seeds for use 
on their own land.
Another agreement is the Convention on 
Biological Diversity, particularly the provisions 
concerned with informed consent to use of bi-
ological materials and equitable benefit shar-
ing following access. Some people argue that 
these requirements may be in conflict with this 
requirement of TRIPS. In practice, however, 
whereas UPOV and related sui generis systems 
focus on plant varieties, the Convention on 
Biological Diversity essentially deals with wild 
genetic resources. Exceptions include the reach of 
the Convention into genetically modified crops 
through the Cartagena Protocol on Biosafety, but 
this is not related to intellectual property.
The International Treaty on Plant Genetic 
Resources for Food and Agriculture (the Treaty) 
is a recent addition to international agreements. 
The Treaty establishes a multilateral system that 
embodies a sort of genetic commons within which 
the exchange of germplasm in major crop varieties 
between member states is facilitated. Conditions 
limit the rights of recipients to seek IP rights in 
material obtained and support the rights of do-
nors to share in some form of benefit. The Treaty 
further recognizes the contribution of farmers 
and indigenous peoples’ traditional knowledge 
to agricultural biodiversity. This is accomplished 
through the development and conservation of 
landraces, in primitive varieties developed to deal 
with local climate and diseases and to appeal to 
local tastes, by interbreeding locally occurring 
undomesticated plants with cultivated plants, as 
well as by exchanging different genotypes among 
farmers and farms. Again, some argue that cer-
tain terms of the Treaty may not be compatible 
with UPOV standards but overall this assessment 
seems unlikely.
GUIDE TO SECTION 
0 | HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE
A distinct but closely related topic is that of 
information resources. These include computer 
software and systems, databases, geographic 
information systems (GIS), remote sensing (RS) 
information, and library resources. The integra-
tion of these is increasingly prevalent in advanced 
agricultural systems such as the forecasting of 
disease and harvests. Dodds and colleagues9 in 
Chapter 4.8 discuss the various IP elements re-
lated to information resources and how they can 
be managed effectively. The chapter also addresses 
licensing elements.
A very different topic is that of data protec-
tion and data exclusivity. These systems of protec-
tion are especially important in pharmaceuticals 
and agricultural chemicals. Two chapters review 
these complex topics, Chapter 4.9 by Clift10 and 
Chapter 4.10 by Cook.11 In short, regulatory data 
are the data that the researcher or manufacturer of 
a product must provide to the appropriate regula-
tory agency in order to prove that the product is 
safe and efficacious. Regulatory data are protected 
from disclosure or acquisition for a certain period 
of time, usually five to ten years from the product’s 
first authorization to market, during which time 
no other applicants are allowed to use it to obtain 
marketing authorization for the same product. 
Regulatory data protections are substantively 
different from other sorts of intellectual protec-
tion, including confidential information protec-
tion and patents. The provisions in Article 39.3 
of TRIPS, concerning the protection of regulatory 
data, are broad and subject to interpretation. Both 
the United States and the European Union have 
interpreted and implemented the obligations in 
different ways (as explained in Chapter 4.10).
The chapters by Clift and Cook also examine 
data exclusivity from the perspective of specific 
TRIPS requirements (Article 39) which essential-
ly include three obligations on governments:
•	 protect data on new chemical entities, the 
collection of which involved considerable 
effort, against unfair commercial use
•	 protect such data against disclosure, except 
where necessary to protect the public 
•	 protect such data against disclosure, unless 
steps are taken to ensure that the data are 
protected against unfair commercial use 
It is important to note that these require-
ments do not create new IP rights (other than 
defining the reach of trade secrets). Article 39.3 
only articulates widely accepted trade secret and 
unfair competition law and is not an invitation to 
create new IP rights per se for test data. ■
All chapters refer to: Intellectual Property Management 
in Health and Agricultural Innovation: A Handbook of Best 
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thom-
son, AB Bennett, K Satyanarayana, GD Graff, C Fernandez 
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis, 
U.S.A. Available online at www.ipHandbook.org. The online 
version contains for each chapter a detailed Editor’s Sum-
mary, Implications, and Best Practices.
1 Chapter 4.1 by J Dodds and A Krattiger titled The 
Statutory Toolbox: An Introduction, p. 337.
2 Chapter 4.2 by C Nottenburg titled How to Read a 
Biotech Patent, p. 351.
3 Chapter 4.3 by W Needle titled Trademark Primer, p. 
361. Trademarks and trademark licensing are further 
discussed in detail in Chapter 11.6 by WT Tucker and 
GS Ross titled Use of Trademarks in a Plant-Licensing 
Program, p. 1059.
4 Chapter 11.5 by KF Jorda titled Trade Secrets and Trade-
Secret Licensing, p. 1043.
5 Chapter 4.4 by JP  Kesan titled The Statutory Toolbox: 
Plants, p. 371.
6 Chapter 4.5 by WH Lesser titled Plant Breeders’ Rights: 
An Introduction, p. 381.
7 Chapter 4.6 by J Dodds, A Krattiger, and SP Kowalski 
titled Plants, Germplasm, Genebanks, and Intellectual 
Property: Principles, Options, and Management, p. 389.
8 Chapter 4.7 by M Blakeney titled Plant Variety 
Protection, International Agricultural Research, and 
Exchange of Germplasm Legal Aspects of Sui Generis 
and Patent Regimes, p. 401.
9 Chapter 4.8 by J Dodds, S  Somersalo, SP Kowalski, and 
A Krattiger titled IP and Information Management: 
Libraries, Databases, Geographic Information Systems, 
and Software, p. 419.
10 Chapter 4.9 by C Clift titled Data Protection and Data 
Exclusivity in Pharmaceuticals and Agrochemicals, p. 
431.
11 Chapter 4.10 by T Cook titled Regulatory Data Protection 
in Pharmaceuticals and Other Sectors, p. 437.
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4 The statutory tools of iP, such as patents, copyright, trademarks, trade secrets, geographic 
indications, and plant variety protection, are tools that can be used to achieve a goal. 
The tool in itself is neutral; what matters is how the tool is used.
4 When setting up a patent office, notwithstanding considerable latitude provided 
under TRIPS, there are advantages in implementing practices that are consistent 
and compatible with the practices of other countries. Doing so will facilitate greater 
opportunities for international collaboration in R&D and technology transfer. 
Particularly important is making patent applications and issued patents available 
online. This furthers innovation and licensing.
4 copyright is also an important form of IP that can be used to encourage innovation. 
The recent trend, at least in the United States, to provide for ever-increasing duration 
of protection (now exceeding four generations) should be avoided as this approach 
prevents the availability of important commercially but insignificant works.
4 The use of trademarks is important for building integrity and stability in commerce 
and for offering new opportunities for national innovations. Trademarks can also be 
highly valuable for public sector entities.
4 Judicious plant variety protection of new varieties will encourage investments in the 
development of crops that are essential for food security, a better environment, and 
economic development. As with patents, domestic innovation, the transfer of foreign 
varieties for increased production and productivity, and spurring national investments 
in crop breeding can be enhanced significantly through membership in international 
bodies, such as UPOV. This can lead to the earlier availability of improved varieties.
4 Notwithstanding the above, countries can exercise significant latitude in regulating 
access to certain categories of plant genetic resources they consider strategically 
important. Plant breeding, however, and the enhancement of crops, is based on the 
stepwise improvement of existing varieties, and this requires broad access to genetic 
material. Related to this are geographic information systems and corresponding data 
protections that can add substantial value to biodiversity resources and traditional 
knowledge.
4 Introducing stringent confidentiality of data and exclusivity laws can prevent early 
introduction of generics and promote competition critical for improving access to life 
saving drugs. There is a need to balance the various competing interests.
4 IP protection mechanisms, however, depend upon effective and equitable enforcement 
by national governments. This requires effective, transparent, and enforceable contract 
law that can be implemented to protect natural, cultural, and economic resources, all 
by furthering useful interactions with the global community. This balance is critical. 
FOR GOVERNMENT POLICYMAKERS
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
FOR SENIOR MANAGEMENT
(UNIVERSITY PRESIDENT, R&D MANAGER, ETC.)
4 The implementation of a broad institutional iP policy, consistent with the institution’s 
mission, can foster the integration of the various forms of IP protection in furtherance of 
an institution’s mission and goals. 
4 For public sector institutions, trademarks can be a valuable element in an institutional 
strategy that aims at fostering a positive image (or brand) and generating value. Because 
of the broad value of trademarks, they assist institutions in maintaining a good image 
and brand, thus serving as a tool for senior management in maintaining and enhancing 
the institution’s reputation, standing, and value.
4	 Scientists can gain a lot from regularly reviewing newly issued patents from around 
the world. Patents often disclose much more than scientific publications but are 
generally overlooked as valuable sources of scientific and technical know-how. Such an 
information-gathering approach requires appropriate staff training and the availability 
of good Internet connections, which make it possible for patents to be downloaded. All 
patent office Web sites provide patents free of charge as does the Worldwide Intellectual 
Property Organization (WIPO).
4	 A sound patenting strategy is an extremely useful tool to bring inventions to fruition 
that make an impact on economic development and meeting public sector goals. 
4	 Although many public sector institutions have for years provided their improved germplasm 
free of charge or at nominal costs to breeders and farmers, the protection of improved 
varieties can be a critical tool in furthering broad access and simultaneously meeting 
commercial and humanitarian objectives through appropriate “market segmentation.”
4	 In many countries, but not in the United States, patent law includes a broad research 
exemption. This should not be confused with possible restrictions on materials obtained 
through material transfer agreements. Although extremely useful, material transfer 
agreements should be used judiciously, particularly when intellectual property is also 
embedded in material. This aspect also requires well-trained licensing/technology-
transfer personnel and good management systems.
4	 The delivery of innovation for the greater public good by public sector institutions is 
not necessarily inconsistent with appropriate patent and other forms of IP protection. 
Trade secret protection in particular may be a valuable—and cost effective—means of 
achieving greater accessibility by disadvantaged members or groups of society. Whereas 
academic institutions in particular may regard such protection as inappropriate, it 
should be remembered that their mission is gradually shifting and increasingly include 
the delivery of products. This requires adjustments in the way information and know-
how are managed. In turn, the changes require much internal discussion and sometimes 
culture change. 
4	 Senior management’s backing of the technology transfer office is important as is its 
support in the implementation of rigorous IP-related policies and procedures (such as 
those related to confidentiality). 
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 Research endeavors can go much further, in certain circumstances, if appropriate 
iP protection is sought. If appropriately managed, this is not in conflict with the 
broad dissemination of research results but encourages that your inventions serve 
humanity. 
4	 Patents often disclose much more technical and scientific information than do 
academic publications. Make it a habit of regularly reading up on newly published 
patent applications or issued patents in your field. You can access this information for 
free on the Internet (such as on www.uspto.gov).
4	 Your institution’s good reputation and standing can be used as a valuable trademark or 
brand. Maintaining the high reputation requires strict adherence to your institution’s 
policy and best practices. 
4	 Good data management, especially accurate record keeping through comprehensive 
notebooks, is the foundation for building a portfolio of IP assets. Essentially, best 
practices in scientific record keeping should be precisely the same as best practices in 
record keeping for purposes of IP management. 
4	 Conversely, you should always know the origin and possible restrictions of data and 
information you use, no matter how insignificant they might seem. Make sure you 
document the source of important data and information in your laboratory notebook. 
If you have questions, never hesitate to contact your technology transfer office for help 
or clarifications. 
4	 Particularly if your research is related to product development, the confidentiality 
of your data may be critical in ensuring global access. Data is a valuable form of 
intellectual property that can be used to obtain certain price or access terms in licensing 
negotiations. Whereas, as a researcher in an academic environment you may regard 
such protection as inappropriate, remember that it is the goals of your research that 
should drive the IP tools applied to your inventions. If you are engaged in the delivery 
of products, adjustments in the way your information and know-how are managed 
may be necessary to speed-up the translation of your research findings into innovative 
products or services.
4	 If a given invention cannot be patented in your own country (for example, a biological 
invention, including gene sequences), the invention may still be patentable in another 
country. The United States and Canada tend to have the broadest interpretations with 
respect to the patenting of organisms and biological materials. In pursuing patenting 
elsewhere, under certain circumstances, your research endeavors may leverage 
additional investments required to bring the fruits of your research to benefit your 
























































Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 Intellectual property is often perceived as constraining research, particularly in public 
sector institutions. your role in communicating the importance of judiciously using 
patents, trademarks, trade secrets, and so forth, and the benefits of good IP management, 
is critical. Such communication should be tailor-made to senior management, and 
even to your institution’s board, as well as to scientists. Each responds to a different 
language. (And different colleagues will require different degrees of understanding. For 
example, your discussions on patents will necessarily differ with scientists and patent 
counsel. Choose your words and the level of detail you provide judiciously.)
4	 In many institutional settings, making better use of patents and other forms of 
intellectual property requires a culture change to a greater or lesser degree. This may 
include establishing an expectation for scientists in your institution to regularly review 
patents. Encouraging scientists to share a broader iP awareness and culture will be 
potentially powerful and valuable.
4	 trademarks are a critical, and often overlooked, option for IP protection. They can be 
used as stand-alone IP protection, or they can be integrated into an overall strategy 
for integrated IP protection, for example, a strong trademark for a patented product or 
process. 
4	 Your job requires a judicious balance of work that relates directly to your benchmarks 
and targets, and of contributing to the overall iP culture of an organization. The latter 
is often not spelled out in your job description but it is important nonetheless. The 
greater the general level of awareness related to intellectual property, the more likely 
it is that the value of IP assets can be captured and utilized. And your job also becomes 
easier when you gain a broader understanding of intellectual property.
4	 Genebank management and that of genetic resources, in general, is increasingly 
becoming a sensitive issue. An organized, stepwise approach is vital for effectively 
managing a genebank and for avoiding difficulties. Ownership of genetic resources can 
be tricky, so rigorous documentation and clear procedures on incoming and outgoing 
genetic resources may be critical.
4	 The above point applies equally to data, both incoming and outgoing. Particularly if 
your institution conducts research related to product development (especially clinical 
trials), the confidentiality of data may be critical in ensuring global access. Specific data 
are a valuable form of intellectual property that can be used to obtain a certain price or 
access terms in licensing negotiations.
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result in private entities appropriating elements of 
the value without major regard to the mission of 
public institutions, or it could lead to the intellec-
tual assets becoming useless due to lack of further 
investment and development. This is the most im-
portant reason why the public sector should take 
IP management more seriously than it tradition-
ally has. IP management is a fundamental element 
in the public sector’s strategy of putting intellectual 
property to work for the public good.
Appropriately, the first chapter in this section 
of the Handbook is a comprehensive discussion 
on IP strategy by Pitkethly.1 His definition of 
strategy relevant to IP management is:
•	 the formulation and adoption of courses of 
action enabling the reaching of long-term 
goals and objectives of an institution 
•	 the allocation of resources (financial and 
human) necessary for carrying out these 
actions
By extension, IP strategy is an integral part 
of an overall business strategy that uses IP rights 
to manage technology. 
Pitkethly begins by mapping out how IP 
rights systems fulfill four purposes: 
•	 providing incentives for innovation
•	 allowing for the packaging of intellectual 
assets into innovative processes
•	 encouraging the diffusion of technical 
information
EXECUTIVE GUIDE TO HANDBOOK SECTION 5
(VOLUME 1: PAGES 459-533)
The boundaries of any property must be clear. As 
a farmer needs to know where his or her field be-
gins and ends, an innovator must know exactly 
the definition of his or her invention. But it is 
more difficult by far to delineate where rights to 
something intangible begin and end. In addition, 
intangible assets can be difficult to keep track of, 
to share, and to use. Yet in a research-and-devel-
opment environment, intangible assets are often 
the most valuable and important ones. How then, 
can they be leveraged to reinforce the mission of 
an institution? How can the specific objectives be 
achieved more effectively and efficiently through 
the incorporation of best practices in IP (intellec-
tual property) management? What are these prin-
ciples and practices? And how does an IP policy 
relate to an operational IP strategy?
This section offers insights into achieving and 
maintaining clarity about the ownership of intel-
lectual property in public sector institutions and 
stresses the value of IP strategies and IP policies. 
These are important for achieving success and have 
been increasingly encouraged—or required—by 
certain donors as a strategy to ensure global access. 
Global access, especially by the poor, and ownership 
of intellectual property go hand in hand. Indeed, 
the most important aspect of IP protection is that 
it bestows control over intellectual assets. If an orga-
nization—especially a public institution—fails to 
obtain IP rights for its inventions, it risks losing 
control over them. Failure to maintain rights may 
Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007. 
5: Institutional Policies and Strategies. In Executive Guide to Intellectual Property Management in Health and Agricultural 
Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), 
Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Avail-
able online at www.ipHandbook.org.
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•	 enabling the capturing of added value (eco-
nomic and/or humanitarian) through the 
control of intellectual assets
Viewed in this way, IP rights systems can be 
instrumental in enabling the diffusion of techno-
logical information. For example, patent specifi-
cations provide detailed embodiments of inven-
tions, which are available for all to see. Using the 
Internet, these records can be accessed for free 
anywhere in the world. This availability of and ac-
cess to information greatly facilitates innovation, 
since others will be able to work to improve or 
invent around the disclosed patented invention. 
Patents can also be useful sources of information 
for scientists, since the patent application may be 
the first and only publication about a competing 
innovation. 
Organizations should have both external and 
internal IP strategies. Broadly speaking, this is 
referred to as litigation, licensing, and learning.
An external IP strategy involves exploiting 
inventions (by developing them in-house, sell-
ing them, or licensing them). Litigation denies 
IP rights to others; licensing allows rights to oth-
ers. Learning can be a part of technology out-li-
censing, since it not only gives others access to 
these technologies but also provides learning op-
portunities for the organization. This strategy is 
especially effective if an institution’s aim is to dif-
fuse technology as widely as possible and ensure 
global access.
As a result, donors are increasingly requir-
ing grantees to take IP management seriously. 
Ballantyne and Nelki2 of the Wellcome Trust (the 
Trust) in the United Kingdom, a major charitable 
funder of biomedical research, is one such pio-
neering funding entity. The Trust requires insti-
tutions that have produced intellectual property 
using the Trust grants to determine whether the 
public will benefit from the protection of that 
property and whether all participants in the pro-
cess receive proceeds proportional to the amount 
of money, equipment, knowledge, or labor they 
contributed. But above all, the Trust insists that 
intellectual property arising from its grant awards 
be adequately exploited; the Trust does not shy 
away from taking over activities if grantees fail to 
adequately exploit the intellectual property. The 
chapter ends with a series of case studies that il-
lustrate the practical aspects of IP strategies.3
Grantees more and more frequently will 
need to present IP management strategies as part 
of their proposals. In the case of the Bill and 
Melinda Gates Foundation, certain grantees are 
required global access strategies4 that outline 
how recipients will manage new and existing in-
tellectual property. Certain minimum standards 
may also be required, such as:
•	 keeping the research field open by prohibit-
ing any licensee from enforcing intellectual 
property against universities and research 
institutions that carry out noncommercial 
activities
•	 retaining licensable research rights to any 
invention developed with donor funding
•	 obtaining freedom to operate for all back-
ground intellectual property owned by col-
laborating institutions
•	 ensuring good IP management, which in-
cludes exploitation of intellectual property, 
with the goal of ensuring its use in develop-
ing countries
Some granting agencies also require prospec-
tive grantees to explicitly state their IP policies. 
Kowalski5 reviews and discusses several institu-
tions’ policies and concludes that, at a minimum, 
an IP policy should define IP ownership, out-
line the patenting policy, describe the manner 
in which an institution will handle confidential 
information, set out the principles of its IP li-
censing and marketing approaches, explain how 
income arising from intellectual property will be 
distributed, and delineate the rights and obliga-
tions of inventors and the institution, as well as 
any rights the institution will retain (such as for 
research and for humanitarian uses). 
Any new or revised IP policy (and IP strat-
egy) will have to be “sold” to people both in-
side and outside an institution. It is important 
to explain what the policy contains and why the 
policy is designed the way it is. And perhaps staff 
at multiple levels should be involved in develop-
ing and revising, as needed, the IP policy. This 
group will be able to have extensive discussions 
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about the role and function of intellectual prop-
erty in the organization. These discussions will 
be an effective mechanism for building capacity 
and staff support of the policy. Some of the most 
controversial issues can be resolved before they 
become an obstacle, such as: Who owns what? 
Who benefits and how? 
These sometimes-troublesome questions are 
discussed by Weidemier,6 who reviews how uni-
versities in the United States are handling these 
aspects. Her chapter examines eight possible cases 
that illustrate and clarify the somewhat abstract 
principles of ownership of university inventions 
and are followed by a series of hypothetical sce-
narios. Weidemier, among others, concludes that 
universities should require all employees and visi-
tors to sign invention assignment agreements on 
their date of arrival. Neither an employee hand-
book that discusses patent assignment nor a pub-
lished university patent policy may be enough to 
ensure that the university is assigned ownership. 
With the assignment of ownership rights to 
an employer comes the duty to disclose that an 
invention has been made. Indeed, an inventor is 
responsible for and has much to gain by making 
timely disclosures of his or her invention to the 
technology transfer office (TTO), the first step 
in enabling technology transfer. Di Sante7 points 
out that successful commercialization is built on 
a foundation of good relations between inven-
tors and technology transfer professionals. Such 
relationships should be established long before 
the transfer services of the technology transfer of-
fice are required, since this will enable technology 
managers to negotiate both faculty and business 
concerns about licensing agreements whenever 
the opportunity arises. The role of the inventor in 
the entire IP protection and IP licensing/trans-
fer process cannot be overstated and should con-
tinue throughout the life of the technology.8 For 
example, years after a patent has been licensed, 
the inventor may be the best-placed person to 
alert a TTO that a certain product being sold 
may infringe the patent. 
But dealing with inventors is not always 
easy.9 Inventors are prone to fall in love with 
their own creations, and, perhaps unreasonably, 
anticipate that theirs is the next great thing. It is 
the technology transfer professional’s responsibil-
ity to tactfully ensure that the inventors’ expecta-
tions are kept in line with reality. 
Establishing good relationships with inven-
tors is an important way to identify the intellec-
tual property being generated in the research in-
stitution. But from an institutional point of view, 
a more comprehensive perspective on intellectual 
property is often warranted. This applies particu-
larly to times when an organization develops a 
strategic plan or IP management strategy. In this 
context, IP audits can be essential and often form 
the basis for an internal review and a revision of 
IP strategy. Blakeney10 provides a comprehensive 
overview of IP audits. Indeed, the importance of 
IP audits is becoming more and more apparent, 
in the private sector as well as in the public sector, 
as public entities increasingly deal with other par-
ties’ intellectual property.
An IP audit seeks to accomplish three broad 
objectives for an institution. First, it seeks to 
identify the intellectual property generated by its 
researchers. This intellectual property is an asset, 
with value that an institution ought to identify, as-
sess, and manage. Second, an audit seeks to iden-
tify and review the management of third-party 
intellectual property as a way of avoiding liability 
for misuse. The IP audit is thus a systematic, me-
thodical identification of the intellectual property 
within the institute.11 As the chapter shows, the 
audit follows a procedure, from start to finish, so 
that at the audit’s conclusion senior managers are 
able to frame and implement good IP manage-
ment practices. This is the third broad objective 
of an IP audit: to contribute to the formulation 
and execution of the IP policy and IP strategy. 
From a practical point of view, an IP audit 
reviews a number of existing practices and estab-
lishes the context in which intellectual property is 
being handled. For example, a research institute’s 
ownership and control over any intellectual prop-
erty will depend on its legal status as an entity. 
An IP auditor will review the incorporation docu-
ments to identify what powers the institute has to 
own and to deal with intellectual property. For 
universities and government institutions, such 
a review will also include the prevailing govern-
ment policies. 
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The IP auditors will also scrutinize the IP 
policy of the institute, if indeed there is a poli-
cy. It should ask questions, such as: Where is it 
posted? What does it say? Are new employees 
required to read it? IP audits may also uncover 
potential conflicts of interest. Bennett12 offers a 
primer on issues related to the management of 
conflict of interest and conflict of commitment. 
Conflict of interest occurs when the financial in-
terests of an institution’s researchers are incom-
patible with the institution’s mission, policy, or 
goals. Conflict of commitment may arise when 
the time a researcher spends in external activities 
related to, for example, downstream technology 
development, interferes with his or her attention 
to duties to the institution (for example, teaching 
or extension responsibilities). 
While conflicts of interest should not be seen 
in a negative light, making exceptions to the rules is 
both dangerous and potentially harmful. Someone 
with a potential conflict of interest is not guilty of 
anything; rather, he or she may actually be a more 
valuable “asset” because of the potential conflict. 
This applies most strikingly when a professor has 
an interest in forming a spinout company based 
on university research. Potentially, larger issues will 
arise due to undisclosed conflicts of interest. What 
a university needs is to define a clear chain of com-
mand and in rare circumstances to establish over-
sight committees. Committees tend to slow the 
process with significant delays in time, which typi-
cally makes the process unmanageable and useless.
Most conflicts arise when potential conflicts 
are not disclosed. Conversely, a major tactic in 
managing conflict of interest is to disclose poten-
tial conflicts. And most conflicts of interest can be 
managed fairly easily provided the policy is clear 
and precise. M.I.T., for example, manages an un-
usually large number of spinouts and, therefore, 
has a very strict conflict of interest policy (this is 
discussed by Nelsen13). A technology transfer offi-
cer’s role is to creatively craft arrangements within 
the rules, not to use these rules as deterrents. Put 
differently, Nelsen describes M.I.T.’s operating 
motto: “A firm wall between university and in-
dustry—but a wall with many doors… In sum, 
technology transfer inevitably brings conflicts of 
interest. The challenge is to manage them.”14 ■
All chapters refer to: Intellectual Property Management in 
Health and Agricultural Innovation: A Handbook of Best 
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thom-
son, AB Bennett, K Satyanarayana, GD Graff, C Fernandez, 
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis, 
U.S.A. Available online at www.ipHandbook.org. The online 
version contains for each chapter a detailed Editor’s Sum-
mary, Implications, and Best Practices.
1 Chapter 5.1 by R Pitkethly titled IP Strategy, p. 459.
2 Chapter 5.2 by Z Ballantyne and D Nelki titled 
Management Policy: A Donor’s Perspective, p. 475.
3 The following are reviewed in detail: the development 
of a typhoid vaccine, malaria drugs, the single 
nucleotide polymorphisms (SNP) consortium, and the 
International HapMap Project.
4 For an example of how global access strategies can be 
incorporated into product development partnerships 
and vaccine development, see Mahoney RT, A Krattiger, 
JD Clemens and R Curtiss III. 2007. The Introduction 
of New Vaccines into Developing Countries IV: Global 
Access Strategies. Vaccine 25(2007): 4003–4011.
5 Chapter 5.3 by SP Kowalski titled Making the Most of 
Intellectual Property: Developing an Institutional IP 
Policy, p. 485.
6 Chapter 5.4 by BJ Weidemier titled Ownership of 
University Inventions: Practical Considerations, p. 495.
7 Chapter 5.5 by AC Di Sante titled The Role of the 
Inventor in the Technology Transfer Process, p. 507.
8 An important exception to this is licensing. A TTO 
officer typically would not have the inventor participate 
during negotiations with potential licensees, although 
rare exceptions may apply.
9 See also Section 8 dealing more exhaustively with 
inventions and inventors.
10 Chapter 5.6 by M Blakeney titled Conducting IP Audits, 
p. 515.
11 This may include: patentable biological assets, such 
as germplasm resources, DNA libraries and enabling 
technologies (marker genes, probes); technological 
know-how; confidential information; patents, utility 
models and industrial design rights in equipment; 
copyrighted information (database rights, computer 
programs, and databases); publications; CD-ROMs; 
video materials; online materials; trademarks; and 
more.
12 Chapter 5.7 by AB Bennett titled Conflict of Interest and 
Conflict of Commitment Management in Technology 
Transfer, p. 527.
13 See Box 1 for M.I.T.’s policy (Chapter 3.13 by L Nelsen 
titled The Activities and Roles of M.I.T. in Forming 
Clusters and Strengthening Entrepreneurship, p. 309).
14 Chapter 6.1 by L Nelsen titled Ten Things Heads 
of Institutions Should Know about Setting Up a 
Technology Transfer Office, p. 537.
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	There is an ongoing debate over how IP systems can achieve the optimal balance 
between private rights and public benefits. However, experience suggests that IP rights 
systems, if soundly applied and used by the public sector as well as by the private sector, 
are better than any of the proposed alternatives in achieving public-goods objectives. 
Government policies can be instrumental in helping public sector institutions find the 
right balance.
4	As a specific requirement, public sector institutions should be required to develop and 
publish their institute-specific iP policies that adapt broader principles to the specific 
context of the institution’s mission and strategy. Such policies should include clear 
conflict-of-interest policies.
4	Incorporating the goals of dissemination of public-sector-generated R&D to benefit 
primarily the poorer segments of the population are goals that do not run counter 
to benefiting economically from inventions. Much will depend on the specific context 
and how these seemingly contradictory goals are managed.
4	Public sector institutions can achieve little with their intellectual property in the 
absence of an enforceable system for protecting and promoting local innovation that 
includes clear assignment rules regarding ownership of inventions. 
4	A government may wish to analyze the interface between its laws governing charitable 
organizations and how the laws may impact the freedom of nonprofit institutions in 
owning and licensing both their own and third-party intellectual property. 
4	Policymakers should consider the promotion of legislation that clarifies under what 
circumstances employees in the public sector, including those at universities, shall 
assign patent rights to their employers. This aspect has ramifications for statutory laws 
in many countries with respect to “hired to invent,” “shop-right,” and other matters. 
4	Technology transfer and IP management are complex, requiring the creative input 
and participation of different professionals from varying fields of expertise. Therefore, 
it is important to recognize that investments in public sector education and 
training programs need to consider many aspects, including scientific, business and 
entrepreneurial, legal, judicial, and policy. 
FOR GOVERNMENT POLICYMAKERS
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(UNIVERSITY PRESIDENT, R&D MANAGER, ETC.)
4	 A sound iP policy should address, among others issues, clear ownership of intellectual 
property generated, conflicts of interest and conflicts of commitment, the manner 
in which an institution will handle confidential information, the principles of the 
institution’s IP licensing approaches, how income arising from intellectual property will 
be distributed, and any rights the institution will retain (such as for research and for 
humanitarian uses). 
4	 An iP strategy, on the other hand, describes the courses of action enabling the reaching 
of long-term goals of the institutions and the allocation of resources necessary to carry 
out these actions. Public sector institutions may wish to specifically address in their 
IP strategies how their research endeavors, in general, and IP management strategies, 
in particular, will achieve global access of their products and how the endeavors will 
benefit humanitarian objectives.
4	 Components of such an IP strategy may include how the institution deals with 
incoming third-party intellectual property, how it deals with internally generated 
intellectual property (patenting and other protection strategies that should include 
how the institution balances the public sector component of its mission with economic 
imperatives), and how it will out-license its intellectual property to third parties. 
4	Particular emphasis should be placed on global access strategies, not only because 
philanthropic funding agencies increasingly require grantees to address them, but 
because this approach is especially effective if an institution’s aim is to diffuse technology 
as widely as possible.
4	The process by which an iP policy and iP strategy are developed may be valuable in 
bringing about internal culture change and create strong support from staff.
4	Successful IP commercialization is built on a foundation of good relations between 
inventors and technology transfer professionals. Such relationships should be established 
long before the transfer services of the technology transfer office. 
4	The importance of iP audits is becoming more and more apparent, in the private and 
in the public sector, as public entities increasingly deal with third-party intellectual 
property. IP audits can be useful mechanisms that form the basis for an internal review 
and revision of an institution’s IP strategy and IP policy. 
4	Technology transfer invariably brings conflicts of interest. The challenge is to manage 
them in a transparent and consistent manner. Importantly, potential conflicts of interest 
should not be viewed in a negative light. Most real conflicts arise when potential conflicts 
are not disclosed. 
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4	As the creator of inventions and technologies, your role in technology transfer is critical. 
So please read on! 
4	Your role can best be carried out if you have good relations with the technology transfer 
office and officers. But fulfilling your role also requires a good knowledge of and 
understanding of your institution’s iP policy. The policy will likely articulate ownership 
of intellectual property, conflict of interest, the handling of confidential information, 
and more. Become familiar with the content and the meaning of the various provisions 
and how they may affect you.
4	 The purpose of such a policy, and more importantly of your institution’s iP strategy, 
is not just to protect your inventions, but also to control technologies and IP assets in 
such a way as to allow you and the TTO to determine how your inventions can—and 
should—be used to spur economic growth and contribute to the greater public good.
4	Remember, few inventions will lead to blockbuster products, make millions of dollars, 
or save billions of people. Have realistic expectations, especially regarding what it will 
take for your invention to make a difference. It is not bad to love your own creations as 
long as you have realistic expectations.
4	More and more philanthropic donors expect to find IP management components in 
grant applications and to understand how intellectual property will be used to achieve 
global access and humanitarian benefits. This is just one reason why a close relationship 
with your TTO is important, and becoming even more so.
4	When your institution conducts or commissions an iP audit, view this as an opportunity 
to better identify the intellectual property generated in your research program, 
to improve and streamline the management of third-party intellectual property 
(allowing you to concentrate more on research), and to contribute to the formulation 
and execution of an IP strategy that benefits your program and its (global) impact.
4	One of the most important responsibilities you have is to disclose any potential conflict 
of interest. You are not guilty of anything if you have a potential, perceived, or even real 
conflict of interest. Most problems arise when conflicts are not disclosed. Clear conflict 
of interest policies that are followed and implemented in a transparent manner is all 
that is required to manage them.
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.



























4 An iP policy should address, at a minimum, ownership of intellectual property, conflicts 
of interest and conflicts of commitment, the handling of confidential information, the 
principles of IP licensing approaches, the sharing of income derived from intellectual 
property, and any rights the institution will retain (such as for research and for 
humanitarian uses). 
4	 Public sector institutions will increasingly be expected to define an institutional iP 
strategy that specifically addresses how IP management will be used to achieve 
global access/humanitarian benefits of the inventions and products developed at 
your institution. It should include how the institution deals with incoming third-party 
intellectual property, how it deals with internally generated intellectual property, and 
how it will out-license its intellectual property to third parties. 
4	The process by which an iP policy and iP strategy are developed may be valuable in 
bringing about internal culture change and create strong support from staff.
4	Successful IP commercialization is built on a foundation of good relations between 
inventors and technology transfer professionals. Such relationships should be 
established long before the establishment of transfer services of the technology 
transfer office.
4	The importance of iP audits is becoming more and more apparent, in the private sector 
and even in the public sector, as public entities increasingly deal with third-party 
intellectual property. IP audits can be useful mechanisms that form the basis for an 
internal review and revision of an institution’s IP strategy and IP policy. 
4	Technology transfer invariably brings conflicts of interest. The challenge is to manage 
them in a transparent and consistent manner without granting any exceptions, 
irrespective of the prestige of the scientist or the amount of funding they attract. 
Importantly, potential conflicts of interest should not be viewed in a negative light, 
provided they are disclosed (and managed). Most problems arise when potential 
conflicts are not disclosed. Few conflicts of interest are well managed by committees.
4	All employees (and visitors in some cases) should be required to sign an invention 
assignment agreement on their date of arrival. Neither an employee handbook that 
discusses patent assignment nor a published university patent policy may be enough 
to ensure that the university is assigned ownership. 
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Massachusetts Institute of Technology (M.I.T.) 
offers practical, timely advice about some of the 
most important policy and strategy imperatives 
for an institution starting up a technology trans-
fer office (TTO) or intending to strengthen its 
current endeavors in technology transfer.
Viable strategies to set up and operate a 
TTO must be firmly grounded in realistic eco-
nomic expectations. Technology transfer will 
not really make your university or research in-
stitution rich because building a robust technol-
ogy transfer program will take sustained financial 
investment. It takes time (eight to ten years) to 
build an IP portfolio, establish contacts, and de-
velop skills in technology transfer. And it may 
take up to two decades or more before a univer-
sity technology transfer program (including en-
trepreneurial spinouts) substantially affects the 
local economy. The ultimate impact, however, 
may be very large—both economically and cul-
turally—for the university, its graduates, and the 
wider community.
Successfully implementing these plans will 
require visible and sustained support—fiscal and 
otherwise—from senior administration to set 
the program’s mission, policies, and priorities. 
Clear mandates will help technology transfer 
professionals choose among competing priorities 
and the ever-present trade-offs between business 
and academic values. IP ownership policies, the 
roles of researchers in interactions with industry, 
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Technology transfer is the process of converting 
scientific findings into useful products or ser-
vices for society. A complex endeavor, it takes 
place in the broader context of innovation. Any 
country or institution can undertake health or 
agricultural innovation to varying degrees, but 
some developing countries that are more scien-
tifically advanced are starting to reap the benefits 
of decades of investments in education, health 
research infrastructure, manufacturing and pro-
duction capacity, and regulatory institutions. 
Increasingly referred to as innovative developing 
countries,1 these countries are characterized by, 
among other things, sustained government sup-
port for research, the availability of venture capi-
tal, functioning regulatory systems, and an abil-
ity to partner with local and foreign public and 
private research organizations. All of this requires 
sound IP (intellectual property) management, 
which makes such partnerships more effective 
and allows technologies to be transferred not just 
in one direction but in more complex and valu-
able ways, to benefit more people.
Technology transfer is thus a reward-
ing process for research-based institutions and 
the people who make it happen. It leads to 
new products, services, and jobs. But it is also 
a multifaceted process with important poli-
cy, economic, and managerial ramifications. 
Discussing these aspects in detail, Nelsen,2 who 
leads the Technology Licensing Office of the 
Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007. 
6: Establishing and Operating Technology Transfer Offices. In Executive Guide to Intellectual Property Management in 
Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, 
UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International In-
stitute (Ithaca, USA). Available online at www.ipHandbook.org..
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for non-
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and other ground rules should be set up before 
the program begins because conflicts of inter-
est, both real and perceived, are inevitable. For 
the same reason, clear policies and a well-un-
derstood review-and-appeal process need to be 
put in place early. Finally, technology transfer 
is a talent-based business. It is difficult to find 
people who can speak the two languages of aca-
demia and industry and who also have the cre-
ativity to craft agreements that meet the needs 
of both sides.
The chapter’s conclusion discusses some tech-
nology transfer pitfalls caused by unrealistic ex-
pectations. It emphasizes the role of senior man-
agement in the evolution of the culture (which 
must begin with top-level administration), the 
need for transparent conflict-of-interest policies, 
and the importance of sufficient autonomy and 
infrastructure support for technology transfer of-
ficers. A TTO can create many benefits for the 
university, industry, and the surrounding com-
munity, but it requires carefully planned and 
consistent long-term financial and administrative 
support. And above all, it requires TTO officers 
that are able—and willing—to take risks and 
university presidents to support them.
Moving into the particulars of how to estab-
lish a TTO, Young3 stresses the importance of a 
strong mission statement, attention to staffing 
needs, and to the unique operating contexts of 
each institution. Based on a lifelong experience in 
establishing and running TTOs, with a chapter 
that provides many examples of TTO launches 
from around the globe (Australia, India, China, 
Japan, England, South Africa, Russia, and the 
United States), Young concludes that efficient 
and effective TTOs possess the following key 
characteristics:
• An articulated mission
• Transparent policies and procedures
• Entrepreneurial staffing and an entrepre-
neurial environment
• Customer-friendly relations with both in-
ternal and external constituents 
• A highly supportive university administra-
tion and community
• Strong links to potential industry partners
• Access to risk, or venture, capital
Even so, there is no “right” way to set up an 
office, but success does require considering some 
specific issues, as discussed by Campbell.4 One of 
these issues is establishing business processes at 
the outset. Adequate attention should be paid to 
information management and realistically setting 
budgets. Offices tend to be either a department 
within the institution or a subsidiary company. 
Either way, accountability lines will need to be 
transparent. Like the preceding authors, Campbell 
also stresses that the core element for successful 
technology transfer is people. The TTO should 
be led by an individual who understands the de-
tails of running a business. It is also useful to have 
staff with experience working in the relevant busi-
ness sectors. To be able to recognize new opportu-
nities, the technology transfer manager needs to 
win the confidence of academics, which is why it 
is helpful for the TTO to be embedded within 
the institution. Likewise, staff should be exposed 
to both academics and business people. 
Campbell discusses several examples of TTO 
structures and policies based on her experience in 
the United Kingdom, in particular King’s College 
London (KCL). She also shares useful lessons 
from Switzerland’s experiences with Unitechtra, 
a subsidiary nonprofit technology transfer com-
pany jointly owned by the two universities of 
Bern and Zürich. This model from a small, but 
highly innovative country (when the number of 
patents per capita is used as one measurement), 
is particularly relevant for developing countries 
with limited resources, where several institutions 
may consider establishing a joint TTO to ensure 
economies of scale and critical mass.
Fernandez,5 from Chile, develops a specific, 
yet potentially powerful model for establishing or 
improving technology transfer operations for uni-
versities and research institutes within developing 
countries. The model takes into account several 
key insights about technology transfer. Namely, 
there is a critical mass of R&D activity necessary 
to justify the costs of a fully functioning TTO. 
Some estimates would put this figure within the 
range of US$100 to $500 million in research 
expenditures annually. While it is uncommon 
for a single university within a developing coun-
try to attain a financial critical mass, a group of 
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universities together can attain it relatively eas-
ily. In addition, some of the typical functions of 
technology transfer are more easily scalable than 
others, and are thus more easily shared by a group 
of universities. 
The model developed in this chapter essen-
tially requires sharing the costs of technology 
transfer services among a consortium of universi-
ties, with an additional startup subsidy provided 
by government. A “hub-and-spokes” configura-
tion is proposed, which allows essential policy 
decisions and scalable functions to be moved 
to the center and keeps essential context-spe-
cific and unscalable functions on campuses at 
universities. This also allows for a more efficient 
distribution of scarce resources and of key per-
sonnel who have the necessary skills, allowing a 
few experienced professionals to selectively, yet 
effectively, manage and mentor technology trans-
fer staff across a range of institutions.
Fernandez openly points out the challenges 
of implementing such a model, emphasizing the 
need for articulated policies to be shared by all 
consortium members in at least three areas. These 
areas each represent potential points of real con-
flict within such multi-institutional systems. The 
first area is a clear policy of ownership that en-
sures that everyone involved in the process knows 
who bears ultimate responsibility for a given tech-
nology. The second is a clear policy on the distri-
bution of income from commercialized technol-
ogy. Such a policy should provide incentives that 
will elicit the cooperation and support needed 
from multiple players in the technology transfer 
process. This is also important so that realistic 
financial expectations are established, helping to 
avoid disputes that could threaten the viability of 
the system as a whole. The third area regards the 
prevention and resolution of conflicts of inter-
est. Such a policy is important to maintaining the 
integrity of the university’s main educational and 
research functions amid increased commercial 
opportunities, so that any disputes that do arise 
can be resolved in a systematic and fair manner, 
likewise protecting the viability of the system.
An important feature of this model is that it 
does not lock in its participating member institu-
tions; it is open to competition. As the economy 
grows and member universities’ R&D activities 
increase, their local TTOs can take on more and 
more of the functions that had been delegated to 
the central office. A university would thus be able 
to “graduate” from the system as its own TTO 
becomes self-sustaining. Even prior to that, the 
central TTO may be relied on only if it provides 
effective management of technology transfer proj-
ects that member institutions cannot replicate 
themselves or obtain elsewhere cost effectively. If 
the centralized system fails to be competitive, the 
member institutions can simply elect to manage 
the commercialization of technologies in their 
own offices or through other more competitive 
channels.
Moving into the organizational aspects of 
establishing a TTO, Dodds and Somersalo6 re-
view the specific requirements in terms of hu-
man infrastructure, physical infrastructure, and 
operational plans for the office. The latter is es-
sential for defining office protocol for various 
topics: patents, trademarks, copyrights, and trade 
secrets; plant variety protection; contracts, agree-
ments, and licenses; policy development; tech-
nology evaluation; invention marketing; conflict 
analysis; negotiation support; and strategy inputs. 
Importantly, any TTO must emphasize the im-
portance of confidentiality in all its operations. 
Other wide-ranging organizational matters that 
need to be addressed early include; a coordinat-
ed staffing plan detailing authority, responsibili-
ties, and work plans; a staff employment handbook 
that explains the ethical standards that employees 
must follow; a plan for addressing governmental 
and state filing requirements; a tax plan (includ-
ing accounting standards and auditing); consid-
erations to establish an advisory panel, and criteria 
for drawing on external expertise (such as con-
sulting contracts, patent attorneys, general legal 
counsel, licensing specialists, marketing special-
ists, and database specialists).
The specific organizational and administra-
tive aspects of a TTO are discussed by Hines,7 
based on her experience at Stanford University’s 
Office of Technology Licensing. This chapter of-
fers similar offices in developing countries a de-
tailed outline of how an office can be structured 
in terms of personnel and human resources. The 
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structure consists of a director, seven licensing as-
sociates, eight licensing liaisons, one copyright 
licensing specialist, and the equivalent of eight 
and one-half administrative staff, in addition to 
other administrative staff and industrial contracts 
officers. Much action in such an office revolves 
around the important technology licensing asso-
ciates who work with the inventors (professors, 
graduate students, and research staff) and with 
prospective licensees. In addition to providing a 
list of key personnel for a TTO’s operation, the 
chapter also defines, and gives examples of com-
plex cases, job descriptions, and a comprehensive 
list of standard operating procedures (for licensing 
agreements and for invention disclosures). Like 
the other authors in this section, Hines stresses 
the importance of a well-trained staff.
Continuing and practical training should be 
an integral part of any TTO’s yearly work plan. 
For this, Pefile and Krattiger8 present a few fo-
cused case studies that can be incorporated into 
short courses in IP management. They stress 
the importance of hands-on training programs 
whereby participants play specific roles within 
difficult case studies tailor-made to serve the par-
ticular needs of the TTO or its staff. Such ap-
proaches allow participants to see how a specific 
professional role can affect the complex process of 
crafting beneficial and creative partnerships that 
lead to mutually beneficial solutions. Even for 
those not involved in deal making, this approach 
has great utility because it enables participants to 
view their respective tasks in a broader context, 
and thereby gain a perspective as to the challenges 
presented at various stages in the overall process. 
Indeed, the importance of building networks 
in the technology transfer and licensing com-
munity cannot be overstated. To illustrate this, 
Hersey9 uses the experience of the Association of 
University Technology Managers (AUTM) as an 
extended case study of the building of dynam-
ic, productive, and sustainable networks. Her 
chapter contains numerous lessons applicable 
anywhere. Networking among peers in any pro-
fession is generally understood to be beneficial, 
as it cements relationships between individual 
practitioners and helps build and strengthen the 
profession itself. By working through networks, 
practitioners exchange ideas and experiences, 
forming best practices that become performance 
standards for both individuals and their institu-
tions. Networks thereby contribute to IP man-
agement capacity building at both the individual 
and institutional levels, and this then feeds back 
to further support and expands the network.
As groups of like-minded, mission-driven 
professionals, networks can be formed at differ-
ent geographical levels in order to serve various 
functions. This multilevel approach allows orga-
nizations to address different aspects of their re-
spective missions. Local networking creates oppor-
tunities to work with colleagues in the immediate 
vicinity. National networking can be a mechanism 
for working with colleagues to encourage na-
tional legislation addressing intellectual property 
and technology transfer, as well as for designing 
and implementing systems for appropriate IP 
management, training, and education. Regional 
networking provides opportunities to work with 
neighboring countries in coordinated R&D en-
deavors and related IP management and technol-
ogy transfer initiatives. Importantly, international 
networking will become increasingly important as 
globalization advances. Building networks with 
colleagues around the world will provide oppor-
tunities for many forms of technology transfer 
and IP management capacity building. 
This is particularly relevant in the context of 
TTOs working with external patent counsel as 
developing countries increasingly wish to file pat-
ents in other jurisdictions. From a licensee point of 
view, having patent coverage in the more lucrative 
markets of the United States, Europe, and Japan 
may be a prerequisite for licensing a technology 
from a developing country. Similarly, if a patent is 
drafted poorly or does not provide adequate cov-
erage for the technology, licensing opportunities 
may either be lost or significantly devalued. The 
costs associated with inadequately drafted patents 
can be significant, so it is important for a TTO to 
carefully select a patent attorney whose work will 
enhance the institution’s prospects for obtaining 
optimal licensing arrangements.
Goldman10 reviews the process of selecting, 
hiring, and interfacing with patent counsel. Of 
course, central to this relationship is ensuring that 
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patent counsel can prepare and prosecute patent 
applications in a manner that achieves positive re-
sults in a cost-effective fashion. The chapter pres-
ents the steps in this complex process, and the 
responsibilities that both counsel and the TTO 
should assume. Patent attorneys can also provide 
general counseling, resolve inventorship issues, 
provide licensing and agreement support, and 
resolve disputes. By selecting a qualified patent 
attorney and developing a good working rela-
tionship, a TTO can develop a resource that will 
ease the workload and facilitate its missions. This 
choice of patent counsel is therefore essential for 
operating a viable TTO and should be approached 
thoughtfully. There are several factors that should 
be carefully considered and weighed:
• size of the attorney’s firm11
• scope of the attorney’s legal experience and 
capabilities
• the attorney’s experience with academic 
institutions
• the attorney’s technological background
• the firm’s location
After a patent attorney is selected, deter-
mining how work will be allocated is important. 
Generally, the less work that is sent to the attor-
ney, the lower the TTO’s legal fees. Still, the more 
work the TTO retains for itself, the less time its 
staff will have for other matters. Another critical 
aspect of the relationship between the patent at-
torney and the TTO is payment for services. The 
chapter presents several possible methods and 
schedules for payment, and also cautions against 
certain related practices. For example, a letter of 
retainer can, among other things, specify billing 
procedures, such as fixed fees, hourly billing rates, 
and equity combinations. Another feature of the 
retainer letter will be a specification of the bill 
content: an acceptable bill will include an indica-
tion of which attorney or attorneys worked on a 
particular project, the amount of time spent daily 
on that project, and what that work involved. 
This will make clear the services for which the 
TTO is being charged. 
Dodds12 considers a broader picture of how 
to hire an IP lawyer without going bankrupt. 
While the process can be complex and costly, 
Dodds outlines various strategies for how TTOs 
can make the best use of attorneys. He points out 
the value of retaining an IP attorney, especially 
when a TTO is just getting established. A critical 
initial role of the lawyer should be to work closely 
with the TTO to develop an IP strategy that most 
effectively delivers benefits to the office. If your 
TTO strategy is ill conceived, all the remaining 
activities will be irrelevant.
Any emerging TTO will have a wide range of 
legal matters to be addressed. These include the 
types of IP protection to be provided, when to 
apply trademarks and copyright, how much to 
rely on trade secrets, the development of contracts 
and agreements, license reviews, and negotiations 
support. The lawyer can also be used to think in 
innovative ways about how to capture value from 
an IP portfolio. 
Importantly, the legal relationship between a 
lawyer and a client is protected under a special set 
of legal rules that make up the concepts of client 
confidentiality and legal privilege. This umbrella 
of confidentiality and legal protection from dis-
closure is a very important part of the relation-
ship. The importance of confidentiality and trust 
cannot be underestimated. Such confidentiality 
requires excellent record keeping.
Indeed, a TTO needs to have a systematic 
way of managing agreements and many other 
forms of data as the amount of data will increase 
significantly and year by year. Unfortunately, too 
many TTOs still try to accomplish this task with 
a paper filing system, which is cumbersome, slow, 
and inflexible. Above all, this type of system se-
verely limits the ability to analyze data creatively. 
Using electronic systems, a manager can rapidly 
formulate questions that in a physical file envi-
ronment would be unthinkable, due to the time 
required to locate, assemble, and analyze the in-
formation sets.
Electronic filing systems also provide shared 
communication links and can utilize advanced 
spreadsheet applications. The chapter by Sloman13 
considers the relative merits of spreadsheets, flat-
file databases, and relational databases as TTO 
data management tools/systems. It empha-
sizes the benefits of the latter, highlighting both 
their ability to transfer entire projects from one 
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manager to another with the click of a button and 
their unprecedented power to allow managers to 
look at data and business models in creative ways. 
Such a system requires less data entry and can 
be easier to maintain and audit. For all of these 
reasons, the relational database is frequently the 
preferred system. 
The sooner a functional contract manage-
ment system is implemented, the easier it will be 
to keep track of contracts and make the most of 
them, both for the organization and for its col-
laborators. Two chapters, one by Hamzaoui14 and 
one by Potter and Rygnestad15 discuss the impor-
tance, design, and implementation of contract 
management systems from different, but equally 
pragmatic perspectives. Hamzaoui bases her chap-
ter on the practices of the Whitehead Institute for 
Biomedical Research. Both chapters review the 
specific approaches for actually implementing a 
contract management system, including:
• accessibility (e.g., hard-copy filing, elec-
tronic filing, database systems)
• security (e.g., loss prevention, unauthorized 
access)
• resources for implementation 
• personnel time, training, and management
The value of the proper management of con-
tracts and agreements is usually only seen in its 
absence—lost deals, a poor reputation and, in 
the worst case, lawsuits. Early investments to pre-
vent these sorts of problems are like any prophy-
lactic measure and the savings will certainly be 
substantial.
Graciously, the Whitehead Institute agreed 
to make available, for free, their proprietary 
agreement management system, called WIIPS™, 
through the online version of the Handbook.16 
Users can download a fully functional version 
that they can also modify and adjust to their 
particular institutional needs. WIIPS™ is a rela-
tional database designed to automate essential 
IP management and technology transfer func-
tions. It simplifies record keeping and generates 
useful reports for technology disclosures, patent 
applications, joint invention agreements, licens-
es, and material transfer agreements. In addition, 
the system stores essential information on every 
inventor, owner, and licensee who has interacted 
with a given TTO. 
Finally, the chapter by Pefile17 takes a broad 
view and considers the mission of a TTO in the 
context of knowledge transfer. Indeed, making 
money will always be a consideration when set-
ting objectives, but technology transfer adds value 
in other important ways; as a resource to facilitate 
innovation for the public good and as a way to 
broker the exchange of knowledge between the 
business and public sectors for society’s benefit. 
Transferring knowledge across such disciplines as 
the humanities, law, and social sciences is as im-
portant as transferring knowledge and technol-
ogy across the applied sciences, and TTOs should 
be set up to have the flexibility to accomplish this 
broader knowledge-transfer objective.
An effective evaluation system should 
strengthen an institution’s ability to maintain 
leadership across the frontiers of scientific knowl-
edge. The evaluation system also will stimulate 
partnerships that promote investments in fun-
damental science and engineering, as well as the 
overall more-effective use of physical, human, 
and financial resources for social and economic 
benefit. Without a measurement process, insti-
tutions cannot justify their efforts in R&D, IP 
management, commercialization, and technology 
transfer in relation to their economic and social 
goals. Finally, Pefile calls upon all TTO managers 
to take the time to reflect upon their operations 
and ways in which they can be made more effec-
tive and beneficial for all. ■
All chapters refer to: Intellectual Property Management in 
Health and Agricultural Innovation: A Handbook of Best 
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thom-
son, AB Bennett, K Satyanarayana, GD Graff, C Fernandez, 
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis, 
U.S.A. Available online at www.ipHandbook.org. The online 
version contains for each chapter a detailed Editor’s Sum-
mary, Implications, and Best Practices.
1 Morel CM, T Acharya, D Broun, A Dangi, C Elias, NK 
Ganguly, CA Gardner, RK Gupta, J Haycock, AD Heher, 
PT Hotez, HE Kettler, GT Keusch, AF Krattiger, FT 
Kreutz, S Lall, K Lee, R Mahoney, A Martinez-Palomo, RA 
Mashelkar, SA Matlin, M Mzimba, J Oehler, FG Ridley, 
P Senanayake, P Singera and M Yun. 2005. Health 
Innovation Networks to Help Developing Countries 
ESTABLISHING AND OPERATING TECHNOLOGY TRANSFER OFFICES
HANDBOOK TO BEST PRACTICES: EXECUTIVE GUIDE  | 9 
Address Neglected Diseases. Science 309:401-404.
2 Chapter 6.1 by L Nelsen titled Ten Things Heads 
of Institutions Should Know about Setting Up a 
Technology Transfer Office, p. 537.
3 Chapter 6.2 by TA Young titled Establishing a Technology 
Transfer Office, p. 545.
4 Chapter 6.3 by AF Campbell titled How to Set Up a 
Technology Transfer Office: Experiences from Europe, p. 
559.
5 Chapter 6.4 by C Fernandez titled How to Set Up a 
Technology Transfer System in a Developing Country, p. 
567.
6 Chapter 6.5 by J Dodds and S Somersalo titled Practical 
Considerations for the Establishment of a Technology 
Transfer Office, p. 575.
7 Chapter For 6.6 by S Hines titled Administration of a 
Large Technology Transfer Office, p. 581.
8 Chapter 6.7 by S Pefile and A Krattiger titled Training 
Staff in IP Management, p. 597.
9 Chapter 6.8 by K Hersey titled Building Networks: The 
National and International Experiences of AUTM, p. 617.
10 Chapter 6.9 by ML Goldman titled How to Select and 
Work with Patent Counsel, p. 625.
11 Due to its resources and personnel, a large law firm 
is generally able to handle most legal problems that 
confront a technology transfer office. On the other 
hand, smaller firms might have the advantage of lower 
cost, while still having attorneys with the skills needed 
to serve the technology transfer office.
12 Chapter 6.10 by J Dodds titled How to Hire an IP 
Attorney and Not Go Bankrupt, p. 635.
13 Chapter 6.11 RG Sloman titled Technology Transfer Data 
Management, p. 641.
14 Chapter 6.12 by A Hamzaoui titled WIIPS™: Whitehead 
Institute Intellectual Property System (A Relational 
Database for IP Management and Technology Transfer) 
p. 649.
15 Chapter 6.13 by R Potter and H Rygnestad titled 
Organizing and Managing Agreements and Contracts, 
p. 651.
16 www.ipHandbook.org. In order to run the database, 
users must have access to Microsoft® Access® and a 
Windows XP (or higher) operating system. Users are 
authorized to copy and/or modify both the software 
and its user guide, as long as they acknowledge that 
the resulting product is based on WIIPS™.
17 Chapter 6.14 by S Pefile titled Monitoring, Evaluating, 
and Assessing Impact, p. 659.
GUIDE TO SECTION 



























Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 Technology transfer is the process of converting scientific findings into useful products 
or services for society. Hence encouraging public institutions and private sector 
enterprises to work together is an important element in any national strategy aimed 
at strengthening innovation. 
4	 In the increasingly interlinked and globalized worlds of science, technology, and 
commerce, such collaborations should extend beyond national borders, as success 
will increasingly be measured by the ability to form dynamic, integrated, and mutually 
beneficial networks that span countries and institutions.
4	 Government policies and laws regarding technology transfer ought to be flexible so 
that each institution can shape its approach according to its own culture, mission, and 
context. 
4	 Laws regarding iP ownership are essential for successful technology transfer.
4	 National institutions often require governmental encouragement and sustained 
funding to develop technology transfer offices (TTOs), as well as IP policies (conflict of 
interest management, allocation of revenues, and so forth).
4	 Viable strategies to set up and operate a tto must be firmly grounded in realistic 
economic expectations. Technology transfer will not make any institution rich 
because building a robust technology transfer program will take sustained financial 
investment. It takes time (ten years or more) to build an IP portfolio, establish contacts, 
and develop skills in technology transfer. And it may take up to two decades or more 
before a university technology transfer program (including entrepreneurial spinouts) 
substantially affects the local economy. 
4	 A certain critical mass of r&D activity is necessary to justify the costs of a fully 
functioning tto. Some estimates would put this figure within the range of US$100 to 
$500 million in research expenditures annually.
4	 Several alternative models to an institutional TTO can be successful. costs can be 
shared among a consortium of universities or research institutions. Such hub-and-
spokes configurations allow essential policy decisions and scalable functions to be 
moved to the center, while keeping essential context-specific and unscalable functions 
embedded within individual institutions. This allows for a more efficient distribution 
of scarce resources and of key personnel who have the necessary skills, allowing a few 
experienced professionals to selectively, yet effectively, manage and mentor technology 
transfer staff across multiple institutions.
4	 Recognizing that technology transfer is a talent-based business, the importance of 
building networks in the technology transfer and licensing community cannot be 
overstated. Governments should encourage the creation and operation of national 
technology transfer associations that concurrently build international linkages.
FOR GOVERNMENT POLICYMAKERS
ESTABLISHING AND OPERATING TECHNOLOGY TRANSFER OFFICES











Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
FOR SENIOR MANAGEMENT
(UNIVERSITY PRESIDENT, R&D MANAGER, ETC.)
4	 Successfully establishing and operating a technology transfer office (TTO) will require 
visible and sustained support—financial and otherwise—from senior administration, 
which can set the program’s mission, policies, and priorities. Clear mandates will help 
technology transfer professionals choose among competing priorities.
4	 A TTO can create many benefits for the university, industry, and the surrounding 
community, but it requires carefully planned and consistent long-term financial and 
administrative support. And above all, it requires tto officers able—and willing—to 
take risks and senior management to back them.
4	 Efficient and effective TTOs must have an articulated TTO mission, transparent TTO 
policies and procedures, entrepreneurial staffing and an entrepreneurial environment, 
customer-friendly relations between TTO staff and internal and external constituents, 
a highly supportive administration, strong TTO links to potential industry partners, and 
TTO access to risk, or venture, capital.
4	 The core element for successful technology transfer is people. The TTO should be led 
by an individual who understands the details of running a business. Additionally, staff 
members with experience working in the relevant business sector are required. 
4	 An important factor for a successful TTO is the institution’s entrepreneurial culture. 
4	 Strategies to set up and operate a tto must be firmly grounded in realistic economic 
expectations. Technology transfer will not make any institution rich because building 
a robust program will take sustained financial investment. It takes time (ten+ years) to 
build an IP portfolio, establish contacts, and develop skills in technology transfer.
4	 A critical mass of r&D activity is necessary to justify the costs of a fully functioning tto. 
Some estimates would put this figure within the range of US$100 to $500 million in 
research expenditures annually.
4	 Several alternative models to an institutional TTO can be successful. costs can be shared 
among a consortium of universities or research institutions. Such hub-and-spokes 
configurations allow essential policy decisions and scalable functions to be moved to 
the center, while keeping essential context-specific and unscalable functions embedded 
within individual institutions. 
4	 Implementing a consortium model of a TTO across institutions presents many challenges. 
These can be managed with clearly articulated policies of ownership, the distribution 
of income from commercialized technology, and mechanisms for the prevention and 
resolution of conflicts of interest. 
4	 An important feature of this model is to allow for a certain level of competition, a locally 
embedded TTO officer, and an evolution of the model. As the member institution’s R&D 
activities increase, local TTOs can take on more and more of the functions that had been 
delegated to the central office. 
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
FOR SCIENTISTS
4	 Your power to shape institutional policy should not be underestimated, especially in the 
ways that the fruits of your research can be made to increase economic development 
and benefit humanity.
4	 Know your institutional conflict of interest policy. Most conflict of interest issues arise 
when procedures are not properly followed.
4	 Work with your TTO to ensure that your institution’s disclosure of information form is 
simple and easy for you to use. 
4	 Understand why you might benefit from engaging in technology transfer and what 
you want to get out of the relationship with the TTO.
4	 A national or regional consortium of universities to develop a technology transfer 
system could be beneficial to you and your colleagues because it would be more cost 
effective and would have greater latitude and leverage in exploiting commercialization 
opportunities than would a single campus office.
4	 Establishing networks among colleagues will increase your awareness of opportunities 
and also help you understand the broader implications of your research.
4	 Keep your TTO informed about your networking activities, particularly if there is a 
possibility of shared research endeavors. These collaborative research projects often 
form the foundation of networks for technology transfer and licensing opportunities. 
ESTABLISHING AND OPERATING TECHNOLOGY TRANSFER OFFICES











Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
FOR TECHNOLOGY TRANSFER OFFICERS
4	 You have a duty to ensure that senior management understands that a successful 
technology transfer office (TTO) requires visible and sustained support, financial and 
otherwise. Work with senior management on the definition of clear mandates that will 
help you choose among competing priorities and the ever-present trade-offs between 
business and academic values.
4	 Above all, ensure that senior management knows that it requires tto officers who are 
able and willing to take risk and senior management to support you.
4	 Efficient and effective TTOs must have an articulated TTO mission, transparent TTO 
policies and procedures, entrepreneurial staffing and an entrepreneurial environment, 
customer-friendly relations between TTO staff and internal and external constituents, 
a highly supportive administration, strong TTO links to potential industry partners, and 
TTO access to risk, or venture, capital.
4	 One of the most important factors for a successful TTO is the institution’s entrepreneurial 
culture. This is determined most often by the attitude and degree of support from 
senior management.
4	 A TTO must emphasize the importance of confidentiality in all its operations. 
4	 Any TTO needs to have, from the outset, a systematic way of managing agreements 
and many other forms of data as the amount of data will increase significantly and 
year by year. The sooner a functional contract-management system is implemented, 
the easier it will be to keep track of contracts and make the most of them, both for the 
organization and for its collaborators.
4	 The Whitehead Institute’s proprietary agreement management system (called WIIPS™) 
may constitute a viable software option for emerging and established TTOs. WIIPS™ 
can be downloaded for free from the online version of the Handbook. 
4	 The importance of continued hands-on training programs of TTO staff cannot be 
overstated. 
4	 Similarly, the importance of building networks in the technology transfer and licensing 
community is critical. By working through networks, practitioners exchange ideas and 
experiences, forming best practices that become performance standards for both 
individuals and their institutions. 
4	 When recruiting personnel to staff your office, consider key qualifications. The 
importance of having the best professionals working for you cannot be overstated. 
Staffing can have a significant impact on the success of your office.
4	 Any TTO will have a wide range of legal matters to be addressed, and procedures for 
working with external patent counsel and general counsel should be well established. 
Make sure you are in, and stay in, the driver’s seat. 
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to one or several patents. Technology licens-
es usually include the transfer of know-how 
(which may or may not be a trade secret) 
and sometimes materials. Such licenses 
may provide for the further development 
of a technology or limit production/manu-
facture of a good or provision of a service. 
Commercialization licenses are discussed in 
part 12 of the Executive Guide: Dealmaking 
and Marketing Technology to Product-
Development Partners.
In addition, parties may engage in research 
agreements and distributorship agreements that 
contain elements of the four types of agree-
ments listed above. Many agreements, such as 
MTAs contain confidentiality provisions; patent/
technology licenses often contain confidential-
ity and material transfer provisions as well. But 
certain standard elements are integral to most 
agreements:
• recitals, preamble, and “whereas clauses” that 
lay out the broad motivations and goals of 
the agreement
• a list of the parties entering into the agreement
• definitions of terms used in the agreement
• confidentiality clauses
• territory and exclusivity clauses that define 
the geographic regions in which the licens-
ee is permitted to make, use, and/or sell the 
technology in question
EXECUTIVE GUIDE TO HANDBOOK SECTION 7
(VOLUME 1: PAGES 675-744)
A contract follows the deal that has been made 
between two or more parties. Put differently, form 
(contract) follows function (deal). And any deal 
has a purpose: it is a means of transferring value 
between parties. Ideally, the trust between part-
ners permeates their relationship and interactions, 
from the negotiations of an agreement, through 
project implementation, and into future agree-
ments, collaborations, and projects. However, in 
practice, circumstances are rarely perfect. So ne-
gotiating agreements should be seen as an initial 
step toward longer-term, productive, and mutu-
ally beneficial relationships. 
There are many types of agreements, as noted 
and discussed by Mahoney and Krattiger,1 and 
those related to collaborations fall into one of 
four broad categories:
• Confidentiality agreements protect confidential 
information from disclosure to third parties. 
• Materials transfer agreements (MTAs) protect 
samples (tangible property) from misuse by 
or unauthorized distribution to third parties.
• Co-development agreements and collabora-
tion agreements outline the specific contri-
butions of different parties who work to-
ward a mutual goal. 
• Patent licenses and technology licensing agree-
ments allow one party to further develop, 
use, make, or sell the patented (and/or 
trade-secret-protected) technology of an-
other party. Patent licenses may be specific 
Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007. 
7: Contracts and Agreements to Support Partnerships. In Executive Guide to Intellectual Property Management in Health 
and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), 
PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute 
(Ithaca, USA). Available online at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for 
noncommercial purposes is permitted and encouraged.
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• liability clauses that establish who will ac-
cept liability for a product and that set out 
terms of liability 
• payment clauses that define the forms of 
payment, if any, of up-front fees and/or 
royalties (Terms will ideally balance the 
licensor’s need for short-term income and 
the licensee’s capacity to make further in-
vestments for longer-term development.) 
• an arbitration clause that establishes how 
disputes will be handled
• term and termination, establishing how long 
the agreement will last and under what con-
ditions the agreement may be terminated 
• jurisdiction, warranties, and notices, which 
specify (1) where disputes are to be resolved, 
(2) that the licensor does, in fact, own the 
intellectual property to be licensed, and (3) 
where official communications are to be 
directed
• illegal/unenforceable provisions that specify 
which terms can be discontinued due to inva-
lidity without rendering the agreement void 
• subject law, which specifies where the par-
ties wish to have the agreement interpreted 
and adjudicated 
• signatories (These are representatives, called 
agents, who have the authority to bind their 
respective organizations, called principals, to 
the terms and provisions of the agreement.) 
Public sector research institutions can use a 
variety of agreements to protect and manage in-
tellectual property. These agreements are power-
ful tools to foster competition in the private sec-
tor and reduce prices for consumers in developing 
countries. The authors emphasize the importance 
of establishing and maintaining trust when ne-
gotiating and implementing agreements.
Although no agreement will ever be perfect, 
there are good and not-so-good agreements (and 
poorly written and highly ineffectual agreements). 
The best agreements are generally those that do 
not use technical or legal jargon, that use short, 
clear sentences free of vague adjectives and written 
in active voice. Business people (who have exten-
sive technical knowledge but generally limited legal 
knowledge) and judges (who generally have limited 
technical knowledge but extensive legal knowl-
edge) should find such documents accessible.
Agreements that serve the parties best may 
take longer to negotiate, but each time two par-
ties have successfully developed an agreement, the 
development of subsequent agreements should be 
easier. Taking time to think through and discuss 
the terms of an agreement fosters communica-
tion between the partners, although often tem-
plate agreements2 can be used as starting points 
in building trust.
During collaborations, and in some types of 
licensing agreements, materials and confidential 
information are passed from one party to an-
other. Confidentiality, or nondisclosure, agree-
ments are contracts that govern the disclosure 
of confidential information by one party to an-
other party and can be useful for building trust. 
Kowalski and Krattiger3 explain that disclosures 
may be unilateral, bilateral, or multilateral, and 
confidential information is valuable precisely be-
cause it is not known to business competitors or 
to the public. Key provisions in a confidentiality 
agreement include:
• definition of the information
• important exceptions, which describe cir-
cumstances under which the obligation of 
confidentiality is inapplicable (for example, 
the information was already in the public 
domain or is commonly known) 
• conditions on the use of the confidential in-
formation, which is a detailed description 
of the ways in which the receiving party 
may and may not use the information
• requirements for documentation, which de-
scribe the requirements for written records 
(may include keeping track of the disclosed 
information, whether disclosed in writing 
or orally)
An organization that enters into a confidential-
ity agreement must ensure that all who have access 
to the confidential information understand that 
they must keep sensitive information confidential.
Traditionally, scientists have freely shared in-
formation as well as research materials. However, 
with fundamental research and commercial devel-
opment merging ever closer, in both health and 
CONTRACTS AND AGREEMENTS TO SUPPORT PARTNERSHIPS
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agricultural research, materials that once would 
have been used exclusively for fundamental re-
search increasingly have direct commercial value. 
Therefore, universities, for-profit corporations, 
and nonprofit research institutions now realize 
that they must obtain proprietary protection for 
their research materials. Unrestricted transfers of 
research materials between scientists are becoming 
less and less common, particularly transfers be-
tween scientists in industry and those in academia. 
Biological materials are transferred still, though 
not as freely as before, but now with conditions at-
tached as part of MTAs. Increasingly important in 
the life sciences, MTAs delineate the terms under 
which tangible materials are transferred between 
two or more parties. Technically, MTAs are bail-
ments because they involve the transfer of posses-
sion but not of title. In other words, the party that 
transfers the materials retains full ownership, and 
the party that receives the materials holds them 
“in trust”; an analogy for such a transfer might be 
the act of leaving a watch at a watch-repair shop or 
a suit with a dry cleaner. 
Bennett, Streitz, and Gacel4 explain that an 
MTA specifies the term of a transfer, delineates 
how materials may and may not be used, and 
provides for other related issues such as confiden-
tiality. An MTA may also contain licensing provi-
sions for the transfer of embedded IP rights (such 
as patent rights). Thus, an MTA can be a hybrid 
instrument, covering the transfer of both tangible 
property (via bailment and contract) and intan-
gible intellectual property (via licensing of pat-
ent rights). Thus, MTAs can be quite complex. 
Besides the usual clauses included in MTAs, the 
following are the perhaps the most critical to con-
sider, especially for public sector institutions:
• reach through clauses, which describe the 
extent to which the supplying party may 
“reach”’ into the research and into new 
intellectual property or material generated 
from work with the supplied materials
• derivatives, clauses that explain who will 
own modifications if the receiving institu-
tion makes modifications to the material  
Particular consideration should be given 
to these all-important clauses, and receiving 
institutions must understand the implications of 
such clauses if indeed they are included. As a re-
sult, material transfers between private- and pub-
lic-sector institutions are typically much more 
complex than MTAs between two universities. 
It is less problematic for universities to transfer 
materials than it is for materials to be transferred 
between industry and academia. If a problem 
does occur under a transfer arrangement, it is 
usually because IP rights attached to the materi-
als transferred have been exclusively licensed and 
the terms of that agreement impose constraints 
on the institution providing the material. 
Collaborative research agreements and spon-
sorship agreements are generally more complex 
than MTAs. A collaborative research agreement, 
for example, often involves multiple partners 
(who are increasingly a mixture of private- and 
public-sector actors) working together on a re-
search project. The partners each contribute an 
amount of money, talent, and technology into a 
central pool that all draw from. Chapters by Bair 
Steinbock5 and Gold and Bubela6 explain how to 
write collaborative research agreements and cover-
ing myriad issues, including licensing provisions. 
The authors point out that the following elements 
are the most critical in these agreements (besides 
the usual must-haves for any agreement):
•	 statement of objectives, which explains what 
the parties want to accomplish together 
and why their collaboration is important
• statement of work, which explains the re-
search plan, outlining approaches and 
methodologies, specifying who will be re-
sponsible for work product, and delineat-
ing time frames, benchmarks, and delivery 
dates 
• work plan that specifies what each party will 
be expected to contribute, how necessary 
changes to the work plan will be made, and 
how communication between the parties is 
to take place 
• dispute resolution plan, which explains pro-
cedures and mechanisms that would be 
used in turn, should a dispute arise 
Focusing on patent licensing, Krattiger7 
points out that not every patent needs to be 
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licensed per se. A special form of agreement—
which can also take the form of a public state-
ment—is the nonassertion covenant (nonassert). 
Such an agreement certifies that a party or parties 
in possession of intellectual property will not as-
sert and defend IP rights (typically patents). Such 
nonasserts can be used in a broad range of IP 
management scenarios. For example, nonasser-
tion covenants are particularly useful for grant-
ing developing countries access to essential in-
novations in health and agriculture, since such 
agreements offer simple and effective ways of 
dealing with three major constraints common in 
agri-biotechnology transfer and licensing:
1. Nonassertion covenants can be used to cir-
cumvent liability associated with licensing.
2. Nonassertion covenants can make research 
tools available.
3. Transaction costs can be reduced because 
such costs associated with nonassertion 
covenants are lower than those associated 
with bilateral and multilateral licensing 
agreements.
From a legal perspective, nonasserts are pre-
emptive patent-infringement settlement agree-
ments that are designed and drafted with the pur-
pose of resolving future infringement disputes. 
There are no compelling reasons why nonasserts 
could not become more widely used to foster 
important advances and innovation that address 
needs in developing countries. 
A patentee’s public declaration of nonen-
forcement of a patent via a nonassert can have 
wide-ranging implications in terms of enhanc-
ing public sector R&D. This would be the case 
especially with patent rights covering research 
tools, and particularly in the United States, due 
to limitations on research exemptions. These are 
critical for accelerating the development of es-
sential biotechnological applications in both the 
health and agricultural industry sectors. Carefully 
drafted, targeted nonasserts permitting the use of 
these tools—anywhere in the world—to address 
humanitarian needs (including in a commercial 
setting) could have broad-ranging and significant 
positive impacts. The approach reduces trans-
action costs, encourages innovation to help the 
poor, and accomplishes this without much cost, 
time, or loss of commercial opportunity. ■
All chapters refer to: Intellectual Property Management in 
Health and Agricultural Innovation: A Handbook of Best 
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thom-
son, AB Bennett, K Satyanarayana, GD Graff, C Fernandez, 
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis, 
U.S.A. Available online at www.ipHandbook.org. The online 
version contains for each chapter a detailed Editor’s Sum-
mary, Implications, and Best Practices.
1 Chapter 7.1 by RT Mahoney and A Krattiger titled 
Agreements: A Review of Essential Tools of IP 
Management, p. 675.
2 The online version of the Handbook offers 16 
confidentiality agreements, 22 MTAs, 25 collaboration 
agreements of various types, 39 licenses of various 
types, 17 other types of agreements ranging from 
nonasserts to consultancy agreements, and several 
IP-related clauses in employment agreements. These 
are real agreements from various institutions around 
the world that can be used as starting points for 
generating template agreements. Note, however, that 
whereas template agreements can be useful, they 
should be used cautiously. They are seeds for further 
discussion and negotiation. No generic template will 
be appropriate in every cultural and legal climate.
3 Chapter 7.2 by SP Kowalski and A Krattiger titled 
Confidentiality Agreements: A Basis for Partnerships, p. 
689.
4 Chapter 7.3 by AB Bennett, WD Streitz and RA Gacel 
titled Specific Issues with Material Transfer Agreements, 
p. 697.
5 Chapter 7.4 by M Bair Steinbock titled How to Draft a 
Collaborative Research Agreement, p. 717.
6 Chapter 7.5 by ER Gold and T Bubela titled Drafting 
Effective Collaborative Research Agreements and 
Related Contracts, p. 725.
7 Chapter 7.6 by A Krattiger titled The Use of Nonassertion 
Covenants: A Tool to Facilitate Humanitarian Licensing, 
Manage Liability, and Foster Global Access, p. 739.
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 A public sector institution can use a variety of agreements to both manage and protect 
intellectual property, regardless of whether that intellectual property is owned by the 
public sector institution or by licensing partners in the private sector. The key issue is to 
allow for maximum flexibility whereby institutions can set, or negotiate, the terms that 
best fit the mission and goals of the institution and the purpose of the partnership.
4	 It is important to encourage partnerships that accelerate the development and use of 
new technologies, whether they are domestic or foreign, and to provide support and 
encouragement during negotiation in the form of tangible commitments to capacity-
building, as well as to broader IP management training in patenting, licensing, and 
technology transfer, for example. 
4	 Confidentiality agreements are meant to protect sensitive data that one party transfers 
to another. They do not run counter to public sector missions or to publishing important 
research findings. Many organizations, including public sector institutions, often 
have information that is legitimately kept confidential. Such information can include 
business plans, research proposals, and databases containing business contacts. 
4	 Confidentiality agreements rely on a culture of trust, not a culture of secrecy.
4	 Predictably enforced and fairly construed contract laws will greatly facilitate the 
formation and enforcement of contracts. A functioning court system is essential to 
encouraging partnerships. Indeed, suppliers of biological materials (and of confidential 
information and intellectual property) will be encouraged to enter into agreements 
if the suppliers are confident that their property rights will be protected and that 
agreements will be enforced. Such confidence fosters collaborative research, and drives 
international collaboration. 
4	 It is important that the courts adjudicate contract disputes efficiently and fairly because 
the quality of the judicial system will influence the quality and quantity of a country’s 
international partnerships and agreements and also will influence the complexity and 
sophistication of technologies transferred to and from a given country. 
FOR GOVERNMENT POLICYMAKERS
GUIDE TO SECTION 



























Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 A public sector institution can use a variety of agreements to both manage and protect 
intellectual property, regardless of whether that intellectual property is owned by the 
public sector institution or by licensing partners in the private sector. The key issue is to 
allow for maximum flexibility whereby institutions can set, or negotiate, the terms that 
best fit the mission and goals of the institution and the purpose of the partnership.
4	 It is important to encourage partnerships that accelerate the development and use of 
new technologies, whether they are domestic or foreign, and to provide support and 
encouragement during negotiation in the form of tangible commitments to capacity-
building, as well as to broader IP management training in patenting, licensing, and 
technology transfer, for example. 
4	 Confidentiality agreements are meant to protect sensitive data that one party transfers 
to another. They do not run counter to public sector missions or to publishing important 
research findings. Many organizations, including public sector institutions, often 
have information that is legitimately kept confidential. Such information can include 
business plans, research proposals, and databases containing business contacts. 
4	 Confidentiality agreements rely on a culture of trust, not a culture of secrecy.
4	 No agreement will ever be perfect. Technology transfer officers who negotiate 
agreements that are in keeping with an institution’s policy, ought to be given full 
support by senior management, especially when deals are criticized from outside of 
the organization.
4	 Senior management can be instrumental by signing off on certain template agreements 
that can be used as a basis for negotiating deals. But a template agreement should be 
used only as a starting point for discussion.
4	 Any institution should have clear guidelines stating who is authorized to sign 
agreements.
FOR SENIOR MANAGEMENT
(UNIVERSITY PRESIDENT, R&D MANAGER, ETC.)
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 A public sector institution can use a variety of agreements to both manage and protect 
intellectual property, regardless of whether that intellectual property is owned by the 
public sector institution or by licensing partners in the private sector. The key issue is to 
allow for maximum flexibility whereby institutions can set, or negotiate, the terms that 
best fit the mission and goals of the institution and the purpose of the partnership.
4	 Confidentiality agreements are meant to protect sensitive data that one party transfers 
to another. They do not run counter to public sector missions or to publishing important 
research findings. Many organizations, including public sector institutions, often 
have information that is legitimately kept confidential. Such information can include 
business plans, research proposals, and databases containing business contacts. 
4 Confidentiality agreements rely on a culture of trust, not a culture of secrecy.
4	 No agreement will ever be perfect. Technology transfer officers who negotiate 
agreements that are in keeping with an institution’s policy are making their best effort 
at getting deals that respect and strengthen the institution’s mission. Your role, however, 
is to share with those who negotiate agreements all of the relevant information and 
your insights. In some cases, especially with collaborative research agreements, you 
may be an integral member of a team that will address issues such as research plans 
and purpose.
4	 In most cases, you will not be authorized to sign certain types of agreements without 
review by counsel or by your technology transfer office. Make sure you know whether 
or not you are authorized to sign certain agreements.  
4	 Everyone in your group or laboratory should know—and understand—the obligations 
entered into through certain agreements that affect information, data, and materials 
used in your laboratory and research program. This is especially important for material 
transfer agreements and confidentiality agreements.
4	 You will need to keep track of data and information related to confidentiality 
agreements. Understand what can and cannot be disclosed and to whom information 
can be disclosed. If you have questions, do not hesitate to contact your technology 
transfer office for guidance. 
4	 An MTA should not be viewed as a barrier to materials access. In fact, MTAs are tools 
for gaining greater access to materials from a wider range of sources (scientists from 
the public and private sectors, both in your own country and abroad). However, not all 
clauses in an MTA may be appropriate. Which clauses are appropriate will depend on 
the circumstances, the purposes of the transfer, and the institution from which the 
material is being received.
FOR SCIENTISTS
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 A public sector institution can use a variety of agreements to both manage and protect 
intellectual property, regardless of whether that intellectual property is owned by the 
public sector institution or by licensing partners in the private sector. The key issue is to 
allow for maximum flexibility whereby institutions can set, or negotiate, the terms that 
best fit the mission and goals of the institution and the purpose of the partnership.
4	 Recognizing that no agreement will ever be perfect, you will need to work with senior 
management to obtain their full support and backing, especially when deals are likely 
to be criticized from the outside.
4	 Certain terms should be “negotiated” internally prior to negotiating with third parties. 
Senior management can be instrumental by signing off on certain template clauses 
that can be used as the basis for negotiating deals. 
4	 A template agreement should be used only as a starting point for discussions.
4	 Contracts should be tailored to fit local customs and business practices. Be sensitive to 
cultural and linguistic differences among parties to a contract. 
4	 Your office ought to be the official repository of all agreements dealing with incoming 
and outgoing biological materials. 
4	 Legal jargon in agreements should be avoided. Instead, use short, clear sentences 
that are free of vague adjectives and are written in the active voice. The vocabulary 
should be accessible both to business people (who have extensive technical knowledge 
but limited legal knowledge) and judges (who have limited technical knowledge but 
extensive legal knowledge).
4	 Confidentiality agreements rely on a culture of trust, not a culture of secrecy. Make 
sure that confidentiality agreements contain the necessary exceptions appropriate for 
the mandate of your institution. A tricky question is how broadly the term confidential 
information should be defined. Too narrow a definition may leave out important 
information; too broad of a definition may prevent the parties from getting on with 
their work.  
4	 MTAs call for extra caution with respect to clauses that deal with reach through and 
the ownership of derivatives. These clauses need not be negative. In fact, you may wish 
to impose certain reach through clauses yourself. These decisions will depend on the 
circumstances.
4	 When negotiating collaborative research agreements, you should involve the scientists 
to the maximum extent possible. Also, pay particular attention to a clear and detailed 
work plan, how communication is to happen among the parties, how modifications to 
the work plan are to be agreed upon, and how disputes are to be resolved.
FOR TECHNOLOGY TRANSFER OFFICERS
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sions that can be costly in terms of money, time, 
missed opportunities, and relationships between 
scientists, heads of departments, and TTOs. So 
it is important that university leaders and admin-
istrators—and scientists—work in concert on 
policies and mechanisms that establish the pro-
cedures used for recording inventions, for inven-
tion disclosure, and for sharpening the interface 
between scientists and technology transfer and 
licensing offices. 
Three conspicuous but usually neglected is-
sues deserve special consideration up front. First, 
it is often difficult to know when an invention has 
actually been made. Training of scientists with re-
spect to IP management and an institutional at-
mosphere that encourages inventions and inven-
tion disclosures are essential for making the most 
of scientific endeavors. Second, inventors need to 
have a clear understanding of their rights—and 
responsibilities—when it comes to their inven-
tions. Unrealistic expectations that are either too 
high or too low will get in the way of optimally 
productive research and can be a source of con-
flicts with TTOs. Third, inventions, per se, are 
not necessarily innovations, though they may 
become innovations.1 
The section’s opening chapter by Mutschler 
and Graff2 provides essential information that 
university scientists and inventors need to know 
in order to manage new and existing intellec-
tual property and to deal with TTOs. University 
EXECUTIVE GUIDE TO HANDBOOK SECTION 8
(VOLUME 1: PAGES 747-786)
Universities, inventors, and inventions—and by 
extension intellectual property—are all inextri-
cably intertwined. Scientists are the central force 
behind the research, teaching, and extension 
missions of universities. And inventors can be 
considered the central force behind intellectual 
property, since they generate patentable inven-
tions. Dealing with scientists, and inventors, 
at least from an IP management perspective, is 
not always straightforward or easy, but the tech-
nology transfer process and licensing are made 
easier if scientists know some basics of IP man-
agement and of patenting, and are somewhat 
familiar with best practices. This applies equally 
to high-flying attention-seekers and low-key 
geniuses.
A university research program must frequent-
ly make decisions about whether its research-
ers’ discoveries should be protected. The process 
leading to this decision can place a tremendous 
strain on the relationship between the technology 
transfer office (TTO) and scientists. And it is one 
of the principal reasons why scientists should be 
given an opportunity, from the day they join a re-
search institution, to learn the very basic concepts 
of IP management to better understand the pro-
cess and the challenges faced by TTOs and TTO 
officers. How are decisions made as to when to 
patent, what to patent, and how to protect an in-
vention? When it comes to new inventions, un-
clear and non-transparent procedures lead to ten-
Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007. 
8: Inventors and Inventions. In Executive Guide to Intellectual Property Management in Health and Agricultural Innovation: 
A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). bioDevelopments-International Institute (Ithaca, 
USA), MIHR (Oxford, UK), PIPRA (Davis, USA), and Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil). Available online 
at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for non-
commercial purposes is permitted and encouraged.
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faculty and scientists anywhere need a working 
knowledge of what intellectual property is and 
what can be done with it so that they are able 
to make decisions about their laboratories’ IP is-
sues. These issues range from how to start and 
run a research program (from an IP management 
perspective), how to handle new inventions pro-
duced by that research, and how to manage the 
property of their collaborators. Graduate students 
and postdoctoral scientists should also acquire 
a basic understanding of intellectual property, 
since this knowledge will be valuable to them no 
matter what their future careers hold, whether in 
government, academia, non-governmental orga-
nizations, or industry.
Universities typically have—or should 
have—institutional IP policies that must be 
complied with by all personnel. In the United 
States, these IP policies must conform to the 
guidelines outlined by the Bayh-Dole Act of 
1980. This act was intended, among other pur-
poses, to promote private sector investment in 
federally funded research to facilitate the trans-
fer of federally funded research to industry. For 
these reasons, university employees in the United 
States must sign agreements that state that all 
intellectual property generated under the uni-
versity’s aegis belongs to that university (though 
an inventor is typically given a share of the rev-
enues that come from the sale of any intellectual 
property that he or she generates). One major 
exception to the policy of assigning IP rights to 
the university, however, is copyrighted material 
(books, papers, drawings, paintings, sculptures, 
and so forth).
A university’s IP office or TTO is typically 
responsible for protecting and developing com-
mercial applications (including out-licensing 
patents) for inventions developed at the univer-
sity. Its functions typically include:
• determining the most effective way to 
protect inventions 
• evaluating the commercial potential of 
inventions
• obtaining the appropriate protection for 
inventions
• locating suitable commercial-development 
partners and marketing inventions to them
• negotiating and managing IP licenses
• encouraging and assisting the formation 
of new companies around university-gen-
erated intellectual property (start-ups)
In addition to briefly reviewing the above, 
Mutschler and Graff familiarize scientists with is-
sues they face on a daily basis:
• how to deal with confidential information
• how to deal with materials from third parties
• what constitutes a public disclosure of sci-
entific finding
• how the patenting process works
• understanding the basics of intellectual 
property
 
If scientists read only one chapter in the en-
tire Handbook, Chapter 8.1 is the one they should 
read. But on a daily basis, a scientist’s responsibil-
ity goes further than having a basic understanding 
of IP management. For authoritative IP manage-
ment, university faculty, staff, and students need, 
at a minimum, to appropriately document their 
research findings, use of intellectual property not 
owned by the university, dealings with collabora-
tors outside the university, and places and times 
of public disclosures of research results. Good 
record keeping is not only important for prepar-
ing publications, reports, and grant proposals, 
it is also essential for preparing IP-protection 
documents and supporting IP rights. Universities 
must be very careful when they use materials and 
methods that do not belong to them, in order to 
avoid infringing on the property rights of oth-
ers. In a worst case scenario, third-party materials 
may be used in research, which would mean the 
new intellectual property generated through use 
of that material would belong to that third party. 
Ownership would depend on how the material 
was obtained. Issues related to ownerships (mate-
rial transfer agreement) are discussed elsewhere.3 
But irrespective of the terms of access, good re-
cord keeping in general and laboratory notebooks 
in particular are essential to possibly later disen-
tangle ownership issues.
Scientists should be familiar with the ins-and-
outs of keeping a laboratory notebook to docu-
ment research. As a matter of institutional policy, 
GUIDE TO SECTION 
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the contents of laboratory notebooks should be 
treated as confidential and valuable. Notebooks 
should be stored in a safe place and any loss or 
theft should be reported immediately. A labora-
tory notebook is owned by the institution where 
work is conducted (essentially by the employer of 
the scientist). Therefore, when a scientist leaves 
an institution permanently, he or she should be 
required to turn notebooks over to supervisors 
(though copies can generally be kept by depart-
ing scientists). 
Thomson,4 a scientist herself, shares the prac-
tical aspects of laboratory-notebook keeping and 
her chapter offers a sample policy. Crowell5 ex-
amines the entire range of invention documenta-
tion. It cannot be overemphasized how important 
is good documentation of research. It is a critical 
component of best practices in IP management 
for the following reasons: 
• Well-kept laboratory notebooks are one of 
the most important sources of documenta-
tion. A laboratory notebook should contain 
detailed records of every experiment that 
has been planned or executed (including 
the date it was performed), the reasons 
for performing it, the methodology used 
in performing it, the results of the experi-
ment, and the significance of the results.
• Laboratory notebooks are important instru-
ments of institutional memory. Laboratories 
invariably have high personnel turnovers: 
scientists move on, post docs move up, 
students graduate, and technicians are 
promoted.
• Consistent documentation is important 
to determine patentability, and may even 
be essential for determining inventorship, 
for drafting and prosecuting patent appli-
cations, and (if necessary) for protecting 
patents from third-party challenges such 
as prior-art challenges and (in the United 
States) patent-interference proceedings. 
Once scientists think they may have patent-
able inventions, they should file an invention dis-
closure to their TTO. McGee6 examines the entire 
invention-disclosure process from a practical and 
logistical point of view and stresses the importance 
of involving inventors throughout the protection 
and commercialization process. He discusses how 
IP professionals can best work with inventors to 
develop high-quality invention disclosures. An 
invention disclosure is a description of something 
novel and nonobvious that would allow anyone 
of ordinary skill in the corresponding art to re-
produce the invention. It may be simple in scope 
and include most details in an attached draft of a 
scientific paper (McGee also notes, quite appro-
priately, that carefully kept laboratory notebooks 
can be used in place of an invention disclosure). 
Importantly, an invention disclosure irrefutably 
establishes the date and scope of an invention, as 
well as the identity of the inventor(s). Disclosures 
are essential for managing intellectual property, 
preserving IP assets, “harvesting” inventions and 
securing IP protection for those assets, and even-
tually translating the inventions into innovative 
products or services. 
Thus, an invention disclosure is the beginning 
of what is sometimes a long but often rewarding 
process that can benefit the institutions where the 
disclosures are made, the society at large, and the 
inventors in particular. ■ 
All chapters refer to: Intellectual Property Management in 
Health and Agricultural Innovation: A Handbook of Best 
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thom-
son, AB Bennett, K Satyanarayana, GD Graff, C Fernandez, 
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis, 
U.S.A. Available online at www.ipHandbook.org. The online 
version contains for each chapter a detailed Editor’s Sum-
mary, Implications, and Best Practices.
1 See, also in this Executive Guide, part 9: Evaluation and 
Valuation of Technologies.
2 Chapter 8.1 by M Mutschler and GD Graff titled 
Introduction to IP Issues in the University Setting: A 
Primer for Scientists, p. 747.
3 See, also in this Executive Guide, part 7: Contracts and 
Agreements to Support Partnerships.
4 Chapter 8.2 by JA Thomson titled How to Start–and 
Keep–a Laboratory Notebook: Policy and Practical 
Guidelines, p. 763.
5 Chapter 8.3 by WM Crowell titled Documentation of 
Inventions, p. 773.
6 Chapter 8.4 by DR McGee titled Invention Disclosures 
and the Role of Inventors, p. 779.
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4	 People and institutions typically look after their possessions in a much more serious 
manner than if they have no stake in them. This is applicable to physical property 
and to intellectual property. For this reason, governments should consider enacting 
legislation or, as appropriate, implementing policies that clearly spell out how public 
sector institutions can protect, own, and license inventions made in their institutions. 
This equally applies to government research centers and to universities.
4	 Arguably, the minds of scientists operate differently from those of lawyers, politicians, 
bankers, and policymakers. Similarly, those engaged in managing the intellectual 
property in public sector institutions face different challenges than the scientist-
inventors. These differences can be the source of much tension, but such tension can 
often be preempted if scientists are given an opportunity to learn the basics of iP 
management, including best practices, in terms of data and information management 
related to inventions. Public sector institutions should have the resources to offer 
limited, but essential, training to every scientist when they join an institution. 
4	 Such training programs can be given as a series of short seminars or even half-day 
orientation courses. These are most effective if the institutions have clear IP policies 
that include matters related to ownership of inventions, the duty to disclose inventions, 
and laboratory notebook keeping. The latter is common practice in any private sector 
R&D center. Comprehensive research records are fundamental to best practices in 
science, IP management, and in the regulatory process. 
PROCESS FOR GOVERNMENT POLICYMAKERS
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4	 People and institutions typically look after their possessions in a much more serious 
manner than if they have no stake in them. This is applicable to physical property and 
to intellectual property. For this reason, work with your governments to implement 
policies (or enact legislation, as appropriate) that clearly spell out how public sector 
institutions, including government research centers and universities, can protect, own, 
and license inventions developed at your institution.
4	 Arguably, the minds of scientists operate differently from those of lawyers, politicians, 
and university presidents (although many a president is a former scientist). Similarly, 
those engaged in managing intellectual property in public sector institutions face 
different challenges than do scientist-inventors. The differences can be a source 
of much tension, but such tension can be preempted if scientists are given an 
opportunity to learn the basics of iP management, including best practices, in terms 
of data and information management related to inventions. Public sector institutions 
and companies alike should offer and require limited, but essential, training to every 
scientist, student researcher, and technician when he or she joins a research program. 
4	 Such training programs can be provided as a series of short seminars or even half-
day orientation courses. And they are most effective if the institutions have clear IP 
policies that include matters related to ownership of inventions, the duty to disclose 
inventions, and laboratory notebook keeping. The latter is common practice in any 
private sector R&D center. Comprehensive research records are fundamental to best 
practices in science, IP management, and in the regulatory process. 
4	 University faculty, staff, and students do not have to become IP experts. The IP 
management training programs is best offered by the technology transfer personnel 
that will be interacting with scientists rather than by lawyers and outside consultants 
can be useful facilitators. Part of the aim of such training is team building that 
encourages communication between the scientists, technology transfer personnel, 
and senior management. It is part of creating a culture of IP awareness.
4	 Many scientists at public institutions often do not (initially, at least) appreciate the 
importance of laboratory notebooks and documentation protocols. For private sector 
R&D centers, this is done as a matter of routine. Some argue that good laboratory 
notebook practices lead to better science. laboratory notebooks surely lead to better 
invention disclosures, prevent fraud, clarify inventorship, facilitate patent applications, 
and ultimately, pay off for individuals and institutions in the long term. 
4	 If an invention is protected, then much can be gained if inventors are actively involved 
in all phases of the protection and marketing of their inventions. Inventors not only 
have intimate knowledge of their inventions; they may also have useful leads and 
contacts in companies or have ideas about how an invention could be incorporated 
into existing products or services. The practice of occasional seminars by technology 
transfer personnel for scientists is a practice that will strengthen the interest and 
involvement of scientists in this process.
FOR SENIOR MANAGEMENT
(UNIVERSITY PRESIDENT, R&D MANAGER, ETC.)
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4	 iP management is an important element in facilitating the translation of research into 
useful products or services that benefit your community and country.
4	 Encourage your technology transfer office (TTO) to organize occasional seminars on 
the basics of iP management. Ideally, your institution should provide an IP management 
primer when you join the institution that will help you understand the basic elements of IP 
protection and smooth the interface with your TTO. Even if you have taken such primers or 
seminars before, attend those offered by your new employer and encourage those in your 
group to do so as well. This will facilitate communication with your TTO staff and answer 
your questions about IP management.
4	 One potentially controversial issue faced by many TTOs involves keeping laboratory 
notebooks. For private sector R&D centers, this is done as a matter of routine. Make it a habit 
to use laboratory notebooks, as doing so can lead to better science and easier invention 
disclosures and can facilitate patent applications. 
4	 good practices in laboratory notebook keeping should include the signing of each page by 
a supervising scientist, occasional spot checks, and the setting aside of time for recording 
experiments and results. This applies to research assistants, students, post docs, and 
everyone else working in a laboratory.
4	 good record keeping is important. It includes linking research proposals with material 
transfer agreements, publications, invention disclosures, and so forth. It promotes both 
scientific goals (it facilitates the writing of publications and grant proposals) and legal goals 
(good records make it easier to obtain and defend patents).
4	 Good record keeping goes beyond publications and IP management. Especially in institutions 
dealing with the development of products and clinical trials in health, or biosafety research in 
agriculture, record keeping may be essential for providing regulators the necessary evidence 
that good laboratory practices have been followed and may underpin regulatory filings. In 
many cases, experiments conducted years before regulatory filings can become valuable for 
those filings and, unless laboratory detailed notebooks were kept, experiments may have to 
be repeated at great cost and may also delay filings.
4	 Invention disclosures are the first step in protecting intellectual property. Disclose early and 
often. Rather than wait until your scientific paper is accepted, make it a habit every few 
months to think what might be disclosed and what should be disclosed, and then disclose it. 
But expect only a small portion of your invention disclosures to lead to patent applications.
4	 recognize when you actually have an invention. Often, it is much earlier than you think. By 
filing an invention disclosure with your TTO, you are initiating a dialogue. Even if the TTO 
does not immediately file a patent based on your first invention disclosure, it is a process 
that has started, and follow-up invention disclosures will be much easier. 
4	 Ideally, you should invite your tto liaison to visit your laboratory occasionally and discuss 
with you and your research team what you have been doing. Discussions with technology 
transfer experts, especially patent attorneys, can help you to identify inventions.
FOR SCIENTISTS
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4	 Arguably, the minds of scientists operate differently from those of bankers, politicians, 
and licensing executives. Similarly, those engaged in managing intellectual property 
in public sector institutions face different challenges than do scientist-inventors. The 
differences can be a source of much tension, but such tension can be preempted if 
scientists are given an opportunity to learn the basics of iP management, including 
best practices, in terms of data and information management related to inventions. 
Public sector institutions and companies alike should offer and require limited, but 
essential, training to every scientist, student researcher, and technician when he or she 
joins a research program.
4	 Such training programs can be provided as a series of short seminars or even half-
day orientation courses. And they are most effective if the institutions have clear IP 
policies that include matters related to ownership of inventions, the duty to disclose 
inventions, and laboratory notebook keeping. The latter is common practice in any 
private sector R&D center. Comprehensive research records are fundamental to good 
research practices in science, IP management, and regulatory areas. 
4	 University faculty, staff, and students do not have to become patenting experts. Keep 
any such training programs simple and practice oriented. Generally, the intricacies of 
patenting legislation is not what motivates a scientist; rather, it is a vision of how his 
or her invention can eventually make a difference in people’s lives. The IP management 
training programs should thus be practical and offered by technology transfer 
personnel that will be interacting with scientists rather than by lawyers. Contractors 
can be useful as facilitators. Part of the aim of such training is team building that 
encourages communication between your office and the scientists in your institution. 
It is part of creating a culture of IP awareness.
4	 It is good practice to include senior management as participants in the training 
sessions. This is especially useful when the training program includes case studies.
4	 Prepare simple brochures and Web sites that encourage scientists to contact you with 
their questions and inventions. Similarly, make an effort to attend seminars given by 
the researchers in your organization. It is a great way to show your interest in their 
activities and to build a good understanding of what the researchers actually do. 
Overall it helps to get scientists involved in all phases of protecting and marketing 
their inventions. 
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vaccine	 with	 Syngenta,	 a	 strategic	 alliance	 in	 forest-









Fundación	 Chile’s	 biotechnology	 activities	 in-
volve	 an	 extensive	 network	 of	 Chilean	 and	 foreign	
research	 centers	 and	 universities,	 as	 well	 as	 partici-
pation	 in	 key	 international	 consortia.	 Collaborators	
within	 Chile	 include	 Fundación	 Ciencias	 para	 la	
Vida,	 the	Chilean	National	 Institute	 for	Agricultural	
Research,	 the	University	 of	 Chile,	 the	University	 of	
Concepción,	the	University	of	Santiago,	the	University	
of	 Talca,	 University	 Federico	 Santa	 Maria,	 Andres	
Bello	 University,	 and	 Austral	 University.	 Alliances	
with	 foreign	 research	 centers	 and	 universities	 in-
clude	the	University	of	California,	Cornell	University,	
the	 University	 of	 Florida,	 the	 U.S.	 Department	 of	







As	 a	 result	 of	 this	 networking,	Fundación	Chile	












that	 can	 have	 a	 significant	 economic	 and	 social	 im-
pact.	These	new	companies	are	generally	joint	ventures	
with	strategic	partners,	although	other	models,	such	as	




Fundación	Chile	 is	unusual	 as	 a	nonprofit	 insti-












developing	 applications	 of	 biotechnology	 that	 can	
improve	 productivity,	 add	 value	 to	 existing	 prod-





genetics,	 functional	 genomics,	 and	 genetic	 engineer-
ing.	Strategic	alliances	in	biotechnology	in	the	private	
sector	 include	 a	 licensing	 agreement	 for	 a	 salmon	
Fernandez C. 2007. Somatic Embryogenesis of Grapes: Fundación Chile. In Executive Guide to Intellectual Property Manage-
ment in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR 
(Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-Interna-
tional Institute (Ithaca, USA). Available online at www.ipHandbook.org.
© 2007. C Fernandez. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged.
Somatic Embryogenesis of Grapes: 
Fundación Chile
CASE STUDY 1
CS  | HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE
introduced	into	the	market.	Elite	clones	of	radiata	pine	
developed	 through	 somatic	 embryogenesis	 in	collabo-
ration	with	CellFor	 are	 in	 advanced	 stages	 of	 testing	
and	are	being	scaled	up	for	market	introduction	by	the	
Fundación	Chile	company	GenFor.	Other	biotechnol-
ogy	 programs	 of	 Fundación	Chile,	 including	 genetic	
engineering	 of	 varieties	 of	 pine	 trees,	 peaches,	 and	
grapes,	are	in	earlier	stages	of	development.
THE TEcHnology
Importance of institutional support 
for a long-term R&D program
Agricultural	 biotechnology	 R&D	 programs	 are	 long	
term,	 expensive	 and	 controversial;	 an	 institution	 un-




















•	 enabling	 tools,	 such	 as	 genetic	 markers,	 pro-
moters,	 tissue	 culture	 and	 regeneration	 sys-
tems,	and	transformation	methods
In	 addition,	 human	 resources,	 laboratory	 infra-
structure,	 and	financing	are	needed	 to	 carry	out	 the	
R&D	 required	 to	 adapt	 and	 combine	 these	 compo-




many	different	 objectives,	 and	 sustained	 support	 for	
any	one	specific	program	was	rare.





and	 priority	 of	 different	 components	 were	 assessed,	
and	efforts	were	initiated	to	access,	license,	and	trans-
fer	the	key	components.








with	 little	 or	 no	 interest	 in	 the	 development	 of	 mi-
nor	crops.	A	complete	solution	was	not	possible	in	the	
short	 term	with	 the	 resources	 available.	However,	 it	
was	possible	to	establish	a	position	in	key	technologies	
that	maximized	 the	 likelihood	 of	 being	 competitive	
within	a	specific	niche.
A	 critical	 aspect	 was	 the	 active	 involvement	 of	
personnel	 with	 professional	 experience	 in	 commer-
cial	R&D	programs	and	major	 agri-biotech	 research	
centers	in	other	countries,	as	well	as	experience	in	the	
licensing	 of	 agricultural	 biotechnologies.	 Practices	
vary	from	country	to	country	and	from	institution	to	
institution	within	a	country.	At	 the	 initiation	of	 the	
program	there	was	little	experience	in	Chile	with	pat-
enting	and	licensing	technologies	developed	in	public	
research	 institutions.	 The	 involvement	 of	 personnel	
with	 international	 experience,	 providing	 appropriate	
examples	 drawn	 from	 a	 number	 of	 sources,	 played	
an	important	part	in	bridging	gaps	in	experience	and	
expectations.








ity	 to	 reproducibly	 transform	 the	 target	 species.	 For	
many	transformation	systems,	an	important	factor	 is	














Identification of suitable laboratories
The	search	used	different	and	complementary	channels,	
including	reviews	of	research	publications,	project	da-
tabases,	 conference	 proceedings,	 patent	 documents,	
CASE STUDY 1
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news	 items,	 and	 personal	 contacts.	 All	 of	 them	 are	
relevant,	 and	 each	provides	unique	 and	useful	 kinds	
of	information.	




quality	 documents	 in	 electronic	 form	 has	 greatly	 re-
duced	the	cost	of	access.
Open	 sites	 such	 as	 PubMed	 (www.ncbi.nlm.nih.
gov)	 and	 HighWire	 (highwire.stanford.edu)	 provide	





access,	 the	 availability	 of	 high-quality	 documents	 in	
electronic	form	has	greatly	reduced	the	cost	of	access.
Online	 databases	 such	 as	 those	 at	 the	 World	
Intellectual	 Property	 Office	 (www.wipo.int/ipdl),	
the	 European	 Patent	 Office	 (www.espacenet.com),	





more	 specialized	 content,	 are	online	databases	 of	 re-
search	projects.	These	often	include	information	that	
is	otherwise	difficult	or	impossible	to	find.	Examples	
include	 the	 European	Union	 Community	 Research	
&	Development	 Information	 Service	 (cordis.europa.
eu),	the	Current	Research	Information	System	of	the	
USDA	(cris.csrees.usda.gov),	 the	FAO-BioDeC	data-
base	 of	 biotechnology	 projects	 in	 developing	 coun-
tries	 (www.fao.org/biotech/inventory_admin/dep/de-
fault.asp),	and	a	database	of	biotechnology	activities,	
by	 country,	 of	 the	 Red	 de	Cooperación	Técnica	 en	
Biotecnología	Vegetal	para	America	Latina	y	el	Caribe	
(www.redbio.org).	In	Chile,	the	Web	sites	of	the	ma-
jor	 funding	 agencies	 for	 R&D,	 CONICYT	 (www.
conicyt.cl),	CORFO	(www.corfo.cl),	and	FIA	(www.































It	 is	 important	 to	emphasize	 that	 this	 standard	
form	 was	 designed	 for	 use	 in	 the	 United	 States.	
Intellectual	property	 laws	vary	among	countries,	 so,	
it	 is	 important	 that	 the	 content	 of	 any	 agreement	
is	 reviewed	 by	 a	 local	 lawyer	 knowledgeable	 in	 IP	
matters.	
Most	universities	in	the	United	States,	and	many	








are	 invested	 in	research	 if	 the	 results	cannot	be	com-
mercialized.	Due	to	the	high	degree	of	uncertainty	in	






benefits	 eventually	 realized	 after	 commercialization.	
This	 is	 important	 for	making	 effective	 use	 of	 the	 re-
sources	currently	available,	but,	more	 importantly,	 it	
helps	to	align	the	interests	of	the	technology	provider	
with	 our	 interests.	The	 agreements	 typically	 contain	
modest	up-front	payments,	milestone	payments	based	





In	 the	 case	 of	 grape	 tissue	 culture	 technology	
sought	 by	Fundación	Chile,	 the	 university	 at	which	
the	 technology	 had	 been	 developed	 already	 had	
agreements	 in	 place	 with	 a	 private	 company.	 Thus,	
initially	 we	 had	 to	 negotiate	 a	 sublicense	 agreement	
with	that	company.	Later,	changes	in	the	scope	of	that	
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to	recognize	that	management	of	such	agreements	is	a	
dynamic	process.











was	 to	 use,	 as	 a	 reference,	MTA	 forms	 prepared	 by	




An	 MTA	 should	 be	 carefully	 reviewed.	 In	 the	
past,	investigators	have	sometimes	carelessly	accepted	
terms	 that	could	have	critical	 affects	on	 the	value	of	








Importation of materials 






Exchange of professionals 
between laboratories
Good	communication	between	parties	is	essential	for	




is	 greatly	 facilitated	 by	 the	 active	 participation	 of	
investigators	from	the	provider	and	recipient	laborato-
ries	in	activities	in	both	laboratories.	
In	 the	case	of	 the	grape	 tissue	culture	 system,	a	
Chilean	investigator	first	spent	time	in	the	laboratory	
of	 the	 inventor,	 to	get	hands-on	experience	with	the	
procedures,	 and	 then	 returned	 to	 set	 up	 the	 system	
locally.	Several	months	later,	the	inventor	spent	a	full	
week	working	side	by	side	with	local	investigators,	re-
inforcing	 the	 training	 and	providing	 an	opportunity	
to	 resolve	 issues	 that	had	 arisen	during	 initial	 imple-
mentation.	Some	time	later,	the	project	leader	visited	






Currently	 the	 lab	 in	Chile	 has	 been	 able	 to	master	
grape	 embryogenic	 tissue	 culture	 and	 regeneration	





For further information, please contact:
Carlos Fernandez, Director, Strategic Studies, Foundation 
for Agriculture Innovation (FIA), Loreley 1582, La Reina, 
Santiago, Chile. carlos.fernandez@fia.cl
1 Fernandez C and MR Moynihan. 2007. A Model for the 
Collaborative Development of Agricultural Biotechnol-
ogy Products in Chile. In Intellectual Property Manage-
ment in Health and Agricultural Innovation: A Hand-
book of Best Practices (eds. A Krattiger, RT Mahoney, 
L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, 
U.S.A. Available online at www.ipHandbook.org.
2 The online version of Intellectual Property Management 
in Health and Agricultural Innovation: A Handbook of 
Best Practices provides many sample forms from a host 
of different organizations around the world (see www.
ipHandbook.org).
 HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE  | CS  
lIcEnSIng ARRAngEMEnTS
Sathguru	Management	Consultants,	 the	 regional	 co-




















the	 Danforth	 Center	 for	 TSV-resistant	 groundnut	
cultivars.	
With	 Sathguru	 Management	 Consultants	 as	 fa-









are	 underway	 and	 slated	 for	 commercialization	 in	
2009.
CASE STUDY 2
Groundnut,	 or	 peanut	 (Arachis hypogaea)	 is	 a	 staple	
oilseed	crop	grown	for	food	and	for	forage	in	India.	It	
is	cultivated	on	7.5	million	hectares	with	annual	pro-
duction	of	 about	 eight	million	 tons.	More	 than	five	
million	small	and	marginal	farms	depend	on	this	crop	
for	their	viability.	
During	 the	 monsoon	 season	 of	 2000,	 a	 new	





crosis	 in	 the	 groundnut	 plant	 resulting	 in	 complete	
destruction	of	the	crop.	In	addition,	TSV	infects	sev-
eral	 other	 economically	 important	 crop	 plants,	 such	











crop	 plants	 that	 express	 the	 coat	 protein	 (CP)	 gene	
of	the	target	virus	pathogen	have	been	shown	to	pro-
vide	a	high	degree	of	resistance	to	many	plant	viruses.	
The	 Agricultural	 Biotechnology	 Support	 Project	 II	
(ABSPII),	which	focuses	on	safe	and	effective	develop-
ment	 and	 commercialization	 of	 bioengineered	 crops	




Medakker A and V Vijayaraghavan. 2007. The Groundnut Story: A Public-Private Initiative Focused on India. In Executive 
Guide to Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger 
A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, 
Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
© 2007. A Medakker and V Vijayaraghavan. Sharing the Art of IP Management: Photocopying and distribution through the 
Internet for noncommercial purposes is permitted and encouraged.
The Groundnut Story: 
A Public-Private Initiative Focused on India
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Similar	nonexclusive	licensing	arrangements	have	





Because	 groundnut	 is	 a	 so-called	orphan	 crop,	 there	
was	 little	 interest	 in	producing	 and	 selling	open-pol-
linated	varieties	owing	 to	 their	 susceptibility	 to	viral	
infection.	Moreover,	 private	 industry	 lacked	 the	mo-
tivation	to	commercialize	hybrid	varieties.	Key	policy	
makers	 for	 the	ABSPII	project	 secured	financial	 sup-
port	for	developing	and	distributing	the	TSV-resistant	




and	 increasing	 food	 security	 in	developing	countries.	




For further information, please contact:
akshat Medakker, Associate Consultant-Technology 
Management, Sathguru Management Consultants Pvt. Ltd., 
15 Hindi Nagar, Punjagutta, Hyderabad 500034, India. 
akshatm@sathguru.com
VijayVijayaraghaVan, Founder and Director, Sathguru 
Management Consultants Pvt. Ltd., 15 Hindi Nagar, 
Punjagutta, Hyderabad 500034, India. vijay@sathguru.com 
1 www.absp2.cornell.edu.
2 See also, in the Handbook, Chapter 7.6 by Anatole 
Krattiger titled, The Use of Nonassertion Covenants: A 
Tool to Facilitate Humanitarian Licensing.
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only	two	genes,	phytoene	synthase	(psy)	and	phytoene	




FEATURES oF THE cASE
The	development	of	Golden	Rice	led	to	a	significant	
change	 in	 the	 relationship	 between	 the	 public	 sec-
tor	 and	 intellectual	 property.	 A	 freedom	 to	 operate	
(FTO)	 review	 of	 pro-Vitamin	A-containing	Golden	
Rice	 was	 commissioned	 by	 the	 International	 Rice	
Research	Institute,	a	center	of	the	Consultative	Group	
on	 International	 Agricultural	 Research	 (CGIAR),	
with	 funding	 from	 the	Rockefeller	 Foundation	 (led	
by	one	of	us	[AK]).	The	review	showed	that	about	70	
patents	and	patent	applications	were	applicable	to	the	
improved	 rice	when	all	 patents	 issued	 in	or	 applied	
for	 in	 all	 countries,	 including	 patents	 on	 commer-
cially	 accessed	 research	 tools,	were	 considered.4	The	




developing	 countries,	 together	 with	 a	 few	 material	
transfer	agreements.
Obtaining Freedom to Operate
Fortunately,	these	potential—and	arguably	perceived—
constraints	were	resolved	in	a	few	months	in	the	year	
2000	 by	 a	 straightforward	 IP	 management	 strategy	
comprising	four	goals:






IP	 (intellectual	 property)	 constraints	 are	 often	 per-
ceived	as	barriers	 to	market	entry,	 especially	when	 it	
comes	to	developing	countries.	This	case	study	exam-
ines	 the	 IP	management	 component	 in	 the	 develop-
























beta-carotene-rich	 rice.	 By	 enhancing	 those	 varieties	




Interestingly,	 rice	 plants	 synthesize	 beta-caro-
tene	 in	 foliage	 and	other	parts	of	 the	plant,	but	not	
in	the	grain,	and	all	but	two	steps	of	the	biosynthetic	
pathway	are	present	 in	 the	grain.	By	the	addition	of	
Krattiger A and I Potrykus. 2007. Golden Rice: A Product-Development Partnership in Agricultural Biotechnology and Hu-
manitarian Licensing. In Executive Guide to Intellectual Property Management in Health and Agricultural Innovation: A 
Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz 
Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at 
www.ipHandbook.org.
© 2007. A Krattiger and I Potrykus. Sharing the Art of IP Management: Photocopying and distribution through the Internet 
for noncommercial purposes is permitted and encouraged.
Golden Rice: A Product-Development Partnership in  
Agricultural Biotechnology and Humanitarian Licensing 
CASE STUDY 3





property	 to	public	 sector	 institutions	 in	devel-
oping	countries	that	could	use	the	rights	for	the	
benefit	 of	 resource-poor	 farmers,	 and	 others,	
deficient	in	vitamin	A	
The	 patented	 key	 technologies	 for	Golden	Rice	
production	include	core	patents	related	to	the	specific	
biosynthetic	pathway.	These	patents	were	filed	by	the	
inventors,	 Potrykus	 and	 Beyer.	Their	 work	 built	 on	
myriad	 other	 technologies	 that	were	 published	 in	 is-
sued	patent	documents	and	scientific	literature.	These	
core	 patents	were	 licensed	 to	Zeneca,	which	 already	
owned	 its	 own	 plant-biotechnology-related	 patents.	
Zeneca	then	negotiated	access	to	all	possibly	necessary	




coincidentally,	 almost	 immediately	 merged	 with	
Novartis	 Agribusiness	 to	 form	 Syngenta),	 provided	
access	 to	 their	 technologies,	 free	 of	 charge,	 for	 de-
fined	humanitarian	research	and	use	of	Golden	Rice	





Within	a	 short	 time,	16	 further	 licenses,	 including	 li-
censes	with	the	right	to	further	sublicense	(for	example,	
the	 license	 issued	to	IRRI),	were	 issued	to	public	sec-




Terms of the humanitarian license agreement
The	Golden	Rice	Humanitarian	Board,	although	not	
a	legal	entity,	provides	a	forum	for	discussion	of	stra-










Rice.	Humanitarian	 use,	 and	 research	 leading	
to	it,	is	allowed.	






















•	 With	 regard	 to	 improvements	 to	 the	 Golden	
Rice	technology:	
o	Humanitarian	 use	 of	 any	 improvements	 to	
Golden	Rice	 is	 guaranteed	under	 the	 same	
terms	 of	 the	 original	 agreement	 (and	 thus	
any	 improvements	 to	 the	 technology	 will	
serve	 the	 humanitarian	 purpose).	 Syngenta	
has	acted	on	this—donating	to	the	humani-
tarian	 project	 new	 transformations,	 includ-
ing	 the	 intellectual	 property	 and	 results	 re-
ported	in	Paine	and	colleagues.5








management,	 coupled	with	 strong	 collaborations	 be-
tween	the	public	and	private	sectors,	can	help	achieve	
global	 access	 to	 new	 technologies	 and	 products	 for	
humanitarian	 goals.	The	 IP	 constraints	 identified	by	
Kryder	and	colleagues6	did	not	delay	the	development	
of	the	product,	and	their	clarification	and	resolution	











to	 potentially	 life-saving	 food	 biotechnology	
CASE STUDY 3
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applications,	 in	 general.	These	 constraints	 are,	
in	decreasing	order	of	importance:
•	 the	 necessity	 of	 governments	 to	 establish	
a	 sustained	 and	 positive	 policy	 priority	 for	
the	adoption	of	all	relevant,	including	novel,	
technologies	in	agriculture	
•	 the	 importance	 of	 the	 establishment	 of	 af-
fordable,	workable,	 and	 science-based	 regu-
latory	 systems	 designed	 to	 comply	 with	
international	 obligations	 and	 to	 address	 lo-
cal	 needs	 and	 concerns	 (The	 unnecessarily	
burdensome,	 overly	 politicized	 regulatory	
requirements	for	genetically	modified	organ-






tional	 agricultural	 rice	 research	 institutions	





remote	 areas,	 including	 the	presence	of	pri-
vate	 sector	entities	willing	 to	 invest	 in	 seed	
distribution	systems	(However,	a	major	aim	




develop	 products,	 Syngenta	 was	 instrumen-
tal	 in	 converting	 the	 proof-of-concept	 results	
generated	 at	 ETH	 Zurich	 and	 University	 of	
Freiburg	 into	 deliverable	 products.	 Although	
Syngenta	 retained	 commercial	 exclusivity	 for	
the	 technology,	 the	 company	 decided	 not	 to	
develop	a	commercial	product	of	Golden	Rice	
for	markets	in	developed	countries.	Syngenta’s	






sis,”	 served	 as	 a	wake-up	call	 to	 the	public	 sector	 to	
pay	more	attention	to	IP	management	as	a	powerful	




was	 work	 that	 led	 to	 the	 formation	 of	 the	 Public	
Intellectual	Property	Resource	for	Agriculture	(PIPRA).	
Supported	 by,	 among	 others,	 the	 Rockefeller	 and	
McKnight	 foundations,	PIPRA	is	a	public	 sector	 ini-
tiative	that	recognizes	that	continuing	and	enhancing	
relationships	with	the	private	sector,	and	between	the	




biotechnology.	 In	 the	 words	 of	 the	 study’s	 authors,	
Richard	C.	Atkinson	and	colleagues:	This study found 
that roughly one-fourth of the patented inventions were 
made by public-sector researchers, which is substantially 
larger than the IP portfolio held by any single agricultural 
biotechnology company. It is, however, highly fragmented 
across institutions and across technology categories. And 
much of this IP has been licensed, often under terms that 
are confidential but which have likely resulted in greatly 
restricted access to the underlying technologies.7 This study 
suggested that, apart from a few important exceptions, 
public-sector scientists have invented many of the types 
of technologies that are necessary to conduct basic biologi-
cal research and develop new transgenic plant varieties. 
For instance, they have developed technologies to transfer 
genes into plant cells; have characterized specific DNA el-
ements that drive unique patterns of gene expression; and 
have identified many genes that confer important plant 
traits. Such discoveries underscore the fact that public-sec-












For further information, please contact:
anatole krattiger, PO Box 26, Interlaken, NY 14847, 
U.S.A. afk3@cornell.edu 
ingo Potrykus, Im Stigler 54, 4312 Magden, Switzerland. 
ingo@potrykus.ch
jorge e. Mayer, Golden Rice Project Manager, Campus 
Technologies Freiburg, Stefan-Meier-Str 8, 79104 Freiburg, 
Germany. jorge.mayer@goldenrice.org
1 Golden Rice was invented by Ingo Potrykus, then at ETH 
in Zurich, Switzerland, and Peter Beyer of the University 
of Freiburg, Germany. See also www.goldenrice.org.
2 childinfo.org/areas/vitamina/ .
3 Potrykus I. 2001. Golden Rice and Beyond. Plant 
Physiology 125:1157–1161. 
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4 Kryder D, SP Kowalski and AF Krattiger. 2000. The 
Intellectual and Technical Property Components of pro-
Vitamin A Rice (GoldenRice™): A Preliminary Freedom-
to-Operate Review. ISAAA Briefs No 20. ISAAA: Ithaca, 
NY. www.isaaa.org/kc/bin/isaaa_briefs/index.htm. 
5 Paine JA, Shipton CA, Chaggar S, Howells RM, Kennedy 
M, Vernon G, Wright SY, Hinchcliffe E, Adams JL, 
Silverstone a, Drake R. 2005. Improving the nutritional 
value of Golden Rice through increased pro-vitamin A 
content. Nature Biotechnology 23(4):482–487. 
6 See supra note 4.
7 Only within the temporal and spatial limits allowed by 
the patent system (note added by the authors of this 
case study).
8 Atkinson RC, RN Beachy, G Conway, FA Cordova, MA Fox, 
KA Holbrook, DF Klessig, RL McCormick, PM McPherson, 
HR Rawlings III, R Rapson, LN Vanderhoef, JD Wiley 
and CE Young. 2003. Public Sector Collaboration for 
Agricultural IP Management. Science 301(5630):174–175.
9 Current Golden Rice transformation events in the 
humanitarian project’s development process were all 
designed and made by Syngenta to need access to no 
third party intellectual property.
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Robert	Blanchette,	Ph.D.,	 of	 the	University	of	
Minnesota,	and	the	nonprofit	organization	Rainforest	
Project,	 based	 in	 the	 Netherlands,	 have	 jointly	 de-
veloped	 an	 easy	 and	 inexpensive	method	 to	 induce	
agarwood	formation	in	trees	that	are	only	three	to	six	
years	old.	Now,	instead	of	cutting	down	trees	found	
in	 the	 forest,	 farmers	 can	 grow	 stands	 of	 Aquilaria	
trees	on	plantations,	induce	production	of	agarwood	
in	those	trees,	and	sell	them	as	a	new	cash	crop.










southeast	Asia	 and	 Indonesia—nearly	decimated	 the	
species.	The	trees	produce	the	resin	only	when	injured	
and,	before	 researchers	 stepped	 in,	usually	when	 the	
trees	were	50	or	more	years	old.
Agarwood	and	its	resin	are	highly	prized	in	the	
Middle	 East	 and	 Asia,	 particularly	 in	 Islamic	 and	
Buddhist	cultures,	where	the	wood	and	resin	are	used	
in	 perfumes,	 ceremonial	 incense,	 traditional	 medi-
cine,	 and	 other	 applications.	 Unfortunately,	 deter-
mining	whether	a	particular	standing	Aquilaria	tree	
contains	 agarwood	 is	 nearly	 impossible,	 so	 harvest-
ers	were	 felling	and	 sawing	up	Aquilaria	 trees	until	
they	were	close	to	extinction	in	much	of	their	natural	
range.
AUTM. 2007. Saving Forests and Creating a New Cash Crop in the Middle East and Asia: University of Minnesota.  In Executive 
Guide to Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger 
A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, 
Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us to 
adapt this case study for inclusion in this Executive Guide. The original was published by AUTM. 2006. Technology Transfer 
Works: 100 Cases from Research to Realization (Reports from the Field). Association of University Technology Managers, 
Northbrook, IL. www.betterworldproject.net.
© 2007. AUTM. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial 
purposes is permitted and encouraged.
Saving Forests and Creating a New Cash Crop in the 
Middle East and Asia: University of Minnesota










































Researchers	 at	 the	 University	 of	 Saskatchewan	
developed	a	technology	called	somatic	embryogenesis	
(SE),	a	complex	propagation	process	that	relies	on	the	
splitting	 of	 one	 embryo	 into	 two	 or	more	 identical	
AUTM. 2007. Building Healthy Forests with Early-Stage Propagation: University of Saskatchewan. In Executive Guide to 
Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Ma-
honey, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and 
bioDevelopments-International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us to 
adapt this case study for inclusion in this Executive Guide. The original was published by AUTM. 2006. Technology Transfer 
Works: 100 Cases from Research to Realization (Reports from the Field). Association of University Technology Managers, 
Northbrook, IL. www.betterworldproject.net.
© 2007. AUTM. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial 
purposes is permitted and encouraged.
Building Healthy Forests with Early-Stage 
Propagation: University of Saskatchewan
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University	 of	 California	 (key	 scientists	 at	 Chiron	
were	 inventors	 on	 the	University	patent).	 	Through	
the	 joint	 venture,	 LG	 scientists	 could	 learn	 how	 to	
make	the	vaccine.	Korea	Green	Cross	entered	into	a	
joint	 venture	with	Rhein	Biotech,	which	 had	 devel-
oped	 and	patented	 its	 own	method	 for	making	 the	
vaccine.	 Having	 surveyed	 globally	 for	 a	 partner	 to	








were	 formed	 in	 an	 environment	 that	was	 supportive	
of	biotechnology	innovation.	The	Korean	government	
accorded	high	priority	to	R&D	in	biotechnology	and	
provided	 strong	 support	 for	 overseas	 training	 and	
domestic	 research.	The	biotech	 industry	 received	 the	
backing	of	private	sector	investment,	and	domestic	and	
export	markets	 were	 encouraged	 by	 the	 government.	
High	priority	was	given	by	the	Korean	government	to	







and,	 importantly,	 the	 small	 size	of	 the	global	market.	
The	 international	 public	 sector	 market	 remained	 un-
derdeveloped	 in	 part	 because	 of	 its	 low	 priority	 for	
large	 pharmaceutical	 companies,	 lack	 of	 demand	 by	
CASE STUDY 9
Intellectual	 property	 as	 a	 barrier	 to	market	 entry	 is	










gamated	 with	 the	 GAVI	 Alliance)	 was	 established	





Merck	 and	 GlaxoSmithKline	 licensed	 three	 key	




90	 other	 patents	 relating	 to	manufacturing	 processes	
such	as	isolation	and	purification	were	also	needed.	
The	Korean	companies	pursued	collaborations	or	
joint	ventures	but	chose	not	 to	 focus	on	 the	United	






A	Korean	 company,	 LG	Chem,	 formed	 a	 joint	
venture	with	Chiron.	Chiron	had	a	license	from	the	
Mahoney R. 2007. DNA Hepatitis B Vaccine: International Vaccine Institute, Korea.  In Executive Guide to Intellectual Prop-
erty Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et 
al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-
International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
Editors’ Note: This case study was originally presented at the MIHR conference Using Intellectual Property for Improved 
Health in Developing Countries: An Evidence-Based Approach to Good Practice, Bellagio, Italy, June 14–18, 2004.
© 2007. R Mahoney. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged.
DNA Hepatitis B Vaccine: 
International Vaccine Institute, Korea
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developing	countries,	and	little	procurement	by	inter-
national	donor	agencies.
Each	 company	 sought	 to	 secure	 intellectual	
property	 in	 order	 to	 bring	 its	 vaccines	 to	 market,	
but	 patents	 did	 not	 hinder	 developing	 the	 vac-
cine	 because	 the	 companies	 focused	 on	markets	 in	
countries	where	the	three	key	patents	were	not	filed.	
Intellectual	 property	 had	 some	 affect	 on	 access	 but	
was	much	less	important	than	regulatory	and	manu-
facturing	issues,	and	market	development.	However,	
the	 situation	 might	 be	 different	 post-2005	 when	
most	developing	countries	are	required	to	be	TRIPS	





FEATURES oF THE cASE
Types of agreements
Merck	 and	 GlaxoSmithKline	 obtained	 licenses	 to	
three	 key	 patents	 assigned	 to	 Pasteur	 Institute,	 the	
University	 of	 California,	 and	 Biogen.	These	 patents	
were	 filed	 in	 the	 United	 States,	 Europe,	 and	 a	 few	
other	developed	countries.	Both	companies	obtained	
licenses	to	numerous	other	patents	having	to	do	with	






entered	 into	a	 joint	venture	with	a	 foreign	company,	
Rhein	Biotech	of	Germany,	which	had	developed	an	
alternate	production	method.
Patent and IP rights decisions 
Merck	 and,	 to	 a	 lesser	 extent,	 GlaxoSmithKline	
were	 primarily	 interested	 in	 markets	 in	 developed	
countries	 and	 obtained	 all	 necessary	 licenses	 to	 pat-
ents	filed	 in	 those	 countries.	The	Korean	 companies	
opted	not	to	pursue	the	same	markets	as	Merck	and	













lations	 applicable	 in	 their	 legal	 jurisdictions.	 Each	
company	 sought	 a	 clear	 IP	 path	 to	marketing	 the	
vaccines.	To	the	author’s	knowledge,	no	infringement	
lawsuits	were	brought	against	any	of	the	companies.	
ExTERnAl FAcToRS THAT 
AFFEcTED DEcISIon MAKIng 
Key	factors	that	affected	decisions	made	by	the	Korean	
manufacturers	 were	 the	 costs	 of	 regulatory	 compli-
ance	with	respect	to	and	market	entry	into	the	United	
States	and	Europe.	In	addition,	the	Korean	Food	and	
Drug	 Administration	 had	 been	 undertaking	 certain	
improvements,	 and	 until	 those	 improvements	 were	
completed,	the	Korean	manufacturers	could	not	sup-
ply	 United	 Nations	 agencies.	The	 Korean	 manufac-
turers	also	had	to	obtain	World	Health	Organization	
prequalification	for	their	production	facilities,	which	
LG	Chem	 and	Korea	Green	Cross	 succeeded	 in	 ac-
complishing	 in	 the	 late	 1990s.	The	key	 factor	 in	 al-
lowing	the	Korean	manufacturers	to	supply	low-cost	
vaccine	 to	 the	 public	 sector	 was	 the	 establishment	
of	a	market	through	the	Global	Fund	for	Children’s	
Vaccine,	 initially	 funded	 by	 the	 Bill	 and	 Melinda	
Gates	Foundation.
lESSonS lEARnED AnD 
HEAlTH-AccESS ISSUES 
Intellectual	property	was	an	important	issue	for	all	the	











Further,	 the	 ability	 of	Rhein	Biotech	 and	Korea	
Green	Cross	 to	 exploit	 the	Rhein	Biotech	 patent	 on	
an	alternate	production	method	provides	 support	 for	
the	 argument	 that	 it	 is	 easier	 to	develop	 and	market	
vaccines	in	a	complex	IP	environment	than	it	is	to	de-
velop	 and	market	 new	defined	 chemical	 entities	 that	
have	 been	 patented.	 Vaccines	 are	 complex	 biologi-
cal	products	 that	can	be	made	 through	a	diversity	of	
procedures	while	 defined	 chemical	 entities	 are	 single	
molecules	 that	may	be	easy	 to	produce	only	 through	
one	process.	n
For further information, please contact:
riChard t. Mahoney, Director, Vaccine Access, Pediatric 
Dengue Vaccine Initiative, International Vaccine Institute, 
San Bongcheon-7dong, Kwanak-ku, Seoul 151-818, 
Republic of Korea. rmahoney@pdvi.org
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agreement	between	 ICMR	and	Therion	Biologics.	A	
project	management	committee	was	 set	up,	 compris-




All	 new	 intellectual	 property	 generated	 will	 be	
jointly	held	by	IAVI	and	ICMR,	and	the	Indian	gov-
ernment	 shall	 have	 the	 exclusive	 right	 to	use	 all	 pat-
ent	and	other	new	IP	rights	to	inventions	arising	out	
of	 the	program	 to	benefit	 India	 and	 its	 neighboring	
countries.	The	ICMR	will	grant	nonexclusive	royalty-
free	and	sublicensable	 licenses	 to	all	new	 intellectual	
property	 arising	 out	 of	 the	 project	 to	 selected	 third	
parties	 in	 order	 to	 make,	 use,	 sell,	 and	 import	 the	















an	 IP	perspective,	 it	was	 crucial	 to	 recognize	private	
sector	interests.	Therion	has	global	rights	for	the	tech-
nology	 needed	 for	 the	 vaccine	 construct,	 but	 India	
CASE STUDY 10
This	 HIV/AIDS	 initiative	 is	 a	 collaborative	 venture	
between	 the	 Indian	 Council	 of	 Medical	 Research	
(ICMR),	New	Delhi,	the	International	AIDS	Vaccine	
Initiative	(IAVI),	New	York,	National	AIDS	Control	








Under	 the	 terms	 of	 this	 public-private	 partner-
ship	 (PPP),	 ICMR	 will	 provide	 technical	 expertise,	
obtain	all	necessary	permissions	and	permits,	conduct	
R&D	 to	 develop	 the	 vaccine	 in	 collaboration	 with	
Therion,	 prepare	 the	 community	 (in	 India)	 for	 clini-
cal	trials,	and	conduct	the	trials.	ICMR	will	select	an	
Indian	partner	for	the	manufacture	of	vaccine	and	has	
overall	 responsibility	 for	 ensuring	 that	 the	project	 is	




engage	 in	 capacity	building	 and	advocacy,	 and	 facili-
tate	 technology	transfer	 for	 the	 local	manufacture	of	
the	 vaccine.	Therion	will	 assist	 ICMR	with	 the	 vac-
cine	development	and	help	transfer	technology	to	the	
selected	Indian	manufacturer.	
The	 project	 involved	 an	 overall	 agreement	 be-
tween	 ICMR	 and	 IAVI,	 a	 patent	 and	 technology	
transfer	agreement	between	ICMR	and	IAVI,	and	an	
IP	 (intellectual	 property)	 rights	 and	 confidentiality	
Satyanarayana, K. 2007. HIV/AIDS Vaccine: Indian Council of Medical Research. In Executive Guide to Intellectual Property 
Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). 
MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-
International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
Editors’ Note: An earlier version of this case study was presented at the MIHR conference Using Intellectual Property for 
Improved Health in Developing Countries: An Evidence Based Approach to Good Practice, Bellagio, Italy, June 14–18, 2004.
© 2007. K Satyanarayana. Sharing the Art of IP Management: Photocopying and distribution through the Internet for non-
commercial purposes is permitted and encouraged.
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will	have	rights	to	improvements	made	to	the	vaccine.	
Therion’s	 stringent	 IP	 regulations	meant	confidential-
















from	 the	 beginning	 of	 a	 project	 to	 ensure	 smooth	
progress;	 and	 (3)	 the	equally	crucial	need	 to	 involve	
policymakers,	 lawmakers,	 politicians,	 women’s	 asso-
ciations,	 and	 other	 civil	 society	 organizations	 in	 the	
execution	 of	 such	 projects	 that	 envisage	 clinical	 tri-
als.	This	project	is	offered	as	an	example	of	productive	
North–South	collaboration	and	broad	capacity	build-










•	 a	 separate	 technology	 transfer	 and	 manufac-
turing	 agreement	 between	 Therion	 and	 the	
manufacturer	 identified	 jointly	 by	 IAVI,	 the	
Government	of	India,	and	Therion	












•	 ICMR	grants	 IAVI	 a	nonexclusive,	worldwide,	
royalty-free	 sublicensable	 license	 to	 all	 new	
















activities,	 periodic	 assessments	 and	 updates,	 and	 re-
finements	and	revisions	of	the	R&D	program.
ExTERnAl FAcToRS THAT 
AFFEcTED DEcISIon MAKIng 
A	number	of	external	considerations	influenced	ICMR’s	
strategies	and	decision	making.	These	include:




KEy lESSonS lEARnED 
AnD HEAlTH-AccESS ISSUES 




•	 Only	 through	 strategic	 public-private	 partner-
ships	can	such	ventures	succeed.	
•	 Private	sector’s	interests	need	to	be	considered.	




on	 issues	 relating	 to	 IP	 rights	 and	 technology	
transfer,	 as	 the	 government’s	 role	 is	 crucial	 in	
the	 clearance	 and	 approval	 of	 projects	 of	 na-
tional	interest.	
•	 The	 importance	 of	 (1)	 ethics	 in	 carrying	 out	
clinical	 trials	 and	 (2)	 the	need	 to	 involve	poli-
cymakers,	women’s	associations,	and	other	civil	
society	 groups	 in	 the	 execution	of	 the	project	
cannot	be	overstated.	n
For further information, please contact:
kanikaraM satyanarayana, Director, Intellectual 
Property Rights Unit, Indian Council of Medical 
Research, Ansari NagarNew Delhi-110, 029, India. 
kanikaram_s@yahoo.com
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and	to	ensure	that	they	are	available	and	accessible	in	
the	developing	world.
Among	 the	 candidates	 in	 MVI’s	 portfolio,	
the	 RTS,S	 vaccine	 of	 GlaxoSmithKline	 (GSK)	
Biologicals3	 is	 the	most	 advanced.	Created	 in	1987,	
the	 pre-erythrocytic	 vaccine	 candidate’s	 early	 devel-
opment	was	undertaken	by	GSK	Biologicals,	in	close	
collaboration	with	the	Walter	Reed	Army	Institute	of	
Research.	 In	 January	 2001,	GSK	Biologicals,	MVI,	
and	other	partners—with	support	from	the	Bill	and	
Melinda	 Gates	 Foundation—entered	 into	 an	 agree-
ment	 to	 develop	 the	 vaccine	 for	 children	 in	 sub-
Saharan	Africa.	Clinical	 evaluation	of	RTS,S	began	
in	1992	and	the	results	since	then	represent	a	break-
through	 for	 malaria	 vaccine	 development.	 RTS,S	
has	proved	to	be	effective	 for	at	 least	18	months	 in	
reducing	 clinical	 malaria	 by	 35	 percent	 and	 severe	








•	 a	 nonprofit	 organization,	 PATH	 Malaria	
Vaccine	Initiative
•	 a	pharmaceutical	company,	GSK	Biologicals
•	 two	 health-research	 centers,	 the	 Center	 for	
International	 Health	 (CIH),	 Hospital	 Clínic	
CASE STUDY 11




ill	 from	 the	mosquito-borne	 disease.	Major	 hurdles	
to	 traditional	 prevention	 and	 treatment	 strategies	








being	 the	Plasmodium falciparum species)	 represents	
a	 major	 hurdle.	 While	 each	 stage	 of	 the	 parasite’s	




PATH1	 is	 an	 international,	 nonprofit	 organiza-
tion	 that	 creates	 sustainable,	 culturally	 relevant	 so-
lutions,	 enabling	 communities	 worldwide	 to	 break	
longstanding	 cycles	 of	 poor	 health.	 The	 PATH	
Malaria	 Vaccine	 Initiative	 (MVI)2	 is	 a	 global	 pro-







MIHR/PIPRA. 2007. Malaria Vaccine: Malaria Vaccine Institute and GlaxoSmithKline Biologicals. In Executive Guide to Intel-
lectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, 
L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDe-
velopments-International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
Editors’ Note: This case study was prepared by MIHR members of the Technology Managers for Global Health (TMGH), a 
special interest group of the Association of University Technology Managers (AUTM) (see www.tmgh.org) and adapted 
for this Executive Guide. The original version was published as part of a collection of case studies: MIHR/TMGH. 2007. Aca-
demic Licensing to Global Health Product Development Partnerships (ed. U Balakrishnan). MIHR: Oxford, U.K.
© 2007. MIHR/PIPRA. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged.
Malaria Vaccine: Malaria Vaccine Institute  
and GlaxoSmithKline Biologicals
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This	vaccine	candidate	 is	 a	 recombinant	protein	 that	
fuses	 a	 part	 of	 the	 P. falciparum	 circumsporozoite	
protein	with	the	hepatitis	B	surface	antigen	molecule.	
Combined	with	 a	 proprietary	GSK	 adjuvant	 system,	
RTS,S	induces	the	production	of	antibodies	and	white	
blood	 cells	 that	 are	 believed	 to	 diminish	 the	 capac-
ity	 of	 the	malaria	 parasite	 to	 infect,	 survive	 in,	 and	





PRogRESS, cURREnT STATUS, AnD goAlS
GSK	Biologicals	 and	MVI	are	 currently	 conducting	
several	 small-scale	 trials	 in	 infants	 and	 young	 chil-
dren,	the	groups	most	vulnerable	to	malaria	and	that	
would	benefit	most	from	an	effective	malaria	vaccine.	











ABoUT THE clInIcAl PARTnERS
The Center for International Health (CIH), 
Hospital Clínic of the University of Barcelona
The	Center	 for	 International	Health	 (CIH)	 is	 a	 pio-
neering	structure	within	the	University	of	Barcelona’s	
Hospital	 Clínic,	 the	 leading	 Spanish	 biomedi-
cal	 research	 center.4	The	 CIH	 is	 involved	 in	 health	




tutions,	 are	 a	 central	 component	 of	 the	 activities	 of	
the	CIH.
THE cEnTRo DE InVESTIgAção 
EM SAUDE DA MAnHIçA 
Centro	 de	 Investigação	 em	 Saude	 da	 Manhiça	
(CISM)	is	the	first	peripheral	health	research	center	in	
Mozambique	to	undertake	medical	research	 into	key	
health	 problems	 in	 that	 country.	 Founded	 in	 1996,	
CISM	was	developed	under	 a	 collaborative	program	
between	 the	 Mozambique	 Ministry	 of	 Health,	 the	
Maputo	 School	 of	Medicine	 (Universidade	Eduardo	
Mondlane),	and	the	Hospital	Clínic	of	the	University	
of	 Barcelona	 with	 core	 funding	 from	 the	 Spanish	
Agency	for	International	Cooperation.5	
MozAMBIqUE’S MInISTRy oF HEAlTH 
The	mission	of	Mozambique’s	Ministry	of	Health	is	to	
promote	and	preserve	the	health	of	the	Mozambican	




For further information, please contact:
glaxosMithkline BiologiCals, Alice Grasset, Phone: 
+32-2-656 8774 or +32-475-309 020. 
Path Malaria VaCCine initiatiVe (MVi), Ellen Wilson, 
Phone: +1-301-652 1558 or +1-301-922 4969.
Centro de inVestigação eM saude da Manhiça, 
Hospital Clínic of the University of Barcelona, Marc de 
Semir, Phone: +34-93-227 5700 or +34-62-794 7528.
1 PATH: www.path.org. 
2 Malaria Vaccine Initiative: www.malariavaccine.org. 
3 GlaxoSmithKline Biologicals: www.gsk-bio.com. 
4 University of Barcelona Hospital Clínic: 
www.hospitalclinic.org.
5 CISM: www.manhica.org.
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(WHO),	each	year,	the	disease	is	responsible	for	about	

















at	 the	National	 Institutes	 of	Allergy	 and	 Infectious	




four	 human-bovine	 reassortant	 rotaviruses	 and	 in-
volves	 the	 insertion	 of	 the	 gene-encoding	VP7	 pro-
tein	of	G1,	G2,	G3,	and	G4	human	rotavirus	strain	









The	National	 Institutes	 of	Health	 (NIH),	 as	 part	 of	
the	U.S.	Public	Health	Service	(PHS),	is	dedicated	to	
improving	the	public	health	of	individuals	worldwide	
through	 innovative	 research	and	the	 funding	of	criti-
cal	medical	research	programs.	Immunization	against	
rotavirus	disease	 is	an	 important	public	health	 initia-
tive	 supported	 by	 several	 organizations	 worldwide.	
This	 case	 study	 describes	 the	 partnerships	 between	
PHS	and	institutions	in	Brazil,	China,	India,	and	the	
United	States	 that	have	been	established	 to	 facilitate	
development	of	a	safe,	effective,	and	affordable	vaccine	




•	 from	 government:	 the	 National	 Institutes	 of	
Health/U.S.	Public	Health	Service
•	 nonprofit	organizations:	Fundação	Butantan	(Sao	
Paulo,	 Brazil),	 Chengdu	 Institute	 of	 Biological	
Products	(Chengdu,	China),	and	Wuhan	Institute	
of	Biological	Products	(Wuhan,	China)
•	 for-profit	 companies:	 Aridis	 Pharmaceuticals	
(United	 States),	 Bharat	 Biotech	 International,	
Ltd.	 (Hyderabad,	 India),	 Biological	 E.,	 Ltd.	
(Hyderabad,	 India),	 Shanta	 Biotechnics,	 Ltd.	







MIHR/PIRPA. 2007. Rotavirus Vaccine: NIH Office of Technology Transfer. In Executive Guide to Intellectual Property Manage-
ment in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR 
(Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-Interna-
tional Institute (Ithaca, USA). Available online at www.ipHandbook.org.
© 2007. MIHR/PIPRA. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged.
Rotavirus Vaccine: 
NIH Office of Technology Transfer
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investigators	 generated	 significant	 interest	 in	 the	
human-bovine	 rotavirus	 vaccine	 technology	 from	
companies	 and	 institutions	 worldwide.	 In	 2005,	
eight	 organizations,	 one	 in	 the	United	 States	 and	
seven	based	in	the	developing	world,	were	granted	
licenses	 from	 PHS	 to	 manufacture	 and	 distribute	
the	 rotavirus	vaccine.	The	 licensees	 are	U.S.-based	
Aridis	 Pharmaceuticals;	 Fundação	 Butantan,	 a	
Brazilian	 government	 institution;	 Bharat	 Biotech	
International,	 Biological	 E.,	 Ltd.,	 Shantha	
Biotechnics,	Ltd.,	and	Serum	Institute	of	India,	Ltd.,	
all	 India-based	 companies;	 and	Chengdu	 Institute	
of	 Biological	 Products	 and	 Wuhan	 Institute	 of	
Biological	 Products,	 both	 funded	 by	 the	 govern-




sions	 regarding	 the	 license	 agreements	 were	 based	
on	thorough	evaluation	of	the	applicants	and	their	




materials.	The	 biological	 materials	 include	 all	 the	
vaccine	 strains,	 as	 well	 as	 the	 analytical	 reagents	
necessary	to	develop	the	vaccine.	
Butantan	 was	 awarded	 an	 exclusive	 license	 to	
practice	the	invention	for	development	of	a	rotavirus	
vaccine	 in	 Brazil	 and	 Latin	 America.	 In	 coopera-
tion	with	the	Brazilian	Ministry	of	Health,	Butantan	
plans	 to	 introduce	 the	 vaccine	 into	 Brazil’s	 child	 im-
munization	program,	which	provides	free	vaccines	for	
all	children	of	Brazil.	Similarly,	Chengdu	and	Wuhan	














mission	 to	provide	 free	or	 affordable	vaccines	 to	 chil-
dren	in	their	specific	territories.	









Codevelopment	 will	 include	 collaboration	 with	 the	
NIH.	OTT	staff	was	recently	notified	by	its	partners	
and	the	staff	of	the	Bill	&	Melinda	Gates	Foundation	
that	 the	 latter	 will	 support	 partial	 development	 of	
clinical	 trial	procedures	 for	 screening	 the	 technology	
at	specific	institutions	in	developing	countries.	n
For further information, please contact:
uri reiChMan, Branch Chief, Infectious Diseases, Office 
of Technology Transfer, National Institutes of Health, 6011 
Executive Boulevard, Suite 325, Rockville, MD 20852, 
U.S.A. reichmau@mail.nih.gov






lectual	 property	 and	 clinical	 trials	 of	 IBS	 and	 infan-
tile	diarrhea	disease	(IDD).	Discussions	are	underway	
with	 international	 strategic	 partners	 regarding	 exclu-
sive	 license	agreements;	efforts	 to	 secure	government	
or	 venture	 capital	 funding	 are	 in	 progress.	 Baylabs	
plans	 to	 build	 preprocessing	 field	 plants	 and	 a	 facil-




in	using	 the	waste	 leaf	but	TK	exists	 in	using	 the	A. 
ferox.	A	key	feature	of	this	case	study	is	the	potential	
for	other	treatments;	the	formulation	can	be	used	for	
IBS	 in	 developed	 countries	 and	ARD	 in	 developing	
countries.	 Once	 clinical	 trials	 have	 been	 completed,	
Baylabs	 plans	 to	 register	 the	 product	 as	 a	medicine.	
However,	the	advantages	of	registering	the	product	as	
a	 drug	 rather	 than	 as	 a	 food	 supplement	 have	 been	
questioned.	 Such	 registration	 would	 require,	 among	
other	 things,	 strict	 manufacturing	 quality	 standards	
and	could	be	fraught	with	regulatory	difficulties.	Many	
intended	herbal	remedies,	 if	subjected	to	full	clinical	
trials	and	 toxicity	 (as	 required	by	 regulation),	would	
not	meet	these	standards.	
In	natural	products	a	key	issue	is	long-term	plan-













powder	 form	 from	 the	 discarded	 leaves	 of	 the	 plant	
was	 patented	 by	 South	Cape	 Aloe	 (SCA).	 A	 virtual	
startup	company	with	a	 strong	emphasis	on	 technol-




The	 company,	 Baylabs,	 aims	 to	 form	 local	 part-
nerships	 to	 develop,	manufacture,	 and	 distribute	 the	
product	 to	both	developed	 and	developing	 countries.	
Baylabs’	strategy	is	to	focus	on	R&D	to	generate	and	
protect	 intellectual	property	 and	products,	while	out-
sourcing	 noncore	 functions	 such	 as	 manufacturing,	
sales,	and	distribution.	
SCA	 granted	 the	manufacturer	African	Aloe	 ex-
clusive	rights	to	make	the	powder	and	gained	a	share	




European	 countries	 and	 prosecutions	 in	 the	 United	
States,	Japan,	Australia,	and	China.	
Baylabs	 has	 developed	 four	 over-the-counter	
natural	 remedies	 from	 A. ferox	 that	 are	 distributed	
to	pharmacies.	The	 revenue	generated	 is	used	 to	file	
patents	 and	 obtain	 scientific	 evidence	 of	 efficacy	 for	
Bunn AE. 2007. Gastrointestinal Medicines from African Aloe: Baylabs (Pty) Ltd. In Executive Guide to Intellectual Property 
Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). 
MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-
International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
Editors’ Note: An earlier version of this case study was presented at the MIHR conference Using Intellectual Property for 
Improved Health in Developing Countries: An Evidence-Based Approach to Good Practice, Bellagio, Italy, June 14–18, 2004.
© 2007. AE Bunn. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommer-
cial purposes is permitted and encouraged.
Gastrointestinal Medicines from African Aloe: 
Baylabs (Pty) Ltd.
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ment	 of	 a	 technology	 can	 have	 positive	 commercial	






As	 part	 of	 the	GI	medicines	 from	African	 aloe	 proj-








•	 securing	a	 strong	 IP	portfolio	 through	 interna-





The	 SA	Medicines	 Control	 Council	 (MCC)	 is	 pres-
ently	 formulating	 policy	 on	 traditional	 and	 herbal	
medicines.	Companies	are	therefore	able	to	place	over-
the-counter	 products	 in	 the	market	 without	 clinical	
trials.	These	may	not	make	any	medicinal	claims.	This	
enabled	 Baylabs	 to	 place	 four	 elementary	 products	
(aloe	gel,	a	high	fiber	tablet,	a	laxative	tablet,	and	an	
antiarthritic	 tablet	 containing	 aloin	 as	 the	 active	 in-




ExTERnAl FAcToRS THAT 
AFFEcTED DEcISIon MAKIng  
A	number	of	considerations	influenced	Baylabs’	strate-
gies	and	decision	making.	These	include:
•	 burden	 of	 disease	 from	 ARD	 in	 developing	
countries	









The	 following	 items	 represent	 key	 lessons	 from	 the	
Baylabs	GI	Medicines/Aloe	project,	which	may	be	ap-





•	 have	 a	 global	 commercial	 opportunity,	 which	
big	 pharma	 has	 been	 unable	 to	 effectively	 ad-
dress	(IBS—a	US$15	billion	annual	industry)	








For further information, please contact:
tony Bunn, Director, Technology Development and 
Transfer Office, Medical Research Council, PO Box 19070, 
Tygerberg, 7505, South Africa. tony.bunn@mrc.ac.za
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Lapdap™	 was	 developed	 to	 be	 as	 inexpensive	
as	 possible,	 with	 a	 public	 sector	 target	 of	 less	 than	
US$0.30	per	 dose.	 It	 is	 currently	 sold	 only	 through	
private	 sector	 pharmacies,	 with	 the	 commercial	 sale	
price	 varying	 by	 country.	 The	 drug	 is	 available	 in	
South	Africa,	Nigeria,	Kenya,	and	Ivory	Coast.	
Lapdap’s™	 role	 in	 public	 health	 is	 still	 being	 as-
sessed;	Phase	 IV	 studies	 are	ongoing	 and	 the	WHO	








Successful	 collaboration	 to	 ensure	 that	 develop-
ing	 countries	 benefit	 from	 the	 fruits	 of	 intellectual	
property	 requires	an	 integrated	approach	toward	net-
working	and	capacity	building,	 involving	innovation,	
regulatory	 approval,	 market	 creation,	 licensing,	 and	
distribution.	
The	 lack	of	 formal	health	 infrastructure	 in	 rural	
Africa,	where	there	are	few	physicians	and	where	the	
drug	is	sold	over	the	counter,	has	led	to	great	impor-
tance	 being	 attached	 to	 the	 packaging	 and	 distribu-
tion,	as	well	as	education	to	ensure	proper	dosage.	The	










combination	drug	was	 developed	 in	 response	 to	 the	
growing	 resistance	 among	 patients	 to	malaria	 drugs,	
with	failure	rates	in	Africa	as	high	as	40	percent.	
Lapdap	 came	 out	 of	 early	 research	 funded	 by	
the	Wellcome	Trust	 and	 was	 brought	 to	 market	 by	
a	 public-private	 partnership	 (PPP)	 involving	 GSK	
(GlaxoSmithKline),	 WHO-TDR	 (a	 WHO/UNDP/
World	Bank	Special	Program	in	Research	and	Training	
in	Tropical	Diseases),	 and	 the	U.K.	Department	 for	
International	 Development	 (DfID).	 This	 was	 done	










Early	 patent	 applications	 filed	 on	 the	 basic	 bio-
logical	work	underlying	 the	combination	of	 the	 two	
existing	drugs	were	abandoned	after	filing	because	 it	




MIHR/PIPRA. 2007. Lapdap Antimalarial Drug: GlaxoSmithKline, WHO-TDR, and the U.K. Department for International De-
velopment. In Executive Guide to Intellectual Property Management in Health and Agricultural Innovation: A Handbook 
of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foun-
dation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at 
www.ipHandbook.org.
Editors’ Note: An earlier version of this case study was presented at the MIHR conference Using Intellectual Property for 
Improved Health in Developing Countries: An Evidence-Based Approach to Good Practice, Bellagio, Italy, June 14–18, 2004.
© 2007, MIHR/PIPRA. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged.
Lapdap™ Antimalarial Drug:  
GlaxoSmithKline, WHO-TDR, and the U.K. 
Department for International Development
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public	 sector	 use	 of	 the	 product	 between	 all	 parties	
involved	in	national	malaria	control.	
This	case	study	was	considered	‘IP	neutral,’	since	
the	 academic	 and	public	 health	mission	was	 neither	
impeded	 nor	 driven	 by	 IP	 considerations.	 However,	
the	Wellcome	Trust,	as	part	of	its	mission,	recognizes	
the	important	role	of	industry	and	its	investors	(includ-







It	 could	 be	 argued	 that	 the	 lack	 of	 underlying	








of	 regulatory	dossiers	 (clinical	 trial	data),	know	how,	
terms	of	codevelopment	agreements,	and	trademarks.	
Recognizing	 the	multiplicity	 of	 intellectual	 property	
can	contribute	to	a	more	comprehensive	understand-





is	 a	 vital	 step	 in	products	 reaching	developing	 coun-






product	 support.	 Although	 often	 treated	 as	 undesir-
able	 additional	 costs,	 the	 generation	 of	 royalties	 on	
public	sector	sales	is	an	effective	IP	management	tool	
for	keeping	a	product	on	the	market.	
The	 involvement	 of	 universities	 in	 this	 public	
health	 initiative	drew	attention	 to	 the	 role	of	univer-
sity	technology	transfer	offices	(TTOs).	It	appears	that	
TTOs	 are	 frequently	 given	 competing	 missions	 by	
their	institutions,	with	no	clear	priority	as	to	whether	
making	money	or	delivering	applications	of	 research	
regardless	 of	 returns	 is	 the	 most	 important	 goal.	
Declining	 revenue	 of	 universities	 has	 pressured	 cash-
strapped	TTOs	 to	 increase	 their	 contribution,	 com-
pelling	them	to	turn	to	intellectual	property.	Although	
exploiting	 university	 research	 is	 a	 legitimate	 goal,	 it	
may	be	 short-sighted	 to	 focus	 solely	 on	patents;	 the	
transfer	of	know-how	and	 trade	 secrets	 is	 just	 as	 im-
portant,	and	an	overemphasis	on	revenue	generation	
using	 IP	 rights	may	 limit	 the	potential	 of	 certain	 re-
search	outcomes.	
In	 attracting	 commercial	 interest,	 TTOs	 must	
be	mindful	 of	 overvalued	patents	 and	 overestimated	
royalties,	and	must	know	how	to	manage	hurdles	and	






partnerships	 afford	 the	 opportunity	 to	 segment	 the	
market	in	a	way	in	which	the	public	body	can	benefit	
from	having	 an	 exclusive	 license	 for	 its	 stakeholders	
while	satisfying	commercial	partners.	
TyPES oF AgREEMEnTS 
An	 agreement	 was	 signed	 relating	 to	 establishment	
of	 the	 product-development	 team	 and	 ownership	 of	
nonpublished	data.	Under	the	funding	partnership	be-
tween	GSK,	WHO-TDR,	and	the	U.K.	DfID,	each	
partner	 contributed	 one-third	 of	 the	 development	
costs.	






Kenya)	 as	 named	 inventor.	These	 applications	 were	
later	 abandoned,	 because	 after	 filing	 it	 became	 clear	
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ExTERnAl FAcToRS THAT  




•	 nature	 of	 the	 end	 market	 for	 Lapdap™	 (poor	
countries	in	Africa)	
•	 multiparty	cooperation	and	synergy




als,	 the	 regulatory	 process,	 and	marketing	 are	
necessary	to	accelerate	product	development.	
•	 Establishment	 of	 a	 public	 health	 group	 under	
WHO	auspices	in advance of registration was	a	
useful	 forum	 for	 discussing	 how	 the	 product	
would	be	accessed.	
•	 Consensus	on	 the	use	of	 the	product	 in	Africa	
is	necessary	at	the	country	level	between	parties	
involved	in	malaria	control.	n 
For further information, please contact:
daniel nelki, Head of Legal and Operations, Technology 
Transfer, the Wellcome Trust, 215 Euston Road, London, 
NW1 2BE, U.K. d.nelki@wellcome.ac.uk
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were	linked	to	territories,	regulatory	matters,	and	mar-
ket	penetration.	
Production	 was	 established	 in	 Mexico	 and	
Indonesia,	 supplying	private	 and	public	 sectors	with	
an	affordable	quality	product	that	had	been	dropped	
by	 its	 developer.	 This	 was	 the	 first	 pharmaceuti-
cal	product	 to	 result	 from	 successful	WHO	product	
R&D.	The	Concept	Foundation	is	now	self-sufficient	
and	 provides	 valuable	 technical	 assistance	 and	 intro-
duction	 support,	 alongside	 economic	 development	
and	technology	transfer.	
ExTERnAl FAcToRS THAT 
AFFEcTED DEcISIon MAKIng 
Establishing	a	nonprofit	organization	in	a	developing	
country	 was	 an	 appropriate	 option	 because	 WHO	
could	 not	 own,	manufacture,	 distribute,	 or	 manage	
the	 product.	 PATH	 did	 not	 want	 to	 jeopardize	 its	
own	neutral	role	in	improving	public	health.	Another	
consideration	was	 liability.	PATH,	with	assets	 in	 the	
United	States,	could	not	afford	to	risk	 its	well	being.	
Ultimately,	after	much	discussion	it	was	realized	that	












The	 case	 study	 of	 the	 development	 and	 distribution	










once-a-month	 injectable	 contraceptive	 Cyclofem®.	
Despite	successful	Phase	III	trials	undertaken	jointly	
by	WHO	 and	Upjohn,	 the	 drug	 company	 decided	
there	was	an	insufficient	market	for	the	contraceptive	
and	donated	 the	clinical	 trial	data	 to	WHO.	When	
no	U.S.	 or	 European	 commercial	 partner	 could	 be	
found	to	take	the	product	forward,	WHO	invited	the	
nonprofit	 organization	 PATH	 (to	 which	 it	 licensed	
the	 clinical	 data	 rights)	 to	 come	 up	 with	 a	 viable	
solution.	
PATH	 proposed	 establishing	 a	 new	 nonprofit	
organization,	the	Concept	Foundation,	which	would	
focus	 on	 developing	 countries.	 Intellectual	 prop-
erty	and	know-how	was	transferred	via	PATH	to	the	
Foundation,	 which	 licensed	 developing	 country	 pro-
ducers	on	an	exclusive	basis	in	defined	private	sector	
markets	and	on	a	nonexclusive	basis	for	public	sector	
markets	 to	 ensure	 competition.	 A	 royalty	 stream	 of	





Mahoney R. 2007. Cyclofem Contraceptive: Upjohn, WHO, and the Concept Foundation. In Executive Guide to Intellectual 
Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L 
Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDe-
velopments-International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
Editors’ Note: An earlier version of this case study was presented at the MIHR conference Using Intellectual Property 
for Improved Health in Developing Countries: An Evidence-Based Approach to Good Practice, Bellagio, Italy, June 14–18, 
2004..
© 2007. R Mahoney. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged.
Cyclofem® Contraceptive: 
Upjohn, WHO, and the Concept Foundation
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traceptive	 to	 developing	 country	 markets.	This	 case	
demonstrates	that	clinical	trial	data	can	be	important	
IP	that	can	help	ensure	availability	of	products	in	de-




ity	 of	 products	 to	 the	 poorest	 of	 the	 poor.	 It	 is	 not	
enough	to	ensure	that	the	private	market	helps	public	
sector	distribution.	As	this	case	study	shows,	investing	




milestones	 is	not	 an	 indication	of	 lack	of	 trust;	 it	 is	
rather	 being	 serious	 about	 business	 and	 wanting	 to	
succeed.	n
For further information, please contact:
riChard t. Mahoney, Director, Vaccine Access, Pediatric 
Dengue Vaccine Initiative, International Vaccine Institute, 
San Bongcheon-7dong, Kwanak-ku, Seoul 151-818, 
Republic of Korea. rmahoney@pdvi.org
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and	 China	 (and	 more	 recently,	 Africa).	 Seasonality	
and	 availability	 of	 the	 plant	 contribute	 to	 the	 high	
price	of	the	drug.	The	Gates-funded	project	hopes	to	
eliminate	the	need	for	plant	extraction	by	utilizing	a	
platform	 technology	 of	 synthetic	 biology	 developed	
by	 Dr.	 Jay	 Keasling	 at	 the	 University	 of	 California	
(UC),	 Berkeley.6	The	 goal	 is	 to	 lower	 the	 cost	 of	 ar-





continued	 basic	 research,	US$12	million	 to	Amyris	
for	applied	research	on	the	fermentation	and	chemi-
cal	 processes,	 and	 US$22.6	 million	 to	 iOWH	 to	
perform	 the	 required	 regulatory	 work	 and	 lead	 the	
implementation	of	the	product	development	strategy	
for	the	developing	world.	UC	Berkeley’s	role	focuses	
on	 the	 engineering	 of	 drug-precursor-producing	mi-
crobe.	Amyris’	efforts	span	engineering	of	the	produc-
tion	microbe	to	optimizing	the	semisynthesis	of	the	
drug	 through	 fermentation	 and	 novel	 downstream	
synthetic	 chemistry.	 The	 role	 of	 iOWH	 includes	
developing	 a	 commercialization	 strategy	 based	 on	








In	 December	 2004	 the	 Bill	 and	 Melinda	 Gates	
Foundation1	awarded	a	five-year	product	development	
grant	to	the	Institute	for	OneWorld	Health	(iOWH),2	
a	 nonprofit	 pharmaceutical	 company,	 to	 create	 a	
unique	three-way	partnership	between	iOWH,	a	uni-
versity	 (University	 of	California	 at	Berkeley),3	 and	 a	
for-profit	 company	 (Amyris	 Biotechnologies,	 Inc.).4	
The	goal	of	this	project5	is	to	significantly	reduce	the	
cost	 of	 artemisinin,	 a	 key	 precursor	 in	 the	 produc-
tion	 of	 Artemisinin	 Combination	Therapies	 (ACT),	





Malaria	 is	 a	 parasitic	 blood	disease	 that	 inflicts	
as	many	 as	 500	million	people	 annually.	About	 1.5	
million	people	die	each	year	 from	the	 infection,	pri-
marily	 children	 in	 Africa	 and	 Asia.	More	 than	 half	
of	 the	 deaths	 occur	 among	 the	 poorest	 20	 percent	




course	 of	 drugs	 containing	 artemisinin	 is	 US$2.40,	
which	places	 it	 out	of	 reach	 for	people	 in	many	na-
tions	where	 the	disease	 is	most	prevalent.	Reducing	




MIHR/PIPRA. 2007. Improved Production of a Natural Product Treatment for Malaria: OneWorld Health, Amyris, and the 
University of California at Berkeley. In Executive Guide to Intellectual Property Management in Health and Agricultural 
Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), 
Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Avail-
able online at www.ipHandbook.org.
Editors’ Note: This case study was prepared by MIHR members of the Technology Managers for Global Health (TMGH), a 
special interest group of the Association of University Technology Managers (AUTM) (see www.tmgh.org) and adapted 
for this Executive Guide. The original version was published as part of a collection of case studies: MIHR/TMGH. 2007. Aca-
demic Licensing to Global Health Product Development Partnerships (ed. U Balakrishnan). MIHR: Oxford, U.K.
© 2007. MIHR/PIPRA. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged.
Improved Production of a Natural Product 
Treatment for Malaria: OneWorld Health, Amyris, 
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for	 IP	 that	 is	developed	during	 the	collaboration	 for	
the	treatment	of	malaria	in	the	developing	world	with	





The	university	 benefits	 from	 the	 research	 funding	 as	




















The	 preferred	 and	 most	 effective	 treatments	 for	 ma-
laria	 today	 are	 artemisinin-based	 combination	 thera-
pies	 (ACT).	Artemisinin,	a	complex	natural	product	
known	as	an	herbal	remedy	for	thousands	of	years,	is	





Dr.	 Jay	 Keasling,	 a	 UC	 Berkeley	 professor	 of	
chemical	 engineering,	 developed	 a	 process	 of	 “syn-
thetic	 biology”	 to	 produce	 an	 artemisinin	 precursor	
through	a	multistep	process	 in	bacteria.7	The	precur-
sor	 can	 then	be	 chemically	 converted	 to	 artemisinin	







PRogRESS, cURREnT STATUS, AnD goAlS
During	the	five-year	granting	period,	which	began	in	














Amyris	 will	 optimize	 the	microbial	 strain	 developed	
with	UC	Berkeley	for	commercial	production.	In	ad-
dition,	 Amyris	 will	 develop	 a	 fermentation	 and	 pu-
rification	 process	 for	 the	 precursor.	 Simultaneously,	
Amyris	is	developing	a	scaleable,	inexpensive	chemical	
process	to	convert	the	precursor	to	artemisinin.	
OneWorld	 Health	 is	 the	 product	 development	
lead	and	has	responsibility	for	directing	this	collabora-
tive	effort.	In	addition,	the	organization	is	leading	the	










agreements	 (from	UC	 Berkeley	 to	 each	 of	
Amyris	and	iOWH).
•	 UC	Berkeley	 granted	 iOWH	 a	 royalty-free	
license	 for	 the	 manufacture	 of	 artemisinin-
based	 malaria	 treatments	 used	 in	 the	 de-
veloping	 world.	 UC	 Berkeley	 further	 shall	
grant	 royalty-free	 licenses	 to	 iOWH	 for	 IP	
developed	 under	 the	 three-party	 collabora-
tion	agreement	for	use	in	manufacturing	ar-




•	 UC	 Berkeley	 granted	 Amyris	 licenses	 to	
develop	the	manufacturing	process	 for	the	
developing-world	 malaria	 market.	 Amyris	
also	 has	 licenses	 for	 the	 developed-world	
malaria	 market,	 nonmalaria	 indications	
of	 artemisinin,	 and	 alternative	 uses	 of	 the	
platform	 worldwide.	 UC	 Berkeley	 further	
shall	grant	similar	licenses	to	Amyris	for	IP	
CASE STUDY 20
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developed	 under	 the	 three-part	 collabora-
tion	agreement.
•	 Amyris	 shall	 grant	 iOWH	 a	 royalty-free	 li-
cense	for	IP	developed	under	the	three-part	




•	 The	license	 from	UC	Berkeley	 to	 iOWH	is	
royalty	free.
•	 The	license	 from	UC	Berkeley	 to	Amyris	 is	
royalty	free	for	the	developing-world	malaria	
market	 (development	 for	 iOWH)	 and	 is	
royalty	bearing	for	the	developed	world	and	
nonmalaria	 indications	 in	 the	 developing	
world.
Patents:
•	 Patent	 costs	 for	 UC	 Berkeley’s	 pre-exist-
ing	patents	are	 shared	between	 iOWH	and	
Amyris.	
•	 UC	 Berkeley	 patents	 on	 IP	 arising	 from	
the	 collaborative	 research	 may	 be	 filed	 by	
UC	Berkeley	and	licensed	to	iOWH	and/or	












faith	 by	 the	 joint	 owners	when	 such	 joint	
IP	 arises.	 If	 the	 joint	 owners	 cannot	 agree	
and	if	 iOWH	has	an	ownership	interest	 in	










•	 Similar	 licenses	 to	 all	 relevant	 third-party	
intellectual	 property	 will	 be	 obtained	 by	
iOWH	as	the	need	arises.	n
For further information, please contact:
uniVersity oF CaliFornia, Berkeley, Carol Mimura, 
Assistant Vice Chancellor, IPIRA, 2150 Shattuck Avenue, 
Berkeley, CA 94720, U.S.A. carolm@berkeley.edu
Figure 1: Activities of Project Partners  
(to be carried out by the end of the grant period)
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institute For oneWorld health, Katharine Woo, Director, 
Scientific Affairs, 50 California Street, Ste. 500, San Francisco, 
CA 94111, U.S.A. kwoo@oneworldhealth.org
aMyris BioteChnologies, inC., Neil Renninger, Vice 
President–Development, 5980 Horton Street, Ste. 450, 
Emeryville, CA 94608, U.S.A. renninger@amyrisbiotech.com
.
1 Bill and Melinda Gates Foundation. www. gates 
foundation.org.
2 Institute for OneWorld Health. www.oneworldhealth.org/.
3 Office of Intellectual Property and Industrial Research, 
UC Berkeley. ipira.berkeley.edu/index.php.
4 Amyris Biotechnologies, Inc. www.amyrisbiotech.com.
5 The Artemisinin Project. www.artemisininproject.org.
6 Keasling Laboratory, UC Berkeley. www.cchem.berkeley.
edu/%7Ejdkgrp/.
7 Martin VJ, DJ Pitera, ST Withers, JD Newman and 
JD Keasling. Engineering a Mevalonate Pathway in 
Escherichia Coli for Production of Terpenoids. Nature 
Biotechnology. 21 July 2003. (7): 796–802.
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the	infection,	which	spreads	inside	the	heart	and	gas-
trointestinal	 tract	 of	 the	 victim.	Drugs	 are	 difficult	
to	administer	and	highly	toxic,	leading	to	severe	side	
effects	in	many	patients.	And	no	existing	medicines	





A	collaborative	 research	effort	 among	 scientists	
at	the	University	of	Washington	and	Yale	University	




experts,	 and	 Michael	 Gelb	 and	 Kohei	 Yokoyama,	
chemists,	at	University	of	Washington.	
“It	 was	 a	 wonderful	 collaboration	 between	 or-
ganic	 chemists	 and	 parasite	 biologists	 that	 came	
about	through	reading	the	literature	and	recognizing	
potential	 connections,”	 said	 principal	 investigator	




Buckner,	 of	 the	 University	 of	 Washington	
Medical	 School,	 agreed.	 He	 has	 worked	 for	 years	
with	a	group	of	chemists	led	by	Gelb	to	develop	com-









pharmaceutical	 industry,	 even	 though	 they	 have	 a	
significant	impact	on	vulnerable	populations.	One	of	
these	neglected	killers	is	Chagas’	disease.		
According	 to	 the	 World	 Health	 Organization,	
Chagas’	 disease	 is	 an	 insect-borne,	 parasitic	 illness	
that	 infects	 and	 kills	 millions	 of	 people	 every	 year.	
Chagas’	 disease	 is	 endemic	 in	 21	 Latin	 American	
countries	and	is	a	major	cause	of	heart	failure	in	the	
region.	 Caused	 by	 the	 parasite	 Trypanasoma cruzi,	






Controlling	 the	 disease	 is	 difficult,	 costly,	 and	
risky:	it	depends	largely	on	treating	homes	in	affected	






collABoRATIng To FInD A TREATMEnT  
But	the	standard	drug	treatments	for	Chagas’	disease	
leave	much	to	be	desired.	Most	are	aimed	at	fighting	
AUTM. 2007. Nontoxic Drug Therapy for Chagas’ Disease and Malaria: University of Washington and Yale University. 
In Executive Guide to Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices 
(Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de 
Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us to 
adapt this case study for inclusion in this Executive Guide. The original was published by AUTM. 2006. Technology Transfer 
Works: 100 Cases from Research to Realization (Reports from the Field). Association of University Technology Managers, 
Northbrook, IL. www.betterworldproject.net.
© 2007. AUTM. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial 
purposes is permitted and encouraged.
Nontoxic Drug Therapy for  
Chagas’ Disease and Malaria:  
University of Washington and Yale University
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APPRoAcHIng THE PRoBlEM 
FRoM DIFFEREnT AnglES  
The	 original	 patent	 application	 described	 “com-
pounds	 and	methods	 for	 treating	 infections	 caused	
by	bacterial	protozoal	and	fungal	agents,”	said	Aline	
Flower,	 of	 University	 of	 Washington	 TechTransfer	
Invention	Licensing.		
When	asked	about	 the	potential	 application	of	
the	 compound,	 Hamilton	 said,	 “we	 developed,	 in	
collaboration	 with	 parasitologists,	 compounds	 that	
target	 the	 Chagas’	 disease	 agent	 in	 animal	 models,	
and	we	are	seeing	some	very	encouraging	data.”	
Buckner	 and	 his	 colleagues	 had	 made	 inroads	
targeting	these	diseases,	working	toward	cures	or	vac-
cines.	 “We	 had	 discovered	 that	 protozoan	 parasites	
contain	the	enzyme	protein	farnesyltransferase,”	said	
Buckner.	“This	same	enzyme	plays	an	important	role	
in	 cancer	 cells,	which	meant	 a	 lot	 of	 research	 labo-





















licensing	 associate	 Alan	 Carr	 explained	 that	 an	 in-
terinstitutional	agreement	between	the	University	of	
Washington	and	Yale	University	enabled	the	 institu-
tions	 to	 structure	 a	deal	with	OneWorld	Health	 to	
license	the	compound	affordably.		
Like	 the	 drug	 compound,	 the	model	 for	 drug	
development,	 borne	 of	 innovative	 university	 tech-
nology	transfer,	could	well	have	a	lasting	impact	on	
people	around	the	world.	 n
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parties	 to	 hold	 key	 pieces	 of	 intellectual	 property.	
PATH	routinely	 conducts	market	 and	 industry	 feasi-
bility	studies	to	determine	the	type	of	industry	partner	
to	 pursue,	 to	 determine	which	 is	 best	 positioned	 to	
take	PATH	into	the	target	segments	it	is	interested	in,	




Procurement	 in	diagnostics	 is	not	as	 centralized	
as	other	public	health	products,	such	as	vaccines	and	
drugs.	This	 makes	 it	 more	 difficult	 to	 plan	 for	 the	
global	public	health	sector.	Marketing	is	generally	on	
a	 country-by-country	 basis,	 unlike	 family	 planning	
products,	for	example,	that	have	regional	or	global	dis-
tribution	agencies	for	the	public	sector	markets.	













include	 funding	 a	 portion	 of	 the	 industry	 partner’s	
direct	 R&D	 costs,	 conducting	market	 and	 industry	
assessments,	 developing	 an	 evaluation	 framework	
CASE STUDY 23
The	public	sector	 institution	PATH	aims	to	 improve	
global	 health	 by	 advancing	 technologies,	 strength-
ening	 systems,	 and	 encouraging	 healthy	 behaviors	
through	 effective	 collaborations	with	 the	 private	 sec-
tor.	PATH	tries	to	reduce	risks	for	a	commercial	com-
pany	developing	products	for	resource-poor	countries	
by	 identifying	 gaps	 in	 the	market	 that	 existing	 tech-
nology	 can	fill,	 demonstrating	 value,	 and	partnering	
in	 development	 and	 sustainable	 supply.	 In	 addition,	
PATH	adapts	products	to	different	markets,	provides	








of	 the	 economic	 environment	 of	 the	 technology.	
Successful	 collaborations	 with	 private	 sector	 compa-
nies	impact	positively	the	availability,	accessibility	and	
affordability	 of	 products	 in	 public	 sector	 health	 pro-
grams	in	developing	countries.	











Brooke S. 2007. Diagnostic Tests for Cervical Cancer: PATH. In Executive Guide to Intellectual Property Management in Health 
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PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute 
(Ithaca, USA). Available online at www.ipHandbook.org.
Editors’ Note: An earlier version of this case study was presented at the MIHR conference Using Intellectual Property for 
Improved Health in Developing Countries: An Evidence-Based Approach to Good Practice, Bellagio, Italy, June 14–18, 2004.
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Diagnostic Tests for Cervical Cancer: PATH
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for	 public-health	 use	 of	 the	 new	 test,	 and	 conduct-
ing	multicountry	clinical	evaluation	of	 the	new	tests’	
performance	 for	 registration	 purposes.	The	 industry	
partner	is	responsible	for	development	of	the	products,	






velopment	 committee	 was	 formed,	 and	 PATH	 only	
provides	 funding	 sufficient	 to	 reach	 the	 next	 agreed-
upon	milestone.	During	the	R&D	phase	PATH	can	
terminate,	without	 cost,	 at	 key	milestones,	 although	
industry	partners	terminate	at	a	cost.	
The	 commercialization	 period	 of	 the	 agreement	
runs	 for	 ten	 years	 from	 the	 first	 sale	 of	 a	 registered	
product.	Both	 industry	 partners	 are	 required	 to	 pro-
vide	preferential	public	sector	pricing.	If	these	specific	
products	are	sold	in	developed	countries,	PATH	will	
earn	 a	 royalty,	 however	 PATH	has	 forgone	 all	 royal-
ties	on	developing	country	sales.	Termination	clauses	
covering	 one	 industry	 partner	 involve	 repayment	 of	
PATH’s	 direct	 funding	 and	 the	 transfer	 of	 distribu-
tion	and/or	manufacturing	to	a	third	party;	the	other	
industry	 partner	 is	 only	 required	 to	 grant	 PATH	 a	
nonexclusive	 license	 to	 the	 product	 and	 underlying	
reagent.	
Both	companies	are	working	on	products	that	are	
different	 from	 those	 they	will	 launch	 in	 the	United	
States	and	Europe.	Developing	a	product	with	PATH	






an	 overarching	 cervical	 cancer	 prevention	 initiative	
that	made	 collaboration	 attractive	 and	worthwhile—
in	 this	 case,	 a	 program	 of	 cervical	 cancer	 screening	
including	 clinical	 work,	 advocacy,	 and	 policy	 issues.	
PATH	does	not	expect	to	be	providing	the	product	in	
the	 future;	 its	 industry	partners	have	 the	 intellectual	
property,	are	developing	it,	and	are	responsible	for	its	
management.





not	 just	a	 technology	development	project.	 Issues	 to	
consider	 in	 developing	 a	 public	 health	 initiative	 in-





Over	 the	 years	 of	 diagnostic-test	 development	 and	
commercialization,	PATH	has:	
•		 in-licensed	 key	 diagnostic	 reagents	 to	 PATH	
from	academic,	 government,	 and	private	 com-
pany	sources	
•		 out-licensed	 diagnostic	 test	 and	 reagent	 pro-
duction	 know-how	 from	PATH	 to	 diagnostic	
manufacturers	















for	 efficient	 production	 of	 certain	 diagnostic	
reagents	 even	 when	 the	 know-how	 was	 not	
patentable	







•		 deciding	 whether	 to	 patent	 incremental	 in-









On	 an	 overall	 policy	 basis	 PATH	 works	 under	 its	
Guiding	 Principles	 for	 Private	 Sector	 Collaboration,	
endorsed	 by	 the	 board	 of	 directors,	 which	 is	 most	
often	relevant	to	PATH’s	 intellectual	property	and	li-
censing	activities	with	diagnostics.	To	conform	to	key	
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•		 recognize	 that	 the	 commercial	 partner	 must	
achieve	 commercial	 benefit	 to	 ensure	 their	
sustainable	 commitment	 to	 supplying	 the	
technology	
•		 provide	a	clear	definition	of	 the	 roles,	 responsi-
bilities,	and	expectations	of	both	PATH	and	the	
commercial	producer	
•		 balance	 PATH’s	 need	 for	 transparent	 collabo-
ration	with	the	commercial	producer’s	need	to	
protect	proprietary	information	
•		 reflect	 a	 rigorous	 process	 of	 due	 diligence	 on	
PATH’s	part	before	executing	an	agreement	
The	 IP	 elements,	 working	 relationships,	 and	
technology	 economics	 of	 every	 project	 or	 program	
can	 vary	 from	one	 extreme	 to	 the	 other.	Because	 of	
this,	 PATH	has	 found	 it	 counterproductive,	 for	 the	
most	part,	to	make	broad	institutional	policies	about	
specific	 individual	 elements	 of	 complex	 intellectual	





from	 ever	 coming	 to	market.	 In	 cases	 where	 PATH	






ExTERnAl FAcToRS THAT 












•		 multilevel	 manufacturing	 and	 distribution	
channels	typical	for	diagnostic	products	
•		 distributed	nature	of	global	public	sector	procure-
ment	 of	 diagnostic	 reagents—no	 single,	 huge,	
vertical	procurement	mechanism	as	exists	for	vac-
cines	and,	to	a	degree,	family	planning	products	
KEy lESSonS lEARnED  
AnD HEAlTH AccESS ISSUES 
The	proprietary	control	of	a	single	key	diagnostic	test	
reagent	can	give	some	parties	control	and	power	seem-
ingly	 disproportionate	 to	 their	 contributions	 to	 an	
overall	diagnostic	test	development	project.	It	is	critical	






Noncommercial	 development	 and/or	 steward-
ship	 of	 diagnostic	 platform	 intellectual	 property	 or	
key	component	intellectual	property	can	create	a	posi-
tive	 impact.	For	example,	PATH	enhanced	 the	 local	
production	 of	 key	 rapid-test	 raw	materials	 (nitrocel-
lulose	 filters	 and	 colloidal	 gold	 signal	 reagents)	 in	
India,	which	created	an	impact	beyond	the	transfer	of	
technology	for	 individual	 tests	 to	specific	companies.	
Materials	suppliers	are	now	serving	additional	emerg-
ing	diagnostic	producers.	
Intellectual	 property	 and	 technology	 transfer	
alone	are	 rarely	enough	to	create	a	 lasting	 impact	on	
public	 health.	 We	 are	 all	 working	 on	 solutions	 to	
health	problems	that	have	fundamentally	less	promise	
as	 a	 “business	opportunity,”	 from	a	 commercial	man-
ufacturer’s	standpoint,	than	do	other	health	problems.	
To	make	a	new	diagnostic	test	 that	will	deliver	profit	
to	 the	manufacturer	 and	be	 beneficial	 and	 accessible	
to	 patients,	 there	 needs	 to	 be	 policy	 change,	 advo-
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that makes a difference in people’s lives (eco-
nomically or socially or both) is one of the prin-
cipal reasons for which technology transfer of-
fices exist.
Should the invention be marketed to existing 
companies or be used to develop a spinout company? 
Each approach has advantages and disadvantages. 
An existing company usually has an established 
infrastructure, as well as access to financial instru-
ments and distribution networks. Its financial 
health can be readily assessed. However, con-
necting with existing companies might be chal-
lenging, partly because they already have research 
agendas, networks, and priorities. The biggest risk 
with an established company is that it will lose 
interest in the technology before anything devel-
ops. Spinout companies, on the other hand, are 
focused on their own inventions, but because the 
companies are nascent, they are also fragile.
According to Nelsen,1 who has led the 
M.I.T.’s Licensing Office for the past 20 years, a 
number of other factors should also be considered 
when deciding whether or not patenting a new 
invention is in the public interest. For example:
• Is the technology self-evidently useful as-is? 
Will it be widely used even if it is not patented 
but instead released into the public domain?
• Can the patent-holding institution devise 
a nonexclusive licensing strategy that will 
bring in revenue without restricting the 
availability of the technology? 
EXECUTIVE GUIDE TO HANDBOOK SECTION 9
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Oftentimes, the first question that arises with an 
invention is whether or not it should be patented. 
When devising a patent strategy, three questions 
should be considered: 
• Should a patent application be filed or 
should the invention simply be published?
• Should the invention be marketed to exist-
ing companies or be used to develop a spin-
out company?
• What is the potential value of the invention?
Should a patent application be filed or should 
the invention simply be published? The answer 
depends on a number of factors: the needs (and 
dynamism) of the market, the uniqueness and 
usefulness of the invention, the likelihood that 
patent protection can be obtained, the specific 
mission of an institution, and the “attitude” of 
the inventor, that is, whether he or she is inclined 
to assist the technology transfer office (TTO).
This latter point merits discussion. For prac-
tical purposes, an invention can be defined ac-
cording to patent statute: it must be novel, con-
tain an inventive step (be nonobvious), and be 
useful or have industrial applicability. But often 
an invention is many years away from “working” 
in the real world. In other words, an invention is 
not an innovation until the new knowledge and 
invention are introduced into and utilized in an 
economic or social environment. Determining 
how to translate an invention into an innovation 
Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007. 
9: Evaluation and Valuation of Technologies. In Executive Guide to Intellectual Property Management in Health and Agricul-
tural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, 
USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). 
Available online at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for 
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• If the technology will not be useful with-
out substantial high-risk investment, then 
it will have to be patented and exclusively 
licensed in a developed country in order to 
bring in the adequate revenue. However, if 
this path is taken, then an additional ques-
tion must be asked: should patents be pur-
sued in developing countries in order to en-
courage companies to produce competing 
(lower-cost) generics in those countries? 
• Can the patent holder require the licensee 
to sublicense in order to promote low-
cost manufacture and distribution of the 
technology?
• If the drug (or vaccine) is expected to be 
used only in developing countries, will the 
patenting and distribution of a limited 
number of licenses attract sufficient invest-
ment and create a market? Put differently, 
will such a market be sufficiently profitable 
that it will encourage further development 
and testing of the drug or vaccine?
• Should the patent holder reserve for itself the 
unrestricted use of a patented research tool?
Answers to the above questions will act as 
guidance for patenting decisions. Above all, in-
stitutions should determine whether or not pat-
enting is the most effective way to ensure global 
access to their technologies. Broad licensing 
strategies should also be considered at this stage, 
and through licensing only comes in later. In this 
context, it should be remembered that it can be 
challenging to negotiate a licensing agreement 
that is fair to everyone—licensor, licensees, and 
the public sector. However, Nelsen asserts that it 
is far better to make an imperfect deal than no 
deal at all. People do not benefit until technology 
is developed and brought to market.
What is the potential value of the invention? 
While many inventors believe that their product 
is of supreme importance, many fail to see the po-
tential value of the product. Putting a “price tag” 
on an invention is difficult. In other words, deter-
mining the value of an invention and the resulting 
technology, product, or service will be compli-
cated and at times nearly impossible. Fortunately, 
the “full worth” of an invention need not be 
determined at the time the invention is made, 
nor even when the invention is transferred or li-
censed to a third party through a patent license. 
Value can be realized through the use of royal-
ties—payments to the inventor based on the spe-
cific (negotiated) contribution of the invention 
to a new product or service that are made when 
the product or service is sold. Royalties involve 
a trade-off and add new complications involv-
ing decisions about what to base the royalty rate 
on, how they should be calculated, and so forth. 
Royalties mean revenues are coming years later, 
but many institutions prefer payments now.
With respect to specific valuation techniques, 
Potter2 reviews five major approaches, provides 
illustrations based on agricultural technologies, 
and discusses a hypothetical negotiation between 
a university and a company.3 Potter outlines five 
approaches to valuing technology.
Costs approach. The pricing of a product is 
based on the cost of developing the product. This 
approach is rarely used to assign a value to a tech-
nology because the cost of research is not usually 
correlated with the value of the intellectual prop-
erty that was the basis for the technology.
Income approach. The value of a technology 
is determined by a pure income approach, where-
by future anticipated revenues (cash flows) are 
discounted to present value. The big drawback to 
this approach is that, for a new technology, there 
are generally no sales, markets, or cost data that 
can be used to predict future revenues.
Market approach. The value of a technology 
is determined based on the value of a similar or 
comparable technology. The inherent weakness of 
this method is that it is difficult to find a compa-
rable technology if the technology in question is 
truly novel. 
Hybrid approach. The value of a technology 
is determined by a combination of the income and 
market approaches. This method will deliver both 
the benefits and the drawbacks of both methods.
Royalties approach. The value of a technol-
ogy is calculated based on royalty rates that have 
been applied to similar technologies. With this 
method, the inventor would typically receive a re-
turn on sales of the final product, with risk being 
shared between the inventor and the developer. 
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Regardless of which approach to technology 
valuation is used, the assessor should have the 
foresight to see where the new technology could 
be applied and how useful it might be. The as-
sessor should therefore be familiar with adoption 
rates of the given technology in a defined market. 
The value of both formal (statutory, such as pat-
ents) and informal (such as know-how) intellectual 
property (IP) rights should also be known so that 
negotiation mistakes are avoided. Importantly, 
there is no single best method for technology 
valuation, and different methods may be used for 
different technologies within the same organiza-
tion. Successful technology valuation depends on 
accurate estimates of how successful a product 
will be and how much it will sell for. If one can 
make accurate estimates, one has a good chance of 
building a trustworthy relationship with licensees, 
successfully bringing the technology to market, 
and increasing the chances of making more tech-
nology transfer deals in the future.
More specific methods of valuation and 
methods to price technologies are discussed ex-
tensively by Razgaitis4 who also authored several 
books on the subject. He emphasizes that the val-
ue of a technology depends on how it is used, how 
much it costs to develop, how long it will take be-
fore its sales generate returns, and the probability 
that the technology will be commercially success-
ful. Pricing, on the other hand, refers to the price 
a buyer and seller agree upon. This may be in 
up-front payments (in cash or equity) or deferred 
royalties, or a combination of both. Razgaitis de-
scribes six of these valuation methods.
Method I. The Use of Industry Standards 
Method looks at the range of published royalties 
(and other forms of payment) from technology 
licenses within an industry category and uses that 
information to guide valuation of a technology 
under consideration. 
Method II. The Rating/Ranking Method looks 
at several license agreements for similar technolo-
gies, comparing and ranking a technology under 
consideration against the license agreements with 
respect to stage of development, scope of IP protec-
tion, market size, profit margins, and other factors. 
Method III. Rules of Thumb Methods, such 
as the 25% Rule Method, apportion anticipated 
profits from the commercial use of the technol-
ogy between the seller and buyer. 
Method IV. The Use of Discounted Cash-
Flow Analysis with Risk-Adjusted Hurdle Rates 
Method seeks to split expected returns but adjusts 
basic profit-and-loss accounting terms to account 
for the timing of investments and returns and the 
risks borne by the parties. The method introduces 
a discussion of some possible structures of pay-
ments, as they affect both timing and risk. 
Method V. The Advanced Tools Method ap-
plies statistical methods, such as Monte Carlo simu-
lations, to discounted cash-flow models in order to 
test the influence of various value assumptions and 
license terms on the possible outcomes of a deal. 
Method VI.  The Auctions Method allows 
interested parties to bid on a technology, based 
on their own independent efforts at valuing the 
technology, thus comparing their respective valua-
tions, identifying the highest valuation, and strik-
ing a price based on that highest valuation. 
More than one method can be used in any 
given valuation and, depending on the circum-
stances, it may be advantageous to use a combina-
tion of two or more methods. One should con-
sider the commensurate level of valuation analysis 
appropriate to the magnitude of the potential 
licensing opportunity when choosing methods. 
Razgaitis provides many valuation examples, in-
cluding typical royalty rates obtained by univer-
sities for software, pharmaceuticals, diagnostics, 
and others (see Table 1). The data illustrate a 
trend that appears in other examples discussed by 
Razgaitis: those products and industries with tra-
ditionally high operating margins (profits), such 
as pharmaceuticals and software, tend to exhibit 
higher royalty rates compared with, say, the ma-
terials industry. More specifically, and also for the 
purpose of establishing reasonable expectations of 
both licensors and licensees, Table 2 shows typical 
royalty rates from the medical industry. Note that 
the context of both tables is well defined: early-
stage technologies out of research laboratories. In 
the second table, however, note that there is an 
important economic difference between the ends 
of the royalty ranges given: 1% versus 3% or 2% 
versus 10%, and so on. Unless the technology trans-
fer manager understands where the institution’s 
GUIDE TO SECTION 9
10 | HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE
Table 1: Example Table of Royalties Developed through Experience  
by a University Licensing Office
Product Royalty (%) Comments
Materials processes 1–4 0.1%–1% for commodities; 0.2%–2% for processes
Medical equipment/devices 3–5
Software 5–15
Semiconductors 1–2 Chip design
Pharmaceuticals 8–10 Composition of materials
12–20 With clinical testing
Diagnostics 4–5 New entity
2–4 New method/old entity
Biotechnology 0.25–1.5 Processa/nonexclusive
1–2 Processa/exclusive
a Expression systems, cell lines, growth media/conditions
Table 2: Royalty Rates for the Medical Industry





Reagents/process 1–3 Patent costs 2,000–10,000
Reagents/kits 2–10 Patent costs 2,000–10,000
Diagnostics in vitro 2–6 5,000–20,000 2,000–60,000
Diagnostics in vivo 3–8 5,000–20,000 2,000–60,000
Therapeutics 4–12 20,000–150,000 20,000–150,000




Source: L. Nelsen (M.I.T) as cited by Razgaitis5
Source: Razgaitis6
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opportunity fits in the range identified, it is dif-
ficult to know where to begin. Further, not every 
opportunity falls within even these broad ranges. 
Some opportunities will have only negligible value; 
others could be unusually valuable opportunities. 
Many things can be transferred between a li-
censor and licensee: IP rights, technical data, rights 
over improvements to a technology, rights to subli-
cense the technology, costs related to the patenting 
process, and so on. The price that the licensee pays 
to the licensor can consist of any combination of 
various types of payments, including running 
royalties, fixed payments, common stock (equity), 
R&D funding, lab equipment, consulting services, 
grant-backs, options, or access to other proprietary 
resources. The licensing contract should make al-
lowances for the risks that a licensee will have to 
take in developing and commercializing the tech-
nology. A combination of royalties and equity 
stakes is a particularly effective way of splitting 
the risk between two parties. If a technology does 
not deliver, then the seller only receives the equity 
stake and the buyer does not need to pay any fu-
ture cash. On the other hand, if the technology is 
highly successful, the buyer will have accessed the 
technology without forfeiting important cash that 
may have been crucial in bringing the technology 
to market, and the seller gains in higher royalties 
and higher value of the equity.
Another way to distribute the risk fairly is 
to discount expected returns with an appropriate 
hurdle (or milestone) rate. Alternatively, the sched-
ule of payments may be adjusted as a function of 
milestones. Picking appropriate milestone rates or 
individual payments can be informed by explicitly 
modeling how different stages or factors in the 
development process contribute to the overall ex-
pected returns and to the risk of not realizing those 
returns.
Razgaitis provides many illustrations and of-
fers the following broad conclusions, which are 
supported with examples. There is no “right” price 
for a technology with each licensing transaction 
being unique. To assess the future sources of 
value, the innate economic benefit that can be 
captured by using the technology in some market 
must be identified. That value is dependent upon 
many factors, all of which may change at any 
moment. But there is often only a small window 
of time in which a technology can turn a profit. 
Being cognizant of all information regarding the 
possible market value of and possible risks associ-
ated with a technology, makes it easier to arrive at 
an accurate valuation. This information may be 
difficult to collect, but it will be necessary. In fact, 
in order for pricing to be done properly, all of the 
relevant information must be gathered, preferably 
ahead of negotiations.
Early stage technologies may end up having 
little or no commercial value, but there are rare 
cases of immense value. As the technology ages 
and patents approach expiration, the bargaining 
position of the licensor weakens. This results in 
an inevitable shift in bargaining power from the 
licensor to the licensee, resulting in prices or roy-
alties being renegotiated downward, not upward. 
Regardless of where one is in the process, there 
are methods practiced by technology transfer and 
business development professionals that can be 
used to guide the pricing process.
Pricing is never completely objective and al-
ways carries risk, while risk itself is subjective and 
each party will perceive it differently. Certain events, 
such as additional testing of a technology by the li-
censor, or by a government R&D grant awarded to 
the licensee, or a collaborative venture between the 
licensee and other R&D institutions may reduce 
the risk as perceived by the licensee. The important 
thing is to find a price that is acceptable to both 
parties and that encourages the licensee to invest 
in the development of the technology.
Concluding this section, Lesser and Krattiger7 
use bioprospecting examples to examine how dif-
ferent valuation methods have different policy 
implications for developing countries. For in-
stance, a bioprospecting deal can provide a devel-
oping country the incentive to preserve its natural 
resources if the money it receives from the de-
veloped country institution for the right to bio-
prospect inside the country is greater than what 
the country would receive by allowing destructive 
activities such as logging. 
The trade-offs described earlier between 
up-front payments and royalties are particularly 
relevant from a policy perspective in the context 
of bioprospecting. The authors show that the 
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principal factors used in negotiating price are the 
uncertainty of attributing value and the uncer-
tainty of finding marketable products. 
Negotiations in bioprospecting deals strive 
for an appropriate balance between collection (ini-
tial) fees and royalty (delayed) payments. Lesser 
and Krattiger demonstrate with examples and 
calculations how changes in assumptions lead to 
different outcomes. For example, collection fees 
will reduce total payments except when national 
interest rates are very high. In-country screening, 
including the use of indigenous knowledge, is a 
potentially valuable strategy as it shifts the rise of 
failure to the licensee. The authors outline issues 
for contract negotiators and discuss the implica-
tions for biodiversity conservation. 
A discount rate is what is used to adjust fu-
ture income to present net value. It is often akin 
to an interest rate. Receiving, say, $100 today 
would be $110 in one year’s time if an interest 
rate were 10%. Conversely, receiving $100 in 
one year’s time would be worth $90.90 today 
if a 10% discount rate were applied. Typically, 
personal and corporate discount rates are greater 
than social rates, although the determination of 
the social rate is open to different interpretations. 
As anyone who has paid off a loan over a 10 or 
20-year period recognizes, small changes in the 
discount rate have major implications on the out-
come.  Further, the concept of personal discount 
rate (that is, what the person on the other side of 
the table has internalized about risk), political and 
economic instability, immediate need for money, 
and so forth, could play a large role in the choice 
between collection payments and royalties. 
Importantly for developing countries, when 
fees are “shifted forward” by increasing the collec-
tion fee and reducing royalty payments, more risk 
is transferred to the collecting company that de-
velops a product, since it will have to pay the same 
amount of money regardless of whether success-
ful commercial products are developed from the 
collected material. Shifting fees forward have par-
ticularly interesting possibilities in countries where 
interest rates are high (since the discount value 
of future payments is lower with higher interest 
rates). This leads to important policy consider-
ations for national governments, nongovernmental 
organizations (NGOs), and development agencies. 
The chapter reviews these policy considerations and 
concludes that providing grants/loans and train-
ing/equipment for in-country screening should be 
given a high priority because in-country screening 
may be productive in the long term. With regard to 
national policy, Lesser and Krattiger discuss several 
policy considerations8 involving both in-country 
screening and the allocation of payments between 
collection fees and royalties. 
With adequate in-country funds lacking, in-
ternational donors should seriously consider loans 
or grants for training and equipment purchases. 
This coupled with a series of other initiatives8 will 
bring many closer to realizing the promise of bio-
prospecting. ■
All chapters refer to: Intellectual Property Management in 
Health and Agricultural Innovation: A Handbook of Best 
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thom-
son, AB Bennett, K Satyanarayana, GD Graff, C Fernandez, 
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis, 
U.S.A. Available online at www.ipHandbook.org. The online 
version contains for each chapter a detailed Editor’s Sum-
mary, Implications, and Best Practices.
1 Chapter 9.1 by L Nelsen titled Evaluating Inventions 
from Research Institutions, p. 795. 
2 Chapter 9.2 by RH Potter titled Technology Valuation: 
An Introduction, p. 805.
3 The online version of the Handbook provides a 
spreadsheet (in Microsoft® Excel®) for the user to 
see how various results are obtained depending on 
different inputs and assumptions. 
4 Chapter 9.3 by R Razgaitis titled Pricing the Intellectual 
Property of Early-Stage Technologies: A Primer of Basic 
Valuation Tools and Considerations, p. 813.
5 Ibid.
6 See supra note 4, with data adapted from an article 
published by Corey G and E Kahn. 1991. How to 
Negotiate Reasonable Royalty Rates for Licensing 
Novel Biomedical Products. Genetic Engineering News 
July–August 1991. p.4.
7 Chapter 9.4 by WH Lesser and A Krattiger titled 
Valuation of Bioprospecting Samples: Approaches, 
Calculations, and Implications for Policymakers, p. 861.
8 Cabrera Medaglia J. 2004. Bioprospecting Partnerships 
in Practice: A Decade of Experiences at INBio in 
Costa Rica. IP Strategy Today No. 11 (2004): pp. 27–40. 
www.bioDevelopments.org/ip lists a number of 
important policy conclusions stemming from 
experiences at INBio in Costa Rica.
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 Determining how to translate an invention into an innovation that makes a difference 
in people’s lives (economically or socially or both) is one of the principal reasons 
technology transfer offices exist. 
4	 Government policies ought to be flexible and enable research institutions to customize 
technology transfer strategies that align with the institutions’ missions. Different 
approaches will serve different types of research and academic organizations working 
within various disciplines and cultures. 
4	 It can be challenging to negotiate licensing agreements that are fair to everyone and 
conducive to making inventions become innovations. it is often better to make an 
imperfect deal than no deal at all. People do not benefit until technology is developed 
and distributed.
4	 Public sector institutions should therefore be supported in their overall deal making 
efforts rather than using individual deals as particularly good or bad examples.
4	 A government can make technology transfer less risky and more attractive for licensees 
by applying such policies as government R&D grants, subsidies, encouragement of 
clusters, financing of business incubators, and offering complementary R&D inputs or 
regulatory requirements that are conducive to the emergence of new technologies. 
4	 Bioprospecting and related activities raise important issues with respect to pricing. 
Importantly for developing countries, when fees are “shifted forward” by increasing the 
collection fee and reducing royalty payments, more risk is transferred to the collecting 
company, which is developing the product, since the company will have to pay the 
same amount of money regardless of whether successful commercial products are 
developed from the collected material. Shifting fees forward may have particularly 
interesting possibilities, as doing so allows countries to invest resources early on to 
capture additional value in bioprospecting activities. 
4	 It is important to adopt national policies that facilitate access to biological resources 
under fair and equitable terms with prior informed consent. Access mechanisms 
should be transparent, predictable, and managed by experts. 
4	 There is a strong interaction between bioprospecting activity and national scientific 
capabilities. In countries with strong scientific capability, bioprospecting is robust. 
Moreover, such capacity increases the negotiating strengths and benefit sharing 
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 Determining how to translate an invention into an innovation that makes a difference 
in people’s lives (economically or socially or both) is one of the principal reasons 
technology transfer offices exist. 
4	 It can be challenging to negotiate licensing agreements that are fair to everyone and 
conducive to “moving” inventions to innovations. it is far better generally to make an 
imperfect deal than no deal at all. People do not benefit until technology is developed 
and distributed.
4	 institutions need to assess whether or not patenting is the most effective way to 
ensure high economic and/or humanitarian impact of their technologies. 
4	 A public institution’s decision with regard to patenting should depend on (1) whether 
such patenting would be socially responsible, (2) whether there is public interest in 
the technology, and (3) whether patenting would help the local economy (where 
applicable).
4	 Putting a “price tag” on an invention early on is difficult, if not impossible. Fortunately, 
the full value of an invention need not be determined when the invention is transferred 
or licensed, as value can be realized later through the use of running royalties, fixed 
payments, common stock (equity), R&D funding, lab equipment, consulting services, 
grant backs, or access to other proprietary resources. For public sector organizations, 
in-kind contributions may sometimes be particularly appealing.
4	 evaluating a new technology is difficult and the evaluation will necessarily be imprecise. 
It is better to encourage a TTO to make deals creatively and expeditiously, without the 
imposition of minimum royalties and other restrictive terms. The important thing is 
to find a price that is acceptable to both parties and that encourages the licensee to 
invest in the development of the technology.
4	 Senior management should be supportive of the overall deal making of its technology 
transfer officers rather than be critical of individual deals. Naturally, TTO officers need to 
follow procedures, apply policies, and be well trained and experienced in deal making.
4	 Putting pressure on tto officers to break even or to generate revenues can constitute a 
perverse incentive, almost forcing a TTO to go with up-front payments. This may drain 
a startup of critical financial resources and thus reduce the level of investment that is 
allocated to making the invention work.
4	 Probabilistic modeling software can aid pricing efforts. The most effective software is 
expensive and may not be a good investment if fewer than 100 deals are made per 
year. Quite often the best approach is to get as many licenses as possible completed 
in a short period of time, even if an individual license does not provide the maximum 
possible income. The more licenses, the higher the probability that one, or a few, will 
generate returns. 
FOR SENIOR MANAGEMENT
(UNIVERSITY PRESIDENT, R&D MANAGER, ETC.)
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 The best approach by your TTO is usually to disclose inventions early and disclose often. 
4	 You should even consider disclosing what you think might not yet be a full invention. 
Experience shows that scientists are, in fact, not very good at determining when they 
have an invention. In many cases, they have a dozen when they themselves think they 
have none!
4	 If your TTO officers decide not to file for patents, you shouldn’t be discouraged. This 
is not a critique on your research, its importance, or its relevance. the tto has many 
priorities to balance, including financial.
4	 It can be challenging to negotiate licensing agreements that are fair to everyone and 
conducive to “moving” inventions to innovations. it is generally far better to make an 
imperfect deal than no deal at all. People do not benefit until technology is developed 
and distributed.
4	 Some of the key questions TTOs address early on when an invention has been made 
is whether a patent application should be filed at all, how the invention would be 
marketed, and what value the invention might add to existing processes or products or 
what value might come out of a new product or process. Determining how to translate 
an invention into an innovation that makes a difference in people’s lives (economically 
or socially or both) is one of the principal reasons technology transfer offices exist. 
4	 Scientists must insist that the TTO have transparent procedures for reviewing invention 
disclosures and making decisions. You should not only be informed of the basis and 
rationale for a decision, but also, in most cases, be fully involved in the process.
4	 It is important to keep a detailed record of your research procedures. Your records may 
help determine inventorship and may provide clues as to the value of your inventions.
4	 Once your TTO patents your invention, don’t expect a big revenue flow. For a TTO, quite 
often the best approach is to get as many licenses as possible completed in a short 
period of time, even if an individual license does not provide the maximum possible 
income. The more licenses, the higher the probability that one, or a few, will generate 
returns. Both you and senior management should be supportive of the overall deal 
making of the tto rather than criticizing individual deals. Naturally, TTO officers need 
to follow procedures, apply policies, and be well trained in deal making.
4	 Additional research by yourself or your group often increases both the likelihood of 
finding a licensee and the economic value of the license. But this is only true if the 
research is specifically aimed at reducing the risks of commercializing the technology. 
Basic research may do little to reduce these risks. Discuss this issue with your TTO 
officer. Especially in an academic environment, he or she will be reluctant to provide 
unsolicited advice regarding this issue.
4	 Remember that licensing incomes reward the commercial value, and not the scientific 
value, of your invention. technology licenses may provide you with follow-on grants 
and other intangible incentives to conduct further research.
FOR SCIENTISTS
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 A combination of royalties and equity stakes is a particularly effective way of splitting 
risk between two parties. If a technology does not deliver, then the seller receives only 
the equity stake, and the buyer does not need to pay any future cash. Another way to 
distribute the risk fairly is to discount expected returns with an appropriate milestone 
rate. 
4	 many valuation approaches exist. none is perfect. Considering that each deal is highly 
context specific, each technology transfer office should be able to select the best 
approach and adapt it to the specific circumstances. 
4	 Licensing is always risky and no deal will be perfect. it is often better to make an 
imperfect deal than none at all. 
4	 When devising a patenting strategy, you will need to make three decisions: First, should 
you seek patent protection? Second, what is the best patent-marketing approach? 
Third, what license fees or royalties ought to be levied?
4	 Since there is no single best way to assess the value of a technology, all parties should 
agree on the valuation method to be used.
4	 Probabilistic modeling software can aid pricing efforts. The most effective software is 
expensive and may not be a good investment if fewer than 100 deals are made per 
year. Quite often the best approach is to get as many licenses as possible completed 
in a short period of time, even if an individual license does not provide the maximum 
possible income. The more licenses, the higher the probability that one, or a few, will 
generate returns.
4	 Putting a “price tag” on an invention early on is difficult, if not impossible. Fortunately, 
the full value of an invention need not be determined when the invention is transferred 
or licensed, as value can be realized later through the use of running royalties, fixed 
payments, common stock (equity), R&D funding, lab equipment, consulting services, 
grant backs, or access to other proprietary resources. For public sector organizations, 
in-kind contributions may sometimes be particularly appealing.
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goods (such as street lights) and they also provide 
private goods (for example, housing and medi-
cal care). Similarly, the private sector may provide 
public goods, such as technical norms or street-
lights. The example of the streetlight illustrates 
how private goods (patented, high-efficiency light 
bulbs, electricity produced by companies, street 
posts installed by local private contractors) be-
come public goods because they are made avail-
able to all. The creation of a public good is not 
free of cost. Costs may have been borne by society 
at large (the street light will have been paid for, 
indirectly, by the taxpayer) but the enjoyment or 
use of it is free to any and all individuals who pass 
along that particular street.
Further, these examples demonstrate how 
public and private are in some respects two sides of 
the same coin; both are needed for the coin to ex-
ist and have value. But as Boettiger and Chi-Ham1 
show, the manner in which this plays out with in-
formation and inventions generated by science is 
not as straightforward as the examples above sug-
gest. Complications are due, in part, to the fact 
that inventions, unlike real and tangible property, 
once they are disclosed are essentially nonrival and 
nonexcludable. Unless, of course, IP rights systems 
regulate ownership, access, and use. 
Boettiger and Chi-Ham discuss the nexus of 
public and private property and provide in-depth 
guidance on using defensive publishing and the 
public domain as tools to achieve a range of IP 
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The nature of public and private and balancing 
individual rights with public welfare has been a 
perennial concern for many societies. For more 
than two thousand years in the West, scholars, 
philosophers, and politicians have debated ques-
tions of individual rights and of a government’s 
responsibility to protect those rights while pro-
moting the public good. Plato argued against 
private property (he said it would corrupt the 
personality by infecting it with greed), while 
Aristotle essentially argued for private property 
stating it would enhance an individual’s sense of 
identity and self-esteem and, in addition, allow 
for the optimal economic use of the commons.
Private goods are those over which there can 
be competition or rivalry, their use can be exclud-
ed from nonowners. Private goods typically are 
traded in markets. If a market is able to agree on a 
price (such as for bread), the ownership or use of 
the good (the bread) is transferred. Further, once 
the good is consumed (the bread has been eaten) 
others are precluded from also eating it.
Public goods are goods the use of which 
neither competes with nor rivals use by oth-
ers (nonrival), and no person can exclude other 
persons from use of the goods (nonexcludable). 
Sunlight, traffic lights, street signs, sewer systems, 
and a smallpox-free world are examples of public 
goods. Crucially, who provides the public good 
is not a factor in determining whether a good 
is public or private. Governments provide public 
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management goals. The authors examine the ex-
tent to which the public domain can in fact be 
depended upon and even leveraged to facilitate and 
preserve access to technologies. The authors view 
defensive publishing and utilizing public domain 
research inputs as options within a broader set of 
IP management strategies, including the options 
of patenting, trade secrecy, trademark protection, 
and bailment contracts. All of the above can be 
used in various combinations to find the balance 
between protection and accessibility that both 
promotes technology development and fosters 
ongoing innovation. They argue that the choice 
of the strategic option depends on a pragmatic 
and realistic understanding of the nature of the 
public domain. In order to clarify and illustrate 
this, the public domain is compared to two differ-
ent, but closely related, property rights concepts: 
open source and the commons. 
Open source is defined as the body of knowl-
edge over which owners claim property rights, 
but with access to that knowledge being provided 
systematically by the owners under terms of a li-
cense that regulates access. According to the au-
thors, the commons is, by its nature, a less clearly 
defined concept that varies according to context, 
but includes a lack of private ownership, open ac-
cess, or collective management.
It should be noted that defensive publishing 
strategies can be more viable than patenting in 
the following two cases:
•	 development of the technology will not de-
pend on private sector investment
•	 the leverage ownership could provide, such 
as the ability to segment markets or bargain 
for access to complementary technologies, 
is not important
Defensive publishing can be less costly, 
eliminating patent costs and transaction costs in 
licensing, especially when the ultimate desired 
outcome is to provide broad access to a technol-
ogy. When cost or infeasibility makes enforcing a 
patent unlikely, defensive publishing is the more 
sensible alternative for companies. It can be very 
effective when combined with patenting.
The second aspect of the chapter by Boettiger 
and Chi-Ham deals with the use of public domain 
technologies as research inputs. The authors out-
line how this approach can reduce transaction 
costs and mitigate potential IP access problems in 
downstream R&D. However, as for any IP man-
agement strategy, attention should be paid to the 
overlapping, web-like nature of patent claims and 
the ever-shifting boundary of the public domain. 
Even when a technology is preliminarily believed 
to be in the public domain, such as from an early 
scientific publication or an expired patent, sub-
sequent publications or patents can still claim 
certain uses of the technology, such as in particu-
lar combinations, applications, or with possible 
improvements. 
The public domain can be a vital resource 
to public sector institutions and also companies. 
Judicious defensive publishing and the careful use 
of public domain technologies offer IP managers 
everywhere effective, flexible, and less-expensive 
tools for exploiting these resources. Intellectual 
property is not a panacea for the management of 
innovation. Neither is open source. All have util-
ity and limitations. Artful management involves 
the creative and balanced use and handling of 
both public and private goods.
If patenting is the chosen route, it must be 
remembered that patenting decisions need to 
be made well before it is clear whether or not 
an invention has value. It makes business and 
strategic sense, therefore, to minimize the initial 
costs of such decisions. If the invention appears 
to have significant market potential, then a cost-
minimizing approach toward patenting is not 
recommended. However, most inventions have 
questionable or uncertain future value, and so a 
cost-minimizing approach is an appropriate strat-
egy for patent application filings. 
One cost-minimizing approach is the fil-
ing of provisional patent applications, which is 
possible in many countries. Importantly, foreign 
inventors may also file provisional applications 
in the United States. Provisional patents allow 
inventors an extra year of protection, effectively 
extending the patent period from 20 to 21 years. 
As Cruz2 explains, the benefits of provisional ap-
plications include cost and simplicity. Provisional 
applications are not substantively reviewed by a 
patent office examiner, but are simply checked 
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to ensure that they meet minimal filing require-
ments. A provisional application also does not 
require a prior art search. Since these applica-
tions are so quick and inexpensive to prepare, 
they offer an easy way for inventors to establish 
a priority date for an invention and avoid statu-
tory bars. 
But there are also limitations associated with 
provisional applications. While inexpensive to file, 
provisional patent applications do not reduce the 
costs of preparing and filing subsequent utility ap-
plications, meaning that the total cost of filing will 
increase, if only by a small amount. More impor-
tantly, provisional applications require a degree of 
disclosure, so inventors should be sure not to dis-
close something they wish to retain as a trade secret. 
Also, provisional patents may not be amended; they 
trigger the time line for Patent CooperationTreaty 
(PCT) and Paris Convention filings, and without 
filing nonprovisional patent applications, provi-
sionals do not mature into patents.
Livne3 then discusses various avenues for re-
ducing costs in patent filings and presents a high-
ly useful decision tree. He cautions that the use of 
patent attorney is generally an essential guide in 
such matters. The stakes are often high and mis-
takes can be costly. When publication is immi-
nent and patent protection in foreign countries is 
desired, a provisional or nonprovisional applica-
tion should be filed in the United States before 
publication. Once disclosed, filing in many coun-
tries will no longer be possible. 
Although licensing is discussed elsewhere,4 
the manner in which patent applications are writ-
ten, particularly the claims, can be instrumental 
in facilitating certain licensing strategies, particu-
larly field-of-use licensing. The foundation of an 
effective field-of-use licensing strategy is a patent 
application that foresees certain licensing oppor-
tunities and accommodates unforeseen opportu-
nities. Olson5 discusses this using examples from 
the agricultural, pharmaceutical, biochemical, and 
chemical disciplines and illustrates how this strat-
egy applies equally to inventions with commercial 
and humanitarian applications. He urges technol-
ogy managers to retain control over the patent ap-
plication process and to encourage creative think-
ing when preparing patent applications.
Applying for patents is only one element in a 
strategy to create IP portfolios of substantial val-
ue. For both public and private sectors, patents 
are a central element, but an IP portfolio should 
also take advantage of other forms of protection: 
trademarks, copyrights, and trade secrets. Dodds6 
presents various strategies for building an IP for-
tress and discusses the limitations and strengths 
of various approaches. For example, an offensive 
patent strategy is designed to build barriers to ex-
clude competitors from proprietary technologies. 
With a defensive patent strategy, a company files 
patents primarily to ensure that innovations can 
be practically used. To build an IP fortress of pro-
tection, several forms of intellectual property may 
be used for the same invention or improvement, 
with different forms of IP protection serving of-
fensive or defensive tactics. 
Notwithstanding the different missions, 
objectives, and motivations of the public and 
private sectors, the central forces behind their 
respective IP protection strategies are identical 
(though the relative strength of the forces will 
vary significantly). Private sector organizations, 
primarily corporations, are profit-oriented and 
respond to the pressures imposed by the market-
place and by shareholders who expect returns on 
their investments. Therefore, the private sector 
will use defensive and offensive patenting strat-
egies, often obtaining numerous patents with 
narrowly drafted claims. In this way, a series of 
patent portfolios is strategically used to build 
proprietary fortifications and the private sector 
organization can stake out its territory, protect 
its interests, and secure its profits. In the expand-
ing world marketplace, this strategy has only be-
come more telling, with the increasing reliance 
on foreign filing and patent families confirming 
the predominant global strategic perspective of 
multinational companies. 
The public sector, on the other hand, has a 
very different mission, which is to serve the great-
er public good. Patenting strategy will focus on 
more broadly drafted claims that will encompass 
a technology or (as is often, and more important-
ly, the case) a key process, method, or technique, 
for example a technique of genetic transforma-
tion. These types of patents, when appropriately 
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strategically licensed, enable effective develop-
ment, broad dissemination, and maximum soci-
etal impact of a technological advance precisely in 
line with the public sector mission of providing 
for the general public, in contrast to the much 
more limited constituency of the private sector. 
Patent protection is limited geographically, 
protecting the invention only in countries where 
the patent issues. Private sector companies and 
public sector institutions can reduce costs by fo-
cusing the patent protection to those geographic 
areas where there are business or humanitarian 
opportunities. But filing in foreign jurisdictions 
is not easy or cheap. For this reason, two chapters, 
one by Viksnins and McCrackin7 and the other 
by Schneiderman,8 review foreign filing strate-
gies and tactics, with particular emphasis on fil-
ing patent applications using the PCT. The two 
chapters are complementary and discuss the prac-
tical aspects from different points of view. 
Several key factors should be reviewed when 
approaching the international production, mar-
keting, distribution, and sales of a new and in-
novative product or process for which patent 
protection will be sought. These factors include a 
full range of various business and legal issues that, 
once considered, will provide the international 
patent protection options that can then be evalu-
ated and appropriately selected, according to 
an organization’s business goals and financial 
resources. 
Depending on an organization’s goals and 
resources, specific patent-application options will 
have advantages and disadvantages. One option 
is to file a separate patent application for each 
nation or region where protection is sought. 
Another option is to file a patent application, in 
accordance with the Paris Convention, which es-
tablishes a priority filing date. This gives, for one 
year, the exclusive right to file for patents in other 
Paris Convention countries. This approach has 
advantages when filing in a very limited number 
of countries. It also avoids the costs associated 
with the intermediate steps of filing in the PCT 
or regional patent offices prior to filing nation-
ally. This option has the following disadvantages: 
each application will be independently examined 
(that is, no deference is given to a prior favorable 
review in a different country) and government fil-
ing fees and translation costs will be due early in 
the patenting process.
An indispensable tool for delaying, con-
solidating, and minimizing international patent 
costs, the PCT offers a unified and simplified 
procedure for filing multiple foreign patent ap-
plications using a single initial application. The 
PCT has standardized the filing and preliminary 
evaluation of international patent applications. 
Consisting of over 130 member countries, the 
PCT is administered by the World Intellectual 
Property Organization (WIPO), which reviews 
PCT applications and then distributes them to 
designated member countries. The process of 
filing the PCT application in individual pat-
ent offices can be delayed for up to 30 months. 
During this time, the applicant will receive the 
results of the WIPO International Preliminary 
Examination of the PCT application. For many 
countries, especially those still developing capacity 
in patent prosecution, national patent offices give 
considerable deference to the PCT International 
Preliminary Examination Report.9
Using best practices in IP management in-
volves identifying IP assets, organizing resources, 
building capacity, formulating options, and then 
pursuing strategies that will maximize the value 
of an organization’s IP assets. Managing patent 
portfolios is always challenging, even more so 
now with the rapid globalization of technology 
markets. Globalization makes best practices in 
patent portfolio management more critical for 
effectively distributing innovations in the health 
and agricultural sciences, whether for commercial 
purposes or for facilitating humanitarian access. 
As public and private sector institutions increas-
ingly work in a global context, choosing where 
and under what circumstances to file for patents 
is becoming more important, and, according to 
Yin and Cunningham,10 the following factors 
should be considered: 
•	 objectives of the organization with respect 
to its issued patents
•	 assertion of patents offensively, either as 
part of a licensing strategy or in litigation, 
if companies are unwilling to license 
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•	 assertion of patents defensively, as leverage 
in licensing negotiations or to ward off liti-
gation by others 
•	 identifying where potential targets are lo-
cated or doing the bulk of their business, if 
a portfolio is to be used offensively, 
•	 identifying where an organization may 
most likely encounter licensing approaches 
or litigation offensives by others, if a port-
folio is to be primarily defensive
A global patent program should be proactive 
as well as preemptive in its outlook, especially re-
garding the potentiality of patent litigation, where 
knowledge of options can save time and money. 
Yin and Cunningham compare and contrast the 
advantages and disadvantages of pursuing patent 
litigation in either a federal district court or in 
the U.S. International Trade Commission (ITC). 
Although the ITC’s jurisdiction is essentially lim-
ited to cases dealing with the illegal importation 
of alleged infringing products, there are times 
when it might be a good idea to pursue patent 
litigation in the ITC. In addition, one can also 
pursue litigation in both the federal district court 
(patent infringement action) and the ITC (unfair 
trade practices action) at the same time. 
Obtaining patent protection and regulatory 
approval for biotechnology and pharmaceutical 
products is an extremely time-consuming and 
expensive process. For nonprofit organizations 
working with limited resources, it is especially 
crucial to manage the process efficiently and 
make the most of patent protections while they 
last. Fernandez, Huie, and Hsu11 suggest that 
public sector entities can use private sector tech-
niques to maximize revenue and, in turn, provide 
drugs to the public at the lowest possible price. 
The authors suggest that organizations carefully 
plan the timing of patent and Food and Drug 
Administration (FDA) applications to maximize 
the effective life of a patent and avoid unnecessary 
disclosures.
Nonprofits especially should note that the 
U.S. Patent and Trademark Office (PTO) gives 
special priority to certain biotechnology patent 
applications from small entities and nonprofits. 
The FDA likewise expedites approval if there are 
indications that the product will provide signifi-
cant therapeutic benefit over existing therapies. At 
the other end of the patent lifecycle, after having 
gone through the steps of obtaining FDA approv-
al, it is in the best interests of innovating compa-
nies to extend the patent term for as long as pos-
sible. This chapter is included in the Handbook 
to show the important interface between patents 
and the regulatory drug approval process and to 
show how this interplay affects market entry. It 
is not intended as an endorsement of extending 
effective patent life to delay the market entry of 
generic drugs.
As part of certain patent application filings,12 
biological resources may have to be deposited in 
support of a patent application. According to 
Harney and McBride,13 in the United States a de-
posit of biological materials is not a requirement 
per se, but under U.S. patent law it can satisfy 
three main requirements: 
•	 the enablement requirement, that is, that 
it would allow a person skilled in the art 
could make and use the invention 
•	 the written description requirement, that is, 
it would describe the invention in sufficient 
detail to allow such a person skilled in the 
art to reasonably conclude that the appli-
cant was in possession of the claimed inven-
tion at the time of filing 
•	 the best mode requirement, that is, that it 
would disclose the best mode of carrying 
out an invention in sufficient detail to al-
low a person of ordinary skill in the art to 
practice it 
Plant varieties constitute a biological re-
source. While in the United States while plant 
varieties can be protected as utility patents, the 
United States and many other countries also have 
protection mechanisms specifically adapted to 
the biological and self-replicating nature of plant 
varieties. Pardee14 provides detailed and step-by-
step instructions for how to obtain a U.S. Plant 
Variety Protection (PVP) certificate. Although the 
chapter focuses on PVP application procedures in 
the United States, the chapter is generally useful 
for illustrating the principles, preparations, and 
procedures for applying for and obtaining a PVP 
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certificate. This is because the U.S. provisions of 
the PVP Act of 1970 closely follow the model de-
veloped by the Convention of the International 
Union for the Protection of New Varieties of 
Plants (UPOV). Moreover, UPOV procedures 
have been adopted by many countries around the 
world, even by many who are not members of 
UPOV. 
In sum, the factors that drive decisions about 
what type of protection to seek and where to seek 
it are complex and will heavily depend on the con-
text in which the decisions are made. Public and 
private institutions will consider the same factors 
but weigh them using different criteria. For exam-
ple, the prospect of litigation in a foreign jurisdic-
tion for a public sector entity will be marginally 
important per se but highly relevant to its potential 
to license. The result is that both public and private 
sectors will consider whether to adopt offensive or 
defensive protection and litigation strategies.
Because the rights accorded to the patentee 
are divisible (the right to exclude one from selling 
or the right to exclude another from manufactur-
ing) one can divide the countries of the world into 
those where the invention can be manufactured 
versus countries where the invention will be sold. 
And even after identifying those countries where 
the invention might be marketed, it is often un-
necessary to file in all of the identified countries. 
In order to best determine what strategy to pur-
sue, an organization must know what it has and 
decide where it’s going. The first step, therefore, 
in developing an IP strategy is to document what 
technologies already exist in the organization, 
what technologies are in development, and what 
partnerships are feasible. It will then be possible to 
intelligently choose the best ways to protect intel-
lectual property and enhance its value, be it for 
economic or humanitarian objectives, or both. ■
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4	 The use of IP rights is not a panacea for the management of innovation, nor is the 
public domain. Both public and private goods have utility and limitations. The art of 
innovation management is in using both public and private goods and to manage the 
interface between them.
4	 Because public domain technologies play an important role in publicly funded research, 
defensive publishing can be used by public sector research institutions to help 
expand and reinforce the accessibility of technologies in the public domain. Academic 
institutions in particular should be encouraged to publish, in addition to considering IP 
protection.
4	 Because of the case-specific applicability of defensive publishing, blanket policies 
that require defensive publishing by national research institutions deny them the 
opportunity to develop their research results strategically in combination with IP rights 
protection. 
4	 In order to realize the commercial and humanitarian potential of international 
markets for products and processes arising from public sector research investments, 
public sector research-based institutions ought to develop strategies that judiciously 
balance the public domain and iP rights. Commercial and humanitarian objectives and 
strategies are not in conflict, but rather are complementary aspects of best practices in 
IP management. 
4	 A country’s membership in the Patent cooperation treaty (PCT) can greatly help 
national institutions—public and private—to strengthen international technology 
transfer, licensing and research, and product development partnerships and can aid 
access to global markets.
4	 Membership in the Pct can provide significant advantages and can lead to much more 
cost-effective examination of patent applications.
4	 harmonizing national patent systems across regions, as well as globally, can be a useful 
strategy for improving the effectiveness of the IP system and improving a national 
institution’s ability to reach foreign markets. 
4	 Providing for legislation, or for amendments to current statutes, that facilitates patent 
filing by foreign entities can be an important component of technology transfer and 
development.
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4	 The use of IP rights is not a panacea for the management of innovation, nor is the 
public domain. Both public and private goods have utility and limitations. The art of 
innovation management is in using both public and private goods and to manage the 
interface between them.
4	 Because public domain technologies play an important role in publicly funded research, 
defensive publishing can be used by public sector research institutions to help 
expand and reinforce the accessibility of technologies in the public domain. Academic 
institutions in particular should be encouraged to publish, in addition to considering IP 
protection.
4	 Because of the case-specific applicability of defensive publishing, blanket policies that 
require defensive publishing deny the opportunity to use research results strategically 
in combination with IP rights protection. 
4	 Few institutions anywhere in the world have transparent incentives for researchers or 
technology transfer officers to prepare defensive publications. Encouraging publication 
with maximum inventive disclosure through a balanced set of incentives for researchers 
and technology transfer officers is a useful strategy.
4	 Scientists should be encouraged to use public domain technologies as research 
inputs whenever feasible to reduce possible future constraints in the downstream 
commercialization of innovations. In many circumstances, however, relying on patented 
technologies may be the more effective way to go, particularly when the goal is to 
develop products. 
4	 Building strong institutional capacity in iP management will enable technology 
managers and scientists alike to understand the complex array of options that 
should be considered before publishing research results or filing patent applications. 
Development of protocols and strategies will clarify options and retain and maximize 
value.
4	 One such capacity centers on the decision of whether patents for an invention should 
be filed in a manner that does not delay publication of research results. Provisional 
patent applications, where possible, offer one such avenue.
4	 An important component of developing an iP strategy is to document the technologies 
that already exist in the organization, plus those technologies in development (for 
example, through an iP audit). Other essential components of such a strategy are the 
promotion of international patent protection and the concrete steps an institution is 
taking to drive innovation and technology transfer. 
4	 Management should encourage good laboratory practices and diligent record keeping 
of data to ensure that research can later be used in possible regulatory filings. Doing so 
could lower costs and reduce the time to market.
FOR SENIOR MANAGEMENT
(UNIVERSITY PRESIDENT, R&D MANAGER, ETC.)
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4	 Published information, or research tools provided by a colleague, may be covered by IP 
rights. In the life sciences, the web of patents extends far and wide. This should neither 
deter nor distract you from good science. An awareness of basic iP management best 
practices will minimize possible future problems. 
4	 You can intentionally make your inventions and the associated technologies accessible 
to everyone by publishing results instead of patenting them. Publishing results, however, 
does not guarantee full public access. Patents can still encroach upon the technical 
content of the work. Speak to your technology transfer manager about publications, 
and ask him or her to help with performing the necessary steps for turning your 
publication into a readily identifiable disclosure of patentable technology.
4	 if public disclosure is your goal as a way of preventing others from patenting a particular 
invention, it may be valuable to consider posting online or in searchable databases, 
with a valid date stamp, a longer working-paper version, supporting materials, or 
appendices. For this purpose, consider using dedicated services, such as a university 
technical disclosure bulletin or a centralized registry of unpublished papers, with 
official date stamps posted on faculty Web sites for online searches.
4	 if patenting and public disclosure are your goals, first consult with your institution’s 
technology transfer manager prior to disclosure. Your institution should have an 
effective mechanism in place to determine whether or not a patent should be filed 
without significantly delaying publication. But be aware that premature publication 
can lead to a loss of IP rights. 
4	 Your institution’s technology transfer managers will need your input in order to make 
strategic decisions about where to pursue foreign patent applications. You likely know 
where competitors are located and where products arising from your research are 
needed. 
4	 One of the services of PiPrA is to advise researchers in the plant sciences about which 
research is in the public domain and which is available for licensing on reasonable 
terms. If you are engaged in the development of biotechnology crops, you may find 
PIPRA’s Web site and services useful.
4	 Good laboratory practices and comprehensive laboratory notebooks can ensure that 
your research is suitable for subsequent regulatory filings. This can reduce costs and 
time to market.
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4	 The use of IP rights is not a panacea for the management of innovation, nor is the 
public domain. Both public and private goods have utility and limitations. The art of 
innovation management is in using both public and private goods and to manage the 
interface between them.
4	 Because public domain technologies play an important role in publicly funded 
research, defensive publishing can be used by public sector research institutions to 
help expand and reinforce the accessibility of technologies in the public domain. 
4	 It helps to have other tools besides patents to get technology out of the lab and into 
the marketplace. Consider first whether a technology requires investment by the 
private sector (and, thus, exclusivity) to be put into practice.
4	 Defensive publishing may run contrary to your instincts if you tend to think in terms 
of controlling a technology by ownership (and thus excluding others from using it). 
Think instead in terms of maintaining control of the technology—or elements of it—
by casting it into the public domain and, thereby, preventing others from owning it.
4	 Researchers will need advice on how to craft defensive publications.
4	 It is important to understand the advantages of provisional patent applications. 
They can be very useful in controlling costs and, also, in providing additional time for 
weighing options as to whether it is worthwhile to pursue a full patent application.
4	 Delaying patent applications involves risk. Subsequent prior art that blocks an 
application might appear. Or, the same invention might be patented by a competitor. 
4	 For any invention, evaluate whether foreign patent rights are truly required. This will 
require a combination of business, marketing, and legal analyses. 
4	 When assembling a patent application, attorney costs can be reduced by providing 
a cohesive document containing all data and information relating to the invention, 
such as alternative methods, compositions and/or devices. Use attorneys, at least, to 
review draft patent applications and to write the all-important claims.
4	 The foundation of an effective field-of-use licensing strategy is a patent application 
that foresees certain licensing opportunities and accommodates unforeseen 
opportunities. It will thus be important for your office to establish and implement 
strategies for patent application preparation that seek to anticipate any and all 
licensing opportunities that can arise from an invention.
4	 It is essential to retain control of patent applications. Don’t permit a licensee to gain 
control; their interests and your interests are likely very different. 
4	 tiered or layered iP protection strategies utilize several forms of protection for a 
single product or process. For example, a hybrid maize variety may be simultaneously 
protected by patents, trade secret, trademark, and plant variety protection.
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more time than the actual negotiation, since the 
goal of a negotiation is to formulate an agreement 
that meets the needs of both the licensor and the 
licensee in a manner that ensures mutually bene-
ficial future relationships between the institutions 
and individuals. Anticipating the other party’s 
needs and wants, and considering alternatives 
for resolving possible competing interests, is just 
one aspect of the preparation. Price, quite often, 
will not be the most difficult aspect to negotiate. 
Other terms can be more critical and of greater 
relevance, and value.
The first chapter by Freeman2 discusses the 
central issues that licensors and licensees need 
to consider before negotiating agreements. 
After providing an overview of licensing in the 
field of biotechnology, he considers the main 
components of a license agreement, highlight-
ing concerns specific to the field of biotechnol-
ogy. A license agreement will include several key 
components:
• The background section sets out the factual 
predicates for the license, including the 
names of the parties, the effective date of 
the agreement, and the parties’ motivations 
and expectations. 
• The definitions section explains key terms 
used in the agreement. 
• The grant section establishes whether only 
the licensee may practice the invention (an 
exclusive license) or whether others may 
EXECUTIVE GUIDE TO HANDBOOK SECTION 11 
(VOLUME 2: PAGES 991-1152)
Buyers want to get the most for their money; sell-
ers want to get the most for their products. Put 
differently, no one wants to pay more for an item 
than what is necessary. And sellers expect a fair 
price for their products.1 These universal pricing 
concerns apply not just to food, shelter, and any 
other goods and services, but also to intellectual 
property. As a licensee, how much should you pay 
for a license? How much should a licensor charge 
for a license? And what form should payments 
take? Royalties on products sold? Fixed payments 
per year? Equity in a business? Provision of services 
(bartering) or some other form of remuneration? 
And what exactly are you paying or charging for? 
Answers to these questions are always complex. 
The chapters in this section offer some points 
of reference from which to explore these and 
other questions that emerge during IP licensing 
transactions (a license being the transfer of cer-
tain property rights between two or more parties 
under a specified sharing of rights and obligations 
between those parties). These considerations ap-
ply to companies and public sector institutions 
alike. With a license, as distinguished from a sale, 
possession of property does not transfer but re-
mains with the original owner.
Negotiation is one way to establish the terms 
under which a transaction takes place. But nego-
tiation is just one aspect of establishing the terms 
of a specific transaction. Preparation for a nego-
tiation can—or should—require at least ten times 
Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007. 
11: Technology and Product Licensing.In Executive Guide to Intellectual Property Management in Health and Agricultural 
Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), 
Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Avail-
able online at www.ipHandbook.org.
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practice it. This section may stipulate rights 
to sublicense or rights to assign, or it may 
say that there are no such rights.
• The section on fixed payments and royalties 
sets out payment terms of the agreement.
• The confidentiality section specifies provi-
sions for and restrictions on the disclosure 
of information shared between the parties. 
• A section on enforcement against infringers 
specifies which party shoulders the bur-
dens and realizes the benefits of enforcing 
the licensed patent against infringers. This 
enforcement often involves allocating the 
risks and rewards of the overall success of 
the venture. 
• The term of the agreement and termination 
procedures should be fully spelled out. As 
with most licenses, the biotechnology li-
cense will often have a term that coincides 
with the patent term. 
Freeman discusses a series of other points 
that require special attention, including the com-
plexities of confidentiality clauses that are par-
ticularly pertinent when working with academic 
and public sector research institutions. Finally, to 
help make negotiations easier and more realistic, 
the chapter discusses incentives for licensors and 
licensees and considers some of the finer issues of 
developing collaborations. 
Cahoon3 addresses issues related to agri-
cultural biotechnology (agri-biotech) licenses. 
Although these license agreements are similar in 
many ways to other kinds of license agreements, 
agri-biotech license agreements have some unique 
elements. The chapter explores the basic nature 
and purpose of a license agreement, and preferred 
licensing methods and terms are suggested. The 
chapter then turns to the complex—but highly 
important—singularities of agri-biotech licenses, 
focusing on such issues as multiple property types 
that cover a single technology and/or product, 
freedom-to-operate issues that may drive anti-
royalty-stacking provisions, philanthropic and 
humanitarian-use clauses, and stewardship obli-
gations. The chapter emphasizes the uniqueness of 
agri-biotech licenses in regard to the concept of field 
of use, which may be broadly or narrowly defined. 
The complex and rapidly evolving nature of 
agri-biotechnology requires (at the moment) that 
each license agreement be tailored to the particu-
lar context in which the invention will be used. 
Still, such licenses do not have to be invented 
from the beginning, and Cahoon’s chapter elu-
cidates both the common and unique aspects of 
agri-biotech licensing. For practical purposes, 
any organization engaged in high-volume licens-
ing will find it useful to develop its own internal 
template agreements4 that are then modified and 
adapted to suit each special circumstance.
In addition to the more generic licensing 
aspects, this section of the Handbook contains 
a series of chapters that review more specific IP 
licensing strategies. The in-licensing and out-li-
censing of plant varieties are the two sides to the 
licensing equation. In-licensing of plant varieties 
can increase market share, building a competi-
tive advantage by providing for customer needs. 
In-licensing varieties also enhances or completes 
a company’s variety portfolio, both for in-house 
breeding programs (facilitating access to breed-
ing materials) and for in-licensed varieties ready 
for commercial distribution. The most common 
reason for out-licensing varieties is for a com-
pany to maximize return on investment by al-
lowing others to produce and sell varieties in 
markets that cannot be reached satisfactorily 
through the current marketing setup.
Importantly, the licensing of varieties is in-
creasingly becoming more important for pub-
lic sector breeding institutions. These are often 
funded, at least in part, by governments, and so 
they have a fundamental mission of serving the 
public interest. The same applies to the Centers 
of the Consultative Groups on International 
Agricultural Research (CGIAR). These institu-
tions are eager to ensure that resource-poor farm-
ers have the greatest possible access to value-add-
ed crop varieties. The central question here is how 
can these public sector breeding institutions pro-
vide broad access to improved germplasm? How 
can a combination of plant variety protection 
(PVP) and licensing accelerate the dissemination 
and adoption of improved varieties? 
Private sector licensing expert Nilsson open-
ly addresses plant variety licensing, sharing the 
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experiences and approaches of a private sector en-
tity. Nilsson5 illustrates how plant variety licensing 
is a practical tool that plant breeding companies 
(in the private sector) or institutions (in the pub-
lic sector) use to commercialize or provide access 
to their products (crop varieties). Licensing also 
facilitates technology transfer (where technology 
is defined as know-how, improved germplasm, a 
range of breeding tools, and genes) in a simple 
delivery mechanism:
• the seed as a vehicle for technology transfer
• the seed itself as a commodity-embedding 
technology 
Nilsson provides practical guidance for in-
licensing and out-licensing crop varieties, with 
a special focus on developing countries. Because 
of decreased funding of public sector breeding, 
the seed sector is gradually being served by pri-
vate companies, often small-scale and local en-
terprises. This has created increased demand for 
new varieties, and seed companies are seeking to 
in-licence varieties while private sector breeders 
may desire to out-license their varieties. Capacity 
for negotiating and executing license agreements, 
therefore, is becoming all the more critical. In an 
organized, detailed, and understandable fashion, 
Nilsson’s chapter presents the fundamentals of 
seed licensing, emphasizing how the licensee and 
the licensor should focus on the practical content 
of a license agreement: exclusivity to plant mate-
rial and territory, plant variety protection, variety 
trials, national registration, royalty payments, and 
information transfer. 
The best licenses are those that recognize 
that relationships—like markets—are not static. 
An agreement should thus include sufficient flex-
ibility for evolution. The agreement should reflect 
changes in the market, competitors, technology, 
seed legislation, and PVP laws. Enabling such 
flexibilities is perhaps the greatest art in drafting 
and negotiating variety licensing agreements. 
Overall, the successful licensing of varieties is 
contingent on the strength of PVP legislation. A 
PVP framework generally supports the interests 
of the variety owner and the farmer, facilitates the 
transfer of technology, and provides incentives for 
further investments in the development of new 
plant varieties. In many countries, PVP legislation 
is based on the Convention of the International 
Union for the Protection of New Varieties of 
Plants (UPOV). The relevance of UPOV in ac-
celerating access to improved varieties is its har-
monization and documentation of a PVP aspect 
that facilitates licensing by foreign seed compa-
nies and public sector institutions alike. 
Due to numerous complexities in terms of 
geographical, cultural, and paradigmatic distanc-
es, prospective licensors and licensees frequently 
spend a lot of time becoming acquainted and 
developing a certain level of trust. Over time, 
they reach a point where they are speaking the 
same language of contracts and licenses, and 
they reach a satisfying agreement. This lengthy 
process, however, can deter or derail licensing 
efforts. Companies may not wish to invest such 
time and energy, because even commercial li-
censes with entities in the developing world sim-
ply take up too much valuable management time 
and resources; the necessary funds for extended 
and repeated face-to-face meetings are simply 
unavailable.
A complementary approach is therefore 
needed—a way to bridge this communication gap 
and more rapidly arrive at a common language. 
Modern computer and Web technology might 
provide an answer. The chapter by Krattiger, 
Dodds, and Bobrowicz6 examines the potential of 
a software decision tree linked to template con-
tract language that allows individually custom-
ized contract documents to be generated and that 
could ameliorate many of the aforementioned 
problems. Provided that some key players agree to 
the basic template, an appropriate software pack-
age could improve opportunities for assembling 
a greater array of potential partners. A test ver-
sion of such a computer-generated contract tem-
plate (CoGenCo) system has been developed and 
could be a pragmatic step toward increased licens-
ing of proprietary and finished varieties that may 
or may not incorporate proprietary technologies 
for input or output traits. The CoGenCo system 
is aimed at establishing a certain international 
standard license, that is, a standard that all under-
stand and agree on. In this way, a meeting of the 
minds is facilitated and accelerated. A standard 
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license can be downloaded for free from the on-
line version of the Handbook.7
The approach of CoGenCo is to facilitate the 
awarding of out-licenses of germplasm to devel-
oping country institutions, including by and for 
the CGIAR and national programs. Under the 
legally binding terms of CoGenCo-generated li-
cense agreements, several entities in a given coun-
try could compete against one another on price 
in poor countries but would not be allowed to 
compete against the patent holder in developed 
countries, in which revenues and the incentives 
for developing new varieties and new technolo-
gies would be undiminished. Under appropriate 
circumstances, the germplasm and/or traits could 
be licensed royalty free. Use of out-licensing in 
this way separates these fundamentally different 
markets and promotes access to improved germ-
plasm and technologies, all by reaffirming various 
statutory protections as indispensable for success-
ful agricultural research and development. 
Moving on to other forms of IP licensing, the 
licensing of trade secrets presents an entirely dif-
ferent set of challenges. A trade secret (also called 
know-how in certain jurisdictions) is any pro-
prietary technical or business information, often 
embodied in inventions, know-how, show-how, 
and tacit knowledge. The most common defini-
tions agree on three requirements that should be 
met for enforceable trade secrets to exist. The pro-
prietary information should be: 
1. Secret in the sense that it is not generally 
known in the trade
2. Valuable to competitors that do not possess 
the information
3. The subject of reasonable efforts to safeguard 
and maintain the information in secrecy
Everyone knows that trade secrets are secret. 
Patents, on the other hand, require inventions to 
be publicly disclosed. But does this mean that 
these two forms of IP protection cannot be used 
together? The chapter by Jorda8 argues emphati-
cally that trade secrets are complementary to pat-
ents. By using both trade secrets and patents, the 
combined IP protection is stronger than if either 
one were used alone. But how is it possible to use 
both patents (which are publicly disclosed) and 
trade secrets (which are kept secret) to protect 
something? In practice, there is no conflict be-
tween the two. Patent applications are usually filed 
early during the research stage to get the earliest 
possible filing or priority date. The patent claims 
tend to be narrow to achieve distance from prior 
art, and the specification normally describes ru-
dimentary laboratory experiments or prototypes 
and/or embryonic embodiments of an invention. 
The best mode for commercial manufacture and 
use are almost invariably developed later. The re-
sults of such later research need not be disclosed 
to obtain the patent on the early invention and 
can be kept as trade secrets.
As a practical matter, therefore, patent li-
censes are most valuable when coupled with 
access to associated know-how. A patent li-
cense alone is often inadequate for commercial 
development of a technology. This associated 
know-how is immensely important and should 
be part of licensing agreements; effective tech-
nology transfer requires not only patent licens-
ing but also, and perhaps more importantly, 
trade secret licensing.9
Anyone engaged in product development, 
including developing countries in particular, will 
want to keep in mind that trade secret protection 
operates without delay and without undue cost. 
Patents, on the other hand, are territorial and 
thus expensive to obtain and maintain, and they 
can be acquired only in certain countries. 
When considering the forms of IP protection 
available for plants, what usually comes to mind 
are PVP and utility patents. But as the chapter 
by Tucker and Ross10 points out, trademarks are 
an effective form of IP protection for plants and 
plant products, either used alone or in combina-
tion with one or more other forms of IP rights 
protection. Furthermore, trademarks can be used 
to effectively protect IP rights for plant varieties 
internationally. Similarly, the value of trademarks 
for varieties and products from developing coun-
tries can be tremendous. The relative strength of 
trademarks is determined by how distinctive the 
mark is. When consumers see the trademark, they 
are able to easily distinguish the goods or services 
of the trademark owner from the related goods or 
services of competitors. 
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Two international agreements, the Madrid 
Arrangement and the Madrid Protocol govern 
international trademark registration. For plant 
trademarks, understanding and utilizing these 
provisions will become increasingly important to 
developing countries. Many tropical and subtrop-
ical regions are rich sources of novel fruit prod-
ucts, and an owner of such a product will want 
to adopt a strategy that both stimulates global de-
mand for the product and maximizes commercial 
returns. Trademarks will be integral for such IP 
rights protection and global marketing strategies. 
In particular, three critical aspects should be con-
sidered if new branded fruit products are to be 
successfully launched from developing countries:
1.  Determine what is to be trademarked.
2.  Promptly register the trademark in the 
countries in which it will be used.
3.  Enforce the trademark.
A successful global trademark program, built 
around exciting products, may be more achiev-
able than a PVP-based strategy that relies only 
on licensing for returns. Instead of managers and 
lawyers securing licensing deals, the market itself 
can fuel value creation in the trademark. If suc-
cessful, the returns can be tremendous.
Shifting topics once again, a very important 
and quite difficult aspect (especially for public sec-
tor entities) is the granting of options and rights 
of first refusal. As either a stand-alone agreement 
or as a clause within a broader agreement, options 
are a unique way of granting rights to intellectual 
property. The chapter by Anderson and Keevey-
Kothari11 provides a detailed discussion of the 
various forms of options, with tips and strategies, 
sample causes, and template agreements. The 
chapter delves deep into the legal and commer-
cial promises and perils of granting options and 
concludes with a helpful section on administer-
ing options.12 
Of special interest to university administra-
tors and technology transfer professionals will be 
the sections on incorporating options as a part of 
research agreements. Universities in the United 
Kingdom and the United States have different 
approaches to handling privately sponsored re-
search. In the United Kingdom, sponsors are often 
granted an option to acquire a license to develop 
and commercialize results, or the sponsor might 
in some cases own all the results. In contrast, a 
university in the United States normally retains 
ownership of any intellectual property resulting 
from its own research, though the university may 
grant rights to a sponsor to commercialize results. 
This emphasis on university control of research in 
the United States stems, in part, from provisions 
in the Bayh-Dole Act that prohibit universities 
from transferring ownership of intellectual prop-
erty created from government-funded research.
Also instructive to university personnel will 
be the chapter’s discussion of where and when 
not to grant a pipeline agreement to a university 
spinout company. A pipeline agreement gener-
ally refers to an option granted to a university 
spinout company to acquire rights over intellec-
tual property that may, in the future, be gener-
ated by university faculty. Although a pipeline 
agreement may make sense, universities should 
be careful to stipulate how pipeline intellectual 
property will be identified. They will likely want 
to limit the agreement to intellectual property 
generated by specific faculty members and their 
labs. Universities should also recognize that in 
some cases spinouts may not be the licensee of 
choice and should therefore craft pipeline agree-
ments with care.
Licensing is about choices, and it can be ar-
gued that no choice is more important than the 
field of use granted in a license. When licensing 
complex technologies, the licensor usually can 
partition patent rights based on time (duration 
of license grant), location (where rights may be 
practiced), and field of use. Shotwell13 explains 
and clarifies the last of these three considerations. 
By partitioning a bundle of patent rights and dis-
tributing them to one or more licensees, field-of-
use licensing maximizes value, optimizes delivery, 
and facilitates the most effective use of new tech-
nologies, whether in agriculture, biotechnology, 
pharmaceuticals, vaccines, or diagnostics. 
With field-of-use licensing, the licensor gains 
greater control while maximizing the use and 
value of the technology. However, field-of-use 
licensing requires more work. The technology li-
censor should identify, motivate, negotiate with, 
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and manage more than one licensee—and quite 
possibly many. Nonetheless, this hard work can 
increase royalty streams to the licensor, since mul-
tiple licensees, each with different and specialized 
access to the technology, can efficiently speed dif-
ferent types of products to market. 
When using field-of-use licensing, a licensor 
should be flexible. For example, even if a licen-
sor envisions only one possible field of use for 
an invention, it makes sense to specifically limit 
a licensee to just that field. This is because tech-
nology changes so rapidly that a new use for the 
invention has a very good chance of developing 
later during the life of the patent. By limiting li-
censees to a particular field, a licensor retains the 
ability to work with the best possible licensee(s) 
for a new use when it arises. 
Shotwell recommends that the licensor retain 
control over patent prosecution, while seeking to 
fairly distribute costs over field-of-use licensees. 
When considering reimbursement, the field-of-
use licensor should manage patent expenses cre-
atively. For example, the licensor can cover patent 
expenses up front, later reimbursing them from 
the royalty stream, or, if costs are to be reimbursed 
by the licensees, language can be used to include 
future licensees in that reimbursement.
One of the complexities of field-of-use li-
censing is that it raises the important question 
of how to deal with patent infringement/inter-
ference problems with multiple licensees. As 
with patent costs, the simplest approach is for 
the licensor to carry interference and infringe-
ment costs alone, recovering them through roy-
alties or settlements. This approach retains more 
control for the licensor and correspondingly less 
for the licensees. Another approach to address 
possible infringement and interference actions 
would be to work out a mechanism to share the 
costs and management of these activities with 
one or more licensees.
Possible problems with field-of-use licensing 
include rights that overlap across licenses. This 
can arise from different interpretations of the 
rights granted under licenses or from unexpected 
future technical developments. It is therefore 
wise to lay the groundwork for resolving disputes 
related to these types of potential issues. 
Licenses that include royalty stacking and 
royalty packing clauses are becoming more 
ubiquitous because virtually all products de-
veloped now using biotechnology, genetic en-
gineering, and chemistry are technologically 
complex and incorporate many different inputs. 
As if this were not enough, there is also the 
added consideration of relevant IP rights, held 
by third parties that may be attached to these 
many inputs. For example, a vaccine might be 
identified and tested using proprietary research 
tools with IP rights owned by several companies. 
Later, the vaccine might be produced using pat-
ented recombinant techniques and proprietary 
DNA sequences. Transformation vectors might 
be owned by others. Production of the vaccine 
might employ a proprietary cell line. The vac-
cine might be packaged with one or more pro-
prietary adjuvants and then be delivered using 
a patented device. Hence, when the vaccine is 
ultimately “ready for use,” it will likely be sub-
ject to royalty obligations to several different 
companies, or licensors. A dilemma results, as 
the various licenses involved can combine to 
impose aggregate royalty obligations, perhaps 
up to 20%, and sometimes more, of the selling 
price of the product. There will also be separate 
reporting and accounting obligations to each of 
the licensors. Similar problems arise in agricul-
ture when a genetically engineered crop might 
be made using proprietary varieties, vectors, 
gene sequences, and research tools—each with 
IP rights owned by different entities.
Jones, Whitham, and Handler14 discuss two 
scenarios that can arise when multiple royalty 
rates are attached to one product—royalty stack-
ing and royalty packing: 
• Royalty Stacking. A biotechnological prod-
uct might have multiple patents attached, 
and thus require multiple licenses in order 
to make, use, or sell the product. 
• Royalty Packing. With some biotechnolo-
gies, it usually is necessary to combine 
one technology with many other tech-
nologies. (In this situation, the royal-
ties imposed on each of the proprietary 
products that are administered will be 
“packed” together.)
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The chapter then presents several techniques 
for managing royalty stacking and packing:
• Royalty Ceiling. A licensee may seek a ceil-
ing for royalties in agreements it makes 
with licensors. 
• Royalty Floor. A licensor may seek a floor 
below which its share of the royalties may 
not be reduced. 
• Variable Royalties. Licensees and licensors 
also might agree to have variable royalties 
that are conditioned on the importance of 
the technology in relation to the creation of 
the product. 
• Royalty Alternatives. Finally, alternatives to 
royalty bearing arrangements can also be 
considered; these include lump-sum pay-
ments and patent pooling. 
The last point shows that managing royalty 
stacking and packing does not necessarily require 
royalty streams. For example, a lump-sum pay-
ment for the use of a research tool may be an op-
timal way to disseminate and exploit a patented 
technology. Some technologies may be best as-
sembled in patent pools that provide either free 
use of or fixed-price access to the technologies. 
Patent pools can thereby facilitate R&D using a 
variety of proprietary technologies without the 
need to negotiate licenses.
As all of the above chapters make clear, in our 
post-TRIPS environment, leaders in developing 
countries who seek to improve economic devel-
opment and public health are advised to be well-
versed in the details of global IP management. 
Unlike the past, today no country can comfort-
ably remain isolated from the global IP system. 
Yet among many public sector institutions in 
developing countries, knowledge of IP licens-
ing practices is often insufficient. To address this 
gap in expertise, the chapter by Satyanarayana15 
lays out several of the important features of in-
licensing agreements, common problems faced 
by developing countries in constructing and im-
plementing these agreements, and ways to avoid 
these common pitfalls.
In-licensing by public sector institutions is a 
useful, if complex, method for bringing technolo-
gies into the public sector through patent license 
agreements with the private sector. Although the 
interests of the private and public sector entities 
involved in these agreements will almost neces-
sarily be in tension, it is possible for a well-crafted 
license to allow all parties to feel as though they 
have benefited from the agreement. From a pub-
lic sector perspective, as Satyanarayana argues, 
the goal is ultimately to provide a product (be it a 
vaccine, drug, or new agricultural crop) to people 
who would not have access to it without govern-
ment support. For developing countries, the good 
news is that legal expertise is often locally avail-
able, since many firms are already familiar with 
basic licensing procedures. The trick is to put 
this knowledge in the service of public officials 
to develop a comprehensive and effective plan to 
license and develop much-needed-technologies. 
These strategies include:
• developing a business strategy that balanc-
es the needs of the public sector with the 
needs of the private sector
• developing a marketing strategy that prices 
products realistically and is based on good 
market research to aid valuation
• forming partnerships with other suitable 
agencies to help manufacture and market 
new products
• making sure legal, business, and scientific 
experts are working together for optimal 
success
• establishing, as an important initial step, a 
national technology transfer office
The final chapter by Bobrowicz16 offers a 
useful checklist for negotiating licensing agree-
ments. For the seasoned technology transfer 
professional or contract attorney, the idea of 
preparing a detailed checklist for every licensing 
agreement may seem like unnecessary busy-work. 
Yet these same professionals could probably re-
late stories where a missed detail or vague con-
tract provision led to a costly and protracted legal 
battle. Given the high stakes, it is certainly in the 
best interest of those involved in IP deal making 
to make sure that every last detail is checked and 
rechecked. When multiple deals are being ne-
gotiated at once, it is only reasonable to assume 
that something could get missed. To help avoid 
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this unfortunate and potentially costly error, this 
chapter provides a comprehensive, yet flexible, 
checklist that can be deployed to help manage 
the details of license agreements. Although the 
author provides a template for most elements of 
the license, she is quick to note that users should 
feel free to alter the checklist to suit their particu-
lar business practices. 
The checklist covers all the major elements 
of a standard IP license, particularly as used in 
agriculture, starting with a section detailing the 
most basic, yet crucial, matter of getting all the 
parties’ pertinent contact information. Sections 
covering clauses, definitions, rights granted, sub-
licenses, improvements, warranties, and infringe-
ment, and other matters are discussed, with useful 
sample checklists included for each component. 
The chapter concludes with a consideration of 
boilerplate sections, including confidentiality and 
arbitration stipulations. Although each section is 
annotated, an online version can be downloaded 
without accompanying text. 
In sum, licensing is about the development of 
relationships. As important as the terms of agree-
ments are, few are more important than the long-
term opportunities offered by forging good partner-
ships, be they between companies or between public 
and private sector entities. Negotiating an agreement 
is just the beginning of what may—or should— 
become a long-lasting and beneficial relationship. ■
All chapters refer to: Intellectual Property Management in 
Health and Agricultural Innovation: A Handbook of Best 
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thom-
son, AB Bennett, K Satyanarayana, GD Graff, C Fernandez, 
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis, 
U.S.A. Available online at www.ipHandbook.org. The online 
version contains for each chapter a detailed Editor’s Sum-
mary, Implications, and Best Practices.
1 In an ideal world, exchanges would take place based 
on “fair” and “equitable” pricing, in both the eyes of 
the seller and buyer. But equitable exchanges are at 
least in part based on perceived moral obligations 
that are difficult to capture in financial and market 
terms. Such nonmonetary and moral perceptions, 
often strongly personal-, cultural-, and even religion-
based, are important, but there is no system, at least 
for the moment, for weighing different perspectives 
on morality or ethical grounds or for translating them 
and making them work in the marketplace. To be sure, 
it can be satisfying to the buyer and seller when each 
perceives a transaction to have been equitable. And 
we need to strive for better balance in an inequitable 
world. But how much is owed to whom and for what 
and how to achieve general satisfaction has surely 
eluded our modern society (and, indeed, has eluded 
societies for centuries, if not millennia). We can all 
support equity, or at least pay lip-service to it, but 
it is far more difficult to determine what equitable 
transactions, in fact, consist of.
2 Chapter 11.1 by JW Freeman titled Licensing 
Biotechnology Inventions, p. 991.
3 Chapter 11.2 by RS Cahoon titled Licensing Agreements 
in Agricultural Biotechnology, p. 1009.
4 The online version of the Handbook provides a 
large number of template agreements from myriad 
organizations. These templates include confidentiality 
agreements, material transfer agreements, contract 
research agreements, collaborative research 
agreements, and a range of licensing agreements.
5 Chapter 11.3 by M Nilsson titled The In- and Out-
Licensing of Plant Varieties, p. 1017.
6 Chapter 11.4 by A Krattiger, J Dodds, and D Bobrowicz 
titled Potential Use of a Computer-Generated Contract 
Template System (CoGenCo) to Facilitate Licensing of 
Traits and Varieties, p. 1029.
7  www.ipHandbook.org. 
8 Chapter 11.5 by KF Jorda titled Trade Secrets and Trade-
Secret Licensing, p. 1043.
9 This is perhaps the principal reason why (1) most 
issued patents are not practiced in developed countries 
although their information is freely available on 
the Internet and (2) why compulsory licensing has 
tremendous limitations.
10 Chapter 11.6 by WT Tucker and GS Ross titled Use of 
Trademarks in a Plant-Licensing Program, p. 1059.
11 Chapter 11.7 by M Anderson and S Keevey-Kothari titled 
Commercialization Agreements: Practical Guidelines in 
Dealing with Options, p. 1069.
12 These include practical suggestions for keeping 
track of options, including tips for writing standard 
operating procedures (SOP), generating nondisclosure 
agreements, developing a useful database for data, and 
if and when necessary, calling in legal professionals for 
more-specialized advice. 
13 Chapter 11.8 by SL Shotwell titled Field-of-Use Licensing, 
p. 1113.
14 Chapter 11.9 by KJ Jones, ME Whitham and PS Handler 
titled Problems with Royalty Rates, Royalty Stacking, 
and Royalty Packing Issues, p. 1121.
15 Chapter 11.10 by K Satyanarayana titled In-Licensing 
Strategies by Public-Sector Institutions in Developing 
Countries, p. 1127.
16 Chapter 11.11 by D Bobrowicz titled A Checklist for 
Negotiating License Agreements, p. 1133.
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
FOR GOVERNMENT POLICYMAKERS
4	 licensing is highly context specific. For this reason, blanket policies on minimum 
requirements for licensing terms applicable to public sector institutions can discourage 
creative and beneficial deals and reduce the potential for national institutions to forge 
international linkages. 
4	 Notwithstanding the above, public sector institutions should, as a matter of policy, 
consider the routine incorporation of philanthropic use provisions in their licenses and 
should always retain research and teaching rights to any of their inventions.
4	 The dual goals of economic growth and social/humanitarian benefits through licensing 
are not mutually exclusive. Indeed, they are often complementary.
4	 Companies regularly license their own varieties to third parties as a strategy to maximize 
returns on investment and reach markets that the company itself cannot easily reach. 
Conceptually at least, public sector plant breeding institutions have much to gain from 
variety licensing as a strategy of serving markets they do not typically reach.
4	 Overall, the successful licensing of varieties between and among public and private sectors 
is contingent on the strength of plant variety protection legislation. Such legislation 
can support the interests of the variety owner and the farmer, facilitates the transfer of 
technology, and provides incentives for further investments.
4	 Recognizing that patent applications are usually filed early in the research stage and 
require full disclosure, companies typically keep inventions developed later on as trade 
secrets. These may include the best mode for commercial manufacture. Patent licenses 
are most valuable when coupled with access to associated know-how. Comprehensive and 
enforceable trade secret laws are thus conducive to the transfer of know-how through 
licensing. The two, disclosed patents and protected secrets, are thus complementary.
4	 Using trademarks as a strategy allows public and private institutions to capture more 
added value. To benefit from trademarking strategies, internationally accepted legislation 
is important. Also important is the maintenance of high quality standards and stewardship, 
since trademarks (and geographical indications) provide the consumer with information 
on the source of the products. 
4	 Although IP rights are governed by national statutory protection, contract law is arguably 
even more important than statutory protection law, as contracts allow institutions to 
exchange intellectual property in an orderly and predictable manner. 
4	 Along with investing in a country’s R&D infrastructure and capacity, it is important to 
sustain long-term growth. human and institutional capacity in iP management adds 
value to r&D efforts. In- and out-licensing in particular enhance an institution’s economic 
and social impact. Among a government’s top priorities should be providing support to 
public sector institutions for establishing and operating effective technology transfer 
offices, coupled with training programs for creating capacity commensurate with the 
complexities of modern biotechnological products. Ideally, these capacities should reside 
at the institution level because of the context-specific nature of licensing.
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 licensing is highly context-specific. For this reason, blanket policies on minimum 
requirements for licensing terms applicable to your technology transfer office can 
be counterproductive to making sound deals and can reduce the potential to forge 
international linkages. 
4	 Public sector institutions should, as a matter of policy, consider the routine incorporation 
of philanthropic-use provisions in their licenses and should, as a matter of routine, 
always retain research and teaching rights to any of their inventions.
4	 The dual goals of economic growth and social/humanitarian benefits through licensing 
are not mutually exclusive. Indeed, they are often complementary. Much will depend 
on a sound institutional licensing strategy and on good relationships with licensees.
4	 The value of trademarks for both varieties and products, from developed and developing 
countries alike, cannot be understated. To benefit from trademarking strategies, 
particularly of global reach, the maintenance of high quality standards is important, 
since they provide the consumer with information on the source of the products. In 
addition, using trademarks as a strategy allows public and private sector institutions 
alike to capture more of any added value.
4	 Licensing is about choices, and it can be argued that no choice is more important than 
the field of use granted in a license. A public sector institution should have a clear policy 
statement on how it deals with field-of-use licensing and may even wish to consider 
making field-of-use licenses the preferred method of licensing. This is especially 
applicable to platform technologies and diagnostics. However, field-of-use licensing 
requires more work. A well-trained and well-staffed technology transfer office will be 
essential.
4	 A public sector institution can contribute significantly to its mission through in-licensing 
intellectual property from private sector entities. For this, it is useful to develop a set 
of strategies (business, marketing, partnership building, and legal) during discussions 
with the licensing office that balance the needs of the public sector with the needs of 
the private sector.
4	 Business decisions, more than legal aspects, should determine licensing terms. 
Nevertheless, lawyers should ensure that the contracts comply with prevailing law. This 
is equally applicable to private sector and public sector deals.
4	 Patent licenses are most valuable when coupled with access to associated know-how. 
Comprehensive staff training in the handling of confidential information from third 
parties is therefore critical. 
4	 But public sector organizations should exercise caution when accepting trade secrets 
(as opposed to confidential information). In some jurisdictions there may be significant 
liability obligations related to trade secrets, and public sector institutions may not be in 
a position to cope with all such obligations. 
FOR SENIOR MANAGEMENT
(UNIVERSITY PRESIDENT, R&D MANAGER, ETC.)
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
FOR SCIENTISTS
4	 Ideally, you will leave detailed aspects of negotiations, such as collaboration or license 
agreements, to the relevant offices of your institutions. However, do participate in 
the internal discussions prior to in- or out-licensing negotiations. Your input will be 
important and should be valued. 
4	 The dual goals of economic growth and social/humanitarian benefits through licensing 
are not mutually exclusive. Indeed, they are often complementary. Much will depend 
on a sound institutional licensing strategy and on good relationships with licensees. 
Your role in the latter may be critical.
4	 Make an effort to consistently document the origin of biological and other materials 
you use in your research, and keep a comprehensive record. Although it is not your 
responsibility to resolve IP conflicts, your detailed records will help if such a conflict 
arises. 
4	 Interface with the technology transfer office (TTO) in order to understand options 
and whether you might have a role in their implementation or fulfillment. Although 
options are complex and a matter most appropriately addressed by your TTO officers, 
the granting of options may significantly impact your research options. Make sure you 
discuss the implications with them prior to the incorporation of options in licenses 
that relate to your research.
4	 When you disclose an invention to your TTO officers, inform them of any ideas you may 
have on the various fields of endeavor in which your invention could find applicability. 
This will help the TTO write better patent applications and, later to draw up license 
agreements for many different players under different field-of-use licenses. This 
approach can maximize the value of your research and may accelerate commercial and 
humanitarian development of technologies based on your research. 
4	 your role in field-of-use licensing is essential. You can provide your TTO with valuable 
information on licensable components for different applications and entities. 
4	 The products arising from your program’s research efforts, particularly from product 
development activities, will invariably embody numerous technologies, including 
components and processes that might have IP rights from third parties attached to the 
technologies. This can create complex IP management and licensing issues as these 
products approach commercialization. If you are engaged in product development, 
maintain a good line of communication with your tto and ensure that early on they 
address IP ownership by third parties. 
GUIDE TO SECTION 11



























Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
FOR TECHNOLOGY TRANSFER OFFICERS
4	 Besides reflecting the business deal that has been made, few components are more 
important in a license than clear and unambiguous definitions. 
4	 For practical purposes, any organization engaged in high-volume licensing will find it 
useful to develop its own internal template agreements that are then modified and 
adapted to suit each special circumstance. checklists for different types of recurring 
licensing negotiations should be reviewed prior to and during negotiations. 
4	 Recognize that relationships—like markets—are not static. Any provision in an 
agreement must, of course, be adhered to, but the practice of including sufficient 
flexibility in licensing agreements can be a valuable strategy in forging strong 
partnerships.
4	 The granting of options (rights of first refusal, pipeline agreements, and so forth) 
can be a rather controversial aspect for public sector licensing. But options can be 
tremendously powerful in forging strong and lasting relationships and in optimizing 
your institution’s economic returns and humanitarian effects. 
4	 field-of-use licensing should be adopted as the preferred method of licensing 
whenever possible. It allows you to gain greater control while maximizing the use and 
value of your licensed technology. But be flexible and study the licensee’s motivations 
and business model carefully as a way of conferring the highest possible incentives. 
Always strive to retain control over patent prosecution and infringement actions when 
adopting a field-of-use licensing strategy. 
4	 Familiarize yourself with the various ways to deal with royalty stacking and royalty 
packing issues as a way of balancing risks and returns. The choice will depend on how 
far downstream into product development your institution stays involved.
4	 Negotiating about low-probability events can sidetrack progress toward agreement 
on core issues, so care should be taken during the negotiation to attend to issues in a 
manner commensurate with their strategic importance. It is often best to focus on the 
overall deal before entering into discussions about specifics.
4	 In a license agreement, the rights to sublicense and assign a license ought to be 
explicitly articulated.
4	 In research collaborations, in which employees of two or more entities share ideas and 
information, confidentiality provisions are important. Make sure the scientists in your 
institution understand these obligations and rights.
4	 Licensee agreements are contracts. Hence, a practical understanding of contract law will 
be fundamental to negotiating and drafting good license agreements. Many smaller 
TTOs use outside counsel to ensure that agreements are compliant with national law.
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• In general, the public sector organization 
should consider offering the first draft of a 
licensing agreement (the draft needs to cov-
er a number of topics of particular concern 
to public sector organizations that would 
probably not be addressed by a company).
• The use of a term sheet that lists the major 
issues expected to arise in the negotiations 
should be shared ahead of time indicat-
ing the outcome that the proposing party 
hopes to achieve. Such a sheet could also 
include the needs and wants (in other words, 
the must-have terms and the desired ones) 
of each party.
Furthermore, says Mahoney, negotiating 
such agreements requires talent, expertise, and 
sound tactics that cover the following areas: 
• business strategy. The business strategist is 
usually the lead negotiator with considerable 
experience in structuring business relation-
ships, assembling the inputs of other experts, 
and maximizing the benefits to all parties. 
• marketing. Market analysis is essential to 
negotiating a good agreement. Failure to 
carry out such an analysis is dangerous be-
cause it can lead either to overestimation 
or underestimation of the market potential, 
which, in turn, can lead to a suboptimal 
agreement or rejection of an agreement 
that could have been successful. 
EXECUTIVE GUIDE TO HANDBOOK SECTION 12
(VOLUME 1: PAGES 1155-1250)
A licensing agreement establishes, in written form, 
the rules of an ongoing relationship, the success 
of which will depend on many factors. Mutual 
trust is one of the factors. Another is the develop-
ment of a certain dependence based on the value 
that is being transferred between the parties. As 
Mahoney1 explains, one party may have a prod-
uct that can potentially have a very large market, 
while the other party has research, manufactur-
ing, or distribution capabilities essential to reach-
ing that market. The key to successful negotiation 
is having a clear understanding of the value each 
party brings to the relationship. But value is mul-
tifaceted. There is an objective value, represented 
by, for example, how many units can be sold at 
a certain price yielding a certain level of profit. 
There are also qualitative values, for example, the 
additional value assumed to exist when one com-
pany feels that a particular product, owned by a 
second company, would enhance or complete a 
particular product line. 
Perhaps the most important element in 
a negotiation is to be clear—internally and 
in discussions with the negotiating partner—
about the benefits that will or could be realized 
through a license agreement. Only with a clear 
understanding of the transfer of value can both 
parties intelligently and fairly negotiate an agree-
ment. Mahoney discusses this along with numer-
ous suggestions for successful licensing negotia-
tions, including the following:
Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007. 
12: Dealmaking and Marketing Technology to Product-Development Partners. In Executive Guide to Intellectual Property 
Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). 
MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-
International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for 
noncommercial purposes is permitted and encouraged.
Dealmaking and Marketing Technology 
to Product-Development Partners
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• legal inputs. A lawyer should be retained at 
least to review agreements and, more appro-
priately, to be part of the negotiating team 
and possess intellectual property (IP) exper-
tise and valuation skills, understand knowl-
edge of freedom to operate issues, and be 
able to access country-specific legal advice.
• scientific and regulatory. A negotiating 
team must have scientific expertise and 
detailed knowledge about regulatory issues, 
product safety, and related matters
• production. Staff members who can contrib-
ute their knowledge about required produc-
tion equipment and good manufacturing 
processes as well as their understanding of 
time lines, cost implications of various man-
ufacturing processes, and so forth should be 
involved in the licensing negotiation.
• finance. A careful financial assessment of 
the project is essential, even before nego-
tiations. The assessment often can help the 
business strategist determine options for 
approaching a deal, to decide which new 
funds will be required to launch and sus-
tain the project, and so forth.
In addition, Mahoney illustrates specific best 
practices for public sector entities to meet public 
sector goals. These are summarized in Table 1 and 
serve as guidelines for public sector organizations 
striving to widen and improve access to innova-
tion through various licensing strategies. Price is 
probably the most difficult area for a licensor to 
get involved in.
Up to this point we have dealt with the over-
all strategies and best practices used to meet pub-
lic sector goals. The chapter by Mongeon3 pro-
vides a broad overview of marketing tactics as a 
way of understanding what buyers need and how 
to meet those needs. In essence, he invites the 
reader to think of marketing not as simply a way 
to push technologies into the market rather than a 
way of allowing the needs of buyers to pull them 
in. Indeed, marketing is not merely advertising 
or selling. Rather, marketing is a multistage pro-
cess: first, the essential characteristics or benefits 
of a technology must be quantified; next, people 
who would find these characteristics or benefits 
desirable and therefore be willing to pay for them 
must be identified; and finally, the benefits of the 
technology must be communicated clearly and 
compellingly to those potential users. Mongeon 
offers five basic marketing questions that would-
be licensors will need to address:
1. Who will buy the technology? Will the pur-
chasers be producers or consumers? 
2. What does the buyer of the technology 
want? What characteristics, qualities, or ca-
pabilities of the technology are valuable to 
the buyer, and how valuable are they? 
3. Why would a party choose to license or 
purchase a technology? What is particularly 
compelling about it? 
4. Where are potential users of the technology 
located? In which markets? Through which 
channels can they be reached? 
5. When can you sell the technology to buy-
ers? Is the technology so new that the mar-
ket is not yet receptive to it? 
The answers to these questions should guide 
a marketing plan and be supported through mar-
ket research. Such research may even reveal that a 
technology can be used in a completely new and 
unexpected way in a previously unanticipated 
market. Perhaps the most important advice this 
chapter has to offer scientists and technology 
managers is that the “unique selling proposition” 
of a technology—that is, the features, advantages, 
or benefits that it offers the user—is rarely the 
science behind the technology. Good marketing 
makes a technology understandable and attrac-
tive to buyers, then allows their demand to draw 
the technology into the market.
But how does one “find” potential licensees? 
And how should one approach them? Marketing 
workshops tend to suggest a haphazard mix of 
different tools and strategies that may or may not 
work. For these reasons, MacWright and Ritter4 
offer a detailed and systematic approach to tech-
nology marketing (which is different from prod-
uct marketing). The chapter contains many mod-
els for establishing contacts and prioritizing these 
according to specific criteria, as well as numerous 
worksheets that will help plan for different mar-
keting approaches.  
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Table 1: Illustrations of Best Practices for Licensing to Meet Public Sector Goals
Topic Basic concept Public sector consideration
Areas 
of use
Specifies limitations on the 
application of the patent in 
developing products; simplest 
approach: grant an exclusive 
right to all applications, includ-
ing not only those specified in 
the patent, but others that may 
emerge as further research and 
development proceeds.
The clause could grant an exclusive license only for 
those products that the licensor actually wishes to 
pursue. Also, the clause could grant an exclusive 
license only for those products that were unlikely 
to have a significant market among the poor in 
developing countries.
Territory Specifies the geographic areas 
in which the licensee has the 
right to exercise a patent; 
simplest approach: grant a 
worldwide exclusive license. 
(A license is valid only in the 
countries where a patent has 
been issued, but rights can be 
granted, at licensee’s expense, 
to file for patent protection in 
additional countries.)
The clause could grant an exclusive right to a set of 
developed countries and another exclusive license 
to other developed countries. Both licensees, and 
perhaps a third one, could receive nonexclusive 
licenses for an agreed list of developing countries. 
Then the two (or more) licensees would have to 
compete for sales to developing countries.
Price In most licensing agreements, 
there will be no conditions 
with respect to price. The li-
censor assumes that the li-
censee will determine the 
best price to ensure the great-
est return on investment.
•   The price could be specified. This is feasible when 
the licensor has detailed technical knowledge of 
the production, marketing, and distribution costs. 
•    The price could be set as cost plus (cost of production 
plus a reasonable markup, say 15%). This is feasible 
when the licensor has a reasonable expectation of 
being able to monitor the cost of production.
•   The price could be set at “no higher than the low-
est price offered to any private sector buyer.” This 
may be preferred when there are large bulk pur-
chases by private sector buyers who are good at 
negotiating the very best price.
Labeling In most licensing agreements, 
there will be no conditions 
about labeling. The licensor 
assumes the licensee will 
prepare labeling in conformity 
with national drug regulatory 
agency requirements. 
The licensor can help ensure that the product is 
licensed properly, especially in developing countries 
in which national regulatory agency requirements 




This concept has been 
developed by the U.S. National 
Institutes of Health. It calls 
for the licensee to undertake 
some specific actions that 
will benefit the public sector.
This could include a donation of products for clinical 
evaluation in public sector research programs, 
joint efforts to develop markets, free supply under 
specified conditions to developing countries, and so 
on. 
Royalties Usually a licensee will nego-
tiate the highest royalty in 
order to maximize revenue 
from the license.
The licensor can specify that royalties apply to sales 
only in developed countries and zero royalties in 
developing countries. The impact for the licensor 
would normally be minimal. 
Source: Modified from Mahoney2
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In essence, the marketing approach compris-
es four basic steps: 
1. Collect information about the invention 
from the inventors. 
2. Collect information from potential clients.
3. Review and prioritize your prospective cli-
ent list.
4. Make contact with potential clients.
It is relatively easy to sell a finished product, 
such as shoes, and more difficult to sell a technolo-
gy to make better shoes. It is even more difficult to 
sell (or license) the intellectual property for making 
better shoes, especially if the intellectual property 
has not yet been proven in a productive process. 
For this reason, university technology managers in 
particular often find it difficult to license individ-
ual patents. Burdon5 thus argues that universities 
could gain a lot by pursuing a portfolio approach, 
or rather, an integrated intellectual property 
management (IPM) approach that blends sophis-
ticated IP data search-and-analysis techniques with 
continuous product improvement.
At the highest level, an integrated IPM ap-
proach is differentiated into strategic and tactical 
decision-making. Strategic decision-making is a 
broad analysis; tactical decision-making analyzes 
specific products or technologies in a known 
competitive landscape. Each approach to manag-
ing IP portfolios requires different types of tools, 
searches, and analyses, ranging from very broad 
technology scans to very specific patent infringe-
ment or validity searches. Importantly, attention 
should be paid to how data analysis can be inte-
grated with a product innovation process, how to 
identify new opportunities or resolve old prob-
lems (that may also lead to the amendment of 
patent applications). Perhaps the most important 
reason for an IPM approach is that it enhances 
understanding of the processes in which licens-
ees are engaged and how a licensed technology 
would support their endeavors, thus reinforcing 
Mahoney’s earlier points on the importance of in-
tegrating business strategy, marketing, scientific 
and regulatory expertise, and so forth. 
Unfortunately, inventions by universities are 
generally not developed in response to market 
needs, which presents challenges for technology 
transfer offices (TTOs). Keiller6 addresses this 
challenge and stresses the importance of having 
a clear sense of the IP goals and IP strengths of 
one’s own institution. An IP audit7 is a useful 
way to improve an institution’s marketing prow-
ess, because it identifies and classifies an institu-
tion’s intellectual property, whether it is owned, 
licensed, or simply possessed. Unless the technol-
ogies, their IP status, and their respective levels of 
development are known, at least to some extent, 
it will be difficult to persuade others to pursue a 
license deal. Keiller describes a range of market-
ing approaches and shares persuasion techniques. 
In short, marketing packages should be tailored 
to accommodate customers’ needs, the benefits 
of the invention should be emphasized, effective 
time management must be adopted, and above 
all, contacts must be followed up on.
It is important with any IP management ac-
tivity to be clear about the context in which it oc-
curs. For example, dealing with a small company 
will require a fundamentally different approach 
than would be taken with a large one. Dealing 
with an agricultural company will require a dif-
ferent approach than would be taken with a 
pharmaceutical company. Neagley8 describes in-
licensing strategies (and typical terms) as they 
apply to small agri-biotechnology  companies 
that typically depend on strong IP portfolios. 
IP portfolios are the foundation for their R&D, 
encouraging outside investment and making 
product commercialization possible. In-licens-
ing is especially important as it allows a company 
to obtain IP rights without having to invest in 
research. 
Neagley discusses the entire range of provi-
sions in a typical license agreement, including: 
• exclusive versus nonexclusive
• enabling technologies versus traits versus 
plant materials
• rights granted to the licensee (covering such 
topics as sole licenses, coexclusive licenses 
and territoriality)
• compensation due to the licensor 
• liability, diligence terms, and milestones,
• the licensee’s responsibilities vis-à-vis the patent
• license term and termination
• issues of assignability 
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Importantly, compensation may be a combi-
nation of fixed fees, which can be paid up-front 
and/or periodically, and earned royalty fees. Both 
the level and timing of compensation are impor-
tant to the company with respect to its planning 
and budget. In determining what compensation it 
is willing to pay, the company will need to esti-
mate the potential value of the licensed technology 
and assess the potential value of any commercial-
ized products that might be developed under the 
license. But compensation may also take nonmon-
etary forms: stock in the licensee company, an 
exchange of license grants, a cross-license arrange-
ment, or a grant-back to the licensor (grant-back is 
compensation that involves the licensee granting 
the licensor rights to future inventions made by the 
licensee using rights received from the licensor).
Dunn, Lund, and Barbour9 share the ap-
proaches of a multinational agri-biotech com-
pany with emphasis on market and policy factors 
that influence and constrain agricultural com-
panies regarding how to market technologies to 
them, and on what these companies look for in 
terms of license agreements.
Early-stage agricultural technologies, wheth-
er they are genetically modified technologies or 
conventional ones, can be risky because they may 
not have commercial applications or they may 
fail to receive regulatory approval in the neces-
sary markets. Gaining regulatory approval can be 
a slow and costly process. In addition, a low mar-
ginal revenue is made on agricultural inputs, and 
there are only a handful of crop species with suf-
ficient acreage to generate the necessary returns 
to warrant significant investments in regulatory 
clearances. For these reasons, a few large corpo-
rations develop most transgenic technology; only 
they have the necessary capital and can assume 
the high risks involved.
For a university to market its technology suc-
cessfully to a large company, it is useful to have 
good contacts inside the company, someone 
who is willing to accept the risk and “sell” the 
deals internally. Indeed, the value of networking 
cannot be overstated. For any company, though, 
the value of a new technological opportunity is 
determined by the risk involved, the additional 
investments required to develop the technology 
(and the corresponding opportunity costs), and 
the type of technology in question. 
These concepts are further explored by 
Edwards10 who surveyed deals made by biotech-
nology and pharmaceutical companies during the 
last ten or so years and analyzed the types of alli-
ances and their terms. The four characteristics of 
an alliance that generally defines the allocation 
of value of a technology between an originator 
and a commercial partner are: 
• the stage of development of the technology 
• the role retained by the licensor in product 
supply or other ongoing activities 
• the size of the market opportunity 
• the scope of the market granted to the de-
velopment partner
Because biotechnology companies have be-
come highly specialized, it is no longer necessary, 
or even possible, for any one company to be in-
volved in every stage of the R&D process. Up to 
half of the product candidates in pharmaceuti-
cal companies’ R&D pipelines originate from 
elsewhere, and 60 to 80 percent of the leading 
therapeutics on the market were developed or dis-
tributed through some form of alliance.
Edwards shows that universities and research 
institutes are a significant source of early-stage tech-
nology, drug leads, and, occasionally, more mature 
technologies. A biotechnology company with the 
appropriate business model is most likely to find 
early-stage technologies and drug leads attractive. 
Once smaller biotechnology companies have de-
veloped technologies and drugs, they will probably 
need to enter into alliances with larger pharmaceu-
tical companies in order to conduct clinical trials 
on, commercialize, and then market these products. 
A university developing a more mature technology 
might ally itself directly with larger pharmaceuti-
cal companies. Empirical evidence shows that the 
more mature the technology is when an alliance 
agreement is assigned, the more profitable that 
technology is for the technology provider.
Edwards goes on to discuss some of the fun-
damental terms found in biotechnology alliance 
agreements such as fixed fees, reimbursement of 
expenses, development milestones, equity invest-
ments, and royalties, as well as the terms for other, 
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more specialized, types of postcommercialization 
payments.  No matter whether a university wants 
to join a commercialization alliance itself or li-
cense an innovation to a biotechnology company 
that is allied to other companies, it is essential for 
university TTOs to understand and influence the 
terms of the alliance agreements in order to pro-
tect the value of their intellectual property. 
Finally, Shotwell11 integrates the ideas of this 
section in a discussion of a core theme of the 
Handbook: how public sector and nonprofit efforts 
can utilize intellectual property to achieve their 
goals in serving society. To illustrate this impor-
tant point, the chapter focuses on product develop-
ment partnerships (PDPs) and their innovative IP 
strategies. PDPs, in essence, facilitate and acceler-
ate the flow of public and philanthropic investment 
through the innovation pipeline, to a far greater ex-
tent than has been typical of universities alone. 
With a two-pronged approach of product 
specialization and taking advantage of the effi-
ciencies of the larger marketplace for technologies, 
PDPs strategically mobilize intellectual property. 
Investments are made in a new product technol-
ogy to advance it through the stages of develop-
ment. This happens within the overall market-
place through the selective targeting of projects 
based upon their risk–reward profile. Using this 
approach, the measure of “reward” is not returns 
to the organization, but rather the potential im-
pact on social welfare that the new drug or vaccine 
might have. 
There are certain similarities between PDPs 
and biotechnology companies. Both occupy a 
similar niche in the innovation pipeline. Both 
share many IP goals. Both seek to maintain an 
appropriate mix of access and exclusivity to in-
novations, in order to have sufficient freedom to 
operate and sufficient bargaining power to imple-
ment the overall strategy of their organizations. 
There are also similarities between the IP strat-
egies of PDPs and public research institutions. 
Both PDPs and public research institutions use 
intellectual property to entice or leverage private 
investment, enhance access to other intellectual 
property, build partnerships, and cultivate politi-
cal goodwill to advance their missions.
Just as there are several business models used 
by the biotechnology industry, so there are sev-
eral business models used by PDPs. The business 
model that a PDP chooses will depend on the 
technologies it deals with, the stage of develop-
ment of the technologies, and the nature of the 
market. One factor that determines which kind 
of business model a PDP or any other entity will 
adopt will depend on whether or not the product 
being developed is potentially profitable and can 
therefore attract the interest of for-profit compa-
nies. Sound IP strategies and product develop-
ment partnering also will uncover opportunities 
to use new technologies to benefit those who are 
traditionally excluded from markets. ■
All chapters refer to: Intellectual Property Management in 
Health and Agricultural Innovation: A Handbook of Best 
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thom-
son, AB Bennett, K Satyanarayana, GD Graff, C Fernandez, 
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis, 
U.S.A. Available online at www.ipHandbook.org. The online 
version contains for each chapter a detailed Editor’s Sum-
mary, Implications, and Best Practices.
1 Chapter 12.1 by RT Mahoney titled Negotiating an 
Agreement: Skills, Tactics, and Best Practices, p. 1155.
2 Ibid.
3 Chapter 12.2 by MD Mongeon titled An Introduction to 
Marketing Early-Stage Technologies, p. 1165.
4 Chapter 12.3 by RS MacWright and JF Ritter titled 
Technology Marketing, p. 1173.
5 Chapter 12.4 by J Burdon titled IP Portfolio Management: 
Negotiating the Information Labyrinth, p. 1195.
6 Chapter 12.5 by TS Keiller titled The IP Sales Process, p. 1203.
7 See Chapter 5.6 by M Blakeney titled Conducting IP 
Audits, p. 515.
8 Chapter 12.6 by CH Neagley titled Patent Licensing for 
Small Agricultural Biotechnology Companies, p. 1213.
9 Chapter 12.7 by M Dunn, B Lund, and E Barbour titled 
Business Partnerships in Agriculture and Biotechnology 
that Advance Early-State Technology, p. 1221.
10 Chapter 12.8 by MG Edwards titled Biotechnology and 
Pharmaceutical Commercialization Alliances: Their 
Structure and Implications for University Technology 
Transfer Offices, p. 1227.
11 Chapter 12.9 by SL Shotwell titled Product Development 
and IP Strategies for Global Health Product 
Development Partnerships, p. 1247.
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 technology marketing is a process by which owners of a technology create relationships, 
between themselves and potential users that will enable the technology to be 
developed and made widely available, through commercialization, alliances or other 
methods. 
4	 Policies that encourage alliance building between the public and private sector have 
been particularly successful in bringing innovation to market.
4	 Product development partnerships (PDPs) facilitate and accelerate the flow of public 
and philanthropic investment through the innovation pipeline. The ultimate measure 
of success is not maximum profit but maximum social benefit.
4	 In addition to the IP legislative and capacity framework, other determinants of 
innovation need to be addressed by governments to ensure a vibrant and innovative 
technology industry. In agricultural biotechnology in particular, many current regulatory 
approaches and frameworks significantly increase regulatory costs, causing years and 
years of delays. The result often is that only multinational companies can afford to 
introduce new technologies, thus stifling national innovation significantly.
4	 Negotiating between public and private sectors ought not be confrontational and 
should be seen as an opportunity to forge a long-lasting and mutually beneficial 
relationship. Put differently, negotiating a fair licensing agreement should not be seen 
just as a process of “bargaining” toward a win-win outcome. 
4	 For the private sector party, a well-tested and successful approach to negotiating an 
agreement is to offer initial terms that the public sector organization would be willing 
to agree to if it were on the other side of the negotiating table.
4	 negotiation and technology marketing skills are fundamental for successful licensing 
and technology transfer. People working in the public sector need to be well qualified 
and have strong negotiating skills, thereby enabling institutions to take advantage of 
their own R&D efforts and to realize broad public sector and commercial goals. 
4	 Policies and legislation that are beneficial to small biotechnology companies and 
startups, in general, can be instrumental in accelerating the pace of innovation in 
a country, particularly when it comes to commercializing public sector–generated 
inventions. 
FOR GOVERNMENT POLICYMAKERS
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 For private sector companies, the ultimate purpose of IP management is to enhance 
competitiveness and reduce risk. For public sector institutions, the ultimate purpose of IP 
management is to serve the greater public interest. These are not mutually exclusive goals, 
and they can be reconciled through sound technology marketing and licensing practices.
4	 The four characteristics of an alliance that generally define the allocation of value 
between an originator and a commercial partner are (1) its stage of development, (2) the 
role retained by the licensor in product supply or other ongoing activities, (3) the size of 
the market opportunity, and (4) the scope of the market granted to the development 
partner under the alliance agreement. 
4	 The key to successful negotiation is having a clear understanding of the value each 
party brings to a relationship. Value may be objective and quantitative, or of a more 
qualitative nature.
4	 Perhaps the most important element in a negotiation is clear communication—also 
internally—with the negotiating partner about the benefits that will or could be 
obtained through a license agreement.
4	 In general, the public sector organization should consider offering the first draft 
of an agreement to cover a number of topics of particular concern to public sector 
organizations that would probably not be addressed by a company.
4	 Negotiating between public and private sectors ought not be confrontational and 
should be seen as an opportunity to forge a long-lasting and mutually beneficial 
relationship. Put differently, negotiating a fair licensing agreement should not be seen 
just as a process of “bargaining” toward a win-win outcome. 
4	 For the private sector party, a well-tested and successful approach to negotiating an 
agreement is to offer initial terms that the public sector organization would be willing 
to agree to if it were on the other side of the negotiating table.
4	 Specific best practices and terms that allow public sector entities to meet public sector 
goals (ensuring broad access to innovation) include area of use, territory, price, labeling, 
white-knight conditions, and royalties.
4	 Senior management can set a positive tone for negotiation that will ensure that deals 
made with others are a vehicle for building strong relations and trust between parties. 
4	 integrated iP management (IPM) considers the critical role of IP management throughout 
the entire innovation life cycle. IPM allows managers to intervene, change course, amend 
or enhance patent applications, and in-license useful patents or technologies.
4	 networking is important, if not essential, for successful technology marketing. Technology 
transfer officers and scientists particularly should be encouraged to network. 
FOR SENIOR MANAGEMENT
(UNIVERSITY PRESIDENT, R&D MANAGER, ETC.)
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 The “unique selling proposition” of your technology—in other words, the features, 
advantages, or benefits it offers—is probably not the science behind the technology. 
The science behind an invention is usually not its selling point.
4	 technology marketing is a process by which owners of a technology create relationships, 
between themselves and potential users, that will enable the technology to be 
developed and made widely available, through commercialization or other methods. 
4	 Negotiating between public and private sectors ought not be confrontational and 
should be seen as an opportunity to forge a long-lasting and mutually beneficial 
relationship. Put differently, negotiating a fair licensing agreement should not be seen 
just as a process of “bargaining” toward a win-win outcome. 
4	 You should think about the practical applications of your inventions. Or dream about 
them! And share your ideas about what applications you think your invention might 
have. Good marketing makes a technology understandable and attractive to buyers.
4	 As much as your science may be interesting and fascinating, when you speak to potential 
licensees or investors, it is often best not to place emphasis on the science. Rather, in 
extremely simple language, stress the potential applications of your invention.
4	 Remember to keep an eye on newly published patents and patent applications. They can 
help inform R&D decisions and keep you abreast of the latest technical developments 
in your field.
4	 Collaborations create contacts. Contacts build networks. networks provide 
opportunities. 
4	 your contacts and network can help your technology transfer office’s marketing 
efforts. For example, private sector colleagues may facilitate licensing deals with their 
organizations. 
FOR SCIENTISTS
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 One of your responsibilities will be to bring together individuals with different 
backgrounds and experiences before negotiating agreements. Ideally, a team should 
include business strategy, marketing, legal, scientific, regulatory, production, and 
finance expertise.
4	 Marketing inventions should not simply be a push of technologies; rather, it should be 
an approach that allows the needs of buyers to pull inventions. 
4	 Marketing is not merely advertising or selling but a multistage process that addresses 
the who, what, why, where and when of an invention.
4	 Marketing inventions should use a systematic approach (which is fundamentally different 
from product marketing). Particularly useful are portfolio approaches to marketing (also 
called integrated intellectual property management which blends sophisticated IP data 
search-and-analysis techniques with continuous product improvement).
4	 Public sector institutions should pay particular attention to the following terms or 
aspects of a license when negotiating with companies: exclusive versus nonexclusive; 
enabling technologies versus traits versus plant materials; rights granted to the licensee 
(covering topics such as sole licenses, coexclusive licenses, territoriality, duration, field 
of use, and retained rights issues, as well as options or rights of first refusal, and 
favored-nation clauses); grant-back clauses; compensation due to the licensor; liability, 
diligence terms, and milestones; licensee’s responsibilities vis-à-vis the patent; license 
term and termination; and issues of assignability.
4	 Some people believe that licensors should stay away from conditions on final product 
price because of its complexity; this is one reason why the public sector needs to 
develop its skills.
4	 You can help ensure that a licensee will fulfill the terms of the agreement if you require 
milestone payments or certain reporting conditions when milestones are reached, 
minimum annual royalties, or research funding-level commitments. It is particularly 
important to ensure diligence for exclusive licenses. 
4	 There are three key ways that a license grant, either nonexclusive or exclusive, can be 
limited or defined: territorial limitations, field-of-use limitations, and limits on duration.
4	 Conduct comprehensive iP audits to determine where your IP assets are, when IP 
protection is needed, whether there are potential IP liability issues, whether there are 
licensing needs or opportunities, and whether there are inventions to be harvested. 
4	 The key implications and best practices listed for senior management are also pertinent 
for TTO officers.
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Based on the successful experiences of Yale 
University, the authors advocate a hands-on ap-
proach, through which the university actively and 
directly manages the creation of new companies 
and invests in the human and physical resources 
needed for their success. Such an approach may 
provide a greater chance for success than licens-
ing the university’s technology to a start-up com-
pany, which would likely be completely separate 
from the university. The approach of establishing 
and licensing to a spinout does, however, intro-
duce a number of significant risks. Brown and 
Soderstrom identify these risks and demonstrate 
how each of them can be mitigated in order to 
increase the potential for success. 
The strategy of creating university spinouts, 
as opposed to simply licensing technologies to ex-
isting companies, is particularly likely to appeal 
to universities in developing countries for several 
reasons. Licensing is often the “preferred” option 
for university technology transfer. Simply be-
cause it is less complex, it requires an acceptable 
licensee who is both interested in and capable of 
developing the technology. In many countries 
where the biotechnology industry, for example, 
is in the early stages of development and where 
there is a smaller chance of finding an acceptable 
licensee, creating a spinout may hold more prom-
ise. To the extent that the goal of commercializing 
university technologies is to generate economic 
growth, the creation of new companies can have 
EXECUTIVE GUIDE TO HANDBOOK SECTION 13
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Is it better to license a technology to a start up, 
a spin-out, or an existing company? This is one 
of the questions facing public sector technology 
transfer offices (TTOs) around the world. There 
is no simple answer. The choice can depend on 
whether an entrepreneurial spirit characterizes 
the institution that developed the technology. 
The more entrepreneurial, the more likely the 
institution will wish to set up a new company. 
However, if an incubator infrastructure exists, 
then a spinout becomes more feasible. 
This section considers the benefits and risks 
of dealing with spinouts by reviewing experi-
ences, with continual reference to the situations 
of developing countries. The associated factors of 
venture capital, technology transfer intermediar-
ies, and the formation of business incubators are 
also discussed. Anyone engaged in dealing with 
spinouts, venture capital companies, and incuba-
tors will want to read the entire section; it covers 
a range of issues from licensing considerations, to 
the use of milestones, to compensation, and of-
fers plenty of elucidating analyses about realistic 
expectations, based on a series of real examples 
from the United States and the United Kingdom. 
All of these chapters show in one way or another 
that while there is certainly an “art” to entrepre-
neurship, reliable recipes are available.
Brown and Soderstrom1 present the ratio-
nale for, and a comprehensive practical overview 
of, the creation of university spinout companies. 
Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007. 
13: Public Sector and Entrepreneurship. In Executive Guide to Intellectual Property Management in Health and Agricultural 
Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), 
Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Avail-
able online at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for 
noncommercial purposes is permitted and encouraged.
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a greater impact close to home by generating jobs, 
attracting additional investment, and facilitating 
the growth of a biotechnology cluster. Because 
universities and public sector research institutes 
are often the giants of R&D within a developing 
economy, they need to be relied upon as sources 
for human capital and investment in entrepre-
neurship, since there may be no other sources.
Despite the promise spinouts may hold, 
they may not always be appropriate. Garner and 
Ternouth2 address the question of what realistic 
expectations universities and research institutions 
should have concerning the risks of investing in-
stitutional resources in creating and spinning out 
new technology-based companies and they hold 
almost opposite beliefs to those of Brown and 
Soderstrom. The authors conclude that publicly 
funded institutions should consider how best 
to achieve their primary missions of delivering 
social and economic benefits, and they caution 
policymakers against exerting too much pressure 
on their region’s universities to create new com-
panies, because the process is difficult, consumes 
limited institutional resources, and is risky. The 
authors recommend that universities and research 
institutions should, as a rule, favor licensing-out 
to existing companies and third-party start-up 
companies and get involved only in the higher-
risk strategy of investing the institution’s own 
time and resources to create a spinout with mea-
sured and informed caution. 
The process of creating a spinout is essential-
ly one of providing the right social/professional 
environment, legal/financial framework, and re-
sources for something new to grow and succeed 
and—given the risks—to fail “gracefully” if need 
be, without causing harm beyond the loss of op-
portunity and the initial investment. A very im-
portant element of creating spinout companies 
is to channel the enthusiasm and commitment 
of those who believe in the technology, want to 
see it succeed, and aspire to a positive outcome 
(for example, by providing products that improve 
the wellbeing of under resourced populations). 
Finally, a key point is to incubate a spinout long 
enough to enable it to run once it is “out there.”
Pragmatic information about how organiza-
tions can transfer their intellectual property (IP) 
rights to a spinout company (normally through 
a licensing agreement) and then convert the 
intellectual property into products or services 
for the public’s benefit can be found in the chap-
ter by Sandelin.3 Based on three decades of expe-
rience at Stanford University, the chapter identi-
fies some key issues related to negotiating such 
transfers. These include: 
• the general attitude toward spinouts held 
by a public research organization’s senior 
administration and governing board 
• various licensing considerations 
• the use of milestones
• the amount and kind of compensation 
that should be received for licensing a 
technology
The chapter provides guidance on how to 
best reach a successful agreement. The definitions 
of particular terms in a contract, such as infringe-
ment responsibilities, sublicensing, and warran-
ties and indemnities, are all carefully considered. 
In addition, the chapter covers conflict of interest 
(COI) and conflict of commitment (COC) issues 
that arise when employees of public research or-
ganizations become engaged in spinout compa-
nies. The authors provide clear examples to help 
policymakers and administrators better deal with 
the issues involved in a licensing agreement. 
Governments everywhere are encouraging 
public research organizations to use their inven-
tories of IP rights to create spinouts. Successful 
spinouts create new jobs, contribute to economic 
development, and potentially grow into large 
multinational corporations. TTOs are key players 
in this effort, but they should balance the inter-
ests and mission of public research organizations 
with the objectives of the spinout and the needs 
of society.
One surprising way that public research insti-
tutions can more effectively use their intellectual 
property is by attracting venture capital. Wyse4 
advances the premise that, rather than venture 
capital driving the creation of new companies, 
it is the creation of new companies that attracts 
venture capital. Research institutions and govern-
ment policies are able to constructively influence 
the creation of new companies. The chapter seeks 
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to inform those in public research institutions, 
and government policymakers, about the role 
that venture capital can, and does, play in tech-
nology-based entrepreneurship, and the types of 
environments that can encourage entrepreneur-
ship and thereby attract venture capital. 
Venture capital is a specific sector of the fi-
nancial industry that channels investment from 
institutional and private investors, corporations, 
pension funds, and government agencies into 
venture funds that in turn invest in portfolios of 
equity in new companies. The model essentially 
spreads out and shares the technology risks in-
volved in each of the individual companies. It 
also seeks—to the extent possible—to reduce 
the risks involved by specializing in a certain 
field of technology where the venture fund’s 
management has expert knowledge. Venture 
capital may also be actively involved in the 
management of the companies, participating on 
the board and even providing business services. 
In return for bearing and managing such risks, 
venture capitalists expect to achieve sufficiently 
high internal rates of return, typically between 
20 and 40 percent.
The availability of financial capital is not, 
generally, the limiting factor. In 2005, US$34 
billion was invested in U.S. biotech companies 
from all sources (Table 1) with nearly US$4 bil-
lion in investment capital coming from venture 
capital. While venture capital is concentrated 
geographically to a few locations, individuals and 
institutions with interests in investing in growth 
opportunities can be found worldwide—includ-
ing in developing countries. The fundamentals of 
success are straightforward: the formation of new 
companies creates an environment that increases 
their probability for success. Thus, the two essen-
tial pieces that need to be provided are: 
1. Planting the “seeds” of new companies—
encouraging skilled people with new ideas 
to develop those ideas. 
2. Creating an environment favorable for en-
trepreneurship and success. Universities 
and research institutes can plant the seeds, 
while government policies can shape the 
environment.
A favorable environment for creating and 
growing new companies consists of an encouraging 
business culture (one that rewards success and 
treats failure as a learning opportunity), access to 
intellectual capital (such as that flowing from uni-
versities), sufficient financial capital, and reliable 
physical capital (facilities, laboratories, communi-
cations). All of these are enhanced if a region en-
joys a low cost of living and a high quality of life.
While governments cannot legislate entre-
preneurship, they can encourage it by providing a 
favorable environment. Once enough companies 
exist, they will themselves further transform the 
environment, attracting or creating the skills and 
capital that can develop into a technology cluster. 
Ultimately, the practice of investing venture capi-
tal is a skill that can be imported to a region or 
country, where it can be mastered by local inves-
tors. Wyse clearly implies that the next stage in the 
growth of the venture capital industry will involve 
spreading into new regions across the globe.
He also encourages the public sector to pro-
vide more funding for translational research, that 
is, research that moves a technology or product 
further up the value chain and closer to market, 
thus reducing both the investment needed for 
commercialization and the risk (Figure 1). The 
point of the figure by Wyse is that knowledge-
based biotech industries in agriculture require a 
greater emphasis on translational research, com-
pared to the pharma industry, to be able to at-
tract the venture capital and corporate investment 
necessary to commercialize new products and 
technologies 
It is also important to know what other forces 
discourage or encourage the commercialization of 
inventions. Cook5 focuses on the barriers created 
by cultural differences between academic institu-
tions and business. He contends that these barriers 
can be overcome by motivated technology transfer 
intermediaries. Inventors are usually creative, self-
motivated, flexible individuals, but this does not 
mean that they naturally pursue the commercial 
potential of their discoveries. Whether or not an 
inventor ever shows his or her invention to the 
outside world actually depends on two variables: 
1. whether he/she wants to disclose it
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Source: Wyse7
Table 1: Sources of Capital in the Biotech Industry
           Total investments (US$, millions)
Sources of capital      2005      2006 (1st Q to 3rd Q)
  Public IPOa 819 567
  Follow-onsb 4,194 3,032
   PIPESc 2,376 1,817
   Debt 5,565 12,241
Private (venture capital) 3,518 3,186
Other 1,114 303
TOTAl CAPITAl 17,586 21,146
Partnering  17,268 (50%) 12,463 (37%)
TOTAl 34,854 33,609
a.  IPO – initial public offering: a private company files to have a portion of its shares sold to the public on a  
    regulated stock exchange,  such as NASDAQ .
b. Follow-ons – When public companies sell additional shares on the stock exchange to raise additional cash.
c. PIPES – Private investments in public entities: the sale of public shares to private financial institutions that 
    may take public shares off the public market as a way for companies to raise cash.
Figure 1: Commercializing Knowledge-Based Biotech Industries 
in Agriculture and Pharmaceuticals
Agriculture requires much translational research.
Pharmaceuticals industry
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2. whether the environment in which the in-
ventor operates encourages or discourages 
disclosure
Much can be done to improve the environ-
ment surrounding an inventor. If an environment 
promotes creativity and is receptive to invention 
disclosure, it will not matter as much if an inven-
tor has less self-confidence or is less of a risk taker. 
The manager of an institution’s technology trans-
fer effort should make every attempt to create an 
environment that fosters disclosure.
On the other hand, new companies oper-
ate in a very different environment. They gen-
erally have no established market position, are 
trying to convince potential investors that the 
company will succeed, and are usually under-
staffed and under-resourced. Such companies 
are most in need of effective leadership and of 
professional technology transfer intermediaries 
with the ability to translate a pioneering inven-
tion into a successful product. Such intermedi-
aries should: 
• understand the value systems that drive the 
inventor and the market
• be fluent in the vocabulary in both situ-
ations, so they are able to translate while 
retaining all linguistic nuances
•  appreciate the various types of risks and 
how to mitigate them
• be credible to inventors as well as investors 
These same qualities are valuable for those 
who are working to establish partnerships between 
the public and private sectors of developed and 
developing countries. Indentifying, motivating, 
and retaining individuals with the capability to be 
intermediaries should be an important element of 
any effort to commercialize intellectual property. 
The basic message of the chapter (along with the 
other chapters in this section of the Handbook) state 
that the role of the university is to channel its lim-
ited public resources into activities that create new 
opportunities that can be taken up by the market, 
but not to intentionally supplant or engage directly 
in the market. This means leaving venture creation 
to the market whenever possible. Indeed, most uni-
versities do not have sufficient professional resources 
or experience to manage spinout companies. 
This and other chapters explore when and 
how universities can work with the market to 
channel investments into high-risk, high-return 
opportunities. This suggests a further question: 
when and how might universities work with other 
nonprofit and philanthropic funding sources to 
create spinout product development partnerships 
(PDPs) around high-risk, high-social-return op-
portunities? This is a question will be explored in 
the future by leading universities that have begun 
to master the process of spinning-out successful 
for-profit companies.
A more methodical approach has been gain-
ing popularity over the last 15 years: the creation 
of business incubators as tools for stimulating 
local economic development. The concept of an 
incubator is simple and appealing: it provides a fa-
cility and services (for example, business planning 
and legal, accounting, and marketing support) to 
catalyze small business growth. Incubators have 
proven very effective. Incubated companies have 
a dramatically higher rate of survival than the 
average spinout. Additionally, companies that 
“graduate” from incubators provided an average 
of 85 full-time jobs per incubator. Used to pro-
mote the growth of entrepreneurial ventures of 
every imaginable type, small business incubation 
is now entrenched in both urban and rural areas 
throughout the United States. 
Zablocki8 discusses in detail the six steps for 
setting up and operating successful incubators: 
1. Conducting a feasibility study. For a pro-
posed incubator, such a study can achieve 
a number of important objectives and, if 
properly done, can provide a solid basis for 
judging the economic and political viability 
of the proposed project. 
2. Identifying and securing stakeholders. 
While each incubator’s circumstances are 
unique, anticipated stakeholders would 
likely include local and state governments 
and a variety of public and private sector 
organizations (universities, major corpora-
tions) interested in fostering new-business 
development in the region. Stakeholders 
might also include economic-development 
organizations that could fund the rehabili-
tation of a facility or the operation of the 
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incubator program. The support of these 
stakeholders is critical to initiating an incu-
bator program. 
3. Identifying a market niche. This requires 
much attention to detail. Successful busi-
nesses carefully attend to the work of defin-
ing the market position of their products 
and services relative to their competitors, as 
well as to modifying their market position in 
response to changing customer preferences. 
4. The formation process. The basic structure of 
an incubator facility is determined by owner 
attributes and regional demographics (it could 
be private, local-government led, or university 
led or it could be a nonprofit company). 
5. Services. As the incubator concept has 
evolved, the range of services offered by 
incubators has greatly expanded. Early in-
cubators provided access to a photocopier 
and a conference room, clerical support, 
and perhaps switchboard services. Today, 
incubators themselves provide, or provide 
access to, a broad spectrum of office sup-
port, business consulting, and professional 
services. Business consulting services may 
include business-plan preparation, finan-
cial planning, advertising and marketing, 
strategic planning, technical and commer-
cial communications, relocation planning, 
capital development (equity and debt ser-
vices), business taxes, employee relations, 
R&D, and government procurement. 
6. Strategic Planning. Strategic planning com-
pels incubator management to confront 
tough issues. How will the incubator con-
tinue to operate if revenue projections from 
rental income are not achieved? How will 
major facility repairs (for example, a rup-
tured boiler) be paid for? Addressing these 
worst-case scenarios through strategic plan-
ning can provide both a clear course of ac-
tion if things go as planned and, if they do 
not, the necessary contingency plans to nav-
igate what may be a difficult beginning. 
Economic development programs for small 
businesses proliferated in the 1980s. These pro-
grams have been referred to as incubators without 
walls. Well-managed incubators often distinguish 
themselves by serving as a focal point for access 
to the broad spectrum of available business ser-
vices. Incubator managers thus provide the point 
of contact for entry into various programs. Many 
efforts to assist small business are, by contrast, 
programmatic in nature and limited by the scope 
of their intent. A well-positioned incubator, on 
the other hand, will help its tenants to access the 
range of existing programs and, in addition, pro-
vide access to informal networks for business and 
financial advice and assistance. For example, a re-
tired executive may agree to help out a struggling 
firm, or a business angel may appear, discretely 
looking for new investment opportunities. 
Successful incubator programs are marked 
by foresight, focus, and leadership. Successful 
incubator programs also know how to identify, 
organize, and maximize talent and resources, 
making the most of community support and en-
trepreneurial networks. A core group committed 
to starting a business incubator must recognize 
that its efforts cannot be pursued in a vacuum. As 
Zablocki puts it: “The dream of a few must become 
the dream of many.” ■
All chapters refer to: Intellectual Property Management in 
Health and Agricultural Innovation: A Handbook of Best 
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thom-
son, AB Bennett, K Satyanarayana, GD Graff, C Fernandez, 
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis, 
U.S.A. Available online at www.ipHandbook.org. The online 
version contains for each chapter a detailed Editor’s Sum-
mary, Implications, and Best Practices.
1 Chapter 13.1 by A Brown and J Soderstrom titled 
Creating and Developing Spinouts: Experiences from 
Yale University and Beyond, p. 1253.
2 Chapter 13.5 by C Garner and P Ternouth titled New 
Companies to Commercialize IP: Should You Spinout or 
Start-up? p. 1295.
3 Chapter 13.2 by JC Sandelin titled Dealing with Spinout 
Companies, p. 1271.
4 Chapter 13.3 by R Wyse titled What the Public Sector 
Should Know about Venture Capital, p. 1281.
5 Chapter 13.4 by T Cook titled The Role of Technology 
Transfer Intermediaries in Commercializing Intellectual 
Property through Spinouts and Start-ups, p. 1289.
6  See supra note 4.
7  Ibid.
8 Chapter 13.6 by Edward M. Zablocki titled Formation of 
a Business Incubator, p. 1305.
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 Much of the success of a spinout or start-up will depend on the entrepreneurial spirit 
at the institution. The more entrepreneurial, the more likely it will be that someone 
wants to set up a new company. 
4	 Governments should encourage public research organizations to use their inventories 
of iP rights to create spinouts because they create new jobs, contribute to economic 
development, and potentially grow into multinational companies. But governments 
should recognize that setting up a new business is a high-risk activity and should allow 
new companies to fail gracefully. 
4	 Rather than venture capital driving the creation of new companies, it is usually the 
creation of new companies that attracts venture capital. 
4	 The formation of new companies creates an environment that increases the probabil-
ity of success for other companies. Thus, the public sector should (1) plant the seed, 
encouraging skilled people with new ideas to develop those ideas and (2) create an 
environment that favors entrepreneurship and success. Universities and research insti-
tutes can plant the seeds, while government policies can shape the environment. 
4	 While a government cannot legislate entrepreneurship, it can encourage entrepreneur-
ship by providing a favorable environment for creating and growing new companies. 
This would be an environment with (1) an encouraging business culture that rewards 
success and treats failure as a learning opportunity, (2) access to intellectual capital 
(such as that flowing from universities), (3) access to sufficient financial capital, and (4) 
reliable physical capital (facilities, laboratories, communications). 
4	 Public sector institutions may be the largest economic entities present in a developing 
country. Hence, they can contribute much by taking the lead in developing and foster-
ing the establishment of spinout companies that are seeded with technologies gener-
ated in the public sector and protected and managed as IP assets. 
4	 To successfully commercialize intellectual property, a country ought to have a stable 
economic and institutional environment, available investment capital, commercial-
izable intellectual property, a commercial environment that can develop intellectual 
property, and competent technology transfer intermediaries.
4	 Technology transfer of any sort is likely to succeed only if there is sustained commit-
ment at the most senior levels of both government and research institutions.
4	 Governments can encourage regional economic development by fostering and financ-
ing business incubators. Ideally, they ought to be located in strategically selected re-
gions and build on potential synergies of existing institutions. Small business incuba-
tors in particular have proven to be effective economic development tools.
FOR GOVERNMENT POLICYMAKERS
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 Experts are divided as to what approach should be taken by public institutions with 
regard to creating companies. Some advocate a “hands-on” approach in which the in-
stitution actively and directly manages the creation of companies and invests in the 
resources needed for their success. Others argue that the university should channel its 
resources into activities that may result in marketable technologies, but not engage 
directly in marketing activities. 
4	 the creation of business incubators as a tool for stimulating local economic develop-
ment should not be underestimated. Incubated companies have a dramatically higher 
rate of survival than the average spinouts. 
4	 Spinouts often create enhanced opportunities for its faculty. If spinouts remain in the 
region, faculty inventors can remain active as consultants. Also, a university’s success 
with spinouts can attract new talent.
4	 Much of the success of a spinout or start-up will depend on the entrepreneurial spirit 
at the institution. The more entrepreneurial, the more likely it will be that someone 
wants to set up a new company.
4	 The formation of new companies creates an environment that increases the probabil-
ity of success for other companies. Thus, the public sector should (1) plant the seed, 
encouraging skilled people with new ideas to develop those ideas and (2) create an 
environment that favors entrepreneurship and success. Universities and research insti-
tutes can plant the seeds, while government policies can shape the environment. 
4	 When engaging in entrepreneurial activities, risks to the university include potential 
impact on tax-exempt status, liabilities for the actions of the company, conflicts of in-
terest and/or commitment, and conflicts with the university’s mission. 
4	 To be an effective entrepreneurial university, representatives of senior administration 
should routinely review company-founding and business-maintenance activities. 
4	 Clear policies are needed for disposing of equity in spinout companies, both for the 
sake of the university’s integrity—to prevent conflicts of interest—and for the sake of 
the company—to prevent the university’s divestment from sending a damaging signal 
to the market about the value of the company or its technology.
4	 To demonstrate the importance of technology transfer, the tto should generally re-
port directly to upper-level administration.
4	 In order to attract venture capital in agriculture, public sector institutions need to take 
steps to reduce the risk of investing in agricultural projects. 
4	 Rather than venture capital driving the creation of new companies, it is usually the 
creation of new companies that attracts venture capital.
FOR SENIOR MANAGEMENT
(UNIVERSITY PRESIDENT, R&D MANAGER, ETC.)
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 Not all university inventors are entrepreneurs nor are they interested in being company 
founders, and not all spinout company founders from a university are the technology’s 
inventors. 
4	 While inventors are treated equally under university patenting and licensing policies, 
involvement as a company founder entails a greater degree of risk and commitment 
to move an invention to commercialization. You may be valuable as an active partner 
of a spinout company to prevent the repetition of unsuccessful experiments (blind al-
leys) and to add needed creativity with respect to problem solving as development and 
commercialization proceeds.
4	 Participation in a spinout can be a particularly rewarding experience, financially as well 
as personally, as it involves the practical application of your ideas.
4	 Venture capital investors combine a broad view of the market with solid technical ex-
pertise. You will need to be prepared to convince investors not so much of the technical 
merits of your research, but of how your ideas lead to economic returns. 
4	 Rather than venture capital driving the creation of new companies, it is usually the 
creation of new companies that attracts venture capital. 
4	 Venture capital investors can be great allies, but will impose, for good reasons, distinct 
conditions on the project. Be open, patient, and willing to work with investors. 
4	 Much of the success of a spinout or start-up will depend on the entrepreneurial spirit 
at the institution. The more entrepreneurial, the more likely it will be that someone 
wants to set up a new company.
4	 There are many factors that determine the feasibility and success of a spinout com-
pany. The technology’s intrinsic value and your commitment to your invention are only 
part of the picture. If you can find an existing partner with market penetration, the 
chances of success increase. If you are still convinced, even after failing several times 
to find a willing licensee for your technology, then it may be time to consider creating 
a company. As these matters arise, seek the guidance of your institution’s technology 
transfer office. 
FOR SCIENTISTS
GUIDE TO SECTION 1



























Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 Spinouts carry a number of risks, but with certain factors in place they can represent 
the best opportunity for developing early-stage technology. This is particularly true be-
cause the inventor, and other university participants, will have a vested interest in, and 
commitment to, the success of that technology.
4	 Potential investors in a spinout will ask two major IP questions. Could previously ex-
isting intellectual property block the technology? Could your intellectual property 
dominate the market and prevent entry by others? Other key questions involve the 
characteristics of the market opportunity and the financial bottom line of revenue and 
expense projections over the life of the technology.
4	 Solid, long-term support from your institution will be required to: (1) operate the tech-
nology transfer office efficiently, so that it can evaluate invention disclosures, obtain 
IP protection when appropriate, coordinate the search for people or companies that 
will develop the invention into products and services, and negotiate and prepare the 
necessary legal agreements (for example, license agreements for IP rights); (2) cover the 
costs of obtaining IP rights; and (3) provide funding to convert good ideas into working 
prototypes. (A good idea not put into use is wasted.)
4	 Your job is complex and challenging because you have to balance the needs and ex-
pectations of many parties with divergent interests: Remain responsive to such needs 
and interests; keep people informed of progress and developments; effectively utilize 
available resources. 
4	 When licensing to or creating new ventures, several key attributes are essential for at-
tracting venture capital investment: a strong management team, a viable technology, 
a strong IP position, a large potential market, and location in an environment favorable 
for entrepreneurship. 
4	 New ventures in developing countries have much to gain by attracting and building 
on international investor networks. They have the potential to open new markets and 
bring in new alliances.
4	 Much of the success of a spinout or start-up will depend on the entrepreneurial spirit 
at the institution. The more entrepreneurial, the more likely it will be that someone 
wants to set up a new company.
4	 It is necessary to strike a balance between reliance on licensing-out to existing compa-
nies and investing time and resources in creating new companies. 
4	 Rather than venture capital driving the creation of new companies, it is usually the 
creation of new companies that attracts venture capital. 
4	 When creating spinout companies, always remain focused on your institution’s pri-
mary mission, such that the spinout will be consistent with, and even serve, that public 
sector mission.
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rewards, and legal aspects (such as infringement 
risks). That is where an FTO analysis comes in 
as an initial, cursory, or quite possibly detailed, 
overview of the patent landscape and competi-
tors’ positions. Hence an FTO analysis need not 
be a costly legal FTO opinion (note that an FTO 
opinion is rendered by patent counsel whereas an 
FTO review can have any level of legal review, 
or none). Rather, an FTO analysis is an assess-
ment of the set of patents and other IP rights that 
are or would be connected to the product and/or 
method under consideration. Kowalski2 outlines 
in detail how different levels of FTO analyses 
are conducted in practice. Addressing scientists, 
business people, and legal staff, he describes how 
products and/or methods are broken down into 
fundamental components, processes, and combi-
nations thereof, and then how each component is 
carefully analyzed for attached IP rights of third 
parties. An FTO analysis, irrespective of the level 
of detail, requires good preparation, systematic 
review, and rigorous record keeping.
Although FTO is often viewed as simply a 
legal issue, when approached from a more prac-
tical product-development perspective, FTO is 
a strategic risk-management tool; it relies on a 
synthesis of scientific and legal expertise, business 
development, and strategic planning. FTO for 
a given product in a given market is difficult to 
achieve because it can never conclusively be es-
tablished. Obtaining FTO, therefore, becomes a 
EXECUTIVE GUIDE TO HANDBOOK SECTION 14
(VOLUME 2: PAGES 1315-1394)
Freedom to operate (FTO), a simple and straight-
forward concept, means that for a given product 
or service, at a given point in time, with respect 
to a given market or geography, no intellectual 
property (IP) from any third party is infringed. 
But to translate this concept into a productive 
strategy for companies and for public sector insti-
tutions alike is not so straightforward. 
For public sector organizations, the opportu-
nities presented by incorporating FTO consid-
erations into product development strategies are 
numerous. These may include benefits through 
higher competitive intelligence, the ability to 
bring about culture change, and the forging of 
strong partnerships with providers of intellectual 
property and technology. An FTO strategy, there-
fore, is a plan that begins with research into the 
IP landscape of a potential product and evolves 
into an attitude through a product’s R&D and 
commercialization/distribution cycle. Krattiger 
discusses these policy and strategy elements in 
detail.1 It is useful, however, to first consider how 
FTO analyses are conducted before reviewing the 
principal FTO strategies.
At the beginning of a research project, a com-
pany would typically consider scientific feasibil-
ity, the effect of the research on the organization’s 
business position (whether or not the research 
and the product would eventually strengthen its 
competitive position), the project’s impact on 
financial status in terms of costs and potential 
Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez, and SP Kowalski. 2007. 
14: Freedom to Operate and Risk Management. In Executive Guide to Intellectual Property Management in Health and Agri-
cultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, 
USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). 
Available online at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for 
noncommercial purposes is permitted and encouraged.
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strategy, or even a position, mindset, or culture. 
This is because the patent landscape is dynamic: 
new patents issue; old patents expire; some pat-
ents are abandoned. Therefore, freedom to operate 
does not imply absolute freedom from the risk 
of infringing another party’s intellectual property. 
Whether or not FTO exists is an assessment based 
on the analysis and knowledge of IP landscapes 
for a given product, in a given jurisdiction, at a 
given point in time. This statement underscores 
a critically important principle: there can be no 
risk-free decision. 
FTO is thus a concern that remains through-
out the R&D process, to commercialization and 
even afterward. By setting a goal of having reason-
able FTO, a set of ten FTO strategies for manag-
ing potential IP infringement are proposed and 
discussed in detail by Krattiger in Chapter 14.1 
(Table 1). In practice, typically two or more of 
these strategies will be adopted, with the specific 
mix of strategies varying. Which strategies will 
be appropriate depend on, for example, how ad-
vanced the product is, the type of organization 
that develops the product, and relevant market 
dynamics. And not all of the listed strategies are 
feasible for public sector institutions.
How much attention should a public sec-
tor organization give to FTO? Since some pub-
lic sector research is not directly intended for 
commercial use, the answer is sometimes quite 
simple: Not much. This condition certainly 
applies to a great deal of university research. 
However, if the project is specifically aimed at 
product development, a goal that is becoming 
more prevalent in the public sector, then FTO 
becomes a concern. For example, through col-
laborations with product-development partner-
ships (PDPs), the primary reason for funding 
the research is to develop products to help the 
poor. Such is the case also for the research cen-
ters of the Consultative Group on International 
Agricultural Research (CGIAR) and for many 
national agricultural research systems (NARS). 
Universities, too, are shifting their research fo-
cus; some manage their innovations in novel 
ways and aim to bundle technologies and intel-
lectual property in order to license “solutions” 
rather than individual patents. 
A relevant example of the importance of 
the public sector managing FTO is the develop-
ment of Golden Rice.4 No attention was given to 
FTO until the first material was nearly ready for 
transfer to developing countries. The Rockefeller 
Foundation then commissioned an FTO analysis 
that demonstrated, first of all, how many inven-
tions from scientists around the world enabled—
or accelerated—the development of Golden 
Rice. Although a large number of patents—and 
patent applications—were identified, the FTO 
analysis also demonstrated that licenses to only 
a few would be required for the transfer to and 
use of Golden Rice in developing countries. The 
FTO analysis provided a list of primary own-
ers of patents (and of materials that went into 
Golden Rice under material transfer agreements) 
for which licenses were needed. With the leader-
ship of the Rockefeller Foundation and Syngenta, 
a large agro-chemical company headquartered in 
Switzerland, the relevant intellectual property was 
quickly assembled (or in-licensed) into a package. 
That package then was licensed, essentially roy-
alty-free, to public sector institutions in develop-
ing countries. This approach, in essence, repre-
sents the various aspects of FTO, from analysis to 
strategy, to action.
Each of the ten strategic approaches to 
obtain FTO listed in Table 1 presents certain 
risks and opportunities. Any action—includ-
ing the decision not to take action—carries risk. 
Delaying the licensing of third-party intellectual 
property, for example, could lead eventually to 
expensive licensing terms, the inability to obtain 
a license, or the possibility of being sued for pat-
ent infringement. For some organizations, such 
as those developing genetically modified crops 
(GMOs), the opposite may be the case (where it 
might be advantageous to delay in-licensing) due 
to stewardship issues that are the main concern 
with biotechnology crops. Krattiger concludes his 
discussion, in Chapter 14.1, by urging the public 
sector to:
• judiciously evaluate whether and when 
FTO concerns should be considered
• build in-house capacity to conduct patent 
searches and cursory FTO analyses (as op-
posed to legal opinions)
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Table 1: The Ten Strategic FTO Options
Option Pros Cons
legAl/iP mAnAgement StrAtegieS
1.    License-in Is relatively  
straightforward
May not foster in-house R&D 
initiatives and may be costly
2.    Cross-license Involves give and take In certain cases, antitrust issues 
may arise
3.    Oppose third-
party patents
Can be cost effective Can be expensive and result might  
be undesirable (stronger or  
broader patent)
4     Seek 
nonassertion 
covenant
Is cheap and effective Rarely allows for the in-licensing of 
valuable know-how 
5.    Seek compulsory 
license
Allowed under TRIPS under 
certain circumstances
Will not allow for the in-licensing 
of know-how and brings many 
constraints and complexities with it
r&D StrAtegieS
6.    Modify product Can be fairly simple if planned early 
in R&D stage
May not be possible due to lack of 
readily available alternatives; incurs 
opportunity costs
7.    Invent around Could lead to cross-licensing 
position
Could lead to delays in product 
launch and might be costly; incurs 
opportunity costs
BUSineSS StrAtegieS
8.    Wait and see Gives time for strategic 
positioning
Could lead to litigation and 
jeopardize investment already made
9    Abandon project Is simple and effective May be costly (need to write off  
R&D investments already made; 
incurs opportunity costs)
10.   Merger/ 
Acquisition
Is highly effective May distract from main 
business focus
Source: Krattiger, 2007.3 The original table in Chapter 14.1 also includes a column listing the key challenges for 
the public sector for each of the ten strategies.
              in Practice                     A combination of several options implemented concurrently
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One of the underlying “technologies” for 
conducting an FTO analysis is the patent search. 
Such searches are also relevant when an insti-
tution is deciding whether to file a patent on a 
new invention (meaning when one is searching 
for prior art) or when scientists want to review 
patent literature. Fortunately, many IP search 
tools are accessible online at no cost. The chap-
ter by Thangaraj, Potter, and Krattiger5 provides 
a “guided tour” of online patent search engines, 
including a description of the major ones:
• the European Patent Office (EPO’s esp@
cenet)
• the U.S. Patent and Trademark Office (PTO)
• the Patent Cooperation Treaty (PCT) Web 
interfaces of the World Intellectual Property 
Organization (WIPO)
In addition, the chapter reviews subscrip-
tion-based services and other paid services, such as 
Delphion and Derwent World Patent Index (DWPI). 
Although the discussion is by no means exhaustive, 
the chapter lists links to many useful sites. 
The chapter by Fenton, Chi-Ham, and 
Boetiger6 provides an examination of how the 
private sector thinks about FTO. Offering a 
comprehensive overview of the FTO process, the 
chapter sheds light on when to invest in FTO 
analysis and highlights the important role played 
by law firms in obtaining FTO. As mentioned 
earlier, for the public sector the strategic relevance 
of FTO is quite different from that of the private 
sector. Even when the public sector intends to 
commercialize products, its mission and goals 
differ from those of the private sector, and decid-
ing when to pursue FTO becomes a very different 
question. Nonetheless, given the growing num-
ber of public-private partnerships, it is important 
for the public sector to understand how private 
companies approach FTO issues. This chapter 
discusses both private- and public-sector consid-
erations for deciding whether, when, and how an 
FTO analysis should be conducted. 
FTO analysis defines options; it provides 
a map of the relevant IP landscape. Hence, an 
FTO analysis presents the most viable options 
for achieving institutional goals. Fenton and 
colleagues conclude their discussion with a case 
study of an FTO analysis initiated by the Public 
Intellectual Property Resource for Agriculture 
(PIPRA). The case study explains the process used 
by PIPRA, from defining the scope of the investi-
gation, to the delivery of the findings. 
In the last chapter of Section 14, Boadi7 
looks at the aspect of FTO that includes legal li-
abilities beyond intellectual property and, appro-
priately, considers stewardship as the central tool 
to managing liabilities. The legal framework for 
dealing with liability relies on the country, or le-
gal jurisdiction, in which the intellectual property 
is being exploited. Even so, GMOs (and indeed 
non-GMOs) have the potential to cross nation-
al borders. This has led to intense debate about 
whether a liability regime specific to such organ-
isms and crops should be created. Providing an 
overview of current common law and statutory 
theories of liability, the chapter considers liability 
issues facing public sector efforts to develop and 
disseminate agricultural biotechnologies.
While debate rages about liability and re-
dress issues contained in the Cartagena Protocol 
on Biosafety, developing countries need to think 
carefully about how to manage liability today. 
Referencing the African Agricultural Technology 
Foundation (AATF), Boadi provides several li-
ability-management practices that can be of great 
value, including:
• ensuring compliance with intellectual prop-
erty, license, and regulatory requirements 
• including indemnification provisions in 
technology transfer agreements
• using warranty disclaimers 
• obtaining letters of nonassertion
• adhering to appropriate technology stew-
ardship best practices 
Already, innovative developing countries (or 
IDCs), including India, Korea, China, Brazil, 
South Africa, and others are embracing novel 
opportunities provided by the new global IP 
regime. Having established technology trans-
fer offices (TTOs) for organizations in both the 
public and private sectors, these countries have 
overseen the controlled, streamlined transfer of 
crucial technologies, often with clear public ben-
efits. Such efforts, of course, require investments 
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in both infrastructure and personnel to in-li-
cense, out-license, and ensure that investments 
in product development are accelerated through 
appropriate FTO considerations during the R&D 
process and beyond. ■
All chapters refer to: Intellectual Property Management in 
Health and Agricultural Innovation: A Handbook of Best 
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thom-
son, AB Bennett, K Satyanarayana, GD Graff, C Fernandez, 
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis, 
U.S.A. Available online at www.ipHandbook.org. The online 
version contains for each chapter a detailed Editor’s Sum-
mary, Implications, and Best Practices.
1 Chapter 14.1 by A Krattiger titled Freedom to Operate, 
Public Sector Research and Product-Development 
Partnerships: Strategies and Risk-Management Options, 
p. 1317.
2 Chapter 14.2 by SP Kowalski titled Freedom to Operate: 
The Preparations, p. 1329.
3 See supra note 1.
4 See Case Study 3 by A Krattiger and I Potrykus titled 
Intellectual Property Management and Freedom to 
Operate for Golden Rice in the insert of this Executive 
Guide, p. 11-14.
5 Chapter 14.3 by H Thangaraj, RH Potter, and A Krattiger 
titled How and Where to Search for IP Information on 
the World Wide Web: The “Tricks of the Trade” and an 
Annotated Listing of Web Resources, p. 1345.
6 Chapter 14.4 by GM Fenton, CA Chi-Ham and S Boetiger 
titled Freedom to Operate: The Law Firm’s Approach 
and Role, p. 1363.
7 Chapter 14.5 by RY Boadi titled Managing Liability 
Associated with Genetically Modified Crops, p. 1385.
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4 As intellectual property becomes more prevalent in health and agricultural research, 
public and not-for-profit institutions may increasingly need to consider the intellectual 
property of third parties. This may allow for efficient in-licensing of intellectual 
property and accelerate the development of products. For such purposes, a good 
knowledge of “who owns what” is needed. That is what a freedom to operate (FTO) 
analysis provides.
4 Translating an FTO analysis into an effective strategy requires some shifts in culture 
and thinking by those public sector institutions that are engaged in the development 
of products. Although a legal opinion by an attorney may be based on a solid FTO 
analysis, the use of such an analysis is strategic. National governments have a great 
responsibility to encourage the establishment of best practices in IP management, 
through sound national policies and funding allocations.
4 Taking FTO into consideration as one element of any product development strategy 
allows for a more judicious use of resources that can often lead to stronger and more 
effective partnerships, can increase opportunities for international collaboration, and 
may underpin effective public-private partnerships.
4 Governmental policies and programs that support capacity building in IP management 
should include the training of senior management in FTO strategies, including 
institutional boards. A dialogue between boards, which are responsible for policy, and 
senior managers that are more concerned with implementation is essential since 
an FTO analysis is a risk-management tool. This approach increases efficiency in the 
handling of products for further development and/or commercialization, even if the 
goal is to address the needs of the poor. 
4 High speed Internet access and patent databases are valuable tools that can assist 
research-based institutions in the undertaking of meaningful patent and information 
searches that are necessary to conduct FTO analyses. 
FOR GOVERNMENT POLICYMAKERS
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
FOR SENIOR MANAGEMENT
(UNIVERSITY PRESIDENT, R&D MANAGER, ETC.)
4 As public sector and nonprofit institutions increasingly move in the direction of 
product development, whether they do so independently or in partnership with 
other organizations, freedom to operate (FTO) will contribute increasingly to sound IP 
management strategy. As such, an FTO analysis is a management tool for assessing and 
managing certain types of risks.
4 Some public sector institutions need not be concerned with FTO. For example, a typical 
university that mainly licenses patents or occasionally forms a spinout company can 
leave FTO concerns to others.
4 Public sector research institutions should not necessarily assume that they are exempt 
from IP infringement liability due to their nonprofit (or governmental or parastatal) 
status. Although government institutions per se may be shielded from liabilities, FTO 
rarely ends with these institutions. Eventually other institutions taking on the products 
may need to be able to deal with FTO (such as commodity exporters). Hence FTO analysis 
is just one tool for making the technology transfer process more effective, and FTO is 
particularly warranted as an institution expands its mission into product development 
and distribution. 
4 FTO opinions do not eliminate risks related to third-party intellectual property. Instead, 
they allow for the development of sound risk-management strategies (which may be of a 
legal/licensing nature, involve business approaches, or be research based). Implementing 
the strategy requires clear pathways of communication and dialogue between science 
managers, product development, licensing personnel, and senior management.
4 Obtaining FTO includes the review of the patent landscape (FTO analysis) and may include 
a formal legal FTO opinion. But, in essence, obtaining FTO is a process to be “managed” 
as an interdisciplinary endeavor and considered within the context of the institution’s 
overall mission (as such it involves senior management), business development, research 
and technology transfer, and tolerance for risk. 
4 Institutional policies that support capacity building in IP management should include 
the training of senior management in FTO strategies, including institutional boards. 
A dialogue between boards (responsible for policy) and senior management (more 
concerned with implementation) is essential, since FTO analysis is a risk-management 
tool. 
4 Commitment to the principles of FTO will demonstrate that a given institution is 
committed to respecting, and of building upon, the intellectual property of others.
4 The more downstream a research-based institution operates, the more important FTO 
considerations become. A system should be in place to help decide whether, when, and 
how a public sector institution should conduct an in-house FTO analysis or commission 
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4 Collaboration among scientists and the professionals who conduct freedom to operate 
(FTO) analyses is essential. The scientist is the most important person to explain the 
science behind technology, to help others understand the materials and the scientific 
approach, and sometimes to explain what specific patent claims mean. A scientist 
is the expert in his or her area of research and can provide important leads to other 
scientific groups, publications, and terms of art. 
4 Teams conducting FTO analyses will also need to understand precisely what the 
product is, how it was developed, what materials were used, and what reports were 
prepared. The purpose is not to check on the work, but to ascertain that all relevant 
information has been considered in the FTO analysis. It is important also to know what 
tangible property from a third party contributed to a product. A scientific member of 
an FTO team will need to provide this type of basic information for the FTO analysis. 
One of the best ways to manage that information is through careful record keeping, 
including rigorously kept laboratory notebooks. 
4 The results of an FTO analysis may allow you to make better use of technologies in 
the public domain and inform your choice of research tools or vector constructs. The 
analysis also may alert you to scientific discoveries and inventions related to your 
work. 
4 An FTO analysis is a foundation of IP management, but it is also something more. It 
is a way to demonstrate to your colleagues that you respect their property rights and 
understand that, when properly managed, intellectual property leads to the greater 
sharing of technology and related information. In a very real sense, it is a way of 
building relationships based on trust.
4 Both patent search engines and scientific search engines are available at no cost on the 
Internet (such as the U.S. Patent and Trademark Web site and Google® Scholar).
4 Knowledge of how to access, manipulate, and mine these tools for valuable information 
will serve you and your program well. Hence, you should encourage your staff to 
become well versed in Internet database search skills, and do not hesitate to ask your 
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4 The management of patent infringement risks requires a good knowledge of the 
strategic options available. These options include legal/licensing, business strategies, 
and R&D strategies. 
4 Unlike at a private company, where business/legal/financial conditions often determine 
R&D strategies, licensing officers in public sector institutions rarely influence 
research projects and institutional policy. The role of the technology transfer officer 
as communicator in the public sector is therefore much more important for bringing 
about an IP management “culture” throughout the organization.
4 A freedom to operate (FTO) analysis is an interdisciplinary endeavor best executed 
through FTO teams. These teams, made up of legal, business, and scientific 
professionals, are in themselves useful for strengthening intra-institutional dialogue 
and communications. 
4 The role of the technology transfer officer, and that of attorneys who may produce legal 
FTO opinions, is generally to advise senior management. It is a manager’s purview, based 
on your input, to decide how to deal with the risks identified in your FTO analysis.
4 Much work leading to a legal FTO opinion can be done in-house, working with scientists, 
technology transfer professionals, business people, and others. The role of patent 
counsel is important for formal legal FTO opinions, but this expense may not often be 
required or justified in public research settings. 
4 Evaluate the pros and cons of free versus subscription-based patent search sites. Quite 
often, free services are limited in content and scope and do not allow for myriad search 
capabilities of paid services. But many free sites, such as WIPO’s PatentScope, are 
increasingly adding extremely valuable features.
4 For an academic or public institution, legal FTO opinions are unlikely to be needed 
for the majority of technology transfer functions. They might be applicable if the 
institution is engaged in downstream product development and commercialization.
4 One way to cut costs is to conduct the background research for an FTO analysis in-
house. The compiled file of relevant art can then be provided to patent counsel, who 
can then further analyze, conduct additional searching to fill in suspected gaps, and 
render an FTO opinion. Universities with law schools might be able to give law students 
valuable internships in this manner.
4 Through good licensing practices (including appropriate indemnification provisions 
and warranty disclaimers), much of the risk associated with IP infringement can be 
transferred to licensees who take over products from the public sector.
FOR TECHNOLOGY TRANSFER OFFICERS
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Feindt1 details how the Office of Technology 
Transfer (OTT) of the National Institutes of 
Health (NIH) administers its technology licenses. 
Licensing is an important part of NIH’s operation 
and an important part of any technology transfer 
endeavor anywhere. The portfolio of licenses at 
OTT includes over 1,400 active technology li-
censes, 750 of which generate about US$100 
million in revenues.2 These licenses represent five 
types of technology licenses:
1. Commercial evaluation licenses (also 
known as options), which enable compa-
nies to provisionally evaluate whether a 
new technology suits their needs
2. Patent commercialization licenses, which 
provide access to rights in patented or pat-
ent-pending technology. These licenses can 
be either:
a. Exclusive, providing a single licensee 
with the right to practice the patent
b. Nonexclusive, providing patent rights 
to, potentially, multiple licensees 
3. Nonexclusive patent licenses for internal 
use, which provide access to tools or pro-
cesses, useful for research purposes
4. Biological materials licenses, which provide 
access to nonpatented biological materials 
5. Software licenses, which provide access to 
nonpatented software
EXECUTIVE GUIDE TO HANDBOOK SECTION 15
(VOLUME 2: PAGES 1395-1434)
Intellectual property is not a static asset. It is 
dynamic, requiring ongoing attention and man-
agement practices that will allow an institution 
to protect its value and maximize its utilization. 
Treating intellectual property as such is a funda-
mental best practice, regardless of whether an in-
stitution is public or private, whether located in 
a developed or developing country or whether its 
mission is directed toward commercial or public 
interests. Intellectual property, if it is to be an as-
set, cannot be simply be shelved and left alone, 
or even licensed and then left alone. Intellectual 
assets, with patents, as a particularly cogent ex-
ample, must constantly be managed, monitored, 
maintained, and policed as part of a continual 
“cultivation” of IP rights. 
The larger the IP portfolio, the greater the 
likelihood that disputes of one sort or another will 
arise. Few disputes end up in litigation, as there 
are many options and strategies for resolving dis-
putes. Particularly in the context of partnerships 
between entities in developing and developed 
countries, litigation would be a complicated, time 
consuming, expensive, and risk-laden process. 
As Part 7 on contracts and Part 11 on licensing 
demonstrated, good contracts and good licensing 
practices anticipate that disputes arise with part-
nerships and licenses. But the best way to avoid 
disputes is to manage agreements in a manner that 
leads to effective resolution of disputes.
Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007. 
15: Monitoring, Enforcement, and Resolving Disputes. In Executive Guide to Intellectual Property Management in Health 
and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). bioDevelopments-In-
ternational Institute (Ithaca, USA), MIHR (Oxford, UK), PIPRA (Davis, USA), and Oswaldo Cruz Foundation (Fiocruz, Rio de 
Janeiro, Brazil). Available online at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for 
noncommercial purposes is permitted and encouraged.
Monitoring, Enforcement, and Resolving Disputes
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Although the above licenses differ as to the 
types of technology licensed, the specific terms 
of the license, and the reporting obligations, one 
aspect remains consistent: every license is written 
with well-defined financial terms and clearly de-
lineated reporting obligations.
As a licensor, the NIH OTT administers, 
monitors, and enforces its technology licenses. It 
accomplishes this by monitoring licensee compli-
ance with royalty payments and reporting obliga-
tions throughout the term of the license. Typically 
this is not a confrontational relationship. Instead, 
the NIH OTT seeks to build cooperative rela-
tionships with its licensees that, in turn, facilitate 
problem-solving discussions, resolve outstanding 
issues, and identify possible opportunities for ad-
vancing commercialization of products and/or 
services pursuant to the technology license. 
In practical terms, OTT maintains licensee 
contact lists (people within the licensee organi-
zation) as they are important when royalty pay-
ments or issues of noncompliance need to be ad-
dressed. Such a list, and a certain level of personal 
rapport, greatly facilitate communication and 
save much time. Another essential operational 
procedure is maintenance of a well-organized fil-
ing system, possibly with archival, working, and 
computer files. A computer filing system can be 
structured as a searchable database for license ad-
ministration, with integrated interactive modules 
organizing data on contracts, inventions, pat-
ents and license applications, royalties, receipts, 
and reporting. (Such a database is available for 
download free of charge from the online version 
of the Handbook.)3 Many of the best practices 
listed and discussed by Feindt relate to licensees’ 
reporting obligations, to amendments to license 
agreements, and to sanctions for noncompliance. 
Amendments reflect mutually agreeable changes 
in the expectations of licensor and licensee that 
occur with the passage of time and changing cir-
cumstances; they might involve term extensions, 
royalty adjustments, or changes in the field of 
use. Sanctions, on the other hand, are unilateral 
actions by the licensor that are triggered by licens-
ee noncompliance (and may include a threat of 
license termination and even legal action in order 
to enforce lapsed financial obligations).
A different type of dispute is that of patent 
infringement. Patent infringement is, at least 
conceptually, analogous to trespass in that it is 
an invasion and/or misappropriation of another 
party’s exclusive property right. Hence, iden-
tifying and taking action to remedy infringe-
ment is an essential part of IP asset manage-
ment. There are four main categories of patent 
infringement:
1. Literal infringement, in which each and ev-
ery element of a patent claim is found in 
the alleged infringing product or process
2. Doctrine of equivalents infringement, in 
which the alleged infringing product or 
process is substantially the same as the pat-
ented product or process
3. Contributory infringement, in which a party 
contributes to infringement of a patent by 
selling a component that has no use other 
than as part of a patented product
4. Inducement to infringement, in which a 
party actively and knowingly aids and abets 
another who is directly infringing a patent
Maintaining the integrity and value of pub-
lic sector intellectual property is, as Haeussler4 
points out, a strategic process, which will vary 
somewhat depending on the category of infringe-
ment. First, it is important for a patent applicant, 
public or private, to consider claim structure and 
scope when drafting and filing patent applica-
tions. Unless the claims of a patent are sufficiently 
broad so as to confer clear economic potential, 
prospective licensees will be reluctant to enter 
into commercialization agreements or partner-
ships. Second, it is important to stay vigilant, 
establishing surveillance protocols for possible 
infringement of patents. For example, inven-
tors should be contacted, on a regular basis, and 
asked if they know of anyone who is, or might be, 
infringing their patents; in addition, technology 
transfer staff members should regularly review 
key media related to the technology in order to 
watch for potential infringers. Surveillance is not 
only sound business practice but is essential for 
maintaining and preserving patent rights. For ex-
ample, lack of enforcement can lead to a loss of 
patent rights.5  
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Patent infringement can also lead to a law-
suit. And litigation is expensive, risky, uncertain 
and often protracted. With good negotiation, a 
settlement through modified license terms often 
can be amicably reached. If litigation becomes 
inevitable, then a series of questions need to be 
addressed including whether to use in-house or 
external counsel, whether to file suit based on 
patent infringement or breach of contract, and 
where to file the lawsuit. Importantly, cred-
ible communication that the IP owner is serious 
about protecting its IP assets will go a long way 
to bringing infringers to the table to discuss the 
issues and to negotiate. Haeussler concludes that 
early communication with potential infringers, 
and good license and licensee diligence, are the 
foundations for policing and maintaining intel-
lectual property, irrespective of whether the intel-
lectual property is owned by a public or a private 
entity. Feindt, in his chapter, illustrates the im-
portance of early communication with infringers 
using examples from NIH. 
Due to the costs—and risks—associated with 
litigation, alternative dispute resolution proce-
dures, such as mediation and arbitration, should 
under many scenarios be attempted first. These 
forms of dispute resolution do not work through 
formal legal systems, but are instead set up by the 
parties involved. They are established by dispute 
resolution clauses articulated when a partnership 
is set up or a license granted—before any prob-
lems have arisen. The goal is to have an already 
agreed-upon system when difficulties arise.
There are several elements unique to arbitra-
tion and mediation that can help parties resolve 
disputes as Min discusses in detail.6 Figure 1 
shows the two processes side-by-side. For arbi-
tration, the parties have the power to decide on 
the number of arbitrators, the type of arbitration 
(ad hoc or institutional), the place of arbitration, 
the language of arbitral proceedings, and the ap-
plicable substantive law. Unlike judges, whose 
powers are defined by national laws, an arbitral 
tribunal’s powers are limited to those conferred 
by the parties. Mediation involves the same kinds 
of choices, although unlike a judge or an arbitra-
tor, whose mandate is to issue a binding decision 
or award, a mediator does not have the power to 
impose a settlement on the parties. Instead, the 
mediator serves as a catalyst for party negotia-
tions. The advantages of arbitration and media-
tion include the following:
•	 Through arbitration or mediation, the par-
ties can, using a single procedure, resolve 
disputes involving intellectual property in a 
number of countries. 
•	 In both arbitration and mediation, parties 
may resolve a transnational dispute on neu-
tral territory.
•	 Arbitration and mediation are based on the 
consent of the parties.
•	 Parties can select arbitrators or mediators.
•	 Parties to arbitration or mediation can 
keep the proceedings and any results 
confidential.
•	 The protracted nature of litigation, which 
pushes parties into multiple rounds of ap-
peals, is a common problem when litigating 
transnational disputes. The end result of ar-
bitration, however, is a final, binding award.
•	 The mediator’s role is to broaden dispute 
resolution options, allowing the parties, 
with the help of the mediator, to craft in-
novative, common-sense solutions that 
(preferably amicably) settle the dispute. 
•	 Mediation involves low risk. If a party feels 
that it is not making any progress, that the 
procedure is becoming too costly, or that 
the other party is not acting in good faith, 
the party may withdraw from a mediation 
process at any time and seek to resolve the 
dispute through litigation or arbitration.
Min provides a list of the kinds of concerns 
addressed by dispute-resolution clauses. She also 
highlights the usefulness of arbitration and me-
diation for developing countries, but public sec-
tor entities in many parts of the world will find 
the discussion, and these tools, useful. Such enti-
ties often lack the resources to pursue extended 
litigation, a process that also frequently places 
them on unfamiliar cultural and legal ground. 
By formulating dispute resolution policies, in-
stitutions in developing countries can place 
themselves in a fairer, less expensive, and less 
antagonistic forum for resolving disagreements. 
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Figure 1: Principal Steps in a Typical Mediations and (WIPO) Arbitrations
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Finally, the chapter discusses extensively the activi-
ties and services of the Arbitration and Mediation 
Center, which functions under the World 
Intellectual Property Organization (WIPO). 
A different type of dispute may emerge under 
parallel trade practices (involving “gray market” 
imports). As Matthews and Munoz-Tellez write,8 
parallel trade occurs when products produced 
under the protection of a patent, trademark, or 
copyright in one market are subsequently ex-
ported to a second market and sold there with-
out the authorization of the local owner of the IP 
right. Often, the local owner of the IP right will 
also be a local dealer who, through a license or 
other exclusive agreement, has been authorized 
by the patent, copyright, or trademark holder to 
market the protected product. Naturally, when 
the licensed dealer has an exclusive agreement, he 
or she expects to be the only party supplying the 
product in the local market. Importantly, paral-
lel trade does not refer to the trade of pirated 
or counterfeit products. These are unauthorized 
versions of products that infringe an IP right. 
Parallel imports, on the other hand, are im-
ports of genuine, often branded, products that 
do not violate an IP right per se, but importing 
the product will not have been authorized by the 
right holder. 
Engaging in parallel trade is a legal option 
provided within the Agreement on Trade-Related 
Aspects of Intellectual Property (TRIPS). The 
Doha Declaration reaffirmed that developing 
countries can use parallel imports to support 
public health. Such countries can obtain access 
to lower-priced patented and/or branded prod-
ucts, such as medicines and basic agricultural 
inputs, by incorporating legislation to allow for 
parallel imports. TRIPS permits member states 
of the World Trade Organization (WTO) to de-
sign their own exhaustion of patent rights regimes. 
Hence, the state’s legal framework for parallel 
trade is based on its own exhaustion of patent 
rights doctrine:
• national exhaustion, whereby the exclusive 
rights of patent holders cease only after the 
first sale of a product within the national 
borders (parallel imports can be blocked at 
the border)
• regional exhaustion, whereby the exclusive 
rights of patent holders cease after the first 
sale in the regional market (parallel trade 
permitted within the regional group)
• international exhaustion, whereby the ex-
clusive rights of patent holders cease after 
the first sale in any market (parallel trade 
permitted)
The chapter focuses on how parallel trade can 
provide developing countries with greater access 
to medicines and to basic inputs for agricultural 
production (such as pesticides and fertilizers) at 
lower prices.
Thus, developing countries can incorporate 
into their national laws the principle of interna-
tional exhaustion of rights, thus allowing for par-
allel imports on an international scale. In other 
words, developing countries can decide whether 
or not to allow parallel importation for all or par-
ticular IP rights. 
Although parallel trade has obvious benefits 
for developing countries, there are also potential 
disadvantages. For example, the chapter notes 
that parallel trade might:
•	 reduce incentives for investment in the 
pharmaceutical and agricultural sectors
•	 reduce the incentives for rights holders 
to donate products at low cost or free of 
charge to developing countries due to fear 
of re-importation elsewhere
•	 reduce the willingness of rights holders or 
licensed local owners to supply particular 
markets
When implementing measures to facilitate 
parallel trade, developing countries should en-
sure an effective system by adequately regulating 
the quality and safety of parallel imports. At the 
same time, they need to prevent low-priced pat-
ented products in developing countries from en-
tering high-priced developed country markets. 
Otherwise, patent holders, particularly in the 
pharmaceutical industry, could be discouraged 
from pricing their products differently in different 
markets in order to benefit developing countries. 
The chapter offers model legislative provisions to 
enable parallel imports and concludes by urging 
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policymakers in developing countries to promote 
access to medicines and to support poor farmers 
by fully utilizing the parallel trade options avail-
able under TRIPS. ■
All chapters refer to: Intellectual Property Management in 
Health and Agricultural Innovation: A Handbook of Best 
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thom-
son, AB Bennett, K Satyanarayana, GD Graff, C Fernandez, 
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis, 
U.S.A. Available online at www.ipHandbook.org. The online 
version contains for each chapter a detailed Editor’s Sum-
mary, Implications, and Best Practices.
1 Chapter 15.1 by HH Feindt titled Administration of 
Technology Licenses, p. 1395.
2 Although impressive, such revenue flow is not the 
OTT’s principle mission. Rather, by instituting and 
running an organized and professional office, the NIH 
furthers its mission of a timely introduction of new 
products and technologies into the marketplace. In 
this way, the fruits of NIH research and development 
are made commercially available, fostering economic 
development and serving the greater public good 
through the introduction of critical advances in 
health care. Furthermore, the NIH OTT fully recognizes 
that potential licensees will be from both developed 
and developing countries, such that the range of 
beneficiaries is truly global in scope.
3 This database has been provided by the Whitehead 
Institute for Biomedical Research. See also Chapter 
6.12 by A Hamzaoui titled WIIPS™: Whitehead Institute 
Intellectual Property System (A Relational Database for 
IP Management and Technology Transfer), p. 649.
4 Chapter 15.2 by HW Haeussler titled Policing Intellectual 
Property, p. 1405.
5 This may happen pursuant to two defenses in 
equity: (1) laches, when the patentee waits too long 
(an inexcusable delay) before taking action against 
a presumed infringer and (2) equitable estoppel, 
when the presumed infringer, relying on actions 
or communications from the patentee, reasonably 
believes that he or she can practice the patented 
product or process.
6 Chapter 15.3 by EJ Min titled Alternative Dispute-
Resolution Procedures: International View, p. 1415. 
7 Ibid.
8 Chapter 15.4 by D Matthews and V Munoz-Tellez titled 
Parallel Trade: A User’s Guide, p. 1429.
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 A fundamental best practice in IP management, regardless of whether an institution is 
public or private and whether located in a developed or developing country, is to view 
intellectual property as an evolving and dynamic asset requiring ongoing attention, 
management, monitoring, and policing. Only such an “IP cultivation” will allow 
institutions to protect the value and utility of the intellectual property. 
4	 A country’s statutory code, combined with a reliable system of fair adjudication 
and judicial enforcement, is the requisite basis for enforcing institutions’ IP rights. 
Supporting policies that promote this legal infrastructure is essential. 
4	 court action is often stymied because of cost, length of procedure, legal uncertainty, 
the decision maker’s lack of expertise, confidentiality/publicity, the difficulty of 
seeking action in foreign jurisdictions, and the negative impact on existing business 
relationships. But public and private institutions alike should always have the flexibility 
to opt for court action if this seems to be in their best interests.
4	 Policymakers should strive to promote policies and advocate for laws that encourage 
alternative dispute resolution procedures as the best alternatives for settling differences 
between parties to an agreement. These procedures are particularly important in 
international contract dispute resolution. 
4	 Governments and public institutions can help make arbitration or mediation procedures 
accessible and available by identifying and supporting neutral institutions that can 
provide cost-efficient, timely dispute-resolution services. The World Intellectual Property 
Organization offers such services through the wiPo Arbitration and mediation center.
4	 Pursuant to the TRIPS Agreement and the Doha Declaration provisions on parallel 
trade, countries can implement patent rights exhaustion regimes that either permit 
or restrict parallel importation. As a result, developing countries can decide whether or 
not to allow parallel importation for all or for particular IP rights. Despite the evident 
benefits of parallel trade, there are also disadvantages, and both the benefits and 
the risks should be carefully considered. (Drawbacks of broad parallel importation 
practices include the reduction in incentives for investment in the pharmaceutical 
and agricultural sectors and the reduction in incentives for rights holders to donate 
products at low cost or free of charge to developing countries due to fear of re-
importation to lucrative developed country markets. Re-importation hinders the ability 
of governments in different countries to maintain price controls on pharmaceutical 
products within their territory and reduces the willingness of rights holders or licensed 
local owners to supply particular markets.)
FOR GOVERNMENT POLICYMAKERS
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 A fundamental best practice in IP management is, regardless of whether an institution 
is public or private and whether located in a developed or developing country, to view 
intellectual property as an evolving and dynamic asset requiring ongoing attention, 
management, monitoring, and policing. Only such an “IP cultivation” will allow 
institutions to protect the value of intellectual property and maximize its utility. 
4	 Your institution’s technology transfer office should have systematic procedures to 
administer, monitor, and enforce its technology licenses. This includes compliance with 
royalty payments and reporting obligations in a nonconfrontational manner. 
4	 Public and private institutions alike should always have the flexibility to opt for legal 
action if this seems to be in their best interests. But legal action is often stymied because 
of cost, length of procedure, legal uncertainty, a decision maker’s lack of expertise, 
confidentiality/publicity, the difficulty of seeking action in foreign jurisdictions, and the 
negative impact on existing business relationships. 
4	 Encouraging alternative dispute resolution procedures can be a viable strategy and, 
indeed, often a preferred one, for settling differences between parties to an agreement. 
These are particularly important in international contract dispute resolution. 
4	 Public sector institutions should have an institutional policy on the use of arbitration 
and mediation.
4	 Public institutions can help make arbitration or mediation procedures accessible and 
available, by identifying and supporting neutral institutions that can provide cost-
efficient, timely dispute resolution services. The World Intellectual Property Organization 
offers such services through the wiPo Arbitration and mediation center.
4	 Where permitted by national legislation, parallel importation may provide universities 
and public sector research institutes with  lower-cost access to legitimate imports 
produced in other markets. 
4	 For universities and research institutes in particular, parallel importation may have 
substantial benefits as it allows for the lower-cost import of copyrighted products 
(books, computer software, periodicals, and related products). Hospitals may also 
benefit from parallel-trade imports by access to cheaper, patented pharmaceutical 
products. Sometimes, however, the final cost of the parallel-imported product is higher 
than locally supplied goods, while quality and warranty may be lower.
4	 But parallel importation also has drawbacks. These include the reduction in incentives 
for investment in the pharmaceutical and agricultural sectors and the reduction in 
incentives for rights holders to donate products at low cost or free of charge to developing 
countries due to fear of re-importation to lucrative developed country markets.
FOR SENIOR MANAGEMENT
(UNIVERSITY PRESIDENT, R&D MANAGER, ETC.)
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
GUIDE TO SECTION 
4	 A fundamental best practice in IP management, regardless of whether an institution 
is public or private and whether located in a developed or developing country, to view 
intellectual property as an evolving and dynamic asset requiring ongoing attention, 
management, monitoring, and policing. Only such an “IP cultivation” will allow 
institutions to protect the value of intellectual property and maximize its utility. 
4	 As a scientist, you should regularly review all of the agreements that relate to your 
projects. This specifically includes ensuring that milestones are met, royalties paid, and 
that any other obligations are taken care of.
4	 Your institution should continuously monitor patent infringements through various 
surveillance protocols. A lack of patent enforcement can lead to a loss of patent rights. 
Your role in this is important, since you are well connected in the area of your research 
and can indicate to the technology transfer office which companies might be practicing 
your inventions.
4	 Keep laboratory records and notebooks organized, ideally consistent with your 
institution’s laboratory notebook policy. These can be essential for drafting patent 
applications, prosecuting patents and, if necessary, pursuing litigation. 
4	 If your institution conducts alternative dispute resolution procedures such as mediation 
or arbitration, you might be called upon to participate, particularly if aspects of your 
research program are involved in the ongoing discussions. 
4	 If your university or institution is in litigation with a partner you have been collaborating 
with, do not let disputes interfere with your research or your relationships with colleagues 
at the other institution. Many companies litigate with other parties while, at the same 
time, negotiating on other licenses or joint ventures with that party. litigation is nothing 
personal and should never influence your research collaboration. Notwithstanding this, 
you should always be cautious when speaking about matters related to the topic of 
dispute. It is best never to comment on ongoing litigation matters.
FOR SCIENTISTS
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 A fundamental best practice in IP management, regardless of whether an institution is 
public or private and whether located in a developed or developing country, is to view 
intellectual property as an evolving and dynamic asset requiring ongoing attention, 
management, monitoring, and policing. Only such an “IP cultivation” will allow 
institutions to protect the value of intellectual property and maximize its utility. 
4	 A technology transfer office must have systematic procedures to administer, monitor, 
and enforce its technology licenses. This includes compliance with royalty payments 
and reporting obligations in a nonconfrontational manner. 
4	 A TTO should regularly review active license agreements. This specifically includes 
ensuring that milestones are met and royalties paid.
4	 Potential patent infringements should be monitored continuously through sound 
surveillance protocols, and action taken to remedy infringement is an essential part of IP 
asset management. The lack of patent enforcement can lead to a loss of patent rights.
4	 If litigation seems to become inevitable, credible communication that the IP owner is 
serious about protecting its IP assets will go a long way to bringing infringers to the 
table to discuss the issues and negotiate a mutually beneficial outcome. Importantly, 
early communication with potential infringers and good license and licensee diligence, 
are the foundations for policing and maintaining intellectual property, irrespective of 
whether the intellectual property is owned by a public or a private entity. 
4	 Essential to contract management is a well-organized electronic filing system, possibly 
with archival, working, and computer files with integrated interactive modules 
organizing data on contacts, inventions, patents and license applications, royalties, 
receipts, and reporting. A TTO should establish such a system as early as possible and 
before the number of agreements and licenses becomes large.
4	 The online version of the Handbook allows users to download an electronic contracts- 
management system free of charge.
4	 Most iP disputes should not end up in litigation, as there are many options and 
strategies for resolving disputes. Good contracts and good licensing practices anticipate 
that disputes arise with partnerships and licenses. 
4	 mediation and arbitration can be effective dispute-settlement procedures, provided 
they have been agreed upon and established in contract clauses at a time when a 
license or partnership is being negotiated—and before any problems arise. 
4	 The success of an arbitration or mediation depends largely on the “quality” of 
the arbitrators and mediators. The challenge is often to find candidates who have 
arbitration/mediation skills, have experience with the specialized knowledge of the 
disputed subject matter, and are acceptable to both parties. 
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have increasing economic value. Deep concern 
over an environmental crisis was widely expressed 
for the first time in an international forum at the 
United Nations Conference on Environment and 
Development, commonly known as the Earth 
Summit, held in Rio de Janeiro, Brazil, in 1992. 
Concurrent to these activities, biotechnology 
emerged and with it came the promise of creat-
ing life-saving new drugs from genetic resources. 
Modern biotechnologies allowed new and novel 
uses of biological resources, giving additional 
value to biodiversity. At the confluence of these 
world events new concerns emerged over owner-
ship, over the contributions of generations past, 
and over traditional knowledge (TK) held by in-
digenous populations. In short, equity concerns 
arose.
Equity is a moral issue that has repercus-
sions with respect to the distribution of benefits 
and environmental conservation. However, eq-
uity is in the eye of the beholder; different in-
dividuals come to different conclusions about 
what is equitable and about how to achieve eq-
uity. Unfortunately, market systems created to 
place a price on equity do not work because mar-
ket systems are constrained in what they mea-
sure. Furthermore, with regard to indigenous 
knowledge, because its products are intangible, 
once the knowledge or information is dissemi-
nated, control over the knowledge is lost. From 
an objective standpoint, that knowledge has no 
EXECUTIVE GUIDE TO HANDBOOK SECTION 16 
(VOLUME 2: PAGES 1437-1559)
Humankind has always been—and will always 
be—completely dependent on the Earth, there-
fore our treatment of it is paramount to our sur-
vival. We have relied particularly on its wealth of 
biological resources and its biodiversity. For mil-
lennia, a balance has existed between the produc-
tion and consumption of resources. The impact 
of people on the environment has made relatively 
few irreversible changes over this time. That is, 
until recently. Suddenly, the impact of these en-
vironmental changes on human activities (such 
as agriculture, increasing populations, industri-
alization, and rising rates of consumption and 
standards of living) has became clear. The root of 
biodiversity loss and environmental degradation 
is the notion that biodiversity is the “common 
heritage of mankind” (sic) and must be preserved 
for future generations. This means that, while the 
environment belongs to no one, it is entirely our 
collective responsibility. 
Beginning some 50 years ago, biodiversity 
losses began to increase at an alarming pace. 
Desertification became a recognized problem in 
many regions of the world with ensuing biodi-
versity loss. By the late 1970s, biodiversity loss, 
desertification, and even climate change, had be-
gun to receive significant international attention 
as more and more people began to recognize that 
the Earth’s resources were finite and that our ac-
tivities were unsustainable. Due to a accelerating 
depletion of resources, these resources began to 
Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007. 
16: Bioprospecting, Traditional Knowledge, and Benefit Sharing. In Executive Guide to Intellectual Property Management in 
Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, 
UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International In-
stitute (Ithaca, USA). Available online at www.ipHandbook.org.
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direct monetary value unless the knowledge can 
be translated into a market-based commodity (or 
service), whereby the value of different contribu-
tions (knowledge, technology, labor, capital, and 
so forth) can be quantified and traded. 
In addition to these problems, the west-
ern system of IP (intellectual property) rights, 
particularly patenting, is based on the premise 
that anything that is already known cannot be 
protected. Indigenous knowledge is often com-
munal, has been disclosed, and has been passed 
on from previous generations. The very nature of 
indigenous knowledge, therefore, does not meet 
the criteria for intellectual property in today’s IP 
system. Not surprisingly, some people view the 
use of TK in modern science as a form of biopi-
racy, which is the unfair acquisition of biologi-
cal resources and/or associated know-how. Some 
even argue that the modern IP rights system has 
harmful effects on indigenous peoples. 
Karjala1 breaks down these arguments into 
two distinct issues: 
• Biopiracy: to what extent do patent systems 
exploit traditional indigenous knowledge? 
• Patenting of living organisms: how can we 
justify patenting gene-sequence and gene-
product information taken from living or-
ganisms (especially humans) when these are 
naturally occurring substances? And if pat-
ented, how do we answer the ethical ques-
tions surrounding such patents?
Karjala argues that the core of the biopiracy 
problem is not patenting inventions derived from 
traditional indigenous information, but rather bi-
opiracy is unfair acquisition (misappropriation) 
of knowledge and the inequitable distribution 
of benefits derived from developing such infor-
mation into valuable commercial products. But 
he cautions against exclusive information rights 
outside the patent and copyright regimes for in-
digenous peoples, pointing to the need for incen-
tives for product development. Provided that tra-
ditional information is given voluntarily and that 
fair compensation is paid to the group who owns 
the information, it is not the use of TK in a pat-
ent that is inherently wrong. Therefore, the ques-
tion becomes one of how to provide for equitable 
benefit sharing of TK that finds its way into patent 
applications and is subsequently commercialized. 
Policymakers ought to formulate methods 
for equitable access to the TK held by indige-
nous societies and for compensating its owners. 
However, this issue involves a delicate balance: ac-
cess should be granted only via authorized permis-
sion, yet the price that is assessed for permission to 
bioprospect should not be so high that it dissuades 
companies and individuals from seeking access. 
Although nothing in extant patent statutes 
or international IP/trade agreements requires that 
naturally occurring chemicals (such as DNA se-
quences and genes and their natural products) be 
treated as patentable subject matter per se, these 
can be patented once utility and novelty require-
ments are met. Patenting natural products, how-
ever, is not the unique concern of indigenous 
peoples. It is also a concern of policymakers in 
developing and developed countries. 
Furthermore, patents on upstream “inven-
tions,” (in this context, isolated genes) might in-
hibit subsequent downstream research and devel-
opment. This is because the upstream patenting 
of natural products (such as specifically isolated 
gene sequences) would effectively eliminate down-
stream incentives for inventive activity. Also, such 
patents would inhibit information flow, thus pro-
moting over investment in the search for genes 
and under investment in the utilization of genes 
for advanced applications. 
The important ethical issues raised by gene-
related patents include whether: 
• private control over genes or their prod-
ucts monopolizes the “common heritage of 
mankind” 
• patents denigrate human life by reducing it 
to a commodity 
• patents may be inconsistent with individual 
or collective privacy
• patents promote or inhibit distributive jus-
tice when they are concentrated in a few 
economically developed countries. A relat-
ed concern is that patents on crop varieties 
might threaten biodiversity. 
Importantly, Karjala notes that these issues 
affect both indigenous and non-indigenous 
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populations. In addition, where there are dif-
ferences in how costs or benefits are distributed, 
patenting is not necessarily the problem. In ne-
gotiating technology transfer and access, the au-
thor proposes that careful cost/benefit analyses 
should guide decisions. 
Interpreting the concept of the common heri-
tage of mankind broadly, one can include nearly ev-
erything (in other words, the common heritage is not 
limited to indigenous peoples). Therefore the con-
cept does not represent an ideal paradigm for build-
ing a legal strategy. Hence, traditional patent law is 
a better approach. The real question is not whether 
a gene or a gene product should be protected as the 
common heritage of humankind, but whether or not 
it is even an invention within the well-established 
strictures of patent rules and regulations. 
As for the commoditization of genes, it is 
difficult to see how this would impact most in-
digenous societies that, for the most part, are far 
removed from the commodity markets of devel-
oped countries. Furthermore, the human genes 
at issue would most likely confer some sort of 
positive advantage and would therefore not im-
plicate either privacy concerns or stigmatization. 
Once again, patent law would likely most effec-
tively address genes with potential commercial 
value. Nevertheless, freely available information 
should not be protected by IP rights. If IP protec-
tion is appropriate, possibly other forms of statu-
tory protection would be more suitable, such as 
breach of confidence or privacy rights. 
One critical concern is whether patenting 
conflicts with indigenous knowledge and value 
systems. In a theoretical sense, patents can signifi-
cantly add costs to new inventions and thereby act 
as barriers. However, when one balances the costs 
and benefits of patent law in developing coun-
ties, there may be little correlation between access 
and patent status. Furthermore, as Karjala points 
out, there would be essentially no financial loss 
to owners of patented biotechnology products 
if they were to sell at cost in such countries, as-
suming no redirection of such biotechnology to 
more lucrative markets. However, the prevention 
of product “leakage” would entail enforcement 
capacity, and this sort of distribution is not fea-
sible without strict market segmentation.
Costanza, Christofersen, Anderson, and 
Short2 add to this analysis of bioprospecting by 
presenting practical examples of how indigenous 
peoples and companies can reach agreements 
that are fair by most standards and conducive to 
further collaboration. The authors explain that in-
ternational agreements such as the Convention on 
Biological Diversity (CBD) and the International 
Treaty on Plant Genetic Resources (ITPGR) pro-
vide a broad framework for protecting and utiliz-
ing genetic resources.
For bioprospecting activities, companies 
choose countries that have unique and protected 
ecosystems, a solid legal framework, sufficient 
political will, fair and equal treatment for all ac-
cess seekers, and strong science experts or insti-
tutions to partner with. Countries will seek part-
nerships with foreign companies and universities 
that adhere to international conventions and best 
practices, and that have an established track re-
cord. Guiding principles for a successful partner-
ship between collaborators in the host country 
and a company include a commitment between 
parties to maintain a fair, trusting, long-term rela-
tionship, with an efficient and reasonable autho-
rization process, and equitable sharing of benefits 
between partners. 
However, international agreements do not 
provide detailed guidance on structuring the 
relationships between parties involved in com-
mercial bioprospecting activities. Companies 
involved in the exploration, screening, and use 
of genetic resources have begun to accumulate 
experience with building such relationships, in-
cluding selecting countries with rich biodiversity, 
selecting partners, and drafting terms in biodiver-
sity access agreements (BAAs) that govern these 
relationships. 
In order to be successful, these BAAs must 
have a clear definition and assignment of legal 
rights to all genetic resources involved. Informed 
consent from all domestic parties affected by the 
bioprospecting, including landowners and man-
agers, must be attained prior to partnership. There 
must exist a clear delineation of rights to patent 
and commercialization of the products derived 
from these endeavors. Each BAA is a confidential 
document, which supports a lack of competition 
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among the partners to the agreement, and does not 
allow the transfer of proprietary technologies or 
technical capacity to third parties or exclusivity. 
Identification of the parties to the BAA can 
be complicated because there may be multiple 
agencies within a country that have authority 
over access to genetic resources. There may also 
be multiple parties, such as landowners or com-
pany managers who could legally prevent access 
to or receive compensation for the resource if and 
when they are affected by the biodiversity pros-
pecting. Each country that is a signatory to the 
CBD has a responsibility to establish a national 
focal point for access and benefit sharing,3 a desig-
nated individual and national office that is able 
to identify all necessary authorities and potential 
claimants for the partnership.
The rights that need to be spelled out in a 
BAA include rights to retain or distribute sam-
ples, rights to intellectual property under differ-
ent scenarios, (such as conditions of discovery 
and invention) and rights to publish discoveries 
and inventions. Responsibilities, such as the han-
dling of reporting, communications, and admin-
istrative filings also need to be spelled out.
The parties should come to an understanding 
about the relative importance or value of each of 
their contributions (such as carrying out sampling, 
cleaning, or analyzing). This will directly affect 
the equitable sharing of any benefits arising from 
collaborative activities. Given the nature of bio-
prospecting and the regions where bioprospecting 
is often conducted, the full scope of returns is un-
derstood to include both financial and nonfinan-
cial components (that is, various sources of poten-
tial value to the individual parties). The possible 
returns can also be divided roughly into short-
term, medium-term, and long-term time frames. 
Thus, a BAA has enormous flexibility for struc-
turing the terms of compensation to the parties. 
While advanced payments, sample fees, running 
royalties, and milestone payments—terms typi-
cal of many technology agreements—are available 
for financial benefit sharing, there are many more 
possibilities, including the provision of equipment 
and infrastructure, sharing of IP rights or rights 
to product sales, funding of related research, and 
assistance with conservation services.
Despite progress on the technical side, a BAA 
almost always creates controversy. The natural re-
sponse of governing authorities is to move slowly, 
fearing criticism from competing domestic in-
terests and international groups that watch out 
for cases of undervaluing biodiversity and non-
support for economic development. Many such 
groups consider the private sector to be inherently 
corrupt; thus, no matter what benefits are offered 
the arrangement is perceived to be inequitable. 
Ironically, this reaction reflects negatively on those 
companies taking the lead in supporting the CBD 
and creates strong disincentives to engage in bio-
prospecting or to share information about such 
endeavors. This in turn, decreases the very value 
of biodiversity resources. In the end, the commit-
ment of both parties to a sustainable and rational 
use of biodiversity in a way that both encour-
ages commercial development and protects the 
unique resources of the Earth is as important as 
the technical aspects of deal making. 
The technical aspects of technologies, how-
ever, must still be mastered. Indeed, there is an 
emerging new regime, Thornström4 calls it a 
“world order,” regarding biological matter: an in-
ternational regime which govern access to genetic 
resources and the sharing of benefits arising from 
their use. The chapters by Thornström and by 
Thornström and Björk,5 explore the what, why, 
and how of this new regime. The authors provide 
the reader with a comprehensive road map for 
understanding the details and finding the correct 
path to compliance with the laws, rules, and regu-
lations that cover access in a given country. 
The new regime is driven by access and 
benefit-sharing (ABS) systems, which apply to 
research carried out for either scientific or com-
mercial purposes. ABS involves accessing organ-
isms, or parts thereof, and related TK, that are 
obtained (accessed) from a country that is party 
to the CBD. In addition, other international 
treaties, accords, and agreements have also added 
new legal ABS regimes legislation through the 
acquisition and use of biological material and re-
lated information. 
Everyone (tourists, nature conservationists, 
scientists, photographers, journalists) is sub-
ject to these new ABS regulations, but the ABS 
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system especially affects scientists and researchers 
who seek to access and use proprietary genetic 
resources, other biological matter, and related in-
formation, such as TK and farming know-how. 
In national legislation, such knowledge may be 
treated as intellectual property or confidential 
trade secrets, putting it outside the public domain 
and not subject to any form of unauthorized ap-
propriation. Violation by foreign parties (such 
as scientists conducting unauthorized collection 
activities) of the new ABS regimes may result in 
a range of negative and stringent consequences; 
fines and/or imprisonment, denial of future visits 
to the collection site or country, increased trans-
action time for obtaining formal access permits, 
and/or denial of access to colleagues of the vio-
lator. Obviously, it’s important to know how to 
properly proceed. 
To understand the fundamental principles of 
ABS, one needs to know the relevant rules, regu-
lations, laws, customs, and conditions for benefit 
sharing in the country where one intends to con-
duct research and/or collect samples. Basic ques-
tions to ask before collecting include:
• Under which conditions may I, as a scien-
tist, enter another sovereign state’s territory 
in my scientific capacity?
• Under which conditions may I, as a scien-
tist, collect biological material and related 
information?
• Under which conditions may I, as a scien-
tist, carry out or export biological material 
and related information from that sover-
eign state’s territory?
• Under which conditions may I, as a scien-
tist, make further use of collected biological 
material and related information?
Thornström and Björk present a practical 
overview of the principles and procedures under-
lying ABS regimes that will be useful to various 
types of research and access situations. The au-
thors also provide a series of template documents 
as illustrative examples of what might be neces-
sary, depending on the specific requirements of 
the collection activities. To assist in understand-
ing the various ABS scenarios and the documents, 
potentially applicable letters and agreements are 
presented as examples, such as letter of intent, 
research permit, prior informed consent (PIC), 
mutually agreed terms (MAT), model or material 
transfer agreement (MTA), and confidentiality 
agreement.
Although all of this might seem daunting 
initially, the documents are necessary, and in a 
growing number of countries are required by 
law. Careful planning and management will pay 
off in the long term, since they minimize the pos-
sibility of misunderstandings and other problems 
and, in turn, can reduce the chance that legal 
problems will arise. Perhaps most importantly, 
these ABS regimes are in place to facilitate the 
building of solid, equitable, and sustainable net-
works for future partnerships. 
Drawing on the experiences of exemplary 
partnerships, Soejarto and colleagues6 explain an 
organizational model for the responsible gover-
nance of bioprospecting arrangements between 
institutions in developed and developing coun-
tries based upon the International Cooperative 
Biodiversity Groups (ICBG) program of the 
U.S. National Institutes of Health (NIH). The 
model assumes that resources and expertise from 
both the North and the South are required for 
bioprospecting to succeed. Incentives need to 
be properly aligned for both regions to be fully 
engaged and committed. To align incentives, the 
ICBG model offers a clear definition of the ben-
efits that might arise from a project, a clear recog-
nition of all parties involved, negotiation guide-
lines for the parties, and a formal structure for the 
resulting agreement. The agreement contains the 
scope and objectives of the project, the long-term 
benefit-sharing scheme, and milestones, as well as 
terms for IP ownership, informed consent, and 
royalty distribution. Details of how the ICBG 
model works in practice are illustrated with an 
example of one such bioprospecting arrangement 
between the University of Illinois at Chicago 
(UIC), research institutes in Vietnam and Laos, 
and GlaxoSmithKline. 
Informed consent was another critical is-
sued to be covered. In this case, informed consent 
offered provisions for the collection and use of 
plant/genetic materials and for individuals and 
their communities regarding traditional medicinal 
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use or uses of a plant. In addition, prior informed 
consent was to be secured before the implemen-
tation of the work. The governments of Vietnam 
and Laos were acknowledged as the owners of the 
genetic materials and their derivatives in their re-
spective countries. 
Fundamentally, the ICBG model rec-
ognizes and emphasizes the importance of 
several parties and the outcomes they seek. 
Often overlooked in typical international 
research consortia and business agreements, 
these additional parties include poor com-
munities and the regional authorities in loca-
tions where biodiversity prospecting is to be 
conducted. The additional objectives include 
biodiversity conservation, institutional capac-
ity building, and regional economic develop-
ment. The standards established by the ICBG 
program emphasize the core principles of ca-
pacity building and community reciprocity. 
Bioprospecting activities such as those out-
lined in this chapter, in which poor commu-
nities in developing countries are cooperating 
with clear understanding and goodwill, can 
thus serve as a model for future similar agree-
ments and initiatives. 
This is not to say that the conceptual sys-
tems of developed countries work are transfer-
able to developing countries, as the final two 
chapters of this section demonstrate. According 
to Hansen and Van Fleet,7 indigenous knowl-
edge, or TK, particularly that which involves a 
region’s native flora and fauna (biodiversity), is 
not fully amenable to the legal constructs of in-
tellectual property. Fundamentally, TK is cumu-
lative, communal, and largely undocumented in 
the formal literature. Because of these character-
istics, TK often does not fulfill novelty require-
ments for establishing IP rights or the condi-
tion that ownership of the intellectual property 
resides with an individual or individuals. Indeed, 
in the case of TK, it may be exceedingly difficult 
to identify the original individual inventors or 
authors, or even the current holders or curators 
of the knowledge. Finally, because TK is large-
ly unrecorded but exists as “living” knowledge 
passed from individual to individual orally or 
through observation and apprenticeship, it is 
largely unavailable for consideration by IP of-
fices of novelty within the complete repository 
of human knowledge. 
But despite these difficulties in applying the 
criteria for intellectual property to TK, a number 
of forms of IP rights protection (primarily trade 
secrecy, geographical indications, plant variety 
protections, and patents) can be and have been 
used to establish ownership over elements of TK. 
However, the imperfect fit of TK into the defini-
tion of intellectual property has led to two inter-
related dilemmas: 
• In some cases, those who were not part of 
the indigenous community from which 
the TK originated may be able to use, and 
even to establish ownership over, elements 
of the TK without acknowledgment of (or 
recourse to) that indigenous community 
• Those in indigenous communities who 
do hold TK may not be able to establish 
ownership, or even gain acknowledgment 
from others.
To address the first dilemma, anyone should 
make sure TK is disclosed, which will establish 
it as prior art. There are a variety of strategies to 
assist in establishing prior art status of TK. For 
the majority of TK, a defensive disclosure in the 
public domain (such as via a public registry) can 
prevent illegitimate IP claims over existing TK. 
For TK to which IP protections more easily ap-
ply, the TK holders may be able to themselves file 
applications. In addition, governments should re-
quire prior informed consent to be obtained from 
indigenous communities or national authorities 
when engaging in activities that could lead to the 
claiming of IP rights based on TK.
To address the second dilemma—that of 
maintaining control over TK—indigenous hold-
ers of TK can seek to use forms of IP protection. 
Hansen and Van Fleet discuss the advantages 
and disadvantages of the various options avail-
able. At least initially, most TK approximates a 
trade secret, and so it might easily be maintained 
within the original community as a trade secret. 
However, before the knowledge is more widely 
disseminated it may be necessary to use other 
forms of IP protection, including geographic 
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indication, trademarks, plant variety protection, 
petty patents or utility models, or patents. 
In the longer term, governments may create 
new forms of IP protection that accommodate the 
fundamental characteristics of TK (such as under 
the aegis of sui generis systems of plant variety 
protection as defined under the Trade-Related 
Aspects of Intellectual Property Agreement). In 
addressing the dilemma of control over TK, sever-
al issues outlined in the CBD ought to be worked 
out within national legal systems. Of these is-
sues, the foremost are conditions for granting/
gaining access to genetic resources and any TK 
about them and requirements for equitable shar-
ing of revenues or other benefits that might ac-
crue from the development and use of TK-based 
technology in markets around the world.
All of these approaches to preserving and 
protecting TK require a clear identification and 
attribution of specific TK claims. This can be a 
complex endeavor, but TK is important and of-
ten even essential to the survival of indigenous 
communities. It may also be an important source 
of life-giving technological innovation that could 
benefit millions around the world. The ultimate 
goal is to develop practical solutions within our 
legal frameworks that encourage indigenous 
communities both to sustain their traditions and 
to equitably share their knowledge with the wider 
world so that all may benefit. 
Ammann8 raises a different concern about 
how we think about food in developing countries 
and its impact on the developing world. He argues 
that the commonly held distinction between or-
ganic and technologically intensive agriculture 
(focused on genetically modified organisms, or 
GMOs, or more specifically transgenic crops) 
has inhibited pragmatic approaches to creating 
agricultural management systems that build on 
local conditions, help alleviate poverty, respect 
local cultures and traditions, and draw upon a 
successful relationship with science. This distinc-
tion between organic and technologically inten-
sive agriculture is based on a deeper rift between 
systems of indigenous TK and western scientific 
knowledge, a rift that Amman contends is not 
only unproductive (hindering communication 
and exchange between the two) but artificial—
reflecting differences in “worldviews, unfounded 
theories, or quasi-religious beliefs” held by respec-
tive proponents. 
Still, the distinction between organic and 
technologically intensive agriculture is enormous-
ly significant. The designation of a technology as 
organic versus transgenic can attach very differ-
ent regulatory requirements and offer different 
marketing opportunities for the technology, thus 
strongly influencing how and whether it is used 
and what its potential value is. 
Ammann challenges the commonly held 
distinction between organic and transgenic tech-
nologies and proposes a series of tests of the defi-
nitions and principles advanced to define and 
distinguish the two. While they are different in 
some aspects, Amman finds none of the major 
distinguishing principles claimed by organic ver-
sus transgenic technology able to stand up to 
scrutiny. These include: 
• the intrinsic genetic integrity of crop spe-
cies genomes (crop species genes are not 
intrinsically more stable when considered 
transgenic or organic)
• the unnaturalness of transgenesis (transgen-
ics are just as “natural” as organics)
• stability and predictability of progeny (or-
ganics and transgenics have stable and pre-
dictable inheritance patterns that are repro-
ducible over time)
• unnaturalness of monocultures (irrespec-
tive of organic or transgenic status, growing 
all one type of either crop plant is not the 
natural state of the environment)
• erosion of biodiversity by transgenic tech-
nologies (transgenics have not been shown 
to decrease levels of biodiversity)
• systemic environmental superiority of or-
ganic versus transgenic crops (the overall 
conception that organics are superior to 
transgenics as a whole is not substantiated)
It is difficult, if not impossible, to consistently 
maintain a clear divide with respect to organic and 
biotechnology-based agricultural technology and 
methods. Yet, Ammann observes, “power struc-
tures knowledge,” and interests on both sides are 
using and benefiting from a substantiation of 
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the distinction between organic and transgenic 
agriculture. 
Practical solutions to agricultural produc-
tion—and practical solutions to medicine—could 
indeed benefit many if only we could manage 
to build bridges between TK and science-based 
knowledge systems and draw upon the best exist-
ing ideas and practices of both. ■
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Health and Agricultural Innovation: A Handbook of Best 
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thom-
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U.S.A. Available online at www.ipHandbook.org. The online 
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 Equity is a moral issue that has repercussions with respect to the distribution of 
benefits and environmental conservation. Thus, equity is in the eye of the beholder. 
4	 The western system of IP rights, and particularly of patenting, is based on the premise 
that anything that is already known cannot be protected. Indigenous or traditional 
knowledge (TK) is often communal, has been disclosed, and has been passed on from 
previous generations. the very nature of indigenous knowledge, therefore, does not 
meet some of the criteria for intellectual property protection (such as novelty). 
4	 In the longer term, new forms of iP protection that are more amenable to the 
fundamental characteristics of tK could be created by governments, such as under 
the aegis of sui generis systems of plant variety protection (PVP), as defined under the 
TRIPS Agreement. 
4	 indigenous communities often play a significant role as gatekeepers to a country’s 
potential biodiversity wealth. They are the regional specialists with respect to the flora 
and fauna. Their knowledge can often exceed that of leading scientists. 
4	 Patent laws per se do not “create” biopiracy. Rather, biopiracy is a form of 
misappropriation, unfair acquisition, and inequitable sharing of benefits with respect 
to biological resources.
4	 Policymakers ought to formulate methods for equitable access to tK held by indigenous 
societies and for compensating the TK’s owners. However, this issue involves a delicate 
balance: access should be granted only via authorized permission, yet the price that 
is assessed for permission to bioprospect should not be so high that it dissuades 
companies and individuals from seeking access.
4	 Countries should consider implementing an access and benefit sharing (ABS) regime 
that balances equitable access to biological resources, as well as related TK, with op-
portunities arising from R&D expertise of potential foreign partners in develop-
ment. Such policies should be grounded in, and consistent with, the Convention on 
Biological Diversity and the TRIPS Agreement.
4	 ABS regimes, including the process for obtaining permits, should be transparent and 
easily available to any scientist or institution that wishes to enter into biodiversity 
prospecting or collection activities. A complex system discourages foreign bioprospectors 
and may inhibit national researchers in their activities.
4	 The commonly held distinction between organic and biotechnology-based agriculture 
inhibits pragmatic approaches to creating agricultural management systems that 
build on local conditions, help alleviate poverty, respect local cultures and traditions, 
and benefit from a successful relationship with science. The world has much to gain 
by reconciling organic and biotechnology-based agriculture though realizing any gain 
will have to deal with the “power structures of knowledge,” and overcome limitations 
imposed by those people who maintain the distinctions.  
FOR GOVERNMENT POLICYMAKERS
GUIDE TO SECTION 1



























Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 The technology transfer office should work with senior management to establish 
policies and systems for accessing indigenous or traditional knowledge (TK), 
bioprospecting activities, and benefit sharing in an equitable manner. 
4	 Equity is a moral issue that has repercussions with respect to the distribution of 
benefits and environmental conservation. Thus, equity is in the eye of the beholder. 
4	 Given the complexity of the health and agricultural industry and the enormous variety 
of applications and products that could be developed through the biodiversity access 
agreement (BAA), it is very difficult to know the profit margins for a company, product, 
or application ahead of time. Technology transfer, as well as information and data 
sharing, in the long run, may be more important than royalties.
4	 With adequate funds often lacking in public sector research centers, international 
donors should seriously consider loans or grants for training and equipment purchases. 
entering into bioprospecting activities, the public sector has much to gain by:
•  having a clear institutional policy 
•  building national scientific capabilities, and along with it, the possibility of adding 
value to biodiversity elements, which increase the negotiating strengths and benefit 
sharing stipulated in contract agreements 
•  having internal capacity for negotiations, which includes adequate legal and 
counseling skills about the main aspects of commercial and environmental law 
4	 Managers can identify which nonmonetary benefits companies could provide (such 
as capacity building,and technology transfer), that would be of greatest use to the 
institution. This approach will enable flexibility in benefit sharing and sustainability in 
the R&D relationships.  
4	 Public sector institutions can provide important intellectual and programmatic 
leadership in how cross-cutting agricultural research programs can build bridges 
between TK and science and between organic agricultural and science-based 
agricultural practices. In so doing, they will help to advance the state of knowledge, the 
regulatory structure, and public perceptions of agricultural systems.
4	 The commonly held distinction between organic and biotechnology-based agriculture 
inhibits pragmatic approaches to creating agricultural management systems that 
build on local conditions, help alleviate poverty, respect local cultures and traditions, 
and benefit from a successful relationship with science. The world has much to gain 
by reconciling organic and biotechnology-based agriculture though realizing any gain 
will have to deal with the “power structures of knowledge,” and overcome limitations 
imposed by those people who maintain the distinctions.  
FOR SENIOR MANAGEMENT
(UNIVERSITY PRESIDENT, R&D MANAGER, ETC.)
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 Scientists and anyone else accessing biodiversity must ask, and answer, the following 
questions prior to initiating collecting activities: Under which conditions may I enter 
another sovereign state’s territory in my scientific capacity? Under which conditions 
may I collect biological material and related information? Under which conditions may 
I carry out or export biological material and related information from that sovereign 
state’s territory? Under which conditions may I make further use of collected biological 
material and related information?
4	 Scientists must be aware, not only of the biological and sociological value of indigenous 
or traditional knowledge and related genetic resources, but also of their potential 
commercial value. Hence, investigations and research ought to be conducted within 
guidelines set by the technology transfer office, for example, appropriate and timely 
disclosure of any potential inventions. 
4	 interactions with foreign colleagues and collaborators ought to be established 
according to institute or university policy guidelines, guidelines that are established to 
both preserve and reap the full value of these national natural resources. 
4	 When working with colleagues from foreign countries, you should be aware that 
those colleagues may be authorized to make collections of biological materials only 
under specified circumstances. Before proceeding with joint activities, check with your 
institution’s technology transfer office to make sure that all the requirements have 
been met. 
4	 It is essential to understand the fundamental principles of the Convention on Biological 
Diversity (CBD) and Access Benefit Sharing (ABS) regimes. These exist to both protect 
the resources of your country as well as to encourage collaborative projects in r&D 
that would foster a broad and equitable distribution of benefits flowing from the 
development of the country’s biological resources.
4	 The commonly held distinction between organic and biotechnology-based agriculture 
inhibits pragmatic approaches to creating agricultural management systems that 
build on local conditions, help alleviate poverty, respect local cultures and traditions, 
and benefit from a successful relationship with science. The world has much to gain 
by reconciling organic and biotechnology-based agriculture though realizing any gain 
will have to deal with the “power structures of knowledge,” and overcome limitations 
imposed by those people who maintain the distinctions.  
FOR SCIENTISTS
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Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
4	 The three guiding principles for a successful relationship in bioprospecting and related 
endeavors are a commitment to maintaining a fair, trusting, long-term relationship; 
efficient and reasonable authorization; and the equitable sharing of benefits between 
a company and its collaborators in the host country.
4	 The western system of IP rights, and particularly of patenting, is based on the premise 
that anything that is already known cannot be protected. Indigenous knowledge is often 
communal, has been disclosed, and has been passed on from previous generations. the 
very nature of indigenous knowledge, therefore, does not meet some of the criteria for 
intellectual property protection (such as novelty). 
4	 A successful biodiversity access agreement includes a clear definition and assignment 
of legal rights to all genetic resources involved; prior informed consent from all domestic 
parties affected by the bioprospecting (including landowners and managers); a clear 
statement of rights to patent and commercialize products derived from discoveries 
made; and terms of confidentiality. The BAA also establishes a noncompetitive 
relationship between the parties; trust that no transfer of proprietary technologies 
or technical capacity involved under the agreement will occur with respect to third 
parties; and that no exclusivity requirements exist.
4	 Patent laws per se do not “create” biopiracy. Rather, biopiracy is a form of 
misappropriation, unfair acquisition, and inequitable sharing of benefits with respect 
to biological resources.
4	 Prior informed consent is an important principle in bioprospecting. This should include 
informed consent in the case of collection and use of plant/genetic materials, as well as 
informed consent of individuals and their communities regarding traditional medicinal 
use or uses of a plant.
4	 When dealing with foreign bioprospectors, your office will function as the gateway and 
regulator of their activities. As such, technology transfer officers will provide oversight 
to negotiating agreements for equitable sharing of rewards, defining access, discussing 
possible patentability, and protecting the rights of the indigenous peoples who are the 
stewards of these resources. 
4	 Negotiating access to your country’s genetic resources, biodiversity, and TK will require 
a balanced, nuanced approach. equitable benefit sharing must simultaneously ensure 
fair returns to your country, yet not inhibit the R&D initiatives of foreign partners.  Solid 
agreements will benefit all parties: your country, your partnering organization, and 
the country or community that provides the resource. Extreme situations, such as an 
expectation of immediate windfall returns or wanton biopiracy by outsiders, will freeze 
the resources and ultimately lead to their demise.   
4	 Both monetary and nonmonetary benefits may be attractive to the university or 
institute; both, therefore, should be considered. Nonmonetary benefits could include 
training opportunities for scientists and donation of equipment.
FOR TECHNOLOGY TRANSFER OFFICERS
 HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE  | 1 
own institutions, of neighboring countries, and 
of countries around the globe.
ExPERIENCES FROM AROUND THE WORlD
Satyanarayana describes India’s experience 
in the pharmaceutical sector. According to 
Satyanarayana,1 during the past 50 years, India 
has made great strides in science through a se-
ries of policy initiatives promoting high-quality 
research. But especially since 2005, when India 
became fully compliant with the agreement on 
Trade-Related Aspects of Intellectual Property 
Rights (TRIPS), big changes have occurred. 
India’s rigorous IP rights regime and professional 
IP management in both private sector companies 
and public sector research institutions are driv-
ing success. But this is only part of a larger co-
ordinated attempt that includes increased public 
and private R&D expenditures, new policies gov-
erning traditional medicines, overhauled regula-
tory regimes for new drugs and biotechnologies, 
initiatives to emphasize and build on already 
competitive regions or technologies, and newly 
created governmental, research, and educational 
institutions. 
In the pharmaceutical sector, the effects of 
these policies can be seen in: 
•	 a shift in the Indian pharmaceutical indus-
try from an approach based solely on the 
low-cost manufacture of generic drugs to 
EXECUTIVE GUIDE TO HANDBOOK SECTION 17 
(VOLUME 2: PAGES 1563-1850)
“By far the best proof is experience,” wrote Francis 
Bacon. Given the experience of countries—both 
developing and developed—that have used intel-
lectual property, IP (intellectual property) protec-
tion, and IP management to stimulate innovation, 
there is ample proof that good IP management 
has benefited multitudes of people around the 
world with new technologies, products, and ser-
vices. Innovations in health and agriculture have 
greatly enriched lives. But does this experience 
apply to all countries? If the best proof is experi-
ence, then what can be said authoritatively about 
the effects of using IP systems wisely in develop-
ing countries? 
The 28 case studies in this section of the 
Handbook (and the 21 case studies in the insert 
of this Executive Guide and more online) dem-
onstrate that a great deal can be said. Developing 
countries already have a vast amount of experi-
ence with IP protection, and this experience 
proves that they can use intellectual property to 
their advantage. With more chapters than any 
other section, this portion of the Handbook amply 
reveals how developed and developing countries 
alike are deploying and adapting IP management 
to meet their needs. Tapping into the dynamism 
of product development partnerships (PDPs) 
and utilizing the potential of their universities, 
public sector institutions, and private compa-
nies, many developing countries are quickly and 
creatively building on the experience of their 
Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007. 
17: Putting Intellectual Property to Work: Experiences from around the World. In Executive Guide to Intellectual Property 
Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). 
MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-
International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for 
noncommercial purposes is permitted and encouraged.
Putting Intellectual Property to Work: 
Experiences from around the World
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research-driven innovation of novel drugs 
for the global market 
•	 the emergence of an entrepreneurial bio-
technology sector in India
•	 the consideration by multinational phar-
maceutical companies of investing in R&D 
and manufacturing operations in India 
In agriculture, these effects are apparent in a 
rich pipeline of new innovations that promise to 
make India’s agricultural sector more competitive 
and profitable. Besides a substantial allocation of 
funds for R&D by the government, two new initia-
tives were started in 2005: the National Agricultural 
Innovation Project (NAIP) and the Indo-U.S. 
Agricultural Knowledge Initiative (AKI). 
India’s transition from a protected economy 
to an open, global economic power has prompt-
ed the government to take a series of steps to 
address the new challenges of globalization, and 
the lessons it has learned apply broadly to many 
developing countries. Strengthening R&D, 
establishing policies to create and manage in-
tellectual property, and fostering PDPs are all 
important steps for making important health 
products available for public distribution avail-
able in all countries. 
According to Wolson,2 technology transfer 
offices (TTOs) are a crucial part of IP manage-
ment in South Africa. But a number of problems 
challenge nascent TTOs there: a weak flow of in-
vention disclosures, skepticism or a lack of aware-
ness among faculty about the TTO’s role, low 
levels of research funding, high patenting costs, 
few experienced technology transfer practitio-
ners, and unrealistic expectations about financial 
returns. Indeed, many there believe that the main 
motivation for undertaking technology transfer 
activities at a university is to generate income.
Solutions to these problems are being ad-
dressed organizationally by the Southern African 
Research & Innovation Management Association 
(SARIMA), legislatively by the Framework 
for Intellectual Property Rights from Publicly 
Financed Research (the Framework), and finan-
cially through the Innovation Fund. Established 
in 2002, SARIMA is a stakeholder organization 
providing a platform for those from government, 
academia, and industry with an interest in using 
research and innovation management to foster 
networking and promote common interests. 
The Framework is intended to bridge the “inno-
vation chasm”: the gap in South Africa between 
knowledge generators (in particular, universi-
ties and research institutions) and the market. 
It calls for a consistent approach to protecting 
intellectual property developed with public fi-
nancing and draws heavily on the U.S. Bayh-
Dole Act. Of course, as other countries have 
discovered, the Bayh-Dole Act cannot simply be 
imported. Its principles must be adapted to local 
frameworks and needs. In South Africa, for ex-
ample, research funding comes mostly from ex-
ternal sources and requires a different structure 
for determining the use and ownership of project 
intellectual property. 
TTOs in South Africa have already met with 
success. Some have been operating for several 
years and more are being launched. A vibrant 
stakeholder organization provides a platform for 
networking and professional development in the 
field, and links have been forged that strengthen 
international research collaborations and technol-
ogy transfer partnerships. All of this has govern-
ment support.
Other chapters in this section describe the ex-
periences of Brazil,3 Chile,4 China,5 the European 
Union,6 and Japan.7
PUBlIC SECTOR INSTITUTIONS  
AND UNIVERSITIES
Salicrup and Rohrbaugh8 provide more evidence 
of the ability of for-profit and nonprofit institu-
tions in developing countries to bring new prod-
ucts to market that meet critical regional public 
health needs. The authors discuss the technol-
ogy transfer and licensing approach of the U.S. 
National Institutes of Health (NIH). The insti-
tution’s technology transfer experience has shown 
that many combinations of licensing strategies 
can be used to segment the world market to meet 
each region’s needs. Even when patent protection 
is unavailable, unique biological materials (for ex-
ample, an essential component of a vaccine) can 
be licensed for commercial use. 
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Institutions in developing countries have 
been found to be dependable licensees and 
partners. With careful review, a capable institu-
tion with commercialization capabilities may be 
found, and one should keep an open mind be-
cause, depending on the country, it may be a for-
profit company, a nonprofit or government enti-
ty, or a semi-privatized company. NIH has several 
examples of different strategies involving various 
types of institutions that have reached the early 
stages of the commercialization process. 
While discussions continue about IP capac-
ity building in developing countries, some lead-
ing institutions are simply forging ahead and 
building their own capacity. The State University 
of Campinas, or Unicamp, one of the leading 
research universities in Brazil, is an example de-
scribed by Ceron Di Giorgio.9 A large university 
with a diversity of affiliated research institutes, 
Unicamp has moved up the patenting league 
tables in recent years to become the single largest 
patentor in Brazil. The university’s current port-
folio includes almost 50 granted, and 400 filed 
patents. Unicamp emphasizes chemistry, which 
accounts for close to half of its portfolio, and 
engineering, which accounts for a third. In ad-
dition, Unicamp conducts significant research in 
the life sciences (for example, a soy-based phy-
toestrogen for hormonal therapy licensed to a 
Brazilian pharmaceutical company).
These major advances in technology transfer 
at Unicamp are largely due to the efforts of its 
new technology transfer office, Inova Unicamp, 
founded in 2003. Inova began its operations by 
assessing all of the technologies being researched 
in Unicamp’s many laboratories and institutes. 
It then aggressively pursued new patent applica-
tions and licensing deals for the most promising 
technologies. In the short space of two and a half 
years, the office signed 128 technology transfer 
agreements with both private industry and gov-
ernment agencies. It also saw ten start-up compa-
nies in the university’s business incubator become 
self-sustaining.
What lies behind these successes in Brazil? 
New public policy. In particular, the work of 
Inova is directly informed by two pieces of legis-
lation. A 1996 law gave the university ownership 
rights to employee inventions. A 2004 law on 
innovation, however, gives the university the op-
tion to either hand over title to the employee in-
ventors, or share 5%–33% of any royalties with 
them. In addition, the government has instituted 
a number of sector-specific incentives to support 
innovation in Brazil, including tax deductions on 
royalty payments, R&D investments, and foreign 
IP filing fees, as well as subsidies to firms to help 
pay scientists’ salaries. 
The 2004 innovation law requires all govern-
ment universities and R&D institutions to open 
an IP management or a technology transfer of-
fice. One major consequence of these policies will 
likely be increased patenting and licensing activi-
ties at universities throughout Brazil. Currently, 
Unicamp’s rapid establishment of a functioning 
technology transfer office stands as a sterling ex-
ample for other institutions in Brazil to emulate.
Other case studies in this section of the ex-
periences and approaches of a range of institu-
tions include: Arizona State University10 in the 
United States, Chinese Universities,11 the Donald 
Danforth Plant Science Center12 in the United 
States, the National Health Service in England,13 
Stanford University’s Office of Technology 
Licensing,14 the University of California System,15 




Banerji and Pecoul17 describe the Drugs for 
Neglected Diseases Initiative (DNDi) that seeks 
to give patients in developing countries the op-
portunity to directly benefit from new products 
of drug R&D for diseases that lack a viable mar-
ket. Only a tiny fraction (1.3%) of the drugs that 
came to market from 1975 to 2004 targeted trop-
ical diseases (such as human African trypanoso-
miasis, Chagas’ disease, leishmaniasis, helminthic 
infections, schistosomiasis, onchocerciasis, ma-
laria, and tuberculosis) that all together make up 
12% of the global disease burden and kill more 
than 35,000 people a day. The drugs that do exist 
are either inaccessible to patients or unbearably 
costly. DNDi believes that drug research can exist 
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in the public domain, and that patented products 
do not always benefit those who need them most.
As clearly articulated in its IP Policy state-
ment, DNDi is committed to managing intel-
lectual property to pragmatically and effectively 
advance its mission of providing the most vulner-
able populations in developing countries with eq-
uitable access to critically needed medicines. As 
the preamble of DNDi’s IP policy states:
The DNDi IP approach will be pragmatic, and 
decisions regarding the possible acquisition of pat-
ents, ownership, and licensing terms will be made 
on a case-by-case basis. DNDi will put the needs of 
neglected patients first and will negotiate to obtain 
the best possible conditions for them. The DNDi’s 
decisions regarding IP will contribute to ensuring 
access and encouraging further innovations.
DNDi has led two successful campaigns to 
negotiate terms that allowed them to get impor-
tant drugs to the world’s neediest people at mini-
mal cost. In the first case, DNDi approached 
French pharmaceutical giant sanofi-aventis in 
2003 to develop artesunate-amodiaquine, a 
fixed-dose combination therapy for chloroquine-
resistant malaria. The negotiation process eventu-
ally led to a contract with very favorable terms 
for DNDi; the drug was made available for pro-
duction by generic manufacturers with no pay-
ment owed to either sanofi-aventis or DNDi, 
and sanofi-aventis agreed to supply the drug at 
cost to the public sector, NGOs, and interna-
tional organizations. In the second case, DNDi 
successfully collaborated with the University of 
California, San Francisco’s (UCSF) business de-
velopment office to support research leading to 
treatments for the lethal human African sleeping 
sickness. While conventional wisdom holds that a 
university should always seek the largest possible 
return on research investment, DNDi was able 
to convince university officials of the seriousness 
of its mission, and a compromise was reached 
that advances the effort to bring new treatments 
to persons suffering from this deadly and largely 
neglected disease. 
In pursuing its humanitarian mission, 
DNDi has learned that it is crucial to thoroughly 
familiarize all parties with the organization’s aims 
and guiding principles. By the end of contract 
negotiations with UCSF, for example, decision 
makers expressed great personal satisfaction at 
helping to advance DNDi’s work. Through simi-
lar efforts DNDi hopes to have developed and 
made available, by 2014, six to eight field-rele-
vant treatments.
Boadi and Bokanga18 describe the building of 
public-private partnerships in Africa by the African 
Agricultural Technology Foundation (AATF). 
AATF emerged from a Rockefeller Foundation ini-
tiative in the early 2000s following a wide-ranging 
and unprecedented consultation among African, 
European, and North American stakeholders 
who were, and are, actively seeking to improve 
food security and reduce poverty in sub-Saharan 
Africa. AATF recognizes that new and unique 
public-private partnerships (PDPs) are needed to 
remove many of the barriers that have prevented 
smallholder farmers in sub-Saharan Africa from 
gaining access to existing agricultural technolo-
gies. Focusing on the creation of these PDPs, it 
promotes efforts to create sustainable markets and 
seeks to dramatically improve access to agricultural 
technologies, materials, and know-how.
AATF has two unique characteristics: first, 
it is prepared to in-license technologies from 
the private sector, which it then sublicenses to 
its partners. This is no small issue and requires 
careful considerations of a range of issues, includ-
ing liability. Second, AATF strongly focuses on 
downstream activities or, to put it more broadly, 
on technology stewardship. This includes fa-
cilitating access to local, national, and regional 
markets for products based on transferred tech-
nologies. The goals are to create more sustainable 
technology transfer mechanisms and to allow 
national institutions to more effectively absorb 
new technological concepts and adopt them for 
productive use.
But the fundamental raison d’être of AATF 
goes much deeper than “merely” IP manage-
ment. As Gordon Conway, then president of the 
Rockefeller Foundation, put it in the AATF an-
nual report of 2005: 
We should examine the current system and ask 
ourselves, ‘How can those who care about the fate 
of the small-scale farmer make technological options 
more available?’ The rise of a sophisticated global 
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IP system covering many building block technologies 
has meant public researchers [in Africa] have little 
access to new ideas and tools in their field. Left to its 
own devices, the gap is likely to grow—with wealthy 
nations’ farmers using techniques that are ever more 
sophisticated and poor farmers left with the same 
tools they have used for centuries. 
Other case studies sharing PDP experiences 
describe PATH,19 and ICIPE,20 a nonprofit that 
partnered with Africert Ltd in transferring stan-
dards certification know-how, critical for the in-
troduction of new products.
FOCUS ON SOlUTIONS: ACCElERATINg 
PRODUCT DEVElOPMENT AND DElIVERY
Numerous partnership efforts are underway to 
accelerate access and delivery for agricultural and 
health products in developing countries. For ex-
ample, in the tropics, where just about everyone 
eats eggplant, it is commonly infested by eggplant 
fruit and shoot borer (EFSB), which inflicts a 
70% crop loss. Conventional efforts to breed for 
resistance have been unsuccessful, so farmers rely 
heavily on pesticides. These chemicals, however, 
are expensive, and the pest is becoming more and 
more resistant to them. Moreover, some pesticides 
damage the environment and/or are illegal. 
Recently, a new solution to the problem 
of EFSB was developed in partnership with 
many organizations, writes Medakker and 
Vijayaraghavan,21 including by MAHYCO, a 
private Indian company. It was the first company 
in India to develop a transgenic hybrid eggplant 
genetically engineered with a gene that provides 
resistance to EFSB. The gene (cry1Ac) is obtained 
from the bacterium Bacillus thuringiensis (Bt). A 
spore-forming bacterium, Bt produces crystal pro-
teins (called Cry proteins) that are toxic to many 
species of insects, including EFSB. Cultivation of 
the hybrid eggplant reduces the need for pesticide 
applications.
This breakthrough was made possible when 
MAHYCO obtained the rights under license for 
the use of the Bt cry1Ac gene technology for insect 
pest management from the Monsanto Company. 
The license also allows for sublicensing of the 
technology on a royalty-free basis to a partnership 
of public institutes and agricultural universities 
in India, Bangladesh, and the Philippines. This 
consortium is developing a nonhybrid form of Bt 
eggplant for use by farmers in developing coun-
tries. The nonhybrid form will be less expensive, 
but the yield is higher for the hybrid technology. 
Therefore, more farmers might choose the hybrid 
technology.
Commericial release of the first transgenic 
Bt hybrids developed by MAHYCO is planned 
for India by the end of 2007, after the fulfillment 
of all regulatory requirements. The transgenic Bt 
open-pollinated varieties under development by 
the public-private partnership are expected to be 
commercialized about six months later. This ap-
proach to EFSB is an excellent example of how 
biotechnology applications can be concurrently 
commercialized for the market and subsidized for 
poorer market segments.
In health, a prominent example of improve-
ment regarding access to innovations in health is 
the PATH Malaria Vaccine Initiative (MVI), a 
program funded by the Rockefeller Foundation 
that analyzed whether consolidating patents in 
the malaria vaccine field could streamline access 
by advancing and accelerating the development of 
vaccines. The project was designed to ensure mar-
ket access for the malaria vaccine candidates that 
are most likely to receive regulatory approval and 
be developed as products. The study, described by 
Shotwell,22 assessed the status of the relevant pat-
ents, determined their availability for licensing, 
and explored the potential of patent consolida-
tion or technology trust to enhance access to the 
vaccine. Developing a broad-based technology 
trust for existing malaria antigen patents was not 
recommended. Instead, several other steps were 
recommended for consolidating available rights 
and improving access with regard to future pat-
ent families. 
Before this study, MVI had identified some 
potentially obstructive IP issues for a malaria 
vaccine for developing-country markets. Public 
and academic institutions—institutions with 
missions that in many cases include some form 
of public benefit—hold many of the patents re-
lated to malaria antigenss. As the study’s findings 
reveal, with few exceptions the patents held by 
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public and academic institutions have been as-
signed or exclusively licensed to private compa-
nies and, therefore, are currently unavailable for 
licensing from the original public institution pat-
ent holders. 
While it may be possible to sublicense these 
malarial antigen patents from the current private 
holders of the technology, it is likely to be more 
difficult and costly; engaging the patent holders to 
contribute to a patent pool or clearinghouse also 
might be challenging. Moreover, a patent pool for 
a malaria vaccine might generate further obsta-
cles: potential antitrust issues, real or perceived, 
might trigger scrutiny by the U.S. Department of 
Justice and the Federal Trade Commission. And 
while the concept of a technology trust or patent 
pool may be useful for patents filed in the future, 
even some of those would be under option for 
license by the private companies holding the cur-
rent patents. Finally, the number of high-priority 
cases for any malaria antigen is small, as is the 
number of entities likely to seek access to any giv-
en patent family. This makes the expense of a pat-
ent pool even less justifiable. Taking all of these 
things into consideration means fewer missteps 
and faster progress towards a vaccine for malaria.
Other chapters in this section provide case 
studies of licensing experience related to the 
Cohen-Boyer patents at Stanford University,23 
IP issues related to molecular pharming, spe-
cifically for plant-derived vaccines,24 corn/maize 
breeding and the impact of biotechnology on the 
breeding and commercialization process,25 the 
University of California’s Strawberry Licensing 
Program26 (the most successful program in terms 
of the generation of licensing revenues of any 
U.S. university), the successful resolution of IP 
constraints that led to the introduction of virus-
resistant papayas,27 and a project on the somatic 
embryogenesis of grapes in Chile.28
CONClUSIONS
If indeed the best proof is experience, then the case 
studies described here, in the Handbook, and in the 
insert of this Executive Guide do indeed speak for 
themselves. The experiences represented by these 
case studies provide all the evidence needed to 
spur further efforts to build upon the IP strengths 
of developing countries. Many forward-thinking 
people have seen the possibilities, and this section 
broadly maps out work that is already underway 
around the globe to make these possibilities into 
realities. Such experiences offer the most powerful 
proof of the benefits that can be obtained through 
creative IP management in developing countries 
and indeed around the world. ■
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(5) copyright protection independent of whether such 
protection exists in the country of origin.
best mode - A condition for the grant of a patent, found 
in the patent specification. An inventor must describe 
and disclose the best method he or she knows for carry-
ing out the invention.
claims - The section of the patent that defines an inven-
tion (the technology that is the exclusive property of the 
patentee for the duration of the patent) and is legally 
enforceable; that is, the claims set the metes and bounds 
of the patent rights. The patent specification must con-
clude with a claim, particularly pointing out and dis-
tinctly claiming the subject matter that the applicant re-
gards as the invention or discovery. The claim or claims 
are interpreted as set forth in the specification: the terms 
and phrases used in the claims must be sufficiently de-
scribed in the specification, that is, patent claims must 
read in the light of the specification. The specification 
discloses and the claims define the invention.
commercialization - The process of taking an invention 
or discovery to the marketplace. It involves working the 
idea into a business plan, consideration of protection 
options, and determining how to market and distribute 
the finished product.
compulsory license - A license granted by the state upon 
request to a third party that, through the license, is per-
mitted to exploit a patented invention after the owner 
of the patent has refused to provide a voluntary license 
under acceptable conditions.
confidential disclosure agreement - See confidentiality 
agreement.
The definitions contained in the glossary are derived, in 
part, from McCarthy’s Desk Encyclopedia of Intellectual 
Property.1 In addition to this glossary, the reader is en-
couraged to refer, for expanded definitions and addi-
tional terms, to online intellectual property glossaries, 
including those found on the following Web sites:
•  World Intellectual Property Organization: 
www.wipo.int/tk/en/glossary/index.html.
•  U.S. Patent and Trademark Office: 
www.uspto.gov/main/glossary/index.html.
•  U.S. Department of State: 
usinfo.state.gov/products/pubs/intelprp  
/glossary.htm.
assignment - A transfer of intellectual property (IP) 
rights. An assignment of a patent, for example, is a 
transfer of sufficient rights so that the recipient has 
title to the patent. An assignment can be a transfer of 
all rights of exclusivity in the patent, a transfer of an 
undivided portion (for example, a 50 percent interest), 
or a transfer of all rights within a specified location (for 
example, a certain area of the United States). Anything 
less is considered to be a license transfer, rather than a 
patent transfer.
Berne Convention - A major multinational copyright 
treaty, with nearly 150 members. There are five main 
points to the Berne Convention: (1) national treatment, 
that is, nondiscrimination with respect to foreign authors 
and copyright owners; (2) no formalities, that is, copy-
right is automatically granted and is not conditioned on 
formalities such as registration or notice; (3) minimum 
duration of copyright; (4) moral rights provided to au-
thors under the national laws of member nations; and 
MIHR/PIPRA. 2007. Glossary. In Executive Guide to Intellectual Property Management in Health and Agricultural Innovation: 
A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz 
Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at 
www.ipHandbook.org.
© 2007. MIHR/PIPRA. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged.
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confidentiality agreement (nondisclosure agreement, 
confidential disclosure agreement) - A legal document 
through which intellectual property can be disclosed by 
one party to another wherein the latter party is permit-
ted to use the information for certain purposes, and 
only those purposes, that are stated in the agreement 
and agrees not to disclose the information to others.
contributory infringement - An indirect infringement 
of IP rights in which people, or organizations, contribute 
to a direct act of infringement by another (in order to aid 
or abet the act of infringement), for example, knowingly 
selling an article that is used solely to practice a patented 
process or to manufacture a patented product.
copyright - An exclusive right conferred by the govern-
ment on the creator of a work to bar others from repro-
ducing, adapting, distributing to the public, performing 
in public, or publicly displaying said work. Copyright 
does not protect an abstract idea; it protects only the 
concrete expression of an idea. In order to obtain copy-
right protection, a work must have originality and some 
modicum of creativity.
cross licensing - A legal agreement in which two or more 
parties that have potentially conflicting patent claims, or 
other conflicting IP rights, reach an agreement to share 
the IP rights in question through a reciprocal licensing 
arrangement.
dependent claim
A claim in a patent that refers back to a previous claim and 
defines an invention that is narrower in scope than that in 
the previous claim. A dependent claim is written in such a 
way as to be more restricting than the technology defined 
in the previous claim (often an independent claim).
descriptive mark - A word, picture, or other symbol that 
describes some quality or trait of a product or service, 
such as the purpose, size, color, class of users, or end ef-
fect on users. A descriptive term is not considered to be 
inherently distinctive; to establish validity of a descrip-
tive mark for registration or protection in court, proof 
of acquired distinctiveness of the mark is needed. This 
acquired distinctiveness confers secondary meaning. For 
example, “Kentucky Fried Chicken” a mark that origi-
nally was descriptive, subsequently acquired secondary 
meaning as a trademark for a distinctive type of com-
mercial food product.
design patent - A government grant of exclusive rights 
in a novel, nonobvious, and ornamental industrial de-
sign. A design patent confers the right to exclude others 
from making, using, or selling designs that closely re-
semble the patented design. A design patent covers the 
ornamental aspects of a design; its functional aspects are 
covered by a utility patent. A design patent and a utility 
patent can cover different aspects of the same article.
differential pricing (tiered pricing) - The practice of 
setting different prices for different markets—typically 
higher prices in richer markets and lower prices in poor-
er markets.
disclosure of origin - A requirement imposed on pat-
ent applicants to disclose in patent applications the 
geographic origin of biological material on which the 
invention (subject of the patent application) is based.
divisional patent application - A patent application that 
is carved out of a parent application, such that the parent 
application is divided into one or more divisional patent 
applications. Divisional applications are entitled to the 
original filing-date priority of the parent application.
due diligence - Investigations undertaken to assess the 
ownership and scope of one or more IP rights that are 
being sold, licensed or used as collateral in a transaction. 
This is done in order to identify business and legal risks 
associated with the IP rights being analyzed.
duration - The term, or length of time that an IP right 
lasts. A U.S. utility patent on an invention, for example, 
has a duration of 20 years from the date on which the 
patent application was filed, as does a plant patent. The 
duration of a U.S. copyright is usually the life of the 
author plus 70 years (for works created after January 1, 
1978). Protection of information as a trade secret lasts 
as long as the information remains secret. Duration of 
a trademark continues as long as it is used (as a source 
indicator) and properly maintained/protected.
examination - See patent examination.
exclusive license agreement - A legal document licens-
ing intellectual property to another party for its exclusive 
use. Exclusively licensed patent rights cannot, within the 
scope or field of the exclusive license, be subsequently or 
simultaneously licensed to any other party.
field-of-use restriction - A provision in an IP license that 
restricts use of the licensed intellectual property by the 
licensee to only in a defined product or service market.
first to file - A rule under which patent priority is de-
termined. The rule gives priority to the party that first 
files a patent application for an invention, rather than 
to the party that is first to invent. First to file is followed 
by almost every nation in the world except the United 
States. For trademarks, priority between conflicting ap-
plications to register a trademark is handled by publish-
ing the application with the earliest filing date for pos-
sible opposition by the applicant with a later filing date. 
In the United States, ownership of a trademark is deter-
mined by who was first to use it, not by who was first to 
file an application for registration. However, under the 
intent-to-use system, an application for registration can 
be filed prior to actual use of a mark.
GLOSSARY
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first to invent - A rule under which patent priority is 
determined by which inventor was the first to actually 
invent, rather than by who was the first to file a pat-
ent application. This is the rule followed in the United 
States. Compare to first to file.
freedom to operate - The ability to undertake research 
and/or commercial development of a product without 
infringing the unlicensed intellectual or tangible prop-
erty rights of others.
functionality - That aspect of design that makes a prod-
uct work better for its intended purpose, as opposed to 
making the product look better or to identify its com-
mercial source.
Indigenous Cultural and IP Rights - Indigenous 
Cultural and IP Rights refers to the rights to a heritage, 
that its, to the objects, sites, knowledge, and methods 
of transmission of communities that have traditionally 
been defined by the social ownership of knowledge. 
This right privileges customary law over modern law. 
Heritage includes all aspects of culture (art, music, 
dance, literature, and so on), indigenous knowledge 
(medicinal, nutritional), and land management prac-
tices. There are numerous attempts today to give legal 
substance and scientific validity to indigenous knowl-
edge. Article 29 of the Draft Declaration of the Rights of 
World Indigenous People states that “[i]ndigenous people 
are entitled to the recognition of full ownership, control and 
protection of their cultural and intellectual property.”
industrial property - Industrial property is a subset of 
intellectual property, referring to those types of intel-
lectual property that have an industrial application. 
Specifically, it refers to patents, trademarks, designs, 
mask works, and plant breeders’ rights.
infringement - An invasion of an exclusive right of in-
tellectual property. Infringement of a utility patent in-
cludes making, using, or selling a patented product or 
process without permission. Infringement of a design 
patent involves fabrication of a design that, to the or-
dinary observer, is substantially the same as an existing 
design, where the resemblance is intended to induce the 
observer to purchase one thing supposing it to be an-
other. Infringement of a trademark consists of the unau-
thorized use or imitation of a mark that is the property 
of another in order to deceive, confuse, or mislead oth-
ers. Infringement of a copyright involves reproducing, 
adapting, distributing, performing in public, or display-
ing in public the copyrighted work of someone else.
intellectual property (IP) - Creative ideas and expres-
sions of the human mind that have commercial value 
and are entitled to the legal protection of a property 
right. The major legal mechanisms for protecting intel-
lectual property are copyrights, patents, and trademarks. 
IP rights enable owners to select who may access and use 
their intellectual property and to protect it from unau-
thorized use.
international patent application - See Patent 
Cooperation Treaty (PCT).
intellectual property management - The means by 
which an institutionally owned IP portfolio is man-
aged with regard to marketing, patenting, licensing, and 
administration.
invention - The creation of a new technical idea and of 
the physical embodiment of the idea or the means to 
accomplish it. To be patentable, an invention must be 
novel, must have utility, and would not have been obvi-
ous to those possessing ordinary skill in the particular 
art of the invention.
inventive step (nonobviousness) - A condition for pat-
entability, which means that the invention would not 
be obvious to someone with knowledge and experience 
in the technological field of the invention. According to 
the European Patent Convention, “An invention shall be 
considered as involving an inventive step if, having regard 
to the state of the art, it is not obvious to a person skilled 
in the art.” 
joint inventors - Two or more inventors of a single inven-
tion who work together during the inventive process.
know-how - Information that enables a person to ac-
complish a particular task or to operate a particular de-
vice or process. Refer to trade secret.
license - A grant of permission to use an IP right within 
a defined time, context, market line, or territory. There 
are important distinctions between exclusive licenses and 
nonexclusive licenses. An exclusive license is “exclusive” 
as to a defined scope, that is, the license might not be 
the only license granted for a particular IP asset, as there 
might be many possible fields and scopes of use that can 
also be subject to exclusive licensing. In giving an exclu-
sive license, the licensor promises that he or she will not 
grant other licenses of the same rights within the same 
scope or field covered by the exclusive license. The owner 
of IP rights may also grant any number of nonexclusive 
licenses covering rights within a defined scope. A patent 
license is a transfer of rights that does not amount to an 
assignment of the patent. A trademark or service mark 
can be validly licensed only if the licensor controls the 
nature and quality of the goods or services sold by the 
licensee under the licensed mark. Under copyright law, 
an exclusive licensee is the owner of a particular right of 
copyright, and he or she may sue for infringement of the 
licensed right. There is never more than a single copy-
right in a work regardless of the owner’s exclusive license 
of various rights to different persons.
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licensee - A party obtaining rights under a license 
agreement.
licensor - A party granting rights under a license agreement.
license out - The process by which one person, company, 
or institution extends to another person, company, or insti-
tution permission to use the former’s intellectual property.
license in - The process by which a person, company, 
or institution obtains permission to use the intellectual 
property owned by someone else.
material transfer agreement (MTA) - A contract be-
tween the owner of a tangible material and a party seek-
ing the right to use the material for research or other 
assessment purposes. The material may be either pat-
ented or unpatented. Material transfer agreements tend 
to be shorter than license agreements. The purpose of 
an MTA is to document the transfer the material and 
outline the terms of use, including identification of the 
research or assessment project, terms of confidentiality, 
publication, and liability.
maintenance fees - Fees for maintaining in force a pat-
ent. The fees typically have to be paid at irregular in-
tervals, depending on the jurisdiction, and significantly 
increase over time.
notice - A formal sign or notification attached to items 
that embody or reproduce an intellectual property ass-
set—for example, the presence of the word patent or its 
abbreviation, pat., together with the patent number, on 
a patented article made by a patent holder or his/her 
licensees. The formal statutory notice of U.S. trade-
mark registration is the letter R inside a circle: ®, Reg. 
U.S. Pat. & Tm. Off., or Registered in U.S. Patent and 
Trademark Office. Many firms use informal trademark 
notices, such as Brand, TM, Trademark, SM, or Service 
Mark, adjacent to words or other symbols considered 
to be protectable marks. Notice of copyright consists of 
the letter C in a circle symbol: © or the word Copr. or 
Copyright, the copyright owner’s name, and the year of 
first publication.
nonassignable - A condition whereby a licensing agree-
ment and/or the rights, obligations, and terms thereof 





A license under which rights are granted to the licensee 
but not exclusively to that licensee; the licensor reserves 
the right to give the same or similar rights to use the 
licensed materials to other parties.
nonobviousness 
One of three conditions an invention must meet to be 
patentable. See also inventive step.
nontransferable
The licensing agreement and/or the rights, obligations, 
and terms thereof that may not be sold, given, assigned, 
or otherwise conveyed to any party who is not a signa-
tory to the agreement.
novelty
One of three conditions an invention must meet to be 
patentable.
obviousness
A condition of an invention that makes it ineligible to 
receive a valid patent; the condition of an invention 
whereby a person with ordinary skill in a field of tech-
nology can readily deduce it from publicly available in-
formation (prior art). See also ordinary skill in the art.
ordinary skill in the art
The level of technical knowledge, experience, and exper-
tise possessed by the ordinary engineer, scientist, or de-
signer in a technology that is relevant to an invention.
Paris Convention
The main international treaty governing patents, 
trademarks, and unfair competition. The Convention 
is administered by the World Intellectual Property 
Organization (WIPO) and has four principal provi-
sions: (1) national treatment for all seeking protection 
of IP rights, whether foreign or nationals; (2) minimum 
level of protection; (3) Convention priority, with a 
specified time (12 months for patents, six months for 
trademarks) for applications to be filed in other member 
nations; and (4) administrative framework within the 
Paris Union.
patent (U.S.)
A grant by the federal government to an inventor of the 
right to exclude others from making, using, or selling 
his or her invention. There are three kinds of patents in 
the United States: a standard utility patent on the func-
tional aspects of products and processes; a design patent 
on the ornamental design of useful objects; and a plant 
patent on a new variety of a living plant. Patents do not 
protect ideas, only structures and methods that apply 
technological concepts. Each type of patent confers the 
right to exclude others from a precisely defined scope of 
technology, industrial design, or plant variety. In return 
for the right to exclude, an inventor must fully disclose 
the details of the invention to the public so that others 
can understand it and use it to further develop the tech-
nology. Once the patent expires, the public is entitled to 
make and use the invention and is entitled to a full and 
complete disclosure of how to do so.
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patent application - A technical document that describes 
in detail an invention for which a patent is sought.
patent examination - A process of review of a patent 
application, undertaken by a patent examiner, to deter-
mine whether the application complies with all statu-
tory requirements for patentability. The examination 
process reviews prior art to ensure novelty, along with 
determining compliance with other statutory require-
ments, rules, and matters of procedure and form.
Patent Cooperation Treaty (PCT) - An international 
treaty that provides a mechanism through which an ap-
plicant can file a single application that, when certain 
requirements have been fulfilled, may then be pursued 
as a regular national filing in any of the PCT member 
nations. There are currently more than 120 PCT mem-
ber nations.
patent pooling - A patent pool is an agreement between 
two or more patent owners to license one or more of 
their patents to one another or to third parties. A patent 
pool allows interested parties to gather all the necessary 
tools to practice a certain technology.
patent searching - A process carried out by the patent 
examiner for checking the novelty of a patent applica-
tion. The subsequent patent research report lists pub-
lished items comprising both patent and nonpatent lit-
erature relevant to the subject of the invention.
plant breeders’ rights - Plant breeder’s rights are used to 
protect new varieties of plants by giving exclusive com-
mercial rights to market a new variety or its reproduc-
tive material.
plant patent - In the United States, the Plant Patent Act 
of 1930 provides a grant of exclusive IP rights to ap-
plicants who have invented or discovered a new asexu-
ally propagated variety of plant. Tuberous plants are not 
covered by plant patents.
plant variety protection (PVP) - A form of patent-
like protection for sexually propagated plants, as well 
as hybrids, tubers, and harvested plant parts. The Plant 
Variety Protection Act of 1970 is administered by the 
U.S. Department of Agriculture and not the U.S. Patent 
and Trademark Office (which does issue plant patents).
prior art - The existing body of technological informa-
tion against which an invention is judged in order to 
determine whether it is novel and nonobvious and can 
thus be patented.
prior informed consent - The consent given by a party 
with respect to an activity after being fully informed of 
all material facts relating to that activity. The Convention 
for Biological Diversity requires that access to genetic 
resources shall be subject to the prior informed consent of 
the country providing the resources.
priority date - The date of the first filing of a patent ap-
plication that describes an invention in detail. Priority 
date, as well as patentability, with respect to novelty of 
invention, is determined in light of any relevant prior art 
existing at the time of filing. In other words, depending 
on the specific jurisdiction, if the invention was known 
or published previous to the priority date, the applicant 
will be unable to obtain a patent.
provisional application - A provisional application is a 
document in patent actions that serves to establish an 
early priority date of an invention. A provisional appli-
cation will not mature into a regular application, and 
does not form the basis of a grant of a patent. It is a 
document that precedes the complete application upon 
which the grant is based. A provisional application es-
tablishes a priority date for disclosure of the details of an 
invention and allows a period of up to 12 months for 
development and refinement of the invention before the 
patent claims take their final form in a complete, regular 
patent application.
process claim - A claim of a patent that covers the meth-
od by which an invention is performed by defining the 
steps to be followed. This differs from a product claim 
or an apparatus claim, which covers the structure of a 
product.
product-by-process claim - A patent claim through 
which a product is claimed by defining the process by 
which it is made. The product-by-process form of claim 
is most often used to define new chemical compounds, 
since many new chemicals, drugs, and pharmaceuticals 
can practicably be defined only by describing the pro-
cess of making them.
public domain - The status of an invention, creative 
work, commercial symbol, or any other creation that is 
not protected by some form of IP right. Items that have 
been determined to be in the public domain are avail-
able for copying and use by anyone.
reduction to practice - The physical part of the inven-
tive process that completes and ends the process of in-
vention by demonstrating that the invention has a prac-
tical application. Reduction to practice can be carried 
out either by the actual construction of an apparatus, by 
performing the steps in a process, or by formally filing a 
patent application (constructive reduction to practice).
research tools - The term research tool includes the full 
range of tools that scientists may use in the laboratory, 
including cell lines, monoclonal antibodies, reagents, 
animal models, growth factors, combinatorial chemis-
try and DNA libraries, clones and cloning tools (such 
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as PCR), methods, and laboratory equipment and ma-
chines.2 There is concern about the patenting of research 
tools, because such patents may inhibit the free under-
taking of research.
royalty - Income derived from the sale or use of a li-
censed product or process.
tiered pricing - See differential pricing.
trademark - (1) A word, slogan, design, picture, or other 
symbol used to identify and distinguish goods. (2) Any 
identifying symbol, including a word, design, or shape 
of a product or container, that qualifies for legal status as 
a trademark, service mark, collective mark, certification 
mark, trade name, or trade dress. Trademarks identify 
one seller’s goods and distinguish them from goods sold 
by others. They signify that all goods bearing the mark 
come from, or are controlled by, a single source and are 
of an equal level of quality. And they advertise, promote, 
and generally assist in selling goods. A trademark is in-
fringed by another if the second use causes confusion of 
source, affiliation, connection, or sponsorship.
trade secret - Business information that is the subject of 
reasonable efforts to preserve confidentiality and has val-
ue because it is not generally known in the correspond-
ing trade. Such confidential information is protected 
against those who gain access to it through improper 
methods or by a breach of confidence. Misappropriation 
of a trade secret is a type of unfair competition.
traditional knowledge - Tradition-based creations, inno-
vations, literary, artistic or scientific works, performances 
and designs originating from or associated with a par-
ticular people or territory.
Trade-Related Aspects of Intellectual Property Rights 
(TRIPS) - An international agreement that was initiated 
under the forerunner of the World Trade Organization 
(WTO), the General Agreement on Tariffs and Trade 
(GATT), under the Uruguay round of trade negotia-
tions. The TRIPS Agreement is the most comprehensive 
multilateral agreement on Intellectual Property covering 
all IP instruments. It was the first IP rights accord to 
legitimize the patenting of living organisms. TRIPS pro-
vides the guidelines for the harmonization of IP rights 
laws under the WTO. All WTO member countries have 
substantive TRIPS obligations.
unfair competition - Commercial conduct that the law 
views as unjust, providing a civil claim against a per-
son who has been injured by the conduct. Trademark 
infringement has long been considered to be unfair 
competition. Other recognized legal categories of unfair 
competition are false advertising, trade libel, misappro-
priation of a trade secret, infringement of the right of 
publicity, and misappropriation.
UPOV (the Convention of the International Union for 
the Protection of New Varieties of Plants) - An interna-
tional treaty that guarantees to plant breeders in mem-
ber nations national treatment and a right of priority. 
National plant variety protection statutes of member 
nations are brought into harmonization with the vari-
ous UPOV provisions, for example, the requirements of 
distinctness, uniformity, stability, and novelty for new 
crop varieties.
utility - The usefulness of a patented invention. To be 
patentable an invention must operate and be capable 
of use, and it must perform some “useful” function for 
society. ■
1 McCarthy JT, RE Schechter and DJ Franklyn. 1995 and 
2004. McCarthy’s Desk Encyclopedia of Intellectual 
Property, 2nd and 3rd editions. The Bureau of National 
Affairs: Washington, DC.
2 From NIH Research Tools Guidelines. ott.od.nih.gov/
policy/rt_guide.html.
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several awards for his work, including the Wolf Prize 
in Agriculture. The Danforth Center has committed 
significant efforts to research in developing countries, 
including through private-public partnerships, and 
Beachy is involved in a variety of efforts with regard to 
rationalizing regulations that control commercialization 
of agricultural biotechnology. 
Beachy is President of the International Association 
of Plant Biotechnology. He belongs to numerous institu-
tional boards, including the PNAS Editorial Board, the 
NRC Governing Board, the Board on Agriculture and 
Natural Resources (National Research Council of the 
National Academy of Sciences), Malaysia’s International 
Advisory Panel, and the Governing Board of Directors 
of the International Crops Research Institute for the 
Semi-Arid Tropics (ICRISAT), and the Burrill and 
Company Board of Advisors.
Bennett, Alan B.
Alan Bennett currently serves as the Associate Vice 
Chancellor for Research at U.C. Davis. He is responsible 
for technology transfer, strengthening research-based al-
liances with industry, and supporting technology-based 
economic development in the Sacramento/Davis region. 
He is the founding Executive Director of the Public 
Intellectual Property Resource for Agriculture (PIPRA), 
an organization consisting of 37 universities in nine 
countries that is dedicated to the collective management 
of intellectual property and supports broad commercial 
innovation and humanitarian uses of technology in 
agriculture. From 2000 to 2004, Dr. Bennett served as 
the Executive Director of the University of California 
Systemwide Office of Technology Transfer and Research 
Administration, where he was responsible for IP manage-
ment and research policy for the University of California 
system; this task involved managing a portfolio of more 
than 5,000 cases, 700 active licenses, and revenue in 
excess of US$350 million for the four-year period. He 
earned B.S. and Ph.D. degrees in Plant Biology at U.C. 
Davis and Cornell University, respectively. He joined 
the U.C. Davis faculty in 1983. His research in plant 
molecular genetics has focused on cell-wall disassembly 
and fruit development. Dr. Bennett has published over 
130 research papers in leading scientific journals, holds 
several utility patents related to crop quality traits, and 
is a regular speaker at universities, international sym-
posia, and private companies. He is a Fellow of the 
ARntZen, Charles J.
Charles Arntzen is the Florence Ely Nelson Presidential 
Endowed Chair at Arizona State University (ASU) in 
Tempe and a Regents Professor. He was Director of 
Research at the DuPont Company in Delaware from 
1984 to 1988, followed by service as Deputy Chancellor 
for Agriculture, Dean, College of Agriculture and Life 
Sciences and Director, Texas Agricultural Experiment 
Station at the Texas A&M University System. In 1995 
became President and CEO of Boyce Thompson 
Institute, a not-for-profit corporation affiliated with 
Cornell University. He was elected to the US National 
Academy of Sciences in 1983 and to the National 
Academy of India the following year. He currently serves 
as a member of the Council of Advisors on Science & 
Technology of President George W. Bush and the US 
Nanotechnology Advisory Board. 
He is a fellow of The American Association for 
the Advancement of Science and received the Award 
for Superior Service from the U.S. Department of 
Agriculture for international project leadership in India. 
He served as chairman of the National Biotechnology 
Policy Board of the National Institutes of Health, 
as chairman of the National Research Council’s 
Committee on Biobased Industrial Products, and on 
the National Research Council’s Committee on Space 
Biology and Medicine. He served for eight years on 
the Editorial Board of Science. Dr. Arntzen currently 
serves on the Board of Directors and the Scientific 
Advisory Board of Advanced BioNutrition, Inc., and 
is on the Advisory Board of the Burrill & Company 
Agbio Capital Fund and The Nutraceuticals Fund. He 
also serves as a Distinguished Advisor on the Council 
for Biotechnology, and is a member of the Board of 
Directors of the National Center for Genome Resources 
in Sante Fe, New Mexico. 
BeAChy, Roger 
Roger Beachy is president of the Donald Danforth Plant 
Science Center in St. Louis, Missouri. He previously 
held academic positions at Washington University, 
St. Louis, and the Scripps Research Institute, La Jolla, 
California. His research includes projects to reduce vi-
rus infection in plants via biotechnology, and in studies 
of the control of gene expression in plants. Beachy is a 
member of the U.S. National Academy of Sciences and a 
Fellow of the Academy of Microbiology; he has received 
Biographical Sketches of Authors  
and Members of the Board of Patrons
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American Association for the Advancement of Science 
(AAAS) and of the California Council for Science and 
Technology (CCST).
BoRlAug, norman e.
In 1970, Norman Borlaug won the Nobel Peace Prize 
for his lifelong work to feed a hungry world. His work, 
more than that of any other person, is credited with sav-
ing lives.
In 1944, Dr. Borlaug joined the Rockefeller 
Foundation’s pioneering technical-assistance pro-
gram in Mexico, at which he was a research scientist 
in charge of wheat improvement. For the next two 
decades, he worked to solve a series of wheat produc-
tion problems in Mexico and to train a generation of 
young scientists. 
With the establishment of the International Maize 
and Wheat Improvement Center (CIMMYT) in 
Mexico in 1966, Borlaug assumed leadership of the 
wheat program; he continues to serve as a consultant for 
it. The high-yielding, disease-resistant wheat cultivars he 
developed, along with improved management practices, 
transformed agricultural production in Mexico during 
the 1950s and in Asia and Latin America in the 1960s 
and 1970s. This transformation has come to be known 
as the Green Revolution. 
In 1984, Dr. Borlaug joined Texas A&M University 
and was named Distinguished Professor of International 
Agriculture. Since 1986, he has also served as presi-
dent of the Sasakawa Africa Association and leader of 
the Sasakawa-Global 2000 agricultural program in 
Sub-Saharan Africa, in partnership with former U.S. 
President Jimmy Carter and Yohei Sasakawa.
Borlaug has been awarded 58 honorary doctorate 
degrees, and is a member or fellow of the academies 
of science in 12 nations. The U.S. National Academies 
of Science awarded him the National Service Medal 
in 2002 and in 2004 President Bush bestowed upon 
Borlaug the U.S. National Medal of Science. He was 
the driving force behind the establishment of the World 
Food Prize in 1985 and serves as Chairman of its 
Council of Advisors. 
Chen, Zhang liang 
Zhang Liang Chen was born on February 3, 1961, in 
Fujian, China. He received his Ph.D. in 1987 from 
Washington University for his research in the Division 
of Biology and Biomedical Sciences in the field of plant 
molecular biology and his work in early transgenic 
plant research. He then returned to China as an associ-
ate professor. Two years later, he was a full professor 
at Beijing University. He has continued his research 
in transgenic plants and biosafety. He served as direc-
tor of National Key Laboratory of Protein Engineering 
and Plant Genetic Engineering. In 1995, he became 
vice-president of research at Peking University. In 
2002, he became the president of China Agricultural 
University. He and his research group have published 
over 190 international papers and seven book, and 
hold over eight patents.
Dr. Chen is also Chair of the Plant Biotech Committee 
of UNESCO, Consultant for the International Society 
for Plant Molecular Biology (ISPMB), and mem-
ber of the Sino-Euro Administration Committee for 
Biotechnology Cooperation. He also serves as a member 
and Vice-Chairman of the Council of Scientific Advisers 
to the International Center for Genetic Engineering and 
Biotechnology (ICGEB) in Italy and India.
DIouF, Jacques
Jacques Diouf is Director-General of the Food and 
Agriculture Organization of the United Nations 
(FAO). He has held this position since 1994 and is 
currently serving his third six-year term, which began 
in January 2006. Over the years, he has held numer-
ous position including Ambassador for the Senegalese 
Permanent Mission to the United Nations, member of 
the Senegalese Parliament, and Secretary of State for 
Science and Technology for Senegal. In addition, he 
has represented Africa in the Consultative Group on 
International Agricultural Research and served on the 
Council of African Advisers of the World Bank. The 
recipient of numerous awards from countries in every 
corner of the world for his work in agricultural develop-
ment, Dr. Diouf has undertaken field trips to various 
agricultural institutions around the world and has par-
ticipated in major international meetings representing 
Senegal and the Central Bank for West African States. 
He has been a leading voice on issues related to agricul-
tural development and the environment. 
DRyDen, Sam
Sam Dryden is internationally recognized as a successful 
investor and developer of life-sciences ventures. His 
particular expertise is in the application, scale-up and 
commercialization of early-stage technologies worldwide.
Sam is a Managing Director of Wolfensohn & 
Company, a corporate advisory and investment firm 
located in New York, where he focuses on private equity 
investments in biofuels and other alternative energies. 
He is also CEO of Emergent Genetics, LLC—a life-
sciences investment holding company. 
Until June 2006, Sam served as the Chair and 
Corporate CEO of Emergent Genetics, Inc.—a 
global leader in the development and marketing of 
biotechnology-enhanced seed products. Emergent 
Genetics’ operations were based in Europe, the United 
States, Argentina, and Brazil and comprised one of the 
largest seed companies in India. The largest portion 
of the company’s worth was acquired in April 2005 
by Monsanto Company. Remaining operations were 
acquired in June 2006 by Syngenta AG. 
Sam began his career as an analyst with the U.S. 
Department of Commerce, Bureau of Economic 
Analysis, where he was responsible for modeling and 
forecasting selected sectors of the U.S. economy. He 
was then employed by the Union Carbide Corporation 
from 1974 to 1980, with responsibilities for various 
aspects of new corporate ventures. These transactions 
involved extended assignments in Japan, Europe, and 
South America. 
In 1980, Sam led the spinout of Union Carbide’s 
biotechnologies and related business operations and 
subsequently cofounded Agrigenetics Corporation and 
served as its president and CEO. The company grew to 
become one of the world’s largest seed enterprises and was 
acquired in 1985. It is now part of Dow AgroSciences. 
During this same period, he was also chairman of an 
affiliated partnership that managed and invested US$60 
million in proprietary plant sciences research conducted 
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in leading universities, as well as private and public 
research institutions worldwide. 
Following the sale of Agrigenetics, Sam founded and 
became President of Big Stone Inc.—a private venture 
investment and development company focused on the 
life sciences. The firm participated in founding over a 
dozen companies in areas such as biopesticides, novel 
nucleic acid-based therapeutics and diagnostic products, 
transgenic animals, fermentation-based production of 
vitamins, pharmaceutical clinical trialing, environmental 
toxicological testing, and biotherapeutics. Sam also 
served as the nonexecutive chairman of Celgro Inc., 
independent venture of Celgene Corporation and a 
company focused on the development of novel, single-
isomer, agricultural chemical compounds. 
In addition to his for-profit activities, Sam has 
extensive pro bono involvement in efforts relating to 
food security and international economic development. 
Currently he is an advisor to the World Bank regarding 
rural development strategy. He is a member of the board 
of directors of the Global Crop Diversity Trust. Sam 
serves on the National Academies Panel on Science 
and Technology for Global Sustainability. In the past, 
he served on the steering committee for the Global 
Assessment on Agricultural Science and Technology, led 
by the World Bank. He was a member of the executive 
council, as well as chair of the Private Sector Committee 
of the Consultative Group on International Agricultural 
Research. He has been an advisor to the Rockefeller 
Foundation and a member of the Design Advisory 
Committee and Scientific Advisory Board of its African 
Agricultural Technology Foundation—an organization 
created for the advancement of African food security. In 
the mid-80’s, Sam chaired a Rockefeller Brothers Fund 
development initiative to benefit developing country food 
security. He also served on the Board of the South/North 
Development Initiative—a private Rockefeller Family 
foundation for alleviation of rural poverty in less-developed 
countries through entrepreneurial development. He is 
a past member of the U.S. Government’s Agricultural 
Sciences and Technology Review Board. 
Sam is a member of the Council on Foreign Relations 
and serves on its Advisory Committee on Intellectual 
Property and American Competitiveness. He has 
also served on its study group analyzing trade issues 
between the United States and Europe surrounding 
genetically-modified foods. 
He has written and lectured widely on the policy 
issues of food security, the evolving nature of global 
public goods and new mechanisms for public and private 
sector relations. In this regard, his travels have taken 
him on missions to most countries in Latin America, 
including Cuba, as well as Europe, Asia, Africa, and the 
Middle East.
Sam, a native of eastern Kentucky, received his BA in 
economics from Emory University in 1973.
FAthAllA, Mahmoud F. 
Dr. Fathalla is a professor of Obstetrics and Gynecology 
and former Dean of the Medical School at Assiut 
University in Egypt and is currently the chairman of the 
World Health Organization (WHO) Global Advisory 
Committee on Health Research. He has served as the 
Director of the UNDP, UNFPA, World Bank, WHO 
Special Programme of Research, Development and 
Research Training in Human Reproduction and has 
served as a consultant to various international bodies 
such as the WHO, UNPF, IPPF, Population Council, 
and the Ford and Rockefeller foundations. He is the au-
thor of more than 150 scientific publications. Professor 
Fathalla has been an international campaigner for Safe 
Motherhood and a founder of the Safer Motherhood 
Initiative. His scientific interests include women’s health, 
safe motherhood, reproductive health, ethics and human 
rights, and contraceptive research and development.
FeRnánDeZ, Carlos
Carlos Fernández studied agronomy at Universidad 
de Chile. After working as an Assistant Professor at 
the Agronomy Faculty of the same university, he re-
ceived a Ph.D. in Plant Physiology at the University 
of California, Davis. Upon graduation, he joined 
Monsanto Company, where he held various manage-
ment positions that gave him responsibilities in sev-
eral countries. He led the development of agricultural 
technologies in Latin American countries, first from the 
company headquarters in St. Louis and later from Sao 
Paulo, Brazil. Among other things, he contributed to 
the development of new applications for Roundup, the 
most successful herbicide in the world, and the develop-
ment of nontillage systems for various crops. In Europe, 
he developed new products and actively participated 
in the design of the Roundup post-patent policy for 
Europe and Africa.
While working for Monsanto in California, he evaluat-
ed and contributed to the development and introduction 
of transgenic crops to the market. During his stay in 
California, he returned to the University of California, 
Davis, and earned an M.B.A. In 1999, he returned to 
Santiago, Chile, and began working at Fundación Chile, 
where he coordinated programs related to technology 
transfer, intellectual property, regulatory matters, and 
the development of transgenic crops. He contributed to 
the Cooperative Agreement between the University of 
California, Davis and Fundación Chile. In addition to his 
work at Fundación Chile, he serves as a consultant to the 
Food and Agricultural Organization of the UN and the 
Chilean Ministry of Economy. Some of his latest contri-
butions as a consultant include two studies sponsored by 
the Ministry of Economy of Chile: “Comparative Analysis 
of Biotechnology Policies in N. Zealand, Canada, United 
States, Australia, Japan, China, Argentina, Brazil, Spain 
and Chile” and “Formulation of a Model for a Technology 
Transfer Office for Chile.” He also contributed to a recent 
study, sponsored by UNDP, titled “Commercialization 
Impact on Agricultural Export Products Caused by the 
Introduction of GMO in Chile.”
As of July 2006, Dr. Fernández is the Head of 
Strategic Studies and the technology transfer unit of the 
Foundation for Agriculture Innovation.
FReIRe, Maria
Dr. Maria C. Freire is CEO and President of The Global 
Alliance for TB Drug Development, a position she has 
held since 2001. During her service, the Alliance has 
built the largest pipeline of TB drugs in the world, ad-
vanced compounds into clinical testing, and pioneered 
precedent-setting agreements with industry. 
From 1995 to 2001, Dr. Freire directed the Office 
of Technology Transfer at the NIH, where she was 
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responsible of technology transfer policies and procedures 
for the Department of Health and Human Services and 
for patenting and licensing activities at the NIH and 
the FDA.
Dr. Freire is an internationally recognized expert 
in technology commercialization. She is a member 
of the NIH Advisory Board for Clinical Research, a 
Governor of the New York Academy of Sciences, and 
the Chair of the Working Group for New TB Drugs for 
the global Stop TB Partnership. Dr. Freire was select-
ed as one of ten Commissioners of the World Health 
Organization’s Commission on Intellectual Property 
Rights, Innovation and Public Health (CIPIH) and a 
member of Time magazine’s Global Health Summit 
Board of Advisors. 
Born in Lima, Peru, Dr. Freire trained at the 
Universidad Peruana Cayetano Heredia. She holds a 
Ph.D. in biophysics and completed post-graduate stud-
ies in immunology and virology at the University of 
Virginia and the University of Tennessee, respectively, 
and at the John F. Kennedy School of Government at 
Harvard University. She has received numerous na-
tional and international awards, including the Arthur 
S. Flemming Award, DHHS Secretary’s Award for 
Distinguished Service, and the Bayh-Dole Award.
gRAFF, gregory D.
Gregory D. Graff is an applied economist with expertise 
in the economics of innovation, entrepreneurship, intel-
lectual property, and technology transfer, especially as 
they apply to the agricultural life sciences and biotech-
nology. He applies microeconomic and econometric 
tools to scientific, patent, regulatory, and commercial 
data, building uniquely thorough industry-level datas-
ets to analyze the impacts of innovation and technology 
transactions on markets, industrial organization, and 
the political economy of science policy. 
Dr. Graff currently manages research projects for 
the Public Sector Intellectual Property Resource for 
Agriculture (PIPRA), a consortium of 37 agricultural 
research universities and institutes that is hosted by 
the University of California. PIPRA uses an innova-
tive model of collaborative intellectual property man-
agement to mobilize its members’ technologies for the 
purpose of genetically improving “orphan” crops. Dr. 
Graff has taught as a university lecturer at both U.C. 
Berkeley and U.C. Davis and has recently published 
articles in The Review of Economics and Statistics, World 
Development, California Management Review, and Nature 
Biotechnology as well as chapters in several books. Dr. 
Graff has a Ph.D. in agricultural and resource econom-
ics from U.C. Berkeley (2002), an M.A. in economics 
from Ohio State University (1995), and a B.S. in biol-
ogy from Cornell University (1992).
henneSSey, William o.
William Hennessey is Professor of Law at the Franklin 
Pierce Law Center. He directed Pierce Law’s graduate 
programs in intellectual property and summer from 1986 
until 2003. A noted IP expert, author, and lecturer, he re-
cently directed the fourth annual Pierce Law Intellectual 
Property Summer Institute at Tsinghua University 
School of Law in Beijing, China. He co-authored a legal 
casebook on international IP law and policy. 
Professor Hennessey has served as a legal advi-
sor to the governments of Indonesia and the People’s 
Republic of China and has served as a consultant to 
the World Bank, Asian Development Bank, United 
Nations Development Programme, U.S. Agency for 
International Development, U.S. Department of State, 
and the U.S. Patent and Trademark Office. He has also 
served as consultant for the World Intellectual Property 
Organization in many countries on various issues con-
cerning IP protection and economic development.
IDRIS, Kamil
Dr. Kamil Idris has been Director General of the World 
Intellectual Property Organization (WIPO) since 
November 1997. He is head of the International Union 
for the Protection of New Varieties of Plants (UPOV). 
He was formally re-appointed to a second six-year term as 
Director General of WIPO on May 27, 2003. His man-
date will end on November 30, 2009. Formerly, Kamil 
Idris was a member of the International Law Commission 
from 1992 to 1996 and from 2000 to 2001. 
Kamil Idris holds a Bachelor of Law (LL.B.) from 
Khartoum University, Sudan; a Bachelor of Arts in 
Philosophy, Political Science and Economic Theories 
from Cairo University, Egypt; a master’s in International 
Law and International Affairs from Ohio University, 
United States; and a Doctorate in International Law 
from the Graduate Institute of International Studies, 
University of Geneva, Switzerland. 
JAhn, Molly
Molly Jahn holds degrees from Swarthmore College, 
M.I.T., and Cornell University, and pursued 
postdoctoral work at U.C. Berkeley. At Cornell, Molly 
focused her research on plant breeding, genetics, ge-
nomics and molecular biology and on the development 
of improved crop germplasm. Her group at Cornell has 
produced a number of globally successful crop variet-
ies currently grown commercially on six continents. 
Molly has worked extensively internationally in Latin 
America, Asia and Africa to link crop breeding objec-
tives to outcomes that improve human welfare, such 
as nutritional status and income. Molly was recently 
named a Fellow of the AAAS and was elected to the 
Board of Directors of The World Vegetable Center, the 
international research center for vegetables. On August 
1, 2006, she was named the twelfth dean of the College 
of Agricultural and Life Sciences at the University of 
Wisconsin - Madison.
KhuSh, gurdev Singh
Dr. Khush was born in a small village in Punjab. After 
receiving his education at the Punjab Agricultural 
University and the University of California, Davis, Dr. 
Khush, in 1967, joined the International Rice Research 
Institute in the Philippines where he served as the Head 
of Plant Breeding, Genetics, and Biochemistry Division 
until 2002. As a result of wide-scale adoption of his 
high-yielding varieties, rice production increased 135% 
between 1967 and 2000, to feed an estimated one bil-
lion additional consumers. His contributions to rice 
genetics and biotechnology are equally well recognized. 
He has written three books, more than 80 book chapters 
and 160 research papers. 
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Dr. Khush has served as consultant to rice breed-
ing programs of 15 countries as well as The Rockefeller 
Foundation, the Third World Academy of Sciences, 
Italy, and the International Science Foundation, 
Sweden. He is now serving as a member of Scientific 
Advisory Committee (overseas) to the Department of 
Biotechnology, Government of India and member of 
Science Council, an advisory body to Chinese Academy 
of Agricultural Sciences, Beijing.
For his monumental contributions to the World 
Food Security, Dr. Khush has been honored with 
numerous awards and honors such as the Japan 
Prize (1987), World Food Prize (1996), Rank Prize 
(1998), Wolf Prize (2000), International Scientific 
and Technological Cooperation Award from the 
Government of China (2001), and Padma Shriaward 
from the president of India. He is one of five Indian sci-
entists who have been elected to membership of Royal 
Society (FRS) as well as the U.S. National Academy 
of Sciences. Dr Khush has received Doctor of Science, 
honoris causa, degrees from nine universities including 
from University of Cambridge in England and Ohio 
State University.
Commenting on his life work, Dr. Cantrell, Director of 
the International Rice Research Institute said, “While Dr. 
Khush’s name may have passed the lips of many, his life’s 
work has passed the lips of almost half of humanity.”
KoWAlSKI, Stanley P.
Stanley P. Kowalski was born and grew up in a working-
class neighborhood in Pittsburgh, Pennsylvania, where 
he attended Catholic primary and public high school. 
He matriculated at the Pennsylvania State University, 
and later at the University of Pittsburgh, earning B.S. 
degrees in horticulture and biology, with emphases in 
genetics and biochemistry. Later, he earned a Ph.D. in 
plant breeding from Cornell University. Dr. Kowalski’s 
experience as a research scientist has included studies 
of plant nutrition at the Pennsylvania State University, 
wheat breeding at the University of Nebraska, purifica-
tion and characterization of DNA polymerases at the 
University of Rochester, biochemical characterization of 
insect resistance in potatoes at Cornell University, lipid-
mediated signal transduction at the National University 
of Singapore, plant genome mapping at Texas A&M 
University, glycolipid biosynthesis at Cornell University, 
and a study of the biochemical/genetic basis of plant/in-
sect interactions at the U.S.D.A. Beltsville Agricultural 
Research Center. He has been long interested in inter-
national development, due both to his exposure to the 
dynamic international programs at Cornell and the in-
fluence of Professor Norman Borlaug, whose office was 
located directly across the hall from Dr. Kowalski’s labo-
ratory at Texas A&M University.
The second phase of Dr. Kowalski’s career has been 
defined by a transition from research to internation-
al work. He received a foreign language area studies 
scholarship and completed Cornell’s one-year inten-
sive Chinese-language program (Chinese FALCON). 
Subsequently, he worked for the International Service 
for the Acquisition of Agri-Biotech Applications 
(ISAAA) in the intellectual property/technology trans-
fer initiative, during which time he conducted the 
preliminary freedom-to-operate analysis of GoldenRice. 
After working at ISAAA, he earned a J.D. with an 
emphasis in intellectual property at the Franklin Pierce 
Law center. He has published numerous research and 
legal articles. 
KRAttIgeR, Anatole
Anatole Krattiger, a Swiss citizen, began his career as 
a farmer, lived in many parts of the world, and is cur-
rently a research professor at the Biodesign Institute at 
Arizona State University (ASU). As adjunct professor 
at the Sandra Day O’Connor College of Law at ASU, 
he co-teaches a course on innovation management and 
controversies in health and agri-biotechnology. He is 
an Adjunct Professor at Cornell University where he 
co-teaches a course on IP management in the life sci-
ences. He founded, and serves as Chairman of, bioDe-
velopments-International Institute, a nonprofit orga-
nization that brings people together to jointly develop 
solutions to problems that extend beyond geographic 
and cultural frontiers. He recently served as Executive 
to the Humanitarian Board for GoldenRice, a position 
that required him to work on licensing, technology 
transfer, and regulatory issues; he also served as Director 
of Research at MIHR in the U.K. during its formative 
years. In the early 1990s, he contributed to the inter-
national establishment of ISAAA, a global agri-biotech-
nology broker developing public-private partnerships 
in agriculture; he served as executive director of ISAAA 
until 2000. He also briefly worked on biodiversity-policy 
issues at the International Academy of the Environment 
in Geneva, Switzerland, and as a scientist in biotechnol-
ogy at CIMMYT in Mexico. 
Dr. Krattiger is a member of the Advisory Council 
on Intellectual Property of the Franklin Pierce Law 
Center in Concord, New Hampshire, and a member of 
the board of the Black Sea Biotechnology Association. 
He is editor-in-chief of Innovation Strategy Today and 
a member of the editorial boards of the International 
Journal of Biotechnology and the International Journal 
of Technology Transfer and Commercialization. He 
was a Distinguished Advisor to the Council for 
Biotechnology Information in Washington, D.C., un-
til the Council merged with BIO. He holds a diploma 
in farming, a bachelor’s degree in agronomy from the 
Swiss Agricultural College, a master’s degree in plant 
breeding, and a Ph.D. in biochemistry and genetics 
from the University of Cambridge, U.K.
MAhoney, Richard t.
Richard T. Mahoney is Director, Vaccine Access, for 
the Pediatric Dengue Vaccine Initiative, a program 
of the International Vaccine Institute (IVI) in Korea. 
Previously, he was Research Professor in the School of 
Life Sciences and in the Biodesign Institute of Arizona 
State University. As a consultant to the Rockefeller 
Foundation, he played a lead role in the consultative 
process that led to the formation of MIHR. Previously, 
he was responsible for institutional development in 
the establishment and launching of the IVI in Seoul, 
Korea. In this role, he was responsible for cultivat-
ing relations with vaccine manufacturers and man-
aging intellectual property, among other things. Dr. 
Mahoney has had a long career in public health and is 
known for his work with the International Task Force 
on Hepatitis B Immunization, accomplished while 
he was with the Program for Appropriate Technology 
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in Health (PATH). Before co-founding and joining 
PATH, he was a Program Officer in Population with 
the Ford Foundation. He oversaw the development 
and implementation of IP management policies for the 
Ford Foundation, PATH, and IVI. Prof. Mahoney con-
tinues to write on policy and economic research. 
MAngenA, Mosibudi
Mosibudi Mangena is the Minister of Science and 
Technology in South Africa and President of the 
Azanian People’s Organisation (AZAPO). He was born 
in Tzaneen, matriculated from Hebron Training College 
in 1969, and received an M.Sc. degree in Applied 
Mathematics from the University of South Africa (called 
the University of Azania on the AZAPO website). He 
joined the South African Students’ Organisation (SASO) 
and was elected to the Student’s Representative Council 
at the University of Zululand in 1971. Moving back to 
Pretoria, he became chairperson of the SASO Pretoria 
branch in 1972. He chaired the Botswana region of the 
Black Consciousness Movement of Azania (BCMA) 
in 1981 and the BCMA central committee from 1982 
to 1994. He returned from exile in 1994 and became 
leader of Azapo. He was appointed Deputy Minister 
of Education in South Africa by Nelson Mandela in 
2001, and became Minister of Science and Technology 
in 2004.
MAShelKAR, R.A.
Dr. R.A. Mashelkar is presently the President of the 
Indian National Science Academy (INSA) and President 
of Global Research Alliance (GRA), a network of pub-
licly funded R&D institutes from five continents with 
over 60,000 scientists. Prior to this, for over eleven 
years Dr. Mashelkar served as the Director General of 
Council of Scientific and Industrial Research (CSIR), 
an organization with thirty-eight laboratories and about 
20,000 employees. His leadership transformed CSIR 
into a user-focused, performance-driven organization, 
a process of transformation that has been recently her-
alded as one of the ten most significant achievements of 
Indian Science and Technology in the 20th century.
Dr. Mashelkar is only the third Indian engineer to 
have been elected as a Fellow to the Royal Society (FRS), 
London, in the 20th century. He was elected Foreign 
Associate of the National Academy of Science (U.S.) 
in 2005, and was only the eighth Indian since 1863 
to be elected. He was elected a Foreign Fellow of the 
U.S. National Academy of Engineering (2003), Fellow 
of the Royal Academy of Engineering (U.K.) in 1996, 
and Fellow of the World Academy of Art & Science 
(U.S.) in 2000. Twenty-six universities have honored 
him with honorary doctorates, including the universi-
ties of London, Salford, Pretoria, Wisconsin, and Delhi. 
He is currently the President of the Materials Research 
Society of India.
In post-liberalized India, Dr. Mashelkar has played a 
critical role in shaping the country’s S&T policies. He was 
a member of the Scientific Advisory Council to the Prime 
Minister and also of the Scientific Advisory Committee 
to the Cabinet set up by successive governments. 
Dr. Mashelkar has won more than 50 awards and 
medals, including the S.S. Bhatnagar Prize (1982), the 
Pandit Jawaharlal Nehru Technology Award (1991), 
the G.D. Birla Scientific Research Award (1993), the 
Material Scientist of Year Award (2000), the IMC Juran 
Quality Medal (2002), the HRD Excellence Award 
(2002), the Lal Bahadur Shastri National Award for 
Excellence in Public Administration and Management 
Sciences (2002), the World Federation of Engineering 
Organizations (WFEO) Medal of Engineering 
Excellence by WFEO, Paris (2003), the Lifetime 
Achievement Award by the Indian Science Congress 
(2004), the Science Medal by the Academy of Science 
for the Developing World (2005), and the Ashutosh 
Mookherjee Memorial Award by the Indian Science 
Congress (2005), among others.
The President of India honored Dr. Mashelkar with the 
Padmashri (1991) and with the Padmabhushan (2000), 
which are two of the highest civilian honors in India, in 
recognition of his contribution to nation building.
MCCAllA, Alex F.
Alex is Professor of Agricultural and Resource 
Economics, Emeritus, at the University of California, 
Davis. He was born in Alberta, Canada, and received his 
first two degrees from the University of Alberta before 
moving on to the University of Minnesota where he re-
ceived his doctorate in Agricultural Economics in 1966. 
Throughout his academic career he was associated with 
the University of California-Davis where he served as 
Dean of the College of Agricultural and Environmental 
Sciences and Associate Director of the California 
Agricultural Experiment Station (1970–1975) and 
Founding Dean, Graduate School of Management 
(1979–1981).
Dr. McCalla is best known for his research in in-
ternational trade where he has published extensively. 
The quality of his research and communication skills 
has been recognized by the American Agricultural 
Economics Association, which presented him with its 
Quality of Communication Award in 1979 and its 
Quality of Research Discovery Award in 1982. He was 
elected Fellow of the American Agricultural Economics 
Association in 1988, Fellow of the Canadian Agricultural 
Economics Society in 2000, and a Distinguished Scholar 
of the Western Agricultural Economics Association 
in 2004. He was a founding member and co-conve-
ner of the International Agricultural Trade Research 
Consortium. He served as the Chair of the Technical 
Advisory Committee (TAC) of the Consultative Group 
on International Agricultural Research (CGIAR) from 
1988 to 1994.
He elected early retirement from the University of 
California in June 1994 and was appointed Director 
of the Agriculture and Natural Resources Department 
of the World Bank in Washington, D.C., effective 
September 12, 1994. During his tenure he led a ma-
jor effort to revitalize the World Bank’s commitment 
to Rural Development. He was appointed Director of 
Rural Development in July 1997, following a Bank reor-
ganization. He retired from the World Bank December 
31, 1999.
In June 1998 he was awarded the Degree of Doctor 
of Science, honoris causa, by McGill University in 
Montreal, Canada. On December 28, 1999, he was 
awarded the Doctor’s Degree of Honor by the Georgian 
State Agrarian University. In September of 2004 he 
received the Distinguished Alumni Award from the 
University of Alberta.
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He served as Chair of the Board of Trustees of 
CIMMYT, the International Maize and Wheat 
Improvement Center with Headquarters in Mexico, 
(2001–2005) and is a member of the Board of Directors 
of the Danforth Plant Science Center in St. Louis.
MoRel, Carlos
Dr. Carlos M. Morel is currently the Director of the 
Centre for Technological Development in Health 
(CDTS), a new unit being implemented at the Oswaldo 
Cruz Foundation (FIOCRUZ, Rio de Janeiro, Brazil) to 
stimulate health product innovation. 
A molecular biologist and medical doctor by train-
ing, Dr. Morel received his M.D. from the Medical 
Faculty of the Federal University of Pernambuco. 
He completed his graduate studies at the Biophysics 
Institute of the Federal University of Rio de Janeiro 
and at the Molecular Biology Department of the Swiss 
Cancer Institute in Lausanne (ISREC), Switzerland. His 
research has been in the field of molecular parasitology, 
and he has collaborated with various international orga-
nizations and research programs working on neglected 
diseases and capacity building. 
Dr. Morel was previously a Professor at Brasilia 
University (UnB, Brasilia, Brazil) and President of 
FIOCRU. He was also Director of the UNICEF/
UNDP/World Bank/WHO Special Programme for 
Research and Training in Tropical Diseases (TDR) at 
the World Health Organization in Geneva, where he 
established close working relationships with product-
development public private partnerships and global 
ventures committed to public health. He participated 
actively in the establishment of the Medicines for 
Malaria Venture (MMV), the Global Alliance for TB 
Drug Development (GATB), the Drugs for Neglected 
Diseases Initiative (DNDi), and the Foundation for 
Innovative New Diagnostics (FIND). 
A member of the Brazilian Academy of Sciences and 
an Honorary Fellow of the Royal Society of Tropical 
Medicine and Hygiene in London, Dr. Morel holds 
the National Order of Scientific Merit (Brazil) and 
Doctor Honoris Causa from the Federal University of 
Pernambuco (Brazil). He has been a member of the 
MIHR Board of Trustees since its founding. 
nelSen, lita
Lita Nelsen is the Director of the Technology Licensing 
Office at the Massachusetts Institute of Technology, 
where she has been since 1986. Every year, the of-
fice manages over 400 new inventions originating 
from M.I.T., the Whitehead Institute, and Lincoln 
Laboratory. Typically, the office negotiates over 100 
licenses and starts up over 20 new companies each 
year. Ms. Nelsen earned her B.S. and M.S. degrees in 
Chemical Engineering from M.I.T., as well as an M.S. 
in Management from M.I.T. as a Sloan Fellow. Prior 
to joining the M.I.T. Technology Licensing Office, 
Ms. Nelsen spent 20 years in industry, primarily in 
the fields of membrane separations, medical devices, 
and biotechnology; she worked at such companies as 
Amicon, Millipore, Arthur D. Little, Inc., and Applied 
Biotechnology. Ms. Nelsen was the 1992 President of 
the Association of University Technology Managers. She 
serves on the board of the Mount Auburn Hospital and 
the Scientific Advisory Board of the Children’s Hospital 
Oakland Research Foundation. She also serves as the 
intellectual property advisor to the International AIDS 
Vaccine Initiative and is a founding and current board 
member of MIHR. Ms. Nelsen is widely published in 
the fields of technology transfer and university/indus-
try collaborations. She was a CMI Fellow at Cambridge 
MIT Institute (at the University of Cambridge), where 
she studied the role of university/industry/government 
partnerships in technology transfer and local economic 
development. She is a co-founder of Praxis, the U.K. 
University Technology Transfer Training Programme.
PotRyKuS, Ingo
Ingo Potrykus is the engine behind the GoldenRice 
Project and the Humanitarian Board. Together 
with Peter Beyer, he was one of the inventors of the 
GoldenRice technology. Since his retirement as a pro-
fessor in 1999, far from settling down, he has devoted 
enormous efforts to bringing biofortified GoldenRice to 
those who need it. 
Prof. Potrykus was born in 1933 in Hirschberg, Silesia, 
Germany. He has been married since 1960, and has three 
children and eight grandchildren. In 1968, he earned a 
Ph.D. in Plant Genetics at the Max-Planck-Institute for 
Plant Breeding Research, Cologne, Germany. 
He conducted research in botany at the University 
of Basel, Switzerland, and was an Assistant Professor at 
the Institute of Plant Physiology, Stuttgart-Hohenheim 
from 1970 to 1974. From 1974 to 1976, he was 
Research Group Leader at the Max-Planck-Institute for 
Genetics, Ladenburg-Heidelberg, and then, until 1986, 
at the Friedrich Miescher-Institute, Basel, Switzerland. 
From 1986 until his academic retirement in 1999, he 
was Full Professor in Plant Sciences at the Swiss Federal 
Institute of Technology (ETH), Zurich. 
Since 1974, his research has focused on plant-sci-
ence-based contributions to food security in developing 
countries, where he was involved in the development 
and application of genetic engineering technology for 
“food security” crops such as rice (Oryza sativa), wheat 
(Triticum aestivum), sorghum (Sorghum bicolor), and 
cassava (Manihot esculenta). Focusing on problems in 
the areas of disease and pest resistance that were difficult 
to solve with traditional techniques, he worked to im-
prove food quality and yield, improved exploitation of 
natural resources, and improved biosafety. This work was 
performed by an international team of 60 coworkers, on 
average, that was financed from competitive grants and 
core funding. The GoldenRice project, initiated in 1991 
as Ph.D. project, was possible only because of that core 
funding. Details of the GoldenRice project can be found 
in approximately 340 publications in refereed journals 
and 30 international patents. 
Professor Potrykus’s teaching activities have in-
cluded lectures and courses in basic and advanced 
plant biology and plant biotechnology in Biology, 
Agronomy, Pharmacy, Forestry, and Environmental 
Sciences departments, as well as International 
Training Courses such as EMBO. His numerous 
awards include: the KUMHO (ISPMB) Science 
International Award in Plant Molecular Biology and 
Biotechnology in 2000, the American Society of 
Plant Biologists (ASPB) Leadership in Science Public 
Service Award in 2001, the Crop Science of America 
(CSSA) Klepper Endowment Lectureship in 2001, the 
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CSSA President’s Award in 2002, and the European 
Culture Award in Science in 2002. He received an 
Honorary Doctorate from the Swedish University 
of Agricultural Sciences in 2002. He is a member of 
Academia Europaea, the World Technology Network, 
the Swiss Academy of Technical Sciences, and the 
Hungarian Academy of Sciences.
ReDDy, K. Anji 
Dr. K. Anji Reddy is the founder of Dr. Reddy’s 
Laboratories. He spent his early life in Tadepalli village, 
Guntur, Andhra Pradesh. His father was a peasant and 
grew turmeric. After completing his schooling at the local 
high school, Dr. Reddy earned a degree in science in 1958 
from the A.C. College in Guntur City. He also earned a 
BSc in pharmaceuticals and fine chemicals from Bombay 
University. Later he obtained a PhD in chemical engi-
neering from the National Chemical Laboratory in Pune. 
Dr. Reddy started his career working for a state-owned 
company, then called Indian Drugs and Pharmaceuticals 
Ltd. He was the founder and managing director of 
Uniloids Ltd., where he worked from 1976 to 1980, 
and Standard Organics Ltd., where he worked from 
1980 to 1984. In 1984, Dr. Reddy laid the foundation 
for Dr. Reddy’s Laboratories. The company established 
new standards in the Indian pharmaceutical industry 
and transformed the Indian bulk-drug dependency of 
the mid-80s into a self-sufficient industry in the mid-
90s. By then, the Indian pharmaceutical industry had 
developed into an export-oriented industry and has re-
mained such ever since. 
In 1993, Dr. Reddy’s Laboratories emerged as India’s 
first drug-discovering company, and in April 2001, it 
became the first non-Japanese, Asian pharmaceutical 
company listed on the New York Stock Exchange
Dr. Reddy is an active member of the Prime Minister’s 
Council on Trade and Industry. Dr. Reddy founded and 
has donated generously to Dr. Reddy’s Foundation for 
Human and Social Development, which works to sup-
port development. During his long career, Dr. Reddy 
has been the recipient of many awards and civic hon-
ors. These include the Padma Shri Award, Sir P. C. 
Ray Award, FAPA-Ishidate Award for Pharmaceutical 
Research (1998), Businessman of the Year (2001), and 
the Achiever of the Year (2000).
RoDIn, Judith
Judith Rodin has served as president of the Rockefeller 
Foundation since March 2005. Trained as a research 
psychologist, Dr. Rodin was previously the president of 
the University of Pennsylvania, and earlier the provost 
of Yale University. The Rockefeller Foundation was es-
tablished in 1913 by John D. Rockefeller, Sr. to “pro-
mote the well-being” of humanity by addressing the 
root causes of serious problems. The Foundation works 
globally to expand opportunities for poor and vulner-
able people and to help ensure that the benefits of glo-
balization are shared more equitably. 
Judith Rodin was born and raised in Philadelphia, 
Pennsylvania. She graduated from the University of 
Pennsylvania, and received her Ph.D. from Columbia 
University. A pioneer in the behavioral medicine move-
ment, she taught at New York University before em-
barking on 22 years on the faculty at Yale, where she 
ultimately held appointments in both the School of Arts 
and Sciences and the School of Medicine. Named presi-
dent at Penn in 1994, she was the first woman to serve 
as president of an Ivy League institution. 
Dr. Rodin serves on a number of leading nonprofit 
boards, as well as on the boards of AMR Corporation, 
Citigroup, and Comcast Corporation. She is the au-
thor of more than 200 academic articles and chapters 
and has written or co-written 11 books. She served on 
President Clinton’s Committee of Advisors on Science 
and Technology. A member of a number of leading aca-
demic societies, including the Institute of Medicine of 
the National Academy of Sciences, she has received nine 
honorary doctorate degrees. 
SAlIM, emil
Emil Salim is on the faculty of economics at the 
University of Indonesia. Previously, he was the State 
Minister for Population and Environment from 1978 
to 1993. He currently serves as a member of many inter-
national and national committees, including the United 
Nations High Level Advisory Board on Sustainable 
Development. He serves as Chairman of the National 
Economic Board, an economic expert team to President 
Abdurachman Wahid. He was a member of the eco-
nomic expert team to President Suharto on debt and 
development issues of the nonaligned countries, and a 
member of the Indonesian Peoples’ Assembly. In addi-
tion, he was Co-chairman of the World Commission on 
Forestry and Sustainable Development. 
Dr. Salim also serves as Chairman of the Board of 
Trustees for a number of leading Indonesian envi-
ronmental organizations, including the Indonesian 
Biodiversity Foundation, the Foundation for Sustainable 
Development, and the Indonesian Ecolabelling Institute. 
He received his master’s degree and his doctorate in eco-
nomics from the University of California, Berkeley, in 
the United States.
SASSon, Albert 
Professor Albert Sasson, a Moroccan, is a world-re-
nowned international consultant in biotechnology. He 
has authored more than 200 publications concerning his 
research and popularization activities in soil microbiol-
ogy, algology, and agrobiology. He has published books 
and contributed to publications on biology teaching, 
environment and development issues, biotechnologies, 
and food and nutrition. Biotechnologies in Developing 
Countries is one of his outstanding publications. 
Professor Sasson is a prolific speaker, with invalu-
able information and insight in the areas of cloning, 
genetically modified foods, the use of biotechnology in 
agriculture and its possible impact on man and the envi-
ronment, and ethical and legal issues related to biotech-
nology. He has expert knowledge of how biotechnology 
can reduce poverty and the successes and failures of its 
application worldwide. 
After a career as a university dean, he joined UNESCO 
in 1974, where he served as Special Advisor to the UN 
for over 27 years. Since January 2000, Prof. Sasson has 
been senior consultant to UNESCO, Moroccan institu-
tions, and the company Publicis Dialog (Paris). He pro-
vides special advice to governments worldwide on the 
development of national policies on biotechnology, and 
is an advocate for the adaptation of technologies by the 
third world for their social and economic development. 
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Professor Albert Sasson is a man with a passion for 
science, especially for discoveries in the life sciences. 
He is truly fascinated with the application of science to 
food, agriculture, medicine, pharmaceuticals, energy, 
the environment, and bio-remediation.
SAtyAnARAyAnA, Kanikaram 
Kanikaram Satyanarayana holds a doctorate degree in 
biosciences. After a brief postdoctoral stint, he joined 
the Council of Scientific and Industrial Research in 
New Delhi. In 1980, he moved to the Indian Council 
of Medical Research (ICMR). He is involved in science 
and technology policy and evaluation, and is Chief of 
the Intellectual Property Rights Unit. For over twenty 
years, he has worked extensively in the areas of science 
and technology evaluation and science policy issues; he 
was instrumental in the formulation of Indian national 
policies in these areas.
In 1996, Dr. Satyanarayana published the first guide-
lines for promoting industry-academia partnerships in 
medical research in Contract Research, Consultancy and 
Technology Transfer policy of the ICMR. These guidelines 
are currently being revised to be in agreement with the 
new WTO and IPR regimes. He has organized several 
training workshops on WTO and IP rights issues for the 
benefit of scientists at ICMR institutes, medical colleges, 
and other institutes. Some of these training workshops 
were conducted with international funding (WHO). 
He set up the Intellectual Property Rights Unit at the 
ICMR in 1999 and brought out the Intellectual Property 
Rights Policy of ICMR in 2002. He is a member of sever-
al national committees on intellectual property and has 
participated in several national and international con-
ferences on such topics as globalization, the impact of 
TRIPS on public health, access to health care in devel-
oping countries, and so on. An active researcher, he has 
obtained competitive grants from various agencies in 
India and the World Health Organization. He has also 
published several papers in national and international 
journals. He is closely associated with the U.K.-based 
Centre for the Management of intellectual property 
in Health R&D (MIHR) and has contributed to their 
Manual for Technology Transfer Managers. Currently, he 
is the only member of the International Editorial Board 
of the second edition of this Handbook who is from a 
developing country. He is a founder and Secretary of 
the Society for Technology Management, India, and is 
currently a Senior Deputy Director-General and Chief 
of the Intellectual Property Rights Unit at the ICMR.
SeKI, Akinori
Akinori Seki is president of the Sasakawa Peace 
Foundation (SPF), an organization committed to fos-
tering international understanding, exchange, and co-
operation. Seki studied at the Gakushuuin University 
of Economics and received his Ph.D. from the London 
School of Business.
He worked for many years for the Marubeni 
Corporation, where he became General Manager 
(Strategies and Coordination) and Deputy Executive 
Officer (Corporate Strategies Department). He also 
lived in Africa briefly as President of Gambia Fisheries’ 
Co. Ltd. He joined the SPF in 1999, initially as Program 
Director, before becoming Chief Operating Officer, 
then Executive Director, and now President.
He has served as an advisor to many organizations, 
including the Myanmar Economic and Management 
Institute, the United Nations Industrial Development 
Organization (UNIDO), and the University of 
Cambodia, and he was a committee member of 
KEIDANREN and of the study group for Indo-China. 
He serves on the Board of Directors of the Bellagio 
Forum and is Member of the Advisory Committee, 
UNIDO (Tokyo Office). He is an Honorary Professor 
of Tafaccur University, in the Republic of Azerbaijan.
SeRAgelDIn, Ismail
Ismail Serageldin is Director of the Library of Alexandria 
and also chairs the Boards of Directors for each of the 
Biblioteca Alexandria’s affiliated research institutes 
and museums. He is also a Distinguished Professor at 
Wageningen University in the Netherlands. He serves as 
Chair and Member of a number of advisory committees 
for academic, research, scientific and international in-
stitutions and civil society efforts, including the Institut 
d’Egypte (Egyptian Academy of Science), TWAS (Third 
World Academy of Sciences), the Indian National 
Academy of Agricultural Sciences, and the European 
Academy of Sciences and Arts. He is former Chairman 
of the Consultative Group on International Agricultural 
Research (CGIAR, 1994-2000), Founder and former 
Chairman of the Global Water Partnership (GWP, 
1996-2000) and the Consultative Group to Assist the 
Poorest (CGAP), a microfinance program (1995-2000). 
Serageldin has also served in a number of capacities 
at the World Bank, including as Vice President for 
Environmentally and Socially Sustainable Development 
(1992-1998), and for Special Programs (1998-2000). 
He has published over 50 books and monographs 
and over 200 papers on a variety of topics, including 
biotechnology, rural development, sustainability, and 
the value of science to society. He holds a Bachelor of 
Science degree in engineering from Cairo University 
and a Master’s and Ph.D. from Harvard University. He 
has received 19 honorary doctorates. 
SheveluKhA, victor S. 
Victor Shevelukha was born in 1929, currently lives in 
Moscow, and is head of the Agricultural Biotechnology 
Department, Russian State Agrarian University, Moscow. 
He is a member of the V.I. Lenin All-Union Academy of 
Agricultural Sciences (VASKhNIL), the Russian academy 
of Agricultural Sciences, the International Academy of 
Agrarian Education, the Slavonic Academy, the Agrarian 
Academy of the Belarus Republic, the International 
Academy of Informational Sciences, and the Academy of 
Natural Sciences, among other public academies.
Victor has authored more than 400 scientific works, 
including 10 monographs and manuals on plant pro-
duction, plant breeding, seed production, agricultural 
biotechnology, plant physiology, and agricultural eco-
nomic policy. He has advised 45 Ph.D. students and 
12 doctors of sciences and is currently Chairman of the 
Scientific Council in RSAU-MAAS, which confers doc-
torate degrees in the fields of genetics, biotechnology, 
plant breeding, and seed production.
He worked as a senior agronomist at MAAT’s train-
ing farm, Druzhba, in the Yaroslavl region (1955-
1957); as a secretary of the Ryazantcev CPSU district 
committee, Yaroslavl region (1957-1959); as the head 
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of agricultural department, Yaroslavl CPSU regional 
committee; as the first vice-chairman of Yaroslavl re-
gional executive committee (1959-1964); as senior 
lecturer, associate professor, professor, and head of 
Crop Science Department at the Belarus Agricultural 
Academy (1964-1973); the director of Belarus Research 
Institute for Arable Farming (1973-1974); a secretary 
of the Central Committee, Belarussia Communist 
Party (1974-1979); a Deputy Minister of Agriculture 
of the USSR; a member of Collegium in the USSR 
Ministry of Agriculture (1979-1983); academic-secre-
tary of Plant Production and Breeding Department, 
V.I. Lenin All-Union Academy of Agricultural Sciences 
and Russian Academy of Agricultural Sciences (1983-
1994); a deputy of the State Duma, Federal Assembly 
of the Russian Federation; and vice-chairman of the 
Committee for Education & Science, the State Duma 
(1994-2000).
Prof. Shevelukha is also a member of both the Russian 
Federation Union of Writers and the Russian Federation 
Union of journalists. He has written and published 10 
volumes of fiction and sociopolitical journalism. 
Finally, Victor has been awarded the K.A. Timiryazev 
and V.I. Vernadsky gold medals, orders and medals of the 
USSR, Russia, and foreign countries, and honorary deeds 
and titles from the State Duma (Russian Parliament), 
the Federal Assembly of the Russian Federation, the 
Ministry of Agriculture, and the Ministry of Education 
and Science.
SWAMInAthAn, M. S.
Professor M. S. Swaminathan has been acclaimed by 
TIME magazine as one of the twenty most influen-
tial Asians of the 20th century, one of the only three 
from India, the other two being Mahatma Gandhi and 
Rabindranath Tagore. He has been described by the 
United Nations Environment Programme as “the Father 
of Economic Ecology,” and by Javier Perez de Cuellar, 
Secretary General of the United Nations, as “a living 
legend who will go into the annals of history as a world 
scientist of rare distinction.” He was Chairman of the 
UN Science Advisory Committee, set up in 1980 to 
take follow-up action on the Vienna Plan of Action. He 
has also served as Independent Chairman of the FAO 
Council and President of the International Union for 
the Conservation of Nature and Natural Resources. He 
is the current President of the Pugwash Conferences on 
Science and World Affairs. 
A plant geneticist by training, Professor 
Swaminathan’s contributions to the agricultural renais-
sance of India have led to his being widely referred to as 
the scientific leader of the green revolution movement. 
His advocacy of sustainable agriculture leading to an 
“evergreen revolution” has made him an acknowledged 
world leader in the field of sustainable food security. The 
International Association of Women and Development 
conferred on him their first international award for his 
significant contributions to promoting the knowledge, 
skill, and technological empowerment of women in ag-
riculture, and for his pioneering role in mainstreaming 
gender considerations in agriculture and rural develop-
ment. Professor Swaminathan was awarded the Ramon 
Magsaysay Award for Community Leadership in 1971, 
the Albert Einstein World Science Award in 1986, and 
the first World Food Prize in 1987. 
Professor Swaminathan is a Fellow of many of the lead-
ing scientific academies of India and the world, includ-
ing the Royal Society of London and the U.S. National 
Academy of Sciences. He has received 55 honorary 
doctorate degrees from universities around the world. He 
currently holds the UNESCO Chair in Ecotechnology at 
the M. S. Swaminathan Research Foundation in Chennai 
(Madras), India, and was Chairman of the National 
Commission on Agriculture, Food, and Nutrition 
Security of India until October 2006.
thoMSon, Jennifer A.
Jennifer Ann Thomson is Professor of Microbiology 
in the Department of Molecular and Cell Biology at 
the University of Cape Town, South Africa (UCT). 
Previously, she had held the positions of Head of the 
Department of Microbiology at UCT, the Director 
of the Laboratory for Molecular and Cell Biology at 
the Council for Scientific and Industrial Research, and 
Associate Professor in the Department of Genetics at the 
University of the Witwatersrand in Johannesburg. Her 
research involves the development of genetically modi-
fied maize that is resistant to the Maize streak virus (en-
demic to Africa) and tolerant to drought. She received 
an honorary doctorate from the Sorbonne University, 
Paris in 2005, and the UNESCO/L’Oreal award for 
Women in Science in 2004. She is Chair of the Board 
of the African Agricultural Technology Foundation, 
based in Nairobi, Kenya. She is a Director of the South 
African Pebble Bed Modular Reactor (Pty) Ltd. She has 
published a book, Genes for Africa: Genetically Modified 
Crops in the Developing World.
vAn MontAgu, Baron Marc
Baron Marc Van Montagu is an Emeritus Professor at 
Ghent University, and founder and Chairman of the 
Board of IPBO, the Institute for Plant Biotechnology 
for Developing Countries. He received a Ph.D. in or-
ganic chemistry/biochemistry from Ghent University 
in 1965, and served as the Director of the Department 
of Genetics at the Flanders Interuniversity Institute 
for Biotechnology, before joining the faculty at Ghent 
University in 1999. 
Dr. Van Montagu has made pioneering contribu-
tions to plant gene discovery, including the discovery 
of the gene transfer mechanism between Agrobacterium 
and plants, which was central to the development of 
transgenic plants. His work at the Lab of Genetics, 
Ghent University, produced two spin-off biotech com-
panies, Plant Genetic Systems (PGS) and Crop Design. 
His research at PGS led to the construction of the first 
herbicide tolerant plants, as well as the construction of 
the first plants producing the Bt (Bacillus thuringensis) 
insecticide. His was listed among the top 100 living 
contributors to biotechnology by The Scientist magazine 
and, until 2004, was the most cited scientist in the field 
of Plant and Animal Science. 
XuAn, vo-tong
Dr. Vo-Tong Xuan is a distinguished agricultural scien-
tist, an outstanding educator, a low-profile institution 
builder, and a national and international leader in agri-
cultural development. 
As a scientist, he is widely recognized for his expertise 
in the management of saline and acid-sulphate soils and 
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other problem soils in Vietnam. He is an expert in rice 
production and in rice-based farming systems, as well as 
in agricultural diversification in the Mekong Delta. His 
technical expertise and strong farmer-focused leadership 
in the Mekong Delta greatly increased rice productiv-
ity and contributed to the emergence of Vietnam as the 
third-largest rice exporting country in the world. Xuan 
has authored and co-authored six books and more than 
100 technical papers about agricultural, rural develop-
ment, and sustainable food security.
As an educator, he emphasized scientific as well as 
down-to-earth hands-on-training in the University 
of Cantho, at which he served as Chairman of the 
Departments of Bio-Agronomy and Agronomy, and 
Assistant Dean of Agriculture. He rose to the rank of 
Vice Rector of the University of Cantho and, in 2000, 
was elected President of Angiang University, a position 
he still holds. 
As an institution builder, Xuan developed and strength-
ened the Mekong Delta Farming Systems Research 
and Development Institute and served as its Director 
from 1983 to 2001. He also served as FAO Project 
Coordinator for the establishment of Agricultural 
Service Centers for Small Farmers. He organized the 
Vietnam Farming Systems R & D Network and has 
been serving as its Coordinator since 1991. 
As a national leader in agriculture, Dr. Xuan was ap-
pointed member of the National Council on Science 
and Technology, the National Council on Education, 
the National Council on Professorial Titles Advisory 
Council of the Vietnam Chamber of Commerce and 
Industry, the Steering Committee of the Vietnam-
Holland Research Program on Rural Development, and 
the Consultants’ Group to the Prime Minister.
As an international leader in agriculture, he is widely 
recognized for his integrated approaches to agricultural 
development and deep concern for efficient and effec-
tive use of natural resources, sustainability, and envi-
ronmental issues, as well as, for food security problems 
of developing countries. He is a strong advocate of the 
farming system approach in agricultural development. 
He has served in key positions in the following inter-
national organizations: Member, Board of Governors, 
Asian Institute of Management in Manila; Member, 
Board of Trustees of IRRI; Member, Board of Trustees 
of The Rockefeller Foundation; Member, Board of 
Trustees of the International Potato Center at Lima, 
Peru; Member, FAO’s Advisory Committee on Farmer-
Centered Agricultural Resource Management Program; 
Member, Technical Advisory Committee of the CGIAR; 
Member, Policy Advisory Council, Australian Centre for 
International Agricultural Research; Member, Advisory 
Council of the Asian Development Research Forum.
Dr. Xuan served as international consultant, lecturer of 
IFAD, FAO, DANIDA, SIDA, and IDRC-Singapore 
since the 1980’s. 
He received from the Prime Minister of Canada a 
certificate of recognition for his “dedication and con-
tribution to the world of sciences.” The Ministry of 
Agriculture, Fisheries and Forestry of the Republic 
of France, awarded him the “Chevalier de l’Ordre du 
Merite Agricole Medal.” He was elected the 2002 Nikkei 
Asia Prize for Regional Growth; Most Distinguished 
Alumnus of the University of the Philippines College 
of Agriculture Alumni Association; Ramon Magsaysay 
Award for Government Service; and the 2005 ASTD 
Derek Tribe Award. Other awards include: the People’s 
Teacher Award, Vietnam Farmers’ Federation Medal 
“For the Cause of the Farmers’ State Award as “Hero of 
the Working Class,” Outstanding Scientific Achievement 
Award from the Prime Minister, Most Distinguished 
Alumnus Award from the University of the Philippines 
at Los Banos.
yuthAvong, yongyuth
Yongyuth Yuthavong is a scientist. His interests lie in 
antimalarial drug development and broad issues of sci-
ence, technology, and public policy. In 1962, Professor 
Yuthavong was awarded a Thai government scholar-
ship to study in the United Kingdom. He obtained a 
bachelor’s degree in chemistry with first-class honors 
from the University of London in 1966 and a doc-
toral degree in organic chemistry from the University 
of Oxford in 1969. He spent many years at Mahidol 
University in Thailand, where, beginning in 1983, he 
served on the faculty as a professor of biochemistry. 
He was actively engaged in the establishment in 1992 
of the National Science and Technology Development 
Agency (NSTDA) of Thailand (1992) and became the 
agency’s first president, serving two terms. In 1998, he 
returned to the research career at the NSTDA’s National 
Centre for Genetic Engineering and Biotechnology 
(BIOTEC), where he had once served as its director. 
Currently he heads a research group in BIOTEC, where 
he is working on the development of new antimalarials 
with grants from the Medicines for Malaria Venture and 
the Wellcome Trust.
In 2004, Yuthavong received the Nikkei Asia Prize 
for Science, Technology, and Innovation from Nihon 
Keizai Shimbun, Japan, for his work on antimalarial 
drug targets. The same year, Thailand’s National Identity 
Board named him Person of the Year. In 1984, he re-
ceived the Outstanding Scientist of Thailand Award 
from the Foundation for Promotion of Science and 
Technology. He has received honorary doctorates from 
Prince of Songkla University and Mahidol University. 
In 2006, Bangkok’s The Nation newspaper named him 
one of Thailand’s 35 most influential people over the 
last 35 years.
Yuthavong is past chairman of the Foundation 
of Thai Academy of Science and Technology and the 
Foundation for Promotion of Talents in Science and 
Technology. Today, he serves as a member of five state 
university councils. He is a member of the National 
Education Board and the National Research Council 
Committee on Chemistry and Pharmaceutical Sciences. 
He has coauthored 115 research articles published in in-
ternational journals and 16 book chapters and books on 
biomedical science, policy, and general issues of science 
and technology.
Yuthavong was appointed Thailand’s minister of 
Science and Technology in 2006. ■
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Intellectual property can be a powerful tool. When effectively and ethically 
managed, it can accelerate the development of lifesaving, poverty-alleviating 
innovations and provide access to them.
This Executive Guide, companion to the Handbook, discusses and summarizes 
each of the 17 sections of the Handbook and distills best practices related to 
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157 chapters and prefatory comments.
“A resource for translating IP rights into realistic deals and practical solutions,  
the Executive Guide demystifies intellectual property, making the subject accessible to all. ”
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